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Abstract 
The work detailed in this PhD involves two distinct, separate areas of research. The first project 
involved an investigation into the synthesis, characterisation and metal-chelation of pyrido-
imidazo[1,2-a]pyridines in the search for new compounds for the treatment of cancer.  
Previously in our laboratories at the University of the Witwatersrand a small library of 
imidazo[1,2-a]pyridines were synthesized that showed significant activity (IC50 values between 
6.57-21.98 µM) against Caco-2 and HT-29 colorectal cancer cell lines while showing little 
cytotoxicity towards white blood cells; significantly less than camptothecin the ‘golden standard’. 
In an attempt to improve the overall activity of the imidazo[1,2-a]pyridines methodology was 
developed to coordinate zinc, copper and platinum to the imidazo[1,2-a]pyridines to generate 
novel metal-imidazo[1,2-a]pyridine complexes. These novel compounds were characterised by 
NMR spectroscopy (where possible) and Single Crystal X-ray Diffraction (SCXRD) and tested 
against colorectal (Caco-2 and HT-29), leukemic (K562 and HL-60) and breast (MCF-7 and MDA-
MB231) cancer cell lines, where the copper-containing compounds showed the most significant 
activity. A library of 11 copper complexes screened showed excellent activity in all the cell lines 
tested, some of which were more active than camptothecin. 
The second part of this PhD involved a detailed investigation into novel methodology to 
synthesize xanthones and related diones, for example such as 4a-methoxy-2H-xanthene-
2,9(4aH)-dione, discovered in our laboratory. Initially this reaction was reported to be mediated 
by ceric ammonium nitrate (CAN), however it was determined during the course of this 
investigation that the novel reaction was actually mediated by ceric ammonium sulfate (CAS) and 
that different products were isolated depending on which reagent (CAN or CAS) was used. In this 
thesis, the mechanism of the reaction was probed and it was determined that the electronic 
nature of the starting benzophenone (e.g. (2-hydroxyphenyl)(2,4,6-
trimethoxyphenyl)methanone) plays a crucial role in the outcome of the reaction. In addition to 
the furnishing of xanthones (e.g. 4-methoxy-9H-xanthen-9-one) and spirofurans (such as 2',6'-
dimethoxy-3H-spiro[benzofuran-2,1'-cyclohexa[2,5]diene]-3,4'-dione) using this CAS-mediated 
reaction, novel biaryl-fused dimers (e.g. (4,4'-dihydroxy-[1,1'-biphenyl]-3,3'-diyl)bis((2,4-
dimethoxyphenyl)methanone)) were also isolated and these results were explained by the 
mechanisms detailed in this work. Reliable methodology was developed using a sodium 
dithionite-mediated method for the conversion of dione products (such as 4a-methoxy-2H-
xanthene-2,9(4aH)-dione) to hydroxy-containing xanthones (such as 7-hydroxy-9H-xanthen-9-
one).  
iv 
 
Finally, as a proof of concept, this novel CAS-mediated methodology was extended to the 
synthesis of the nitrogen-containing derivatives, the acridones, and a single acridone, 10-benzyl-
2-methoxyacridin-9(10H)-one, was successfully synthesized using CAS as the reagent, albeit in a 
low yield. 
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At the end of my tether: 
Introduction 
1.1. Cancer 
While homeostasis carefully controls changes to the body, some changes such as mutations to 
the cells are not always controlled. These mutated or abnormal cells often grow uncontrollably, 
resulting in tumours. Contributing to this rapid growth is an increase in blood supply around to 
the tumour.
1
 These tumours can detach from the surrounding healthy cells, allowing abnormal 
cells to spread, taking over healthy organs resulting in severe illness and, if untreated, death. 
While there are different types of this disease, they are collectively known as cancer.
2
 
In healthy cells, a process known as apoptosis occurs that causes a cell to die when harmful 
mutations occur in the cell. This process is more commonly known as intracellular suicide or 
programmed cell death.
3
  Apoptosis causes the release of proteases (mainly caspases) and 
nucleases which destroys the proteins, lipids and DNA of the cell when an abnormal change in 
the cell is detected. The cell shrinks, becomes lobed and is quickly ingested by neighbouring cells 
without damage to the surrounding area. This process is considered to be essential for human 
development as it prevents the replication of any unwanted changes in a cell. In cells where 
irreparable damage has occurred – especially DNA damage – an internal signal that is controlled 
by caspases is normally generated to trigger apoptosis, preventing the spread of the mutation.
1
  
In cancerous cells, the release of these caspases is inhibited, preventing apoptosis and allowing 
the mutated cells to multiply rapidly in an uncontrolled fashion leading to a cancerous tumour.  
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Significant advances in the understanding of cancer, early detection and the treatment thereof 
has dramatically increased the average cancer survival rate from an estimated 35 % in 1953 to 68 
% in 2005.
4
 However, the rates of incidence and treatment resistance is on the rise indicating the 
need for further research and discovery.
5
 
Obtaining accurate, updated cancer statistics is difficult for numerous reasons, however there are 
a few reports estimating current cancer statistics. The World Health Organisation has outlined 
the cancer mortality data revealed in a Globocan 2012 report. Figure 1 illustrates the 
contribution of various cancer types towards cancer related deaths. Of particular interest to this 
PhD, it can be seen that breast, colorectal and leukemic cancers accounted for nearly a quarter of 
all cancer related deaths globally in this year.
6-7
 
 
Figure 1 – World Cancer Mortality Rates (%) for 2012 
 
1.1.1. Colorectal Cancer 
Colorectal cancer, as the name suggests, is cancer of the colon and/or rectum. It begins as a 
benign polyp in the lining of the colon or rectum, following which the cancer cells continue to 
multiply, forming a tumour. The tumour is considered to be malignant once multiple significant 
changes have taken place on a DNA level, typically indicated by the presence of at least one 
active oncogene and a loss of tumour suppressor genes.
1
 According to a report released in 2014 
specifically on colorectal cancer statistics, the majority of colorectal cancers occur in the proximal 
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colon (comprising of the cecum, the ascending and transverse colon), the remaining cases being 
shared nearly evenly between the distal colon (the descending and sigmoid) and the rectum.
8
 
There are currently several methods for the detection of colorectal cancer in South Africa. More 
invasive but more definitive methods include biopsy, colonoscopy and sigmoidoscopy while less 
invasive measures such as barium enemas may be used as a form of early detection.
9
 The 
conventional treatment for colorectal cancer is removal by surgical ablation, and depending on 
the degree to which the cancer has spread, the treatment may be supplemented with radiation 
and/or chemotherapy. Unfortunately there is a 40% chance of developing metastases after 
surgery and in more highly metastasized cancers these conventional approaches tend to have 
very little effect on the cancer.
10
 
 
1.1.2. Breast Cancer 
Breast cancer is thought to originate in the cells that line the breast ducts and spread from there. 
However, there are also reported cases where the cancers start in the lobules or the breast tissue 
itself.
11
 The danger in this type of cancer is that the cells can easily metastasize (spread rapidly) to 
the nearby lymph nodes. Once there they can easily be spread to other parts of the body via the 
lymphatic system, making this a particularly dangerous form of cancer if not diagnosed in time. 
According to the World Health Organisation, breast cancer is the leading type of cancer in 
women, making up 25% of the global cancer diagnoses in women.
12
 Due to early detection 
methods and significant advances in treatment only 14 % of these cases result in death.
6
 Breast 
cancer is not limited to woman, and can also occur in men, although significantly less common. 
While the majority of cancers are the result of a seemingly random set of mutations, it has been 
found that in the case of breast cancer there is a genetic link. Those that test positive for breast-
related cancer antigens 1 and 2 (BRCA-1 and BRCA-2) have a 50-85% chance of developing breast 
cancer at some point in their life.
13
 
Unlike most other cancers that require a medical professional’s examination and side effects to 
detect cancer, women are strongly encouraged to do regular self-examinations in order to detect 
any lumps or irregularities in their breasts. This campaign has resulted in early diagnosis and 
treatment of breast cancer before it can spread and become more serious. The Cancer 
Association of South Africa has released an infographic (Figure 2) outlining what woman should 
look out for and to quash common myths.
14
 
Once an abnormality has been detected, a doctor typically confirms the presence of the 
abnormality and, should the doctor feel it is warranted, send for further tests. Typical tests 
include mammograms (X-ray of the breast), breast ultrasound and MRI and these are used to 
 At the end of my tether  
 Introduction  
 
5 
 
show the nature of the abnormality. From these results, a biopsy may be used to confirm the 
presence and stage of the cancer and potentially whole body scans may be done to confirm that 
the cancer hasn’t spread to other parts of the body.
11
 
Treatment for breast cancer is determined depending on the stage of the cancer as well as the 
age and the health of the individual. Surgery to remove the abnormal mass is the normal 
approach. Depending on the size and type of tumour, this is either a lumpectomy (removal of the 
tumour and a small amount of surrounding tissue) or mastectomy (removal of the entire breast) 
followed by reconstructive surgery. All of these treatments are often followed up with radiation 
and/or chemotherapy to ensure that no cancer cells are left behind, preventing the cancer from 
reoccurring.
11
 
 
Figure 2 – Breast Cancer Infographic courtesy of the CANSA Association
14 
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1.1.3. Leukemia 
Perhaps one of the most difficult cancers to treat is leukemia. A broad description for this type of 
cancer is cancer of the blood and bone marrow. The bone marrow contains blood stem cells 
which are responsible for producing red blood cells (erythrocytes), white blood cells (leucocytes) 
and platelets which make up a large proportion of blood. The blood stem cells produce myeloid 
and lymphoid stem cells. The myeloid stem cells produce erythrocytes, platelets and granulocytes 
(certain types of leucocytes) while the lymphoid stem cells produce the rest of the leucocytes. 
Leukemia originates when the bone marrow produces abnormal white blood cells (commonly 
referred to as leukemia cells). These abnormal cells accumulate in the marrow and blood making 
it significantly harder to circulate healthy blood to the tissues, control bleeding and fight 
infections. Since blood circulates around the entire body, it is easy for the leukemic cells to 
spread (often to the lymph nodes, spleen and brain).
15
 
While for most cancers the likelihood of developing cancer increases with age, leukemia is 
prevalent in both children and adults. Leukemia accounted for approximately 31 % of all 
childhood cancers, and 12 % of adolescent cancers in a study on childhood cancers in 2014.
16
 
There are four major types of leukemia: 
 Acute myeloid leukemia (AML) 
 Chronic myeloid leukemia (CML) 
 Acute lymphocytic leukemia (ALL) 
 Chronic lymphocytic leukemia (CLL) 
The myeloid/lymphocytic term refers to where the abnormality occurs. Acute cancers are the 
more aggressive, fast growing and metastatic type of cancers where the affected individual 
experiences fatigue, bruises easily and contracts infections easily, forcing them to seek medical 
attention. The leukemic cells typically collect in the bone marrow and blood. Chronic cancers are 
slow growing and spreading, and are often only discovered as a result of routine checks. They are 
characterised by an increase in the number of leucocytes in the blood.
15
 Diagnosis of leukemia 
can be confirmed by blood tests and/or bone marrow aspiration and biopsy. Other tests such as 
contrast CT scans and MRI’s may be done to detect if the cancer is localised to an area or if it has 
spread to other tissues. Unlike many other types of cancers, leukemia does not form a solid 
tumour. Surgery is therefore not an effective form of treatment, making treatment fully reliant 
on chemotherapy and/or radiation.
17
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1.1.4. Commonly Used Chemotherapies 
Since there is still very little known about the origins of cancer in the body, designing targeted 
treatment for each particular cancer is difficult. As a result, there are a host of chemotherapies 
that are currently employed in the treatment of cancer. Discussed in this section is a selection of 
commonly used chemotherapies in the treatment of leukemia, colorectal and breast cancers. It 
should be noted that many of the chemotherapeutic agents are used for a variety of different 
cancers and may extend past what is mentioned here. These agents may also be used in 
conjunction with each other in an individual’s treatment plan, depending on the severity of the 
cancer. 
For the treatment of colorectal cancer, one or more of the following chemotherapeutic agents 
(as illustrated in Figure 3) are often used: 
 fluorouracil, 1 (marketed as 5-FU or Adrucil®)
18
 
 the prodrug of fluorouracil, capecitabine, 2 (marketed as Xeloda®)
19
 
 oxaliplatin, 3 (marketed as Eloxatin)
20
 
 irinotecan, 4 (marketed as Camptostar)
21
 
 
  
 
1 2 
 
 
 
 
3 4 
Figure 3 – Currently used chemotherapies for colorectal cancer 
 
Certain classes of compounds have inherent anticancer activity, where differing substituents 
show better activity against particular cancers. Several of these families will also be discussed in 
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this section. Camptostar (4) is a derivative of camptothecin (5) shown in Figure 4. Camptothecin 
was first isolated by M. E. Wall in the early 1960’s from the Camptotheca acuminata, Nyssaceae 
tree, which is native to China. The extracts were screened and found to contain high anti-tumour 
activity. It was found that only the (S)-camptothecin enantiomer was biologically active.
22
 
Camptothecin was developed into 4 and approved by the Food and Drug Administration (FDA) for 
the treatment of colorectal cancer.
21
 A further slight variation of 5 results in the derivative 6, 
another drug known as topotecan (marketed as Hycamtin® and shown in Figure 4) although this 
is used more for the treatment of leukemia and small cell lung cancer.
23
 This family of 
compounds acts by binding to the topoisomerase I DNA during the unwinding of the DNA helix, 
preventing  the DNA from recombining after transcription.
22-23
 
 
  
 
5 6 
Figure 4 – Camptothecin (5) and its prodrug, topotecan (6) 
 
Another family of cancer fighting compounds are the platinum-containing drugs. As previously 
mentioned, oxaliplatin (3) is a drug used to treat colon cancer. Considered to be the third 
generation derivative of the platinum-containing drug, cisplatin (7, Figure 5),
24
 this is an example 
of the platinum-containing complexes of significant interest to this project.  
Cisplatin was first reported in 1965 to inhibit cell division and was approved for drug use by the 
FDA in 1978.
25,26
 To date it has been used to successfully treat a variety of human cancers. One 
such example of the success of cisplatin can be seen in the increase in the cure rate of testicular 
cancer, which was about 10% in the late 1970’s and increased to almost 90% after the 
introduction of the cisplatin treatment.
27,28
 However, metastatic colorectal cancer has developed 
drug resistance to cisplatin, making it an ineffective treatment.
29
 The development of 7 led to the 
formation of a second generation drug, carboplatin (8, Figure 5) which has significantly lower 
toxicity compared to cisplatin and was approved by the FDA for the treatment of ovarian, lung, 
head and neck cancers. More recently the third generation of cisplatin, oxaliplatin (3) (in 
combination with 5-fluorouracil (1) and/or leucovorin) was approved for use in Europe in 1996 
and in the US in 2002 for treatment of metastatic colorectal cancer.
8,30
 Over 50% of all cancer 
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patients worldwide are treated using these platinum-containing compounds either alone or 
supplemented by other drugs.  
Once in the body, these platinum compounds are hydrolysed inside the cell. The hydrolysed 
product reacts rapidly with nitrogen donor ligands in DNA.
31
 This binding leads to distortion of 
the overall helical shape of the DNA, preventing replication and transcription from occurring.
32
 
 
  
 
7 8 
Figure 5 – First and second generation platinum based chemotherapy 
 
Drugs that are commonly used in the treatment of breast cancer include: 
 platinum group therapies such as cisplatin (7) and carboplatin (8)
33
 
 capecitabine, 2 (marketed as Xeloda®)
19
 
 docetaxel, 9 (marketed as Taxotere® shown in Figure 6)
34
 
 paclitaxel, 10 (marketed as Taxol shown in Figure 6)
35
 
 
 
 
 
 
9 10 
Figure 6 – docetaxel (9) and paclitaxel (10) used in the treatment of breast cancer 
 
Capecitabine (2) has two modes of action. Firstly it prevents uracil from converting into 
thymidine (important for the synthesis of DNA) by binding to thymidylate synthase, thus 
inhibiting cell division. Secondly, after the metabolism by the cancer cell to the triphosphate 
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analogue, it can be incorporated into the RNA during its synthesis, preventing further RNA 
processing and protein synthesis.
19
 
Paclitaxel (10) was originally isolated by Wall and co-workers in 1966 from the bark of Taxus 
brevifolia, a tree typically found in Washington State. The structure was determined a few years 
later by means of X-ray crystallography in combination with infrared and mass spectrometry.
22
 
Since then, a number of syntheses of paclitaxel have been described and a variety of other 
biologically active analogues such as docetaxel have been developed. The mode of action of 
these compounds is considered to be tubulin binding. The taxel analogues are thought to 
promote the assembly of, and stabilise the stacking of, the microtubules and prevents the 
disassembly of these polymer type structures, preventing mitosis from occurring in the mutated 
cells.
34,35
 
Considering the limited treatment options for leukemia, chemotherapeutic agents used are of 
particular importance. Some of the drugs currently administered (outlined in Figure 7) include: 
 Topotecan, 6 (marketed as Hycamtin®)
23
 
 Cladribine, 11 (marketed as Leustatin®)
36
 
 Fludarabine, 12 (marketed as Fludara®)
37
 
 Etoposide, 13 (marketed as Etopophos®)
38
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Figure 7 – Cladribine (11), Fludarabine (12) and Etoposide (13) used in the treatment of 
leukemia 
 
The mode of action of cladaribine (11) and fladaribine (12) is still under investigation, however it 
is thought that the drugs are metabolised and converted into the active triphosphorylated 
species which inhibit DNA polymerase and primase and ribonucleotide reductase. This prevents 
the synthesis of cancerous DNA.
36,37
 Etoposide (13), on the other hand, is considered to interact 
with the topoisomerase-II-DNA complex preventing replication of the mutated DNA.
38
 
On a more interesting note, while the cause of leukemia is still not known, medical professionals 
are beginning to notice an increase in patients developing leukemia who were previously treated 
with the platinum-containing chemotherapies for other types of cancer.
33
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1.2. The Future of Chemotherapy 
1.2.1. Hybrid Compounds 
Despite significant advances in currently used chemotherapies and the on-going search for new 
chemotherapeutic agents to introduce to the market, cancer continues to plague society. Aside 
from the high toxicity and severe side effects of currently used chemotherapies,
39
 several cancer 
cell lines are becoming treatment resistant, especially in recurring cancers.
29
 
With the high cost of drug development, researchers are continually investigating new ways to 
reduce the cost of development. One such strategy that is of current interest is the development 
of hybrid molecules/drugs. In a review by Meunier, hybrid molecules are defined to be chemical 
moieties with different biological functionalities that form part of the same compound.
40
 The 
biologically active moieties on the hybrid molecule do not necessarily need to be acting on the 
same target site. There are several modes of interaction possible with hybrid molecules as shown 
in Figure 8. These include ‘double-edged’ hybrids, as shown in A, where the active components of 
the molecule both act on the same target, hybrids where each active moiety acts on independent 
targets (B), and finally hybrids where each active part acts on related targets simultaneously (as 
in C).
40
 
  
A B 
 
C 
Figure 8 – The different types of hybrid molecules as described by Meunier
40
 
 
The overall activity of the compounds can be significantly increased when one pharmacophore is 
linked to another by either a covalent or coordination bond. The activity of the hybrid is often 
much higher than the additive activity of both pharmacophores. Significant other advantages of 
hybrid compounds were highlighted in Meunier’s review, including better absorption of certain 
active pharmacophores (for example, a low solubility pharmacophore might be better absorbed if 
Target 1 Target 1 Target 1 Target 2
Target 1 Target 2
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tethered to a significantly more soluble compound). It is also easier to administer a hybrid 
compound than a combination of separate pharmacophores and the pharmacodynamic 
properties are more predictable.
40
 
 
1.2.2. Organic Hybrid Compounds 
One of the most successful hybrid compounds available on the market is Bleomycin – an 
anticancer agent. Effectively a prodrug until administered, it is administered metal free. Once in 
the body it chelates with free iron through the nitrogen atoms indicated by the asterisks (*) in 14 
(Figure 9).
41
  
 
14 
Figure 9 – the structure of Bleomycin with * indicating the iron coordination sites 
 
Derivatives of hybrid 14 have three main areas of activity. Aside from the metal binding domain 
(indicated by *), the molecule also contains a DNA binding domain (highlighted by the square in 
Figure 9) and the sugar/carbohydrate domain which improves cell penetration.
41
 This is an 
example of type C of the hybrids discussed in Figure 8. However, the synthesis of bleomycin is 
troublesome
42
 and unfortunately while bleomycin shows good biological activity they also show 
significant toxicity. 
Nakagawa-Goto et al. investigated the feasibility of tethering paclitaxels (such as 9 and 10) with 
other antitumor agents such as camptothecin (5) and epipodophyllotoxin by means of an ester, 
imine, amine or amide bond. Hybrid 15 in Figure 10 is an example of the type of compounds that 
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were investigated, where paclitaxel (in the circle) has been tethered to camptothecin (in the 
square). It was found that these hybrid compounds showed significantly better activity than the 
unmodified paclitaxel compounds in prostate cancer cell lines.
43   
 
15 
Figure 10 – A paclitaxel-camptothecin hybrid 
 
The hybrid approach to drug discovery is being investigated in many areas of medicinal chemistry 
aside from the treatment of cancer. Dos Santos et al. reported their preparation of phthalimide 
derivatives containing furoxanyl moieties for potential use as a treatment for sickle cell disease 
symptoms.
44
 Saadeh, Mosleh and Mubarak synthesized hybrid compounds combining 
metronidazole, chloroquine and 5-nitrofuranacrylic acid in an attempt to improve their activity 
against parasites, specifically malaria, after they were inspired by work by Peyton and co-
workers.
45,46
 Noted in this study was that the hybrid compounds were better absorbed into the 
desired areas of activity in relation to the conventionally active drugs.
45
 This highlights the 
significant advantage of the pharmacological properties being improved in hybrid molecules. 
 
1.2.3. Metal-Containing Hybrids 
1.2.3.1. Platinum 
Up until this point in this thesis, the covalent linking of multiple organic molecules to afford 
organic hybrids has been discussed. However; metals can also be combined with biologically 
active organic pharmacophores to afford hybrid molecules. Since platinum is currently used in 
chemotherapies, this is an important area of research to consider and is currently a ‘hot’ research 
topic. Significant research is being done into creating platinum-hybrid compounds specifically to 
target cancer cell lines.  
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In hormone-dependent cancers, a high oestrogen receptor count has been noted making them 
potential targets for drug design. Gagnon et al. synthesized a variety of platinum-containing 
hybrids that combine cisplatin with oestrogen. Compared to cisplatin, hybrids such as 16  (Figure 
11) where n = 6 or 8 were found to be up to 7 times more active. In addition to this, these 
compounds were also active against cisplatin resistant cell lines.
39
 Figure 11 is an example of the 
hybrids shown in Figure 8B, the oestrogen component directs the drug to the cancer cells (due to 
the high oestrogen receptor count) and once there enables the platinum moiety to serve as a 
DNA intercalator. 
 
16 
Figure 11 – An oestrogen/cisplatin hybrid 
 
Another promising example of platinum hybrids are platinum-acridines (Figure 12) however, 
while the second generation platinum-acridines (17) show promising results, it was noted that 
the pharmacological properties of this generation of hybrids needed some improvement. Graham 
et al. looked at the effects of the addition of a carboxylic acid ester group to acridine (18).
47
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Figure 12 – platinum-acridine hybrids 
 
In the article it was proposed that in an aqueous environment, the ester would be converted into 
a chelated carboxolato ligand (19). Also proposed was that since these modified platinum-
acridines still showed anticancer activity, adding a receptor targeted component to the end of 
this ester could be a potential method for making these anticancer compounds more selective – 
and potentially more active. This targeted method of action is outlined briefly in Figure 13 and 
serves as an example of targeting hybrid molecules where there are 3 active pharmacophores 
(the targeted receptor, the acridine and the platinum DNA intercalator). In Figure 13, the 
targeted receptor is denoted as R, the moiety attracted to the target (as T) with the platinum 
binding to nitrogen bases in the DNA once in the cell.
47
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Figure 13 – Proposed mode of action of targeted platinum based complexes
47
 
 
While the chemistry and biology of platinum is well established, it is not the only metal that 
shows anticancer activity or, for that matter, the only metal looked at for hybrid compound 
development. There is a vast amount of research into using transition metals (not just platinum 
group metals) in chemotherapy. Historically all metals incorporated into drugs were thought to 
behave like platinum – binding to DNA – however recently discoveries are showing that different 
metals tend to have their own individual modes of action. Alessio and co-workers summarised 
the different possible modes of action of metals to be used in anticancer drugs as functional (i.e. 
the metal binds to the target), structural (metals have particular binding geometries which lend 
their structure to the overall shape of the molecule), carrier (delivers active ligands in vivo), 
catalysis (speeding up naturally occurring reactions) and photo-sensitive (the metal compound 
acts as a photo-sensitizer).
48
 
1.2.3.2. Iron and ferrocene based hybrids 
Iron is another metal of interest for the development of hybrid drugs, often in the form of 
ferrocene. Ferrocene, 20 (Scheme 1) in its simplest form is a Fe
2+
 metal atom sandwiched 
between two cyclopentadiene molecules. Not to be outdone by the significant redox potential of 
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iron (Fe
3+
 + e
-
 → Fe
2+
), ferrocene can just as easily be oxidized to ferrocenium (21) as shown in 
Scheme 1. Under biological conditions, 20 can be oxidized to 21, which can then act as an 
electron (or free radical) scavenger and be reduced back to 20. In cancerous cells, there is a build-
up of superoxide and secondary radicals (such as ˙OH) in the cells which bind to DNA causing 
damage during DNA replication. In theory, 21 can act as a free radical scavenger and thus ‘mop-
up’ the excess superoxide and free radicals thereby reducing the damage done to the DNA and 
preventing the spread of cancerous cells.
49
  
 
 
 
                                           20 
 
 
     21 
Scheme 1 – The redox activity of ferrocene 
 
The use of ferrocene on its own has not found any medical use, however there are many 
examples of ferrocene hybrid molecules, where the presence of ferrocene greatly enhances the 
activity of the organic component that it is linked to by a covalent bond. A particularly surprising 
example of this success was the tethering of ferrocene to tamoxifen derivatives such as 
hydroxytamoxifen (22, Figure 14).
48
 Tamoxifen, as shown in Figure 14, being an oestrogen 
receptor targeting molecule was found to be active on hormone dependent cancerous 
tumours.
50
 Jaouen and co-workers found that by the replacement of a benzene ring with 
ferrocene to this class of therapeutic agents, resulting in the hybrid, ferrocifen (23), was active 
not just to hormone dependent tumours but also to hormone independent tumours.
51
 
  
22 23 
Figure 14 – Hydroxytamoxifen (22) and its ferrocene-containing derivative ferrocifen (23) 
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1.2.3.3. Zinc-containing Hybrids 
Aside from iron, there has been an increase in the amount of research being put into 
investigating the use of other transition metals in cancer treatment. Zinc is perhaps one of the 
less documented metals, however is of significant importance to this project. Zinc pyrithione (24, 
Figure 15) is a complex originally added to shampoo as an antidandruff agent,
52
 but has 
subsequently been investigated for its anticancer properties. Carraway and Dobner found that 
zinc pyrithione induces necrotic cell death in prostate cancer cell lines.
53
 Liguori et al. also noted 
that their synthesized zinc complexes showed significant anticancer activity in three different 
prostate cancer cell lines, especially in comparison to cisplatin. Two of these complexes (25 and 
26) are shown in Figure 15 and were found to induce apoptosis.
54
 
 
 
 
24 25 26 
Figure 15 – Zinc-containing hybrids 
 
Zinc can easily be incorporated into macrocycles such as porphyrins and phthalocyanines. Zhao et 
al. synthesized a variety of metal-containing porphyrins, such as 27 in Figure 16, that were 
tethered to anthraquinone in order to investigate the DNA intercalating and photocleaving 
abilities of the hybrid. The anthraquinone section serves as a DNA intercalator that shows some 
specificity for cancer cells, while the porphyrin portion is responsible for the photocleavage of 
DNA.
55
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Figure 16 – A zinc-containing porphyrin tethered to anthraquinone 
 
While the previous zinc-containing compounds took advantage of the ability of zinc to bind to 
DNA, zinc also has photoluminescence properties making zinc-containing compounds particularly 
suitable for their use in photodynamic therapy.
56
 Alzeer et al. designed luminescent probes which 
target c-myc, an enzyme that is overexpressed in cancer cells. This involved the coordination of 
zinc to a phthalocyanine with a guanidinium modification such as 28 in Figure 17.
57
   
 
28 
Figure 17 – A photoluminescent zinc-containing porphyrin 
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1.2.3.4. Copper in Chemotherapy 
Arguably one of the best kept secrets in the field of anticancer research is the use of copper-
based compounds. Copper is a transition metal that is naturally occurring in many biological 
systems. Nature takes advantage of its significant redox potential to transfer single electrons by 
cycling copper between its 2+ and 1+ oxidation states.
58
 There are a variety of human enzymes 
that are copper-containing, including amine oxidases (that oxidize primary amines), 
ceruloplasmin and haphaestin (in blood plasma and essential for iron and copper transport), 
cytochrome c oxidase (essential in the mitochondrial respiratory chain), dopamine β-hydroxylase 
(involved in catecholamine metabolism), lysyl oxidase (cross-linking of collagen and elastin and 
keratin), superoxide dismutase (destroys superoxide radicals) and tyrosinase (catalyses pigment 
production) amongst others.
59
 While the reactivity of copper is clearly of great importance, the 
body strictly regulates copper levels to prevent any unwanted redox reactivity. Copper is 
absorbed into the body from the stomach and small intestine and is processed through the liver, 
where excess copper is excreted through bile back into the gut.
60
 While there are several diseases 
associated with significant changes in copper levels (such as Wilsons disease, Menkes disease and 
Alzheimers disease)
60
 a significant amount of research is being done into investigating copper’s 
use in cancer treatment. Cancer cells have been found to contain significantly larger amounts of 
copper than their healthy cell equivalents.
58,61
 This abnormal metabolism process provides 
significant selectivity and is something that could be exploited of for the treatment of cancer. 
The nature of the ligands used has been extensively considered. The coordination of copper to 
the ligand needs to be strong enough to survive physiological conditions to get the copper to its 
active site in the cell, however once there the ligand needs to be labile enough to allow the 
copper to act once in the active site.
61
 Sulfur, nitrogen, oxygen, phosphorus and carbon donor 
atoms have all been considered by a variety of different research groups, however for the 
purposes of this project mainly nitrogen donor ligands will be reviewed. 
Belicchi-Ferrari et al. embraced the metal hybrid concept by building a thiosemicarbazidic tether 
onto a uracil moiety (based on fluorouracil 1) in order to house a copper atom. Following the 
synthesis of the uracil based ligands (such as 29, Figure 18), they synthesized a variety of 
tridentate Cu
2+
 complexes using CuNO3.3H2O and CuCl2.2H2O. While their characterisation of 
these complexes did not include any crystal structures to determine absolute configuration of the 
complexes, they made use of infrared and electronic spectra to propose the coordination 
structure, for example compound 30 (Figure 18). Their study found that both the free ligands and 
the copper complexes showed significant DNA binding. They also found that varying the 
substituent on the end of the thiocarbazidic chain has an effect on the uptake of the compound 
into the cells, but has little effect on the DNA binding ability.
62
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Figure 18 – Examples of uracil based hybrids 
 
Bis(thiosemicarbazone) copper complexes were investigated by Palanimuthu et al. Of particular 
relevance to this project, they investigated both zinc and copper complexes against a variety of 
cancer cell lines. One of the most active complexes in their study was 31 (Figure 19) which 
exhibited growth inhibition (GI50) of 0.17 µM in MCF7 breast cancer cell lines and IC50 values of 
1.45 µM and 1.23 µM in MDA-MB-231 breast and HCT116 colorectal cancer cell lines 
respectively. These values are comparable to that of adriamycin and are also significantly lower 
than its zinc equivalent, which displayed a good GI50 value of 2.27 µM in the MCF7 cancer cell 
line. A variety of other copper analogues also showed significant activity against cancer cell lines 
and after further studies in the HCT116 cell lines these workers concluded that the complexes 
partially intercalate with DNA, preventing further DNA synthesis thus inducing apoptosis.
63
  
 
31 
Figure 19 – Copper-containing bis(thiosemicarbazone) hybrid 
 
The detailed mode of action of copper complexes is still under investigation, but most have been 
shown to induce apoptosis. There are, however, examples where the copper complexes induce 
neither apoptosis nor necrosis, but rather another form of programmed cell death known as 
paraptosis.
58
 Dallavalle et al. investigated copper and palladium coordination complexes for their 
activity against fibrosarcoma (HT1080) and human fibroblast (HF) cancer cell lines. As shown in 
Figure 20, the copper complexes (32 and 33) showed significantly greater activity than the 
palladium complex 34 which was virtually inactive. Complex 32 showed the most promising 
activity overall.
64
 Tardito et al. continued the investigation of 32 that was then shown to have 
comparable activity to cisplatin. Investigation of the mode of action of the complex revealed that 
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it does not induce apoptosis. Instead large cytoplasmic vesicles form, swell and become large, 
coalescent vacuoles, eventually filling the cytoplasmic space with these vacuolar formations. 
After ruling out autophagy as the mode of action and having performed a variety of other tests it 
was concluded that 32 most likely acts by means of paraptosis – thus providing a potential new 
target for apoptosis resistant cell lines.
65
 
 
  
32 33 34 
Figure 20 – Examples of copper coordinated hybrid compounds currently under investigation 
 
A variety of copper-containing compounds were synthesized by Ranford et al. where they 
combined a series of substituted phenanthrolines and salicylates. Depending on the conditions 
the reactants were subjected to, the formation of different complexes was possible. Most of the 
compounds synthesized in this series showed comparable anticancer activity to cisplatin in the 
L1210 leukemic, ADJ/PC6 murine plasmocytoma and CH1 human ovarian cancer cell lines. These 
complexes were also investigated as potential HIV inhibitors, however none of them showed any 
significant activity. Three of the most active metal complexes (35, 36 and 37) are shown in Figure 
21. It is thought that the salicylate ligands are important for the transportation of the complex to 
the nucleus, while the phenanthroline moiety is necessary for DNA intercalation.
66
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Figure 21 – Copper-containing phenanthrolines and salicylates 
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A more complex type of phenanthroline, 2-(naphthalen-1-yl)-1H-imidazo[4,5-
f][1,10]phenanthroline was investigated by Bhat et al. as shown in Figure 22. Of particular 
interest to this study was the fluorescent nature of both the free ligand and the copper 
complexes which were used in fluorescence studies to monitor the activity of the complexes in 
DNA. When tested against MCF7 and HL-60 cancer cell lines, compounds 38 and 39 showed 
significant, selective anticancer activity, with 39 showing better activity (IC50 of 1522 nM) than 
the paclitaxel standard (IC50 of 1635 nM) in the HL-60 cell lines.
67
 
 
38 
 
39 
Figure 22 – Mono (38) and di (39) phenanthroline copper complexes 
 
Pitié and co-workers have done extensive investigations into using bisphenanthroline copper 
complexes in order to oxidatively cleave DNA. Amongst the many notable outcomes of their 
research, they concluded that the bisphenanthroline complexes (such as 40 in Figure 23) that 
were linked by a serinol bridge showed significantly more activity than the unlinked 
counterparts.
68
 Their research was further expanded into the hybrid complex domain by 
tethering a bisphenanthroline copper complex to a cisplatin moiety at the end of the tether (42, 
where n=6 or n=10). Both 40 and 42 were tested to investigate their anticancer ability in 
comparison to cisplatin as well as the bisphenanthroline platinum complex without the presence 
of copper (41). The results of these tests were mixed; in some cell lines 40 showed the most 
notable anticancer activity (in the WIDR, EVSA-T, H226 and IGROV cell lines) while in the A549 
cell line the only compound with any activity of interest was 41 where n=10 (showing greater 
activity than cisplatin). In the M19 cell line, both the n=6 and n=10 complexes of 42 showed 
better activity than cisplatin by a full order of magnitude. Complexes 41 where n = 6 and n = 10 
both showed the most notable activity in the MCF7 breast cancer cell lines.
69
 This study suggests 
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that there is some selectivity in cancer cell lines to different metals and is an important aspect to 
consider in the synthesis of metal-containing hybrid compounds. 
 
 
 
40  41 
 
 
 
 42  
Figure 23 – Copper and platinum-containing phenanthroline compounds 
 
Trávníček et al. investigated how the substitution pattern around a purine ring, the ratio in which 
the ligand and metals are added and the solvent system affected the copper complex formed. In 
this study it was found that the 6-(2-chlorobenzylamino)purine and the 6-(3-
chlorobenzylamino)purine ligands resulted in the formation of different metal complexes such as 
43 and 44 (Figure 24). The complexes formed were tested against mouse melanoma (B16-F0), 
human malignant melanoma (G361), human osteogenic sarcoma (HOS) and human breast cancer 
(MCF7) cell lines, with 43 and 44 showing moderate activity.
70
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44 
Figure 24 – Purine based copper complexes 
 
Figure 25 illustrates another example of DNA intercalating copper complexes by Zhang et al. 
where they investigated the complexation of Cu(ClO4)2 and Zn(ClO4)2 with a novel 1-[3-(2-
pyridyl)pyrazol-1-ylmethyl]naphthalene ligand. Yet again it was found that the copper-containing 
compound (45) showed superior anticancer activity when compared to the zinc complex (46) and 
free ligand when tested against the HL-60, BGC-823 (human stomach) and MDA-MB-435 (human 
breast) cancer cell lines.
71
 
  
45 46 
Figure 25 – Examples of DNA intercalating copper complexes 
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The work on copper-containing complexes mentioned thus far represents a small selection of the 
vast amount of research that has been done. Iakovidis et al. compiled a review of copper in 
medicine.
60
 Santini, Tisato and their co-workers have also published two comprehensive reviews 
on the recent advances in copper-containing complexes as anticancer treatments. In these 
reviews, both Cu(I) and Cu(II) complexes and their coordination geometries are investigated. 
What can be concluded from these reviews is that depending on the nature of the donor ligands, 
the copper complexes can act as DNA intercalators, or generate radical oxygen species (ROS) 
which then degrade the affected cell by inducing apoptosis or inhibiting proteasomes.
60
 There are 
also a few examples where paraptosis has been evident.
65
 The types of donor ligands used 
increase the lipophilicity of the complexes and control where they act. Also highlighted in the 
reviews is the lack of testing in animal models, making it difficult to identify what exactly is 
needed to develop these ‘lead’ copper complexes into marketable drugs.
61
 
 
1.2.3.5. Ruthenium based Hybrids 
One of the ‘hottest’ metals currently under investigation for potential chemotherapy is 
ruthenium. This transition metal is a d
4
 (for a 3+ oxidation state), d
5
 (for the 2+ oxidation state) or 
a d
6
 metal (for the 1+ oxidation state) that is proving to behave rather interestingly in biological 
systems in that its behaviour can be fine-tuned by changing the ligands – and in turn binding – 
around the metal centre. There are numerous examples of ruthenium based anticancer 
metallocenes, arenes, carbonyls and carbenes showing the diversity of ruthenium,
72
 but the most 
successful of these are NAMI-A (47), KP1019 (48) and RAPTA-T (49) as shown in Figure 26. These 
compounds did not show significant in vivo activity, however clinically was found to induce 
apoptosis.
50
 Of particular interest with ruthenium is its significant photoluminescent ability. 
Ruthenium is being investigated extensively for its use in solar cells,
73
 however is also gaining 
interest in photodynamic therapy as a theranostic agent where it can be used both for imaging 
purposes (being UV-active) as well as having anticancer properties itself.
56
 The advantage of this 
type of therapy is that the chemotherapy and contrast agents are combined thus the progression 
of the treatment can easily be monitored without the need for additional contrast compounds 
being added to the patient. 
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Figure 26 – Examples of ruthenium based complexes 
 
1.2.3.6. Other metals under investigation 
Other metals currently being invested for their use in cancer treatment include gold (as 
structural, DNA binding and antimitochondrial functions),
74
 osmium (structural and 
photoluminescence mode of action),
72,75
 titanium (in the form of titanocene),
72
 iridium and 
rhodium (which in their half sandwich form are DNA intercalators as well as show structural 
activity)
72
 and cobalt (in the form of cobalt carbonyls, typically used as a carrier).
72
 While 
platinum, ruthenium, gold and iridium are expensive metals, there is potential for developing 
more active and significantly less expensive chemotherapies by using metals such as iron, zinc 
and copper. This also shows that there is still much to be discovered about hybrid compounds – 
in particular metal-containing hybrids. 
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1.3. Imidazo[1,2-a]pyridines 
 
1.3.1. Synthetic History 
A class of compounds that have sparked interest in the medicinal chemistry field are imidazo[1,2-
a]pyridines (Figure 27). Structurally this ring system is fully aromatic, using the lone pair of 
electrons on nitrogen at position 4 to complete the aromaticity. They show significant biological 
activity, most notably as enzyme inhibitors, receptor ligands and anti-infectious agents.
76
 
Imidazo[1,2-a]pyridines are easily accessible through synthesis and can be customised to suit 
their intended biological function.
77
  
 
Figure 27 – The imidazo[1,2-a]pyridine ring and its numbering 
 
The imidazo[1,2-a]pyridine ring system can be synthesized using a variety of approaches. These 
include condensation reactions (from α-halo, α-diazo and α-tosyloxyketones), tandem reactions 
(coupling 2-aminopyridines and nitroolefins or nitroalkenes), intramolecular C-H amination and 
multicomponent coupling reactions (commonly referred to as MCRs).  A recent review by Bagdi 
et al. details these various approaches.
78
 As the name suggests, multicomponent reactions 
consists of the combination of three or more reagents to form a product in such a way that the 
majority of the atoms of the starting materials can be found in the product. The starting 
materials do not react simultaneously, but as a sequence of reactions, the most favourable of 
which has an irreversible step which drives product formation. MCRs are also one-pot reactions 
that are simple to perform and since they are highly atom economical, can be performed under 
environmentally friendly conditions and generate fairly complex molecules in a single step make 
MCR’s close to being an ‘ideal’ reaction. Using MCRs a wide variety of fairly complex compounds 
can be synthesized easily in essentially a single step.
77
  
Isocyanides have been found to be a particularly useful reagent in MCRs due to their α-acidity 
(which can be increased by the addition of electron-withdrawing groups in the α-position) and 
their ability to form radicals easily. Most importantly though, they react with nucleophiles and 
electrophiles at the isocyanide carbon atom resulting in an α-adduct product (a property only 
shared by carbon monoxide and carbenes).
77
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The first published example of an MCR was reported by Strecker in 1850. Since this discovery, the 
coupling of an amine (51), a carbonyl (50) and a cyanide (hydrogen cyanide, 52, or alkaline metal 
cyanides) to form α-amino-nitriles (53) has been named the Strecker reaction (Scheme 2).
79
  
 
     
 
  
50  51  52  53   
Scheme 2 – The first type of MCR developed by Strecker 
 
Over the years, the Strecker reaction has been modified to prevent the use of hydrogen cyanide 
(which is highly toxic); however, the new conditions meant that strong Lewis-acid catalysts were 
needed. More recently, the Strecker reaction has been further modified to make the reaction 
conditions both less harsh and safer to perform. An example of the more recent Strecker reaction 
is by Martinez et al. and is outlined in Scheme 3.
79
  
 
 
 
   
 
      (92 %) 
Reaction conditions: MeCN, 25 °C, 1-3 h. 
Scheme 3 – A more recent example of the Strecker reaction 
 
Another important type of MCR was discovered by Ugi in 1959.
80
 Now commonly referred to as 
U-4CR, the reaction consists of four components; a primary amine, an aldehyde or ketone, an 
isocyanide and a carboxylic acid, which react to form an α-amino acylamide. Scheme 4 shows a 
simplified mechanism of the U-MCR, where the oxo component (54) and the amine (51) 
condense, via a hydroxyl aminal, to form the imine, (55, a Schiff base). While the formation of the 
Schiff base is not always necessary, the reaction works better if the base is activated. The 
activation occurs where the carboxylic acid (56) protonates the nitrogen atom of the Schiff base 
resulting in 57, which increases the electrophilicity of the C=N bond. From there, the protonated 
imine and the nucleophilic acid anion (57) react with the isocyanide carbon atom (58) resulting in 
59, the α-adduct product. The stable Ugi product is obtained from an intramolecular acylation 
from a hydroxylamine to the more stable amide rearrangement, 60.
77
  
 At the end of my tether  
 Introduction  
 
31 
 
 
 
    
 
 54  51  55  
  
 
 
 
  56  57 
 
 
 
 
 
 
 
   58  59  
  
 
 
  60  
Scheme 4 – The Ugi multicomponent coupling reaction 
 
The first important application of this was the single step synthesis of the anaesthetic 
xylocain (also referred to as lidocaine), 64 shown in Scheme 5, from 2,6-dimethylphenyl 
isocyanide (61), formaldehyde (62) and diethylamine (63). The reaction was performed in 
methanol with sodium formate (being a substitute for the carboxylic acid and not 
incorporated into the final structure).77 
 
 
 
 
 
 
 
61  62  63  64 
Reaction conditions: HCOONa, MeOH, reflux. 
Scheme 5 – The MCR synthesis of xylocain (64) 
 
Of interest for this PhD project is the Groebke-Blackburn-Bienaymé multicomponent reaction. 
Groebke and co-workers first published a novel one-pot synthesis of imidazo-annulated 
pyridines, pyrazines and pyrimidines in 1998. The Groebke-Blackburn-Bienaymé reaction involves 
the reaction of amino-pyridines, amino-pyrazines and amino-pyrimidines with aldehydes and 
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isocyanides. An example of the Groebke-Blackburn-Bienaymé reaction with amino pyridines is 
outlined in Scheme 6.
81
  
 
 
 
 
 
 
 
      (54 %) 
Reaction conditions: AcOH (1-2eq), MeOH, rt, 18 h. 
Scheme 6 – An example of the Groebke-Blackburn-Bienaymé multicomponent coupling 
reaction 
 
Groebke also proposed a mechanism for the assembly of imidazo[1,2-a]pyridines which is shown 
in Scheme 7. In a similar manner, imidazo[1,2-a]pryazines and imidazo[1,2-a]pyrimidines can be 
formed from 2-aminopryazines and 2-aminopyrimidines respectively.
81
  
 
Scheme 7 – Proposed mechanism for the Groebke-Blackburn-Bienaymé MCC reaction 
 
Following this initial synthesis, these compounds have been investigated for a host of potential 
biological applications. Published examples relevant to this project include those by Geuiffer et 
al. who investigated the use of imidazo[1,2-a]pyridines for treatment of cytomegalovirus and 
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varicella zoster virus which is especially dangerous in new-born babies and immune-supressed 
patients. They reported the formation of imidazo[1,2-a]pyridine 66 from the condensation of a 2-
aminopyridine derivative (65) with an R-halogenocarbonyl compound (such as 
bromoacetaldehyde, chloroacetone or phenacyl bromide) in ethanol (a general scheme for the 
reactions investigated is shown in Scheme 8).
76
 
 
 
 
 
 
 
 
 65    66  
Reaction conditions: EtOH, reflux, 4 h. 
Scheme 8 – An alternative one pot synthesis of imidazo[1,2-a]pyridines 
 
1.3.2. Biological applications and further development 
Given the significant biological activity exhibited by these compounds, it is not surprising that 
some imidazo[1,2-a]pyridines have been developed into commercially available drugs. Figure 28 
below shows a selection of currently available drugs that are used to treat anxiety (67, 68 and 
69),
82,83
 insomnia (70),
82
 peptic ulcers (71),
84
 acute heart failure (72)
85
 and potentially to treat HIV 
(GSK812397, 73).
86
 It is interesting to note is that these compounds are mostly substituted with 
aryl groups at C-2, amide type chains at C-3 and that if there are any other substituents, they are 
typically at C-6. This could be an important biological feature to consider when designing new 
imidazo[1,2-a]pyridine drugs. 
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70 71 
 
 
72 73 
Figure 28 – Commercially available imidazo[1,2-a]pyridines 
 
Rousseau et al. also made use of the Groebke-Blackburn-Bienaymé MCR in their synthesis of 
imidazo[1,2-a]pyridines.
87
 They reported that the conventional catalyst, scandium(III) triflate,
88  
could be replaced with zinc(II) chloride or Montmorillonite K10 clay,
89
 both of which are 
significantly more affordable than scandium(III) triflate. They did note, however, that zinc(II) 
chloride was not suitable for use with aminated aldehydes as the zinc forms stable complexes 
with the imine intermediate. Also investigated was the use of microwave irradiation to perform 
the MCR instead of utilizing conventional reflux reactions.
87
 
This was not the first mention of using microwave irradiation to perform one-pot MCR’s. Ireland 
et al. performed Ugi-type MCR’s under microwave conditions using scandium(III) triflate in 
methanol, an example of which is given in Scheme 9.
90
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(72 %) 
           Reaction conditions: Sc(OTf)3,(5 mol % eq), MeOH, microwave, 200 W, 160 °C, 10 min. 
Scheme 9 – Groebke-Blackburn-Bienaymé MCR using scandium(III) triflate in methanol 
 
The Groebke-Blackburn-Bienaymé MCC reaction has also been investigated in our laboratory at 
the University of the Witwatersrand. A series of 6-substituted imidazo[1,2-a]pyridines were 
synthesized from 6-substituted 2-aminopyridines, substituted benzaldehydes and commercially 
available isocyanides in dioxane using Montmorillonite K10 clay as a catalyst. Scheme 10 outlines 
the general synthesis previously employed in our labs.
91
 
 
 
 
 
 
 
 
R1 = NO2, Br, Me or H 
R2 = 2,4-dihydroxy, 3,4-dimethoxy, 2,5-dimethoxy, 3,4-dibenzoxy, 2,4-dimethoxy 
R3 = cyclohexyl, xylyl or benzyl 
Reaction conditions: Montmorillonite K10 clay (1 mass eq), dioxane, reflux, 4-18 h. 
Scheme 10 – General synthesis for the imidazo[1,2-a]pyridines previously investigated in our 
laboratory 
 
Of importance to this PhD, was that a number of imidazo[1,2-a]pyridines synthesized previously 
in our labs showed good activity against colon cancer cell lines HT-29 (IC50 = 6.6-22.0 µM) and 
Caco-2 (IC50 = 6.4-20.3 µM). Additionally these compounds showed little toxicity towards white 
blood cells ‒ significantly better than camptothecin which it was compared to. This made these 
compounds of particular interest and their activity was described in a Full Patent Specification 
(PCT Int. Appl. (2010), WO 2010116302 A1 20101014).
92
 Further biological assays showed that 
the imidazo[1,2-a]pyridines trigger the process of apoptosis in the cancer cell lines HT-29 and 
Caco-2, causing the cancerous cells to die thus preventing the spread of the cancerous DNA 
mutations as well as destroying the cancer cells.
91
 This suggested that further development of 
these novel 6-substituted imidazo[1,2-a]pyridines may lead to compounds that could be used as 
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potential anticancer agents and reduce the resistance to current chemotherapeutic regimens of 
the colorectal cancer cells.  
Also noted in this study was that if there was a bromine substituent on the synthesized 
imidazo[1,2-a]pyridine ring, it provided a potential handle to further functionalise the ring by 
making use of Suzuki-Miyaura cross coupling with boronic acids as shown in Scheme 11 below. 
Making use of microwave irradiation, 74 was coupled to a simple phenyl boronic acid resulting in 
imidazo[1,2-a]pyridine 75. It was found that this particular substituent change did not have a 
significant effect on the activity of the compound, with compounds 74 (HT-29 IC50 = 7 ± 2 µM and 
Caco 2 IC50 = 6 ± 1 µM) and 75 (HT-29 IC50 = 9 ± 1 µM and Caco 2 IC50 = 9 ± 1 µM) showing 
comparable IC50 values.
91
 
 
 
 
74  75 (95 %) 
Reaction conditions: Pd(PPh3)4 (10 mol % eq), PhB(OH)2 (1eq), CsF (2.5 eq), DME, microwave, 150 °C, 150 W, 
20 min. 
Scheme 11 – Suzuki-Miyaura coupling reaction to functionalise the imidazo[1,2-a]pyridine at 
the 6-position 
 
The idea of functionalising the imidazo[1,2-a]pyridine was not novel. Odell et al. reported 
functionalization of the 6-position on imidazo[1,2-a]pyridines in their attempt to develop better 
M. tuberculosis glutamine synthetase (MtGS) inhibitors. They investigated Suzuki-Miyaura 
reactions using brominated imidazo[1,2-a]pyridines with various boronic acids (Scheme 12A) as 
well as converting the imidazo[1,2-a]pyridines into boronic acids and reacting them with benzyl 
bromides (Scheme 12B). These reactions were performed using microwave conditions. Although 
they did not successfully generate more active MtGS inhibitors, it is an example of functionalised 
imidazo[1,2-a]pyridines.
93
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 A  
 
 
 
 B  
Reaction conditions: i) Ph(B(OH)3 (3 eq), Pd(PPh3)4 (7 mol %), Cs2CO3 (3.5 eq), DMF, microwave, 120 °C, 20 min; ii) 
benzyl bromide (0.8 eq), Pd(dppf)Cl2 (10 mol %), K2CO3 (3 eq), EtOH, H2O, microwave, 130 °C, 30 min. 
Scheme 12 – An example where the imidazo[1,2-a]pyridine was functionalised using boronic 
acids (A) as well as where it can be made into a boronic acid (B)  
 
Di Mauro and Kennedy made use of an interesting one pot microwave-assisted four-component 
coupling. They investigated the synthesis of substituted imidazo[1,2-a]pyridine-type boronic 
acids using microwave irradiation and then performing Suzuki-coupling with aromatic bromides 
in the same reaction vessel, an example of which is shown in Scheme 13. The remarkable stability 
of the pinacol ester was noted, even under the harsh conditions experienced in a microwave. 
With ethanol or methanol as the solvent, magnesium chloride was used as the catalyst in the 
Groebke-Blackburn-Bienaymé reaction (Scheme 13) while the Suzuki-Miyaura reaction was 
catalysed by [1,1’-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (Pd(dppf)Cl2) instead of 
the traditionally used tetrakis (Pd(PPh3)4).
94
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Reaction conditions: i) MgCl2 (4 mol %), MeOH, microwave, 160 °C, 10 min; ii) aq K2CO3, Pd(dppf)Cl2 (10 mol 
%), microwave, 90 °C, 30 min. 
Scheme 13 – An aminopyridine-containing boronic acid in the MCR (i) and then it being used in 
a Suzuki-Miyaura coupling reaction (ii) 
 
A recent review on metal-catalysed functionalization of imidazo[1,2-a]pyridines highlights a 
variety of different possibilities for further functionalization. These include well known palladium 
catalysed reactions such as Heck, Sonogashira and Suzuki-Miyaura cross coupling reactions, Stille 
cross coupling reactions, copper mediated Buchwald reactions and arylation reactions amongst 
others.
95
 This suggests that there are numerous approaches that could be used to install a variety 
of different functionalities onto the imidazo[1,2-a]pyridine post ring formation. There are two 
main advantages to this in that firstly it allows for a much larger library of compounds to be 
synthesized with the aim of investigating small libraries for biological activity. Secondly, of 
interest to this project was that it provides a unique opportunity to build a tether/linker onto the 
ring which could potentially be used to form hybrid type compounds. 
 
1.3.3. Metal imidazo[1,2-a]pyridine complexes 
A relatively unexplored feature of the imidazo[1,2-a]pyridines is the potential reactivity of the 
free lone pair on nitrogen 1 (see Figure 29). This aspect of the imidazo[1,2-a]pyridines is of 
significance to this project and there are only a handful of reports of metal coordination to this 
nitrogen, most of these investigated for their potential use in new materials rather than for 
medicinal properties. 
Forniés et al. were amongst some of the first to report the synthesis of a metal-imidazo[1,2-
a]pyridine complex. They reported the synthesis of several platinum imidazo[1,2-a]pyridine 
complexes (such as 76, 77 and 78 in Figure 29) in order to study their luminescence properties for 
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potential applications in materials chemistry. Only compounds 77 and 78 showed significant 
luminescence and perhaps more interestingly, 77 shows luminescent thermochromism; 
phosphorescing green at 77 K but orange-red at 298 K.
96
 
  
 
76 77 78 
Figure 29 – Platinum-containing imidazo[1,2-a]pyridines 
 
Another early example of metal-imidazo[1,2-a]pyridine complexes was provided by Yong et al. 
where they synthesized a zinc coordination polymer with imidazo[1,2-a]pyridines (such as Figure 
30). This polymer showed significant antiferromagnetic coupling between the radicals and red-
yellow-green fluorescence emission that could be taken advantage of in LED’s or as part of an 
electroluminescence device.
97
 This was later expanded to include cobalt derivatives as well as to 
vary the counter ion and incorporate a 1,4-benzenedicarboxylate coordination in the polymer. 
The cobalt derivatives showing a change in magnetic phase transition at 344 K.
98
 
 
Figure 30 – An example of a zinc-imidazo[1,2-a]pyridine polymer 
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Liu et al. investigated zinc and nickel coordinative metal imidazo[1,2-a]pyridine polymers in a 
similar manner to Yong et al. They incorporated 1,3-benzenedicarbonate and 1,3,5-
benzenetricarbonate into the polymers in addition to the 1,4-benzenedicarbonate used by Yong 
et al. Resulting from this study was that reaction temperature influenced the type of polymer 
formed and that the zinc compounds also showed fluorescent properties.
99
  
A computational and crystallographic study by Malecki compared the coordination energies of 79 
(Figure 31) to 80. They found that the donation of the ligands to the Pd(II) was greater than the 
back donations from the metal to the ligand. Complex 80 was also calculated to be a stronger 
ligand than 79, and 79 not exhibiting any fluorescent properties.
100
  
  
79 80 
Figure 31 – Palladium-containing imidazo[1,2-a]pyridine and imidazole derivatives 
 
An unusual reported application of metal imidazo[1,2-a]pyridine coordination complexes was 
reported by Li et al. where they synthesized ruthenium(II) based complexes to be used as 
catalysts for the transfer hydrogenation of ketones. After synthesising imidazo[1,2-a]pyridine 81, 
they formed a neutral catalyst, 82 as well as a charged catalyst, 83 (Figure 32). Catalyst 83 was 
found to be the most efficient catalyst, where a variety of ketones could be reduced to secondary 
alcohols by refluxing them in isopropyl alcohol with a 0.1 mol % catalyst loading.
101
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81 82 
 
83 
Figure 32 – Examples of ruthenium-containing imidazo[1,2-a]pyridines 
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1.4. Project Introduction 
The broad aim of this project was to improve and develop the novel imidazo[1,2-a]pyridine 
derivatives synthesized in our laboratories that showed good activity against cancer cell lines, 
while attempting to inflict as little damage to healthy cells as possible.  
The imidazo[1,2-a]pyridines previously investigated had substituents at the 2 and 3 positions, 
with most also having substituents at the 6-position. All the compounds had aromatic 
substituents at the 2-position while the 3-position typically contained xylylamine or 
cyclohexylamine substituents. The most biologically active imidazo[1,2-a]pyridines from the 
previous study in our laboratory were 84 and 75 (Figure 33), with IC50 values of 6.57 ± 1.91 and 
8.56 ± 1.22 µM, respectively, against HT-29 colorectal cells and 6.43 ± 1.01 and 8.73 ± 1.28 µM, 
respectively, against Caco-2 colorectal cancer cells.
91
 
 
 
84 75 
Figure 33 – Examples of imidazo[1,2-a]pyridines synthesized by de Koning and co-workers 
 
This project aimed at expanding the compound library tested against the colorectal cell lines to 
determine if there is some selectivity of these compounds towards cancer cell lines. The first aim 
of this research was to use the Groebke-Blackburn-Bienaymé MCC synthetic methodology used 
previously
91
 to generate an expanded library, optimizing the reaction conditions and purification 
protocol.  
Given the lack of research into the synthesis of metal imidazo[1,2-a]pyridine complexes, 
particularly for biological applications, in this project a second major aim was to develop methods 
for synthesis of such compounds with a variety of different metals, such as platinum, zinc and 
copper. The approach proposed was to form a new “hybrid” molecule containing both an active 
imidazo[1,2-a]pyridine ring as well as an active metal centre. There have been few reports of the 
preparation of bifunctional hybrid compounds containing platinum-based molecules as 
anticancer drugs,
47
 however it has not been satisfactorily explored. It is this area of research we 
proposed to explore by combining our anticancer imidazo[1,2-a]pyridines with metal-containing 
compounds (e.g. cisplatin) to form the bifunctional hybrid adducts. Finally, a third aim, also of 
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interest to this project was to see if metals other than platinum can improve the activity of the 
imidazo[1,2-a]pyridines not just for colorectal cancer, but other cancer cell lines (such as breast 
cancer and leukemia) where traditional metal-based chemotherapies are lacking.  
While there has been some research done on investigating the synthesis of metals coordinated to 
imidazo[1,2-a]pyridines, the examples are limited to platinum,
96
 zinc
102
 and nickel.
99
 To the best 
of our knowledge, there are no reported platinum complexes of imidazo[1,2-a]pyridines 
specifically as anticancer agents, or other reported metal hybrid imidazo[1,2-a]pyridines that 
exhibit anticancer properties.  
Of key importance to this project was to establish if the formation of these hybrid molecules 
would result in lower toxic side effects as compared to traditional platinum derived drugs for 
anticancer treatment.  
From a chemistry standpoint, two approaches were considered in this project. The first was to 
take advantage of the free lone pair of electrons on the N1 of the imidazo[1,2-a]pyridine ring and 
coordinate the metal directly to the imidazo[1,2-a]pyridine core. The second approach was to 
investigate methods for adding a tether to the imidazo[1,2-a]pyridines and coordinate the metal 
to the tether compounds. To the best of our knowledge, there have been only a few reports to 
modify the imidazo[1,2-a]pyridine structure,
93,94
 and no examples of these modifications to be 
used as tethers. 
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At the end of my tether: 
Results and Discussion 
2.1. Synthesis and development of imidazo[1,2-a]pyridine 
library 
The research done by de Koning and co-workers was limited in scope with a small library of 
compounds, making it impossible to determine any structure-activity relationships.
91
 Also 
considering that the exact target of these compounds was unknown, a larger library of 
compounds needed to be synthesized and investigated in order to draw any conclusions about 
structure-activity relationships. We determined that there were three main substituent areas 
that could be varied (shown in Figure 34) – the R1 substituent resulting from the 2-aminopyridine, 
the R2 substituent derived from the aldehyde and the R3 from the isocyanide used.  
 
Figure 34 – The three main areas for modification of the imidazo[1,2-a]pyridine nucleus 
 
Nearly all of the compounds in the previous study contained a R1-substituent in the 6-position on 
the imidazo[1,2-a]pyridine ring (See Figure 27). Thus the first series of imidazo[1,2-a]pyridines 
investigated in this PhD also needed to contain a substituent in this 6-position and the focus was 
placed on varying the substituents at the R2 and R3 positions. A bromide substituent at this 6-
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position was settled on largely because it could later be modified utilizing well-known chemical 
reactions. Using the methodology outlined by de Koning and co-workers, commercially available 
5-bromo-2-aminopyridine was refluxed in dioxane with other commercially available isocyanides 
and aldehydes with Montmorillonite K10 clay as a catalyst, a library of imidazo[1,2-a]pyridines 
was synthesized. Figure 35 shows the compounds synthesized using this methodology along with 
their corresponding yields. 
  
 
85 (59 %) 86 (26 %) 87 (73 %) 
 
  
88 (41 %) 89 (70 %) 90 (53 %) 
  
91 (35 %) 92 (38 %) 
Figure 35 – The first series of imidazo[1,2-a]pyridines synthesized (85 - 92) 
 
Recently it has been shown that the addition of adamantyl substituents to biologically active 
molecules notably improves the overall activity of the compound.
103
 With this in mind we 
decided to introduce an adamantyl moiety onto the imidazo[1,2-a]pyridine nucleus. The simplest 
strategy to do so would be from the R3 substituent stemming from adamantyl isocyanide. While 
adamantyl isocyanide is commercially available, its high cost led to us synthesising it from 
adamantylamine (discussed later). Once synthesized it was used in the Groebke-Blackburn-
Bienaymé multicomponent coupling reaction to result in imidazo[1,2-a]pyridine 93 in an 
excellent yield of 93% as shown in Figure 36 below. 
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93 (93 %) 
Figure 36 – An adamantane-containing imidazo[1,2-a]pyridine (93) 
 
Filtering all of the reaction mixtures directly through a Celite/flash silica gel plug in a glass frit 
funnel was found to successfully remove both the K10 clay as well as most of the dark brown 
sticky by-product that formed during the course of the reaction. After concentration in vacuo 
most of the resulting products solidified. All of the compounds except 91 were purified by 
recrystallization from an appropriate solvent. Compound 91 was a liquid and so was purified by 
means of column chromatography as the reaction was performed on a much smaller scale. 
Compound 93 was also purified by column chromatography. The varying yields obtained are 
unfortunately characteristic of this reaction. Throughout literature it has been noted that the 
yields are notoriously unpredictable and substrate and catalyst dependant.
87
 
NMR spectroscopic analysis of these compounds revealed characteristic imidazo[1,2-a]pyridine 
signals for each of the compounds in Figure 35 and Figure 36. The absence of any aldehyde 
signals and the presence of N-H signals along with the relevant substituent peaks confirmed the 
structure of these compounds. Of particular interest to highlight is the 
13
C NMR spectral shift of 
the bromine substituted C6 at approximately 106 ppm; the presence of bromine in the 
imidazo[1,2-a]pyridines was also confirmed by the characteristic bromine isotopes (
79
Br and 
81
Br) 
in the HRMS spectra. A few unusual splitting patterns were noted, one of which is the coupling of 
the amine N-H proton for certain compounds (85, 88, 90 and 92) to the methine C-H on the 
cyclohexyl ring.  
During the recrystallization process it was noted that large volumes of boiling solvent were 
required to completely dissolve the compounds. Once dissolved, the solvent volume was then 
greatly reduced before the solution reached saturation point and compounds could crystallize 
out of solution. This suggested that strong intra- and intermolecular bonding existed between the 
molecules. Single Crystal X-ray Crystallography (SCXRD) was then used to investigate how 
selected compounds behaved in the solid state to try to rationalise what was seen in the 
laboratory.  
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Interestingly, during the recrystallization of 85 both block and needle crystals were isolated from 
the recrystallization. NMR spectroscopic analysis of these compounds did not show a significant 
difference, bar the presence of what appeared to be a small water signal in the 
1
H NMR spectrum 
in the block crystals. From SCXRD it was discovered that the block crystals formed a hydrate 
crystal, where a water molecule was hydrogen bonded to 85 through O3w―H3b∙∙∙N1 (d = 1.97 Å) 
and C11―H11∙∙∙O3w (d = 2.56 Å) as shown in Figure 37A. Of additional importance in this 
structure is the presence of an intramolecular hydrogen bond, C15―H15∙∙∙N24 (d = 2.62 Å). In 
contrast, Figure 37B shows the crystal structure for the needles collected. This structure only 
contains the intramolecular C11―H11∙∙∙N24 hydrogen bond (d = 2.48 Å). This distance is shorter 
than that of the hydrate and suggests that this particular hydrogen bond is weakened slightly 
when the molecule is involved in hydrogen bonding elsewhere in the molecule. 
 
 
A B 
Figure 37 – The asymmetric units of the block and needle crystals of 85 
 
The crystal structure of imidazo[1,2-a]pyridine 89 showed hydrogen bonding between 
N24―H24∙∙∙O1 (d = 2.19 Å). In Figure 37A and B the imidazo[1,2-a]pyridine core and the aryl R2 
substituent were in the same plane allowing for π stacking in the unit cell. As can be seen in  
Figure 38, however, there is a torsion angle of 42.7(1)° between the imidazo[1,2-a]pyridine ring 
and the R2 aryl substituent in 89 which prevents any π stacking. Most likely this is the reason that 
89 shows better solubility than that of 85 in organic solvents. 
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Figure 38 – The asymmetric unit of 89 
 
Looking at a considerably different imidazo[1,2-a]pyridine, 90 in Figure 39, the only 
intramolecular hydrogen bonding occurs between C17―H17a∙∙∙F1 (d = 2.55 Å). The imidazo[1,2-
a]pyridine ring and the R2 fluorinated aryl group are at an angle of 107.3(1)° to each other. This is 
most likely attributed to the bulky nature of the CF3 group and consequently prevents significant 
π stacking from occurring, making the imidazo[1,2-a]pyridine the most soluble of all. 
 
Figure 39 – The asymmetric unit of 90 
 
Naturally we also needed to investigate compounds with in positions other than 6, as well as 
compounds without any R1 substituents. In order to address this, the first series was expanded by 
synthesizing imidazo[1,2-a]pyridines from commercially available 2-aminopyridine, 2-amino-6-
bromopyridine and 2-amino-3-bromopyridine. Completely removing the bromine atom from the 
molecule was not favourable as it would prevent further modification post imidazo[1,2-
a]pyridine formation. For this reason moving the bromine atom to a position on the R2 aryl 
substituent was also investigated. Making use of bromobenzaldehyde derivatives allows this 
feature to be retained. The next series of compounds and yields are shown in Figure 40. 
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94 (73 %) 95 (40 %) 96 (75 %) 
  
 
97 (62 %) 98 (66 %) 99 (40 %) 
  
 
100 (59 %) 101 (37%) 102 (53 %) 
Figure 40 – Imidazo[1,2-a]pyridines varying the R1 substituent (94 - 102) 
 
It is quite evident that the yields for many of the reactions were unsatisfactory, especially if these 
compounds were to be used in a further series of reactions. In an attempt to increase the yields 
of the reactions the products were purified by column chromatography to determine if the low 
yields were a result of the recrystallization process. Unfortunately, the method of purification did 
not appear to have an effect on the yield. While many articles have also noted the 
unpredictability of yields, the type of solvent used has been shown to have an effect. In order to 
investigate this, the synthesis of 102 was repeated using water and ethanol. Results from this are 
shown in Table 1 where it was noted that using ethanol resulted in the best yield and additionally 
the reaction was found to be much cleaner and easier to recrystallize. All further reactions were 
then carried out in this solvent system. 
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Table 1 – Resulting yields from varying the solvent in the formation of 102  
Solvent Yield 
Dioxane 53 % 
Ethanol 63 % 
Water 50 % 
 
The structures of the compounds in Figure 40 were again confirmed largely by NMR spectral 
analysis. Characteristic imidazo[1,2-a]pyridine signals were observed for these compounds, the 
1
H and 
13
C NMR spectral signals shifted appropriately with the variation in the position of the 
bromine substitution. In compounds 95, 96, 97, 98 and 101 the N-H signals were observed as 
doublets, suggesting that the N-H couples to the methine C-H on the cyclohexyl ring. High 
resolution ESI-MS again revealed the presence of bromine on these molecules showing the 
characteristic isotopic peaks. 
The crystallization of 102 from ether resulted in the formation of block crystals which were 
analysed using SCXRD. Figure 41 shows that in this structure there are no intramolecular 
hydrogen bonds. However, in the unit cell there is intermolecular hydrogen bonding between 
C15―H15∙∙∙N1 (d = 2.66 Å) and N20―H20∙∙∙N-1 (d = 2.47 Å). This compound was significantly 
more soluble than those described in Figure 35, and the lack of notable intramolecular bonding 
interactions seen in Figure 41 may account for this change in solubility. 
 
Figure 41 – The asymmetric unit of 102  
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2.2. Attempts at modification of the imidazo[1,2-a]pyridine 
In order to use these imidazo[1,2-a]pyridines as part of a hybrid molecule, we envisaged that a 
tether needed to be added to the imidazo[1,2-a]pyridine in order to house the platinum (or 
another metal) atom. The ‘house’ would need to consist of atoms that would favour metal 
chelation – such as oxygen or nitrogen atoms – and these atoms arranged in a manner that 
would allow for favourable geometry once coordinated. The ‘house’ would be linked to the 
imidazo[1,2-a]pyridine by a carbon linker of different chain lengths and this linker could be 
attached using a variety of different reactions. We believed the best type of ‘house’ to introduce 
would be a 1,3-diol or a 1,3-diamine.  
The most convenient way to introduce the 1,3-diol or the 1,3-diamine was by reduction of a 
diethyl malonate or malononitrile derivative. While in some instances the diethyl malonate and 
malononitrile could be used directly, the 1,3-dicarbonyl needed to be functionalised further to 
include an alkene. Using a procedure by Ahmed et al., the diethyl malonate was converted into 
diethyl 2-allylmalonate (103) after the addition of sodium hydride and allyl bromide as outlined in 
Scheme 14.
104
 Unfortunately, 103 was found to polymerise easily and so had to be freshly 
prepared and distilled right before use in further reactions. 
 
 
  
 
    103 (67 %) 
Reaction conditions: NaH (1.1 eq), allylbromide (1.5 eq), THF, 0 °C. 
Scheme 14 – Synthesis of tether 103 
 
1
H and 
13
C NMR spectroscopy was used to confirm the formation of compound 103, where 
extensive coupling resulted in complicated spectra. Distinctive ethoxy signals were observed at 
approximately 4.2 ppm (OCH2) and 1.2 ppm (CH3) in the 
1
H NMR spectrum as well as 61 ppm 
(OCH2) and 14.12 ppm (CH3), respectively, in the 
13
C NMR spectrum. The presence of an ester 
carbonyl signal was also observed at 169 ppm. Typical ester-type stretches were also noted on 
the IR spectrum at 1730 and 1643 cm
-1
. 
We attempted to synthesize 2-allylmalononitrile (104 in Figure 42) using a similar procedure, 
however none of 104 was isolated, instead the diallylmalononitrile (105 in Figure 42) formed 
even when reducing the reaction time and the equivalents of NaH added.  
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104 105 
Figure 42 – 2-allylmalononitrile (104) and diallylmalononitrile (105) 
 
2.2.1. Using the Suzuki-Miyaura Cross Coupling Reaction to build the 
tether 
At the commencement of this project, there was little literature supporting modifications being 
made to an imidazo[1,2-a]pyridine ring after synthesis. One of these was reported by de Koning 
and co-workers, using Suzuki-Miyaura cross coupling to introduce a phenyl substituent at the 6-
position.
91
 This concept was expanded upon during this PhD, where substitutions were made at 
the bromine on the imidazo[1,2-a]pyridines with a variety of commercially available boronic 
acids. The use of substituted phenylboronic acids provides the addition of functional groups that 
could be further be built upon. 
Suzuki-Miyaura cross coupling reactions have been used extensively in our laboratories, and 
reliable methods for both conventional and microwave synthesis have been developed.
105
 Using 
microwave irradiation, the Suzuki-Miyaura coupling reaction was performed on the relevant 
imidazo[1,2-a]pyridines using catalytic amounts of Pd(PPh3)4 in dimethoxyethane (DME) using 
cesium fluoride (CsF) as the base. Reaction conditions were typically 150 °C at 120 Watts for 15-
20 minutes. While this is a quick and easy method it is limited by the scale of the reaction (only 
applicable for reactions on a 100-300 mg scale). Conventionally, the reactions were performed 
under inert reflux conditions with catalytic Pd(PPh3)4 and 2M Na2CO3 in DME overnight. 
The first boronic acid of interest was 3-vinylphenylboronic acid which was conducted using 
microwave conditions. Using two different imidazo[1,2-a]pyridines, the reactions were highly 
successful in yields of 97 % for 106 and 82 % for 107 (Scheme 15). Spectroscopically, the aromatic 
region was found to be significantly more complicated than for the starting materials, with the 
addition of 4 more aromatic protons. In addition to this, the most significant changes on the 
1
H 
NMR spectrum were the appearance of the three alkene protons at 6.81, 5.79-5.91 and 5.33 ppm 
for 106 and 6.80, 5.84 and 5.32 ppm for 107. Similarly the presence of 6 additional aromatic 
carbon signals on the 
13
C NMR spectrum further indicated the presence of the vinyl phenyl group 
as well as the alkene carbon signals at 114.75 and 136.70 ppm for 106 and 114.57 and 136.59 
ppm for 107. 
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85  106 (97 %) 
A 
 
 
 
89  107 (82 %) 
B 
Reaction conditions: 3-vinylphenyboronic acid (1.5 eq), CsF (2.5 eq), Pd(PPh3)4 (10 mol %), DME, 150 °C, 150 
W, 20 min. 
Scheme 15 – Suzuki-Miyaura cross coupling reactions to form 106 (A) and 107 (B) 
 
Attaching 3-vinylphenylboronic acid to the imidazo[1,2-a]pyridine ring allowed for the addition of 
a terminal alkene that could then be reacted with 103 by means of cross metathesis using the 
Grubs II catalyst. An example of what we hoped to achieve is outlined in Scheme 16, but 
unfortunately these reactions were unsuccessful, despite extensive investigation. 
 
 
 
106   
Reaction conditions: 103 (2 eq), Grubbs II (5-15 mol %), toluene or DCM or DCE, reflux, 24 h; 103 (2 eq), 
Hoveyda Grubbs (10 mol %), toluene, 24 h. 
Scheme 16 – An example of the cross metathesis attempted during this project 
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Given the failure of cross metathesis to occur on the already formed imidazo[1,2-a]pyridine, 
cross metathesis was attempted on the aldehyde precursor for the reaction. The Suzuki-Miyaura 
coupling reaction of 2-vinylphenyl boronic acid with 3-bromobenzaldehyde was successful, 
however the product was not isolated due to the compound rapidly polymerizing once purified.  
Since the cross metathesis attempts were unsuccessful, another approach needed to be sought. 
The next attempt was made by using 2- and 4-formylphenylboronic acid.  Substitution at the 6-
position (Scheme 17A) as well as on the bromophenyl substituent at the 2-position (Scheme 17, B 
and C) were investigated for these reactions. Conventional methods were used for the synthesis 
of 108, which, after purification by column chromatography, was afforded in a quantitative yield. 
Both 109 and 110 were also synthesized using conventional heating methods and obtained in 
excellent yields.  
Characterisation of these compounds was done spectroscopically, with an increase of 4 aromatic 
signals being observed in the 
1
H and 
13
C NMR spectra. Also evident are the aldehyde protons at 
10.09 (108), 10.04 (109) and 10.03 (110) ppm in the 
1
H NMR spectrum and the aldehyde carbonyl 
signal at 191.5 (108), 192.5 (109) and 191.9 (110) ppm in the 
13
C NMR spectrum. This was further 
supported by the presence of carbonyl stretches for each compound on the IR spectra; 1691 cm
-1
 
on compound 108, 1681 cm
-1
 on 109 and 1711 cm
-1
 on compound 110. 
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85  108 (99 %) 
A 
 
 
 
102  109 (99 %) 
B 
 
 
 
102  110 (87 %) 
C 
Reaction conditions: 2- or 4-formylphenyboronic acid (1.5 eq), 2M Na2CO3 (5 eq), Pd(PPh3)4 (10 mol %), DME 
reflux, 18 h. 
Scheme 17 – Suzuki-Miyaura cross coupling reactions performed using conventional methods 
 
The structure of aldehyde 108 was also confirmed by SCXRD (Figure 43), where an intramolecular 
C11―H11∙∙∙N18 hydrogen bond (d = 2.56 Å) as well as an intermolecular N18―H18∙∙∙O1 
hydrogen bond (d = 2.31 Å) was noted. The imidazo[1,2-a]pyridine ring and the dimethoxyphenyl 
substituent at the R2 position are arranged in a similar plane (at an angle of 19.3(1)° to each 
other) while the formylphenyl C6 substituent is twisted at 52.3(1)° to the main ring structure. The 
torsion in this molecule prevents π stacking and probably as a consequence of this the general 
solubility of 108 was vastly improved in comparison to the starting material, 85.  
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Figure 43 – The asymmetric unit of 108 
 
Diethyl malonate and malononitrile could then be reacted with the benzaldehyde substituent of 
109 by means of a Knoevenagel condensation as shown in Scheme 18A. The method for this 
condensation was adapted from work by Gu and Holland,
106
 where 109, either diethyl malonate 
(Scheme 18A) or malononitrile (Scheme 18B), piperidine and benzoic acid were combined in 
toluene under inert Dean-Stark conditions. This resulted in the successful formation of 
compound 111 with diethyl malonate in a yield of 89 %. However the Knoevenagel condensation 
using malononitrile to form 112 was not successful.  
The 
1
H NMR spectrum for 111 shows a conjugated alkene proton signal at 8.0 ppm along with the 
OCH2CH3 signals at 4.28 (2H), 4.12-4.23 (2H) and 1.14-1.27 ppm (6H). The 
13
C NMR spectrum also 
showed the corresponding changes, where the alkene carbon signals were observed at 143.4 and 
127.3 ppm, and the OCH2CH3 carbon signals at 61.4, 61.3, 14 and 13.9 ppm. Also noted were the 
ester carbonyl signals at 166.4 and 163.8 ppm. 
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109  111 (69%) 
A 
 
 
 
109  112 
B 
Reaction conditions: Diethyl malonate (1.5 eq), piperidine (0.2 eq), benzoic acid (0.1 eq), toluene, Dean-
Stark, reflux, 18 h. 
Scheme 18 – Knoevenagel condensation reactions for the successful synthesis of 111 (A) and 
the unsuccessful synthesis of 112 (B) 
 
The final step in the synthesis was to reduce 111 to the corresponding diol. In theory, this 
reduction could be performed using lithium aluminium hydride (LiAlH4), however these 
reductions were unexpectedly unsuccessful, bringing this approach to another dead end. 
 
2.2.2. Heck coupling reactions 
Changing tack slightly, we opted to make use of a Heck coupling reaction in an attempt to add a 
slightly shorter tether to the imidazo[1,2-a]pyridine. The method for this synthesis was adapted 
from previous work done in our lab by Riaan Petersen, where palladium(II) acetate (Pd(OAc)2) 
and tri(o-tolyl)phosphine were combined with the brominated and alkene-containing reagents in 
an acetonitrile/dimethylformamide/water solvent mixture.
107
 However, it was found that in order 
for the reaction to occur, the formation of the active palladium catalyst from Pd(OAc)2 (which is 
reduced to Pd
0
) and tri(o-tolyl)phosphine in the solvent mixture under inert conditions at 40 °C 
was essential before any of the reactants could be added. Once the catalyst had formed, the 
imidazo[1,2-a]pyridine (either 85 or 102) was dissolved in more acetonitrile and added to the 
mixture along with ethyl acrylate, triethylamine and additional dimethylformamide. This was left 
to react at 78 °C under inert conditions overnight. Temperature control was very important to 
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this reaction; too low and the reaction would not go to completion, when above 80 °C the active 
catalyst decomposed. 
An unforeseen problem with this synthesis was the significant coordination of the tri(o-
tolyl)phosphine to the imidazo[1,2-a]pyridine ring. The reactions were monitored by TLC and only 
a single new spot appeared, however despite numerous attempts at purification using column 
chromatography the tri(o-tolyl)phosphine remained visible in the 
1
H and 
13
C NMR spectra. It was 
found that the best method to purify these compounds was in fact to use a modification of the 
work up procedure. After quenching the reaction, the organic layer was washed several times 
with 1M hydrochloric acid. The imidazo[1,2-a]pyridine was found in the acidic layer while the 
tri(o-tolyl)phosphine remained in the organic layer. Neutralization of the acid with solid sodium 
bicarbonate forced the imidazo[1,2-a]pyridine out of the water layer and extraction with ethyl 
acetate, drying and concentration in vacuo resulted in pure 113 (Scheme 19A). 
The reaction shown in Scheme 19B did not go to completion, and so even post acid extraction 
114 was separated from the starting material (85) by flash column chromatography. Ester 114 
was isolated in a mediocre yield of 55 %. The presence of the vinylic protons was evident at 7.76 
and 6.54 ppm for 113 and 7.65-7.70 and 6.40 ppm for 114. Additionally, the ester CH2 quartet 
and CH3 triplet protons were evident at 4.27 and 1.33 ppm for 113 and 4.29 and 1.36 ppm, 
respectively, for 114. The presence of the ester carbonyl signals at 166.8 and 167.0 ppm in the 
13
C NMR spectra and the carbonyl stretches (1707 cm
-1
 for 113 and 1709 cm
-1
 for 114) in the IR 
spectra for each compound further support the successful formation of the desired compounds. 
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102 (53 %)  113 (94 %) 
A 
 
 
 
85 (59 %)  114 (55 %) 
B 
Reaction conditions: Ethyl acrylate (1 eq), Pd(OAc)2 (0.4 eq), P(o-tolyl)3 (1.6 eq), NEt3 (10 eq), 
MeCN/DMF/H2O, 70 °C, 18 h. 
Scheme 19 – Heck cross coupling reactions to form 113 and 114 
 
Following the addition of an ester based tether, the next objective was to hydrolyse the ester to 
an acid and attempt to chelate the acid to a metal. The hydrolysis of the ester to the carboxylic 
acid appeared to be successful, however the resulting product was significantly insoluble such 
that further development, of this idea along these lines was not possible. 
 
2.2.3. Attempted modification using arylation-type reactions 
Considering that we had no information about the mechanism of the action or the biological 
target of the active site of the imidazo[1,2-a]pyridines we thought it prudent to investigate 
building tethers of shorter length than those previously synthesized. In order to do so, we 
investigated adding shorter tethers onto the imidazo[1,2-a]pyridine using arylation-type 
reactions. Using diethyl malonate or malononitrile and attaching it directly to the imidazo[1,2-
a]pyridine, as shown in Scheme 20, would allow for such a tether. 
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89   
Reaction conditions: i) Malononitrile (1.1 eq), NaOBu
t
 (3 eq), PCy3 (3 mol %), PdCl2 (1 mol %), THF, reflux; ii) 
diethyl malonate (1.1 eq), K3PO4 (1.5 eq), [Pd(PPh3)4Cl2] (5 mol  %), THF, reflux; iii) Malononitrile (1.1 eq), 
NaH (1.5 eq), [Pd(PPh3)4Cl2] (5 mol %), THF, reflux. 
Scheme 20 – Conditions for arylation reactions at the 6-position considered in this project 
 
At the time of synthesis, again there was little literature available for performing these reactions 
on imidazo[1,2-a]pyridines so a variety of methods were investigated based on arylation 
reactions performed on pyridine rings.
108
 Despite extensive investigation, none of the methods 
were successful and starting material was recovered in each case. We considered that 
substitution directly on the imidazo[1,2-a]pyridine directly might be problematic and so, as we 
did with the Suzuki-Miyaura and Heck reactions, we attempted to add the tether to a bromine 
substituent at onto the substituent benzene ring (as shown in Scheme 21). Unfortunately once 
again starting material was recovered from these reactions. 
 
 
 
 
 
 101    
Reaction conditions: i) malononitrile (1.1 eq), NaH (1.5 eq), [Pd(PPh3)4Cl2] (5 mol %), THF, reflux; ii) Diethyl 
malonate (1.1 eq), NaH (1.1 eq), Pd(OAc)2 (5 mol %), dppf (7 mol %), THF, reflux; iii) Diethyl malonate (1.1 
eq), Cs2CO3 (1 eq), CuI (25 mol %), 2-phenylphenol (0.5 eq), THF, 50 °C. 
Scheme 21 - Conditions for arylation reactions on the R2 aryl substituent considered in this 
project 
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2.3. Results from Biological Testing 
The imidazo[1,2-a]pyridines (Figure 35, Figure 36 and Figure 40) synthesized thus far were sent to 
Dr Leonie Harmse at the Pharmacology Department at WITS Medical School for biological testing 
and formed the basis for the Master of Science in Medicine (Pharmacology) for Somayya Ragie
109
 
and Taurai Kurebwa
110
 and current MSc student Zeenat Ismail.
111
 All of the biological results 
reported in this thesis were generated by Ragie, Kurebwa and Ismail and details of the 
experiments performed investigating the mode of action of these compounds can be found in 
their dissertations. 
Firstly, the Caco-2 and HT-29 colorectal cancer cell lines were investigated by Ragie
109
 as in the 
previous study by de Koning and co-workers
91
 but additional cell lines were also tested to 
investigate the full potential of the synthesized imidazo[1,2-a]pyridine. The new cell lines include 
MCF-7 and MDA-MB231 (breast cancer cell lines investigated by Kurebwa
110
) and leukemic cell 
lines, K562 and HL-60 investigated by Ismail.
111
 All the compounds were initially screened at a 
fixed dose of 200 µM in each cancer cell line using an 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. Only the compounds that resulted in a >20% cell 
viability after dosing for 48 hours were carried through to obtain IC50 values. Imidazo[1,2-
a]pyridines 85 to 102 and 113 were considered for the initial testing. Compounds for which IC50 
values were obtained are shown in Table 2, with a comparison to the ‘golden standard’ 
camptothecin. 
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Table 2 – IC50 values in µM obtained for compounds in colorectal (HT-29 and Caco-2), breast 
cancer (MCF7 and MDA-MB231) and Leukemia (K562 and HL-60) cell lines 
Compound 
Colorectal Cancer Lines Breast Cancer Lines Leukemia Lines 
HT-29 Caco-2 MCF7 
MDA-
MB231 
K562 HL-60 
Camptothecin 5.0 ± 0.7 11 ± 2 0.32 ± 0.01 0.33 ± 0.04 2.6 ± 0.2 
0.005 ± 
0.003 
 
85 
- - 42 ± 2 - 11 ± 2 - 
 
87 
- - 71 ± 3 - 13 ± 2 11 ± 2  
 
88 
- - 35.4 ± 0.4 - 36 ± 4  
 
89 
- - - - - 13.0 ± 0.2 
 
90 
- - 32 ± 2 33 ± 3 - - 
 
91 
- 14.0 ± 0.8 43 ± 4 - 51 ± 6 - 
 
92 
10.7 ± 0.4 - - - - - 
 
93 
28.2 ± 0.9 34 ± 3 18 ± 2 30 ± 2 15 ± 3 15.0 ± 0.1 
 
94 
- - - - 21 ± 1 - 
 
95 
8 ± 2 - 35 ± 2 - 24.9 ± 0.9 18 ± 2 
 
102 
4.1 ± 0.4 15 ± 2 32.6 ± 0.9 - 27 ± 1 13 ± 3 
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Imidazo[1,2-a]pyridine 86 had featured in the previous study by de Koning and co-workers. In 
their study the IC50 values for 86 were reported as 9 ± 1 µM in the HT-29 cell line and 9 ± 1 µM in 
the Caco-2 cell line.
91
 Interestingly, in this study 86 was not considered to be active enough to 
obtain an IC50 value in any of the cell lines investigated. Not many of the compounds in this first 
library showed significant activity in the colorectal cancer cell lines, however compounds 92, 95 
and 102 showed activity similar to that seen in the de Koning study,
91
 where imidazo[1,2-
a]pyridine 102 showed the best activity in both HT-29 and Caco-2 cell lines. The imidazo[1,2-
a]pyridines in this first study showed significantly more activity in the leukemic and breast cancer 
cell lines than the colorectal lines, however none of these compounds showed activity 
comparable to that of the camptothecin. 
One of the most positive aspects of the imidazo[1,2-a]pyridines from the de Koning study was the 
low toxicity of the compounds towards leucocytes.
91
 In order to verify these results, leucocytes 
were dosed with the imidazo[1,2-a]pyridines from this first compound library. These tests were 
again performed using an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (or MTT) 
assay, where the leucocytes were dosed with the relevant imidazo[1,2-a]pyridine for 24 hours at 
their respective IC50 values for the K562 and the HL-60 cell lines. Figure 44 shows the results 
obtained for these experiments. 
 
Figure 44 – Leucocyte cell viability after 24 hours of exposure to selected imidazo[1,2-
a]pyridines at their IC50 concentrations 
 
The camptothecin that was used as a standard showed significant toxicity at relatively low 
concentrations (67.3 % at 2.6 µM). A similar level of toxicity was only noted in imidazo[1,2-
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a]pyridine 93 at 26.0 µM (tenfold more concentrated than that of the camptothecin). The 
imidazo[1,2-a]pyridines showed significantly less toxicity than camptothecin towards the 
leucocytes. This correlates with what was previously observed and suggests the imidazo[1,2-
a]pyridines show some selectivity towards cancer cells.  
While the IC50 values in the cancer cell lines may not have been as low as we had initially hoped, 
the relatively low toxicity of the imidazo[1,2-a]pyridines was promising and prompted further 
investigation. 
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2.4. Introducing metals to imidazo[1,2-a]pyridines 
2.4.1. Combining imidazo[1,2-a]pyridines with ferrocene 
Being unable to successfully tether the imidazo[1,2-a]pyridine to a metal using the traditional 
linker approach, a few methods were investigated in order to achieve a different type of hybrid. 
The first of these was to introduce a metal directly to the imidazo[1,2-a]pyridine during the 
Groebke-Blackburn-Bienaymé coupling reaction. This was found to be possible using 
commercially available ferrocenecarbaldehyde, resulting in the formation of 115 to 117 as shown 
in Figure 45. 
 
 
 
115 (55 %) 116 (72 %) 117 (3 %) 
Figure 45 – Ferrocene-containing imidazo[1,2-a]pyridines 115 to 117 
 
These reactions were performed with varying degrees of success. The best yielding reaction was 
116 with 72 %, while 115 formed in a mediocre yield of 55 % and 117 in a very poor yield of 3 %. 
These compounds were characterised mainly by 
1
H and 
13
C NMR spectroscopy with characteristic 
substituted ferrocene proton signals in a 2:2:5 ratio in the 
1
H NMR spectra along with the three 
imidazo[1,2-a]pyridine protons. The 
13
C NMR spectrum corroborates this with a quaternary 
ferrocenyl carbon at approximately 78-79 ppm followed by the remaining three carbon signals 
between 65-70 ppm. Unfortunately compound 117 was found to be significantly insoluble in 
organic solvents so much so that it was not possible to obtain a 
13
C NMR spectrum for this 
compound even in d6-DMSO.  
Crystals suitable for SCXRD were grown and so the exact structure of these compounds could be 
obtained. This resulted in some unexpected interactions. Ferrocene 115 (Figure 46A) was found 
to crystallize with methanol forming intermolecular hydrogen bonds with O1―H1∙∙∙N1 (d = 2.01 
Å) and N26―H26∙∙∙O1 (d = 2.12 Å) to form dimer type crystal packing. Interestingly, while 116 
also included methanol in the crystal structure the same dimer type pattern was not observed. 
Hydrogen bonding through O1―H1∙∙∙N1 (d = 2.82 Å) as shown in Figure 46B, binds the methanol 
to the imidazo[1,2-a]pyridine and no obvious π stacking was noted. 
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A B 
Figure 46 – The asymmetric units of 115 and 116 
 
In a stroke of fortune, the insoluble 117 was crystallized from ethanol. Figure 47 gives us a clear 
indication of why this compound is so insoluble, as there is intermolecular hydrogen bonding 
between C27b―H27e∙∙∙N1a (d = 2.90 Å), C27―H27c∙∙∙N1b (d = 2.78 Å), C28b―H28b∙∙∙N1a (d = 
2.57 Å) and N28a―H28a∙∙∙N1b (2.53 Å). Additionally the small torsion angle of 11.8(1)° between 
the imidazo[1,2-a]pyridine ring and the top cyclopentene ring of the ferrocene ring allowed for 
significant π∙∙∙π interactions between the centrosymmetric pair. The π stacking continues 
throughout the crystal packing.    
 
Figure 47 – The asymmetric unit of 117 (hydrogen atoms not involved in hydrogen bonding are 
omitted for clarity) 
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The compounds shown in Figure 45 were the first successful examples of the types of hybrid 
compounds we were interested in synthesising and were sent for biological testing. 
Unfortunately compound 117 was not soluble under the conditions required for anticancer 
testing and so could not be tested. Compounds 115 and 116 showed no significant biological 
activity despite being soluble in a water-dimethylsulfoxide medium. 
 
2.4.2. Chelation approach to the synthesis of metal hybrids 
The final approach considered in the synthesis of hybrid compounds was based on using the 
inherent electron rich properties of the imidazo[1,2-a]pyridine itself. When considering the 
imidazo[1,2-a]pyridine ring core, the lone pair of electrons on N4 are tied up in the overall 
aromaticity of the compound while the lone pair on N1 are free and could serve as possible sites 
for chelation to a metal ion. The coordinative ability of N1 has already been seen in Figure 37A 
and Figure 46 where water and methanol respectively were included in the crystal structures 
through hydrogen bonding to N1 and suggested that this could be a good starting point.  
Given that there has been very little work done in this particular area of research and metal 
chelation was not common practise in our laboratory we decided to do initial investigations with 
zinc-based compounds before attempting to introduce platinum as originally proposed. Using a 
procedure by Forniés et al., the first attempted synthesis of chelated zinc imidazo[1,2-a]pyridine 
was performed as shown in Scheme 22, chelating imidazo[1,2-a]pyridine 89 and zinc chloride in 
an attempt to form a 6 membered chelate ring (118).
96
 This experiment produced a cream solid 
as a product that showed limited solubility in organic solvents. It was immediately evident that 
characterisation of the product would prove tricky and the use of NMR spectroscopy would be 
fairly limited. NMR spectroscopy could confirm the presence of the imidazo[1,2-a]pyridine in the 
compound collected, and show the expected peak shifts, however it would not give the exact 
position of the chelation or how many organic units were chelated to the zinc. The use of SCXRD 
in the characterisation of these compounds in this project was therefore imperative.  
 
 
 
89  118 
Scheme 22 – Proposed synthesis of a 6 membered chelate coordination compound 
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The crystallization of the cream powder by slow evaporation using methanol resulted in the 
formation of wafer thin colourless plates that were suitable for SCXRD. This showed that the 
product from the reaction was not 118 as expected but an unexpected chelation product 119 
shown in Figure 48. This chelate structure preserved the intramolecular hydrogen bonding that 
was initially seen in Figure 38, the crystal structure of the free ligand 89. This suggests that this 
intramolecular bonding is significant and more energetically favourable than the chelate ring 
would be. Aside from this, Figure 48 is conclusive proof that chelation to N1 is possible and 
preferable, however results in the formation of this zinc-organic ligand complex of relatively high 
molecular mass was not ideal in terms of drug discovery. In addition to this, a single chelation 
may not be strong enough to withstand physiological conditions. 
 
 119 
Figure 48 – The structure and asymmetric unit of 119 (hydrogen atoms are omitted for clarity) 
 
In an attempt to address this, imidazo[1,2-a]pyridine 88 was revisited. In this particular 
imidazo[1,2-a]pyridine, the presence of a second pyridyl group in the R2 position creates the 
potential for the formation of a more stable metal 5-membered chelate ring. The crystal 
structure of 88, Figure 49, revealed that there is significant intramolecular hydrogen bonding 
between N22―H22∙∙∙N-11 (2.54 Å). This hydrogen bonding would need to be overcome in order 
for any metal chelation to occur.  
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Figure 49 – The asymmetric unit of 88 
 
Exposing compound 88 to a variety of different metal salts, as shown in Scheme 23, resulted in 
the successful formation of metal complexes. A procedure from Steffen and Palenik that was 
heavily modified
112
 was used to generate the metal-imidazo[1,2-a]pyridines as shown in Figure 
50 in varying yields. A variety of different methods were used to characterise these complexes, 
depending on their nature. 
 
 
 
                   88   
Reaction conditions: i) ZnCl2, Zn(OAc)2 or Cu(OAc)2 (0.9 eq), diethyl ether, rt, 18 h; ii) PtCl2 (0.9 eq), DMF, 
reflux, 18 h. 
Scheme 23 – General synthesis to form metal chelated imidazo[1,2-a]pyridines 
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120 (83 %) 121 (50%) 
 
 
122 (99 %) 123 (99 %) 
Figure 50 – The first metal complex library 
 
These compounds were found to be unstable under the conditions for Mass Spectroscopy and so 
this method could not be used as an analytical technique for characterisation of these 
compounds.  
Initial investigations were conducted using the inexpensive zinc chloride salt. This resulted in the 
formation of zinc-imidazo[1,2-a]pyridine complex 120 as a cream coloured powder in an 
excellent yield of 83%. Characterisation proved problematic due to the relative insolubility of the 
compound. This compound was not soluble enough to perform NMR spectroscopic analysis, 
however suitable crystals for SCXRD analysis (Figure 50) were grown by slow evaporation from 
isopropyl alcohol. From the crystal structure, it was evident that the pyridyl R2 substituent and 
the imidazo[1,2-a]pyridine ring become planar once chelated to the zinc. This allows for 
significant π-stacking to occur in the crystal lattice, possibly explaining the low solubility of the 
compound. 
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Figure 51 – The asymmetric unit of 120 (hydrogen atoms are omitted for clarity) 
 
Using Zn(OAc)2 instead of ZnCl2 dramatically improved the solubility of the complex and this 
complex - 121 – could be characterised by NMR spectroscopy as well as SCXRD. From the NMR 
spectra it could be seen that there were significant changes to the chemical shifts of both the 
1
H 
and 
13
C NMR signals. It was also noted that the signals were significantly broader than in the free 
ligand 88. The additional CH3 peaks due to the acetate were observed at 2.10 ppm in the 
1
H NMR 
spectrum and at 22.14 ppm in the 
13
C NMR spectrum, and the acetate carbonyl signals was 
present at 180.60 ppm. While this significant signal shifting and the acetate signal presence 
confirmed the formation of a complex, it did not provide and exact location for the chelation of 
the zinc. Slow evaporation of the complex from CDCl3 resulted in colourless crystals confirming 
the structure of 121 by SCXRD as shown in Figure 52. Intramolecularly, hydrogen bonding 
between C15―H15∙∙∙N22 (d = 2.66 Å) was noted. On an intermolecular level, these molecules 
tended to form dimers through noteworthy hydrogen bonds between N22―H22∙∙∙O-4 at 
distances of 2.15 and 2.23 Å respectively. These crystals were found to include the CDCl3 solvent 
which was between the voids in the crystal lattice. 
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Figure 52 – The asymmetric unit of 121 (hydrogen atoms are omitted for clarity) 
 
Given the success of the complexation reactions, this was then attempted using platinum 
chloride. However, due to the insoluble nature of platinum compounds, the reaction was 
performed in dimethylformamide under reflux conditions overnight. This resulted in the 
formation of an insoluble mustard yellow powder that was determined to be 122. Unfortunately 
no crystal structure for this compound could be obtained, however NMR spectroscopy could be 
used to characterise this compound. From this it could be clearly seen that the imidazo[1,2-
a]pyridine signals that were present in the ligand, had shifted appropriately and showed 
significantly reduced splitting. The most significant change in the 
1
H NMR spectrum was the shifts 
of the cyclohexyl ring signals. The appropriate signal shifts were also noted in the 
13
C NMR 
spectrum. 
In order for the compounds to be considered for biological application, the solubility of the 
compounds was of vital importance. Given the large amount of research into the use of copper 
medicinally,
61
 copper acetate was also considered. In the event, stirring 88 with copper acetate 
produced a green powder, 123, that showed significantly improved solubility in organic solvents 
over the zinc and platinum compounds. Due to the paramagnetic properties of copper, 123 could 
not be analysed using NMR spectroscopy. Thankfully the improved solubility made analysis of 
123 by SCXRD significantly easier (Figure 53) after crystallization by vapour diffusion of hexane 
into dichloromethane. Interestingly, the crystal packing of 123 was very similar to that of 121, 
where there is intramolecular C8―H8∙∙∙O2 hydrogen bonding (d = 2.52 Å) and in the unit cell the 
complex forms a dimer through intermolecular hydrogen bonding (C-22―H-22∙∙∙O-4, d = 2.13 Å).  
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Figure 53 – The asymmetric unit of 123 (hydrogen atoms are omitted for clarity) 
 
Initial anticancer biological assays indicated that the 121 and 123 showed good activity against a 
few of the cancer cell lines. This is discussed in greater detail later on, however it did prompt the 
idea of expanding the library to include more zinc and copper-imidazo[1,2-a]pyridine complexes. 
Since the imidazo[1,2-a]pyridine ring core and the pyridyl R2 substituent were necessary, it was 
decided that an investigation into the R3 substituent provided by the isocyanide component 
would be important.  
 
2.4.3. Synthesis of isocyanides 
In order to investigate the biological effect of the R3 substituent the nature of the isocyanides 
needed to have substantial differences. The xylyl isocyanide used previously resulted in very poor 
yields and products with low solubility in organic solvents. Taking this into account, as well as the 
substantial cost of the isocyanide it was excluded from the series. The use of t-butyl isocyanide 
resulted in the most soluble compounds previously, however the reaction was unsuccessful with 
the pyridyl R2 substituent and so this was not further explored. 
Since the cyclohexyl ring is relatively non polar, it was decided that a polar substituent, from 
commercially available ethyl isocyanoacetate, should be included in this study. In the initial de 
Koning study, an imidazo[1,2-a]pyridine with a benzyl R3 substituent showed promising results
91
 
and so the benzyl substituent was reconsidered for this study. Additionally we remained 
interested in the adamantyl cage and how this would affect the biological activity of the complex. 
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While both benzyl and adamantyl isocyanide are commercially available, due to a change in 
shipping regulations and significant cost both needed to be synthesized.  
The synthesis of isocyanides has become of interest to our research lab in recent years
113
 and the 
favoured synthesis is outlined in Scheme 24 demonstrating the synthesis of benzyl isocyanide. 
This involved the formylation of benzylamine followed by dehydration under basic conditions 
using phosphorus oxychloride.
114
 
 
 
 
 
 
     (55 %) 
Reaction conditions: i) formic acid, acetic anhydride, rt, N2, 18 h; ii) NEt3 (10 eq), POCl3 (3 eq), DCM, 0 °C, 2 h. 
Scheme 24 – Synthesis of benzyl isocyanide from benzyl amine 
 
Interestingly, the 
13
C NMR spectrum of the benzyl isocyanide showed a triplet of the isocyanide C 
(157.7 ppm) as well as the benzylic CH2 carbon at 45.6 ppm as a result of the C-N coupling. The 
same splitting was not seen with the adamantyl isocyanide. 
The nature of benzyl isocyanide meant that it was synthesized only when absolutely necessary 
and reacted as soon as possible to prevent any storage of the noxious substance. A similar 
synthesis of adamantyl isocyanide resulted in a product that was significantly more tolerable to 
work with, but proved to be a significantly more volatile reaction. 
 
2.4.4. The R3 substituent effect library 
Following all that we had learnt from the previous libraries, the R3 library compounds were 
synthesized using the Groebke-Blackburn-Bienaymé multicomponent coupling reaction in 
ethanol. The imidazo[1,2-a]pyridines shown in Figure 54 form the ligands which were used to 
assemble this library. 
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124 (40 %) 125 (44 %) 126 (94 %) 
Figure 54 – Pyridyl imidazo[1,2-a]pyridines synthesized for the R3 substituent library 
 
Spectroscopic analysis provided confirmation of the structure of these compounds, where 
distinguishing features such as the benzyl CH2 for 124 at 4.24 ppm in the 
1
H NMR spectrum, the 
ester carbonyl signal at 170.6 ppm on the 
13
C NMR spectrum and the ethoxy group for 125 with a 
quartet at 4.18 ppm and a triplet at 1.19-1.25 ppm in the 
1
H NMR spectrum and the adamantyl 
peaks for 126 at 1.96-2.00 (integrating for 3H), 1.17 (integrating for 6H) and 1.58 ppm 
(integrating for 3H) in the 
1
H NMR spectrum were noted. The amine N-H signal for both 124 and 
125 appeared as triplets, suggesting there is coupling to the CH2 (which appear as doublets). 
SCXRD analysis revealed that the preferred conformation of these structures is similar to that of 
88, where there is intramolecular hydrogen bonding that effectively locks the structure in a 
twisted conformation. Figure 55 shows the crystal structures of the compounds in Figure 54, 
along with the intramolecular hydrogen bonding. 
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124 125 
 
126 
Figure 55 – The asymmetric units of 123, 124 and 125 (hydrogen atoms are omitted for clarity) 
 
Using these ligands as a starting point, zinc and copper complexes were easily synthesized as 
before and characterised using similar methods (Figure 56). We attempted to form platinum 
complexes of 125 and 126 but the reactions formed highly insoluble complexes that were not 
able to be characterised. The complexation reaction of 124 with platinum chloride resulted in a 
yellow powder. This powder was found to be complex 129 after being successfully characterised 
using both NMR spectroscopy as well as SCXRD. 
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127 (65 %) 128 (99 %) 129 (67 %) 
 
 
 
 
 
 130 (76 %)  131 (91 %)  
 
 
 
 
 
 132 (70 %)  133 (67 %)  
Figure 56 – Zinc, platinum and copper complexes synthesized using the imidazo[1,2-a]pyridines 
synthesized in the R3 library 
 
NMR spectroscopy of the zinc compounds 127, 130 and 132  revealed significant shifting of the 
signals in both the 
1
H and 
13
C NMR spectra compared to the ligands. Reduced splitting in the 
1
H 
NMR spectra suggested that the complexation reaction was successful. This was further 
supported by the presence of the acetate CH3 in the 
1
H NMR spectrum and the acetate carbonyl 
signal in the 
13
C NMR spectrum. The structures were also confirmed by SCXRD analysis as shown 
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in Figure 57. Interestingly, in the crystal packing of both 127 and 130  the compounds form 
dimers through hydrogen bonding, while 132 didn’t show any intermolecular hydrogen bonding. 
The dimer in 127 forms through intermolecular N16―H16∙∙∙O4 (d = 2.14 Å) hydrogen bonding, 
and similarly in 130 through N16―H16∙∙∙O6 (d = 2.06 Å). 
 
 
127 130 
 
132 
Figure 57 – The asymmetric units of 127, 130 and 132 (hydrogen atoms are omitted for clarity) 
 
The platinum compound 129 was found to be significantly soluble in d6-DMSO and using NMR 
spectroscopy, characteristic imidazo[1,2-a]pyridine signals were observed on both the 
1
H and 
13
C 
NMR spectra with appropriate signal shifting and peak broadening. On standing, yellow crystals 
formed in the NMR tube and these were analysed using SCXRD to confirm the structure as shown 
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in Figure 58. The confirmation of this structure lends support to the structure of 122 proposed 
earlier.  
 
Figure 58 – The asymmetric unit of 122 (hydrogen atoms are omitted for clarity) 
 
The structures of copper complexes 128 and 133 were confirmed by SCXRD. Green crystals were 
grown from d4-MeOD by slow evaporation and the resulting structures are shown in Figure 59. 
Unfortunately no crystals of complex 131 suitable for SCXRD could be grown. However, given 
that the crystal structure for the zinc complex 130 was obtained and all the previous crystal 
structures tend to form in the same manner, the structure of 131 can be deduced. Elemental 
analysis of compounds 128, 131 and 133 further supported the structures shown.  
  
128 133 
Figure 59 – The asymmetric units of 128 and 133 (hydrogen atoms are omitted for clarity) 
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2.4.5. Complex Stability Studies 
Considering that the complexes synthesized so far were novel, that there are very few reports of 
metal imidazo[1,2-a]pyridine complexes and that these complexes were intended for medicinal 
use, it was important to determine the stability of the metal complexes. A literature search did 
not result in significant insight into the pK value of the imidazo[1,2-a]pyridine ring itself. The only 
reported values and experimental details are summarised in Table 3. 
 
Table 3 – Reported literature values for the pK of imidazo[1,2-a]pyridine 
Reference Substituents Solvent System Temperature pK 
Paulder
115
 R1 = H 90% EtOH/H2O - 5.06 
Paulder
115
 R1 = Me 90% EtOH/H2O - 5.33 
Catalan
116
 R1 = H Water 25 °C 6.49 
Humphries
117
 R1 = H - - 6.9 
 
The lack of significant detail in experimental conditions as well as substituent effects on the pK 
value made it of particular importance for us to independently determine the pK values of the 
free imidazo[1,2-a]pyridines before we considered that of the metal complexes. The common 
practise for the determination of the pK values for compounds in our school was by means of a 
closed cell pK titration. We hoped to employ this method in our study, however once set up we 
found the absorbance spectra obtained from the solution of 88 degraded significantly while 
circulating through the closed flow cell setup. This suggested that there was a reaction occurring 
during the circulation of the compound through the apparatus. Having ruled out the choice of 
buffer system and contaminants in the apparatus setup as the cause of the degradation to the 
compounds, it was proposed that the compounds were reacting with the silicone tubing.  
In order to determine if the tubing was in fact the cause of the problem, a quick study was 
conducted. A 50% methanol/water solution containing zinc complex 120 was divided into three 
separate sample vials in 10 ml aliquots. The first sample vial was kept as the control sample. Into 
the other two sample vials a length of water washed silicon tubing (the same as that used in the 
closed flow cell setup) was placed into the second sample vial and acid and water washed silicon 
tubing to the second was added and the solutions left to stand overnight. Both lengths of tubing 
were dried before being placed into each solution. Obtaining the absorbance spectra for the 
solutions the following morning revealed some interesting results. The control solution showed 
two significant absorption bands at 265 and 356 nm respectively. The two solutions exposed to 
silicone tubing overnight showed significant degradation of these absorption bands (Figure 60). 
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The solution containing water washed tubing showed significant degradation, while the solution 
that had the acid washed tubing showed not only degradation, but also a shift in the 356 nm 
absorption band. Thus it can be concluded that the imidazo[1,2-a]pyridines undergo a reaction 
with the silicone tubing. 
 
Figure 60 – Changes in the absorbance spectra of 120 when exposed to silicone tubing 
overnight 
 
Thus it was determined that the traditional closed cell pK titration would not be suitable for our 
purposes. This meant that an out-of-cell pK titration procedure needed to be employed instead. 
This involved dividing a bulk solution of the desired compound into individual glass vials, and 
adjusting each vial independently to the desired pH and obtaining the absorbance spectrum for 
each vial. 
Considering the apparent reactivity of the imidazo[1,2-a]pyridines, and the significant potential 
for them to form complexes the type of buffer system used for these experiments needed to be 
carefully considered. Using a combination of NaH2PO3 and 2-(N-morpholino)ethanesulfonic acid 
(MES) at a final concentration of 1 mM was finally settled upon. In order to ensure complete 
dissolution of both the free ligands and the metal complexes, a 50% methanol/water bulk 
solution was used. A 5 ml concentrated stock solution for each compound was made up in 
methanol or methanol/water. This stock solution was used firstly to determine the appropriate 
concentration for the pK titration by adding 1 µl of the stock solution at a time to 2.5 ml of 50% 
methanol/water and monitoring the absorbance spectrum. Once at the appropriate 
concentration, concentrated hydrochloric acid and sodium hydroxide was added consecutively in 
order to monitor the maximum changes in the absorbance spectra and to determine which 
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wavelengths would be appropriate to monitor in order to accurately determine the pK of the 
solution, as well as to determine the appropriate wavelength for the source change over. 
The stock solution was then used to form the diluted bulk solutions for the pK titrations. The bulk 
solutions were made by dissolving the NaH2PO3 and MES in water and further diluting to a total 
volume of 125 ml of water purified using the Millipore system. This was then introduced to a 250 
ml volumetric flask and the appropriate volume of stock solution added. The solution was then 
made up to 250 ml with methanol, the solution thoroughly shaken and then left to equilibrate for 
18 hours at 23 °C. The bulk solution was then divided into the individual glass vials in 10 ml 
aliquots and the pH of each solution was adjusted using concentrated hydrochloric acid or 
sodium hydroxide with a pulled capillary tube. The solution was then added to a cuvette and the 
UV-vis absorption spectrum obtained at that pH. In between each sample, the cuvette was 
washed with water and acetone and dried before the next solution was added. The pK titration 
was repeated in triplicate for each ligand and each experiment monitored at 2-3 wavelengths 
between 200 and 600 nm. Figure 61 shows examples of the typical absorbance spectra obtained 
for the ligands (A), the zinc complexes (B) and the copper complexes (C).  
 
Figure 61 – Changes in the absorbance spectra for compounds 123 (A), 126 (B) and 127 (C) over 
a 2-10 pH range 
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The data collected from these experiments were then analysed using SigmaPlot
118
 where the 
total absorbance at the monitoring wavelength AT, is given by Equation 1 (if there is a single pK) 
or Equation 2 (for two pKa values) where Ai is the absorbance due to the i
th
 species. The 
derivation of these equations along with the absorption data for the compounds analysed are 
available in the Digital Appendix, while an example from one compound can be found in 
Appendix A3. An example of the SigmaPlot fits of the changes in the absorbance can be seen in 
Figure 62. 
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 ]      
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 ]        
          
       
    Equation 2 
  
A B 
 
C 
Figure 62 – Examples of SigmaPlot fits for 123 (A), 126 (B) and 127 (C). A shows a single pK fit 
while B and C show a two pK fit 
 
The pK values for each wavelength of each run were then used to determine the average K value, 
the standard deviation in the average K value and consequently, the average pK value, with the 
error calculated using Equation 3 in Microsoft Excel. 
               (                          )  Equation 3 
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The pK values for ligands 88, 124, 125 and 126, zinc complexes 120, 121, 127, 130 and 132 and 
copper complexes 123, 128, 131 and 133 were determined using the method described above. 
The concentration of the solutions and the pK values for each compound are outlined in Table 4. 
Table 4 – pK values for selected compounds evaluated in the out-of-cell pK titration 
Compound pK1 pK2 Concentration (µM) 
88 3.9 ± 0.1 - 32.32 
120 3.5 ± 0.1 6.73 ± 0.08 22.07 
121 3.2 ± 0.1 6.76 ± 0.08 33.73 
123 3.6 ± 0.1 8.8 ± 0.2 31.06 
124 4.11 ± 0.05 - 34.09 
127 3.5 ± 0.1 6.30 ± 0.06 24.85 
128 3.5 ± 0.3 5.6 ± 0.3 30.67 
125 4.00 ± 0.07 - 45.41 
130 2.81 ± 0.08 7.5 ± 0.2 26.69 
131 3.6 ± 0.2 5.6 ± 0.3 35.27 
126 3.9 ± 0.1 - 65.61 
132 3.50 ± 0.07 6.35 ± 0.07 49.65 
133 4.4 ± 0.2 5.2 ± 0.3 58.49 
 
Despite having two ‘free’ nitrogen atoms in the molecule, the ligands 88, 124, 125 and 126 only 
showed a single pK value. While unexpected, this can be explained using the hydrogen bonding 
seen in the crystal structures of the ligands where the pyridyl N11 pyridine experiences hydrogen 
bonding with the amine N-H (Figure 49 and Figure 55). In an attempt to confirm this, crystals of 
the ligand 88 were grown from HBr. Figure 63 is the crystal structure from the crystals grown by 
slow evaporation of HBr, where the N22―H22∙∙∙N11 hydrogen bonding is preserved as it was in 
Figure 49, while the imidazo[1,2-a]pyridine hydrogen bonds to the HBr acid through Br6―H6∙∙∙N1 
(d = 3.21 Å). If even under concentrated acidic conditions, the pyridyl―amine hydrogen bonding 
is preserved then this explains why only a single pK value is seen in the imidazo[1,2-a]pyridines 
shown in Table 4.  
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Figure 63 – The asymmetric unit of 88 under acidic conditions 
The zinc complexes 120, 121, 127, 130 and 132 showed significant spectroscopic changes that 
were successfully modelled using Equation 2. In all the complexes, the pK1 value was significantly 
lower than that of the corresponding free ligand, while the pK2 value varied depending on the 
ligand used. Of all the compounds analysed complex 130 showed pK values that were notably 
different from all the other compounds tested, and currently there is no reasonable explanation 
for this although it could serve as an area to expand on in the future.  
Copper complexes 123, 128, 131 and 133 were more difficult to analyse than the other 
complexes and had to be approached on an individual basis. Since copper complexes form 
Cu(OH)2 after pH 10, the titrations were only performed between pH 2 and pH 9.5. Complexes 
123 and 128 could be successfully fitted using a two pK model (Equation 2). The spectroscopic 
changes for pK1 and pK2 were not always visible at the specific wavelength being monitored for 
complexes 131 and 133. This meant that the pK’s for these compounds had to be considered 
individually using a single pK model (Equation 1) for each pK. The absorbance of the imidazo[1,2-
a]pyridine portion of the molecules was so large in comparison to that of the copper, at the 
concentration required to monitor the changes in the imidazo[1,2-a]pyridine, that the 
characteristic d-d copper absorption bands were not visible. They were however confirmed to be 
present using the stock solutions and found to appear around 670 nm.  
Looking at the data obtained from this study as a whole, we can conclude that these compounds 
can be expected to be stable under physiological conditions (approximately pH 7.35). The 
significant hydrogen bonding seen in the ligands is overcome when exposed to a metal salt to 
form the chelated products, evident by the presence of the second pK observed in the metal 
complexes. The pK1 values for all the imidazo[1,2-a]pyridines are similar and change slightly to 
significantly depending on the metal it is chelated to. The pK2 value shows a much more metal 
dependent correlation.   
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2.4.6. Biological Results for the R3 substituent library 
The isocyanide derived R3 substituent library sent for anticancer testing comprised of ligands 124-
126 as well as metal complexes 120-123 and 127-133. Biological testing of the ligands and the 
compounds was again performed by Dr Leonie Harmse and her team as previously described. IC50 
values for active compounds are outlined in Table 5 with the results for 88 are included for ease 
of comparison. 
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Table 5 - IC50 values obtained for the most active metal-containing compounds in colorectal 
(HT-29 and Caco-2), breast cancer (MCF7 and MDA-MB231) and leukemia (K562 and HL-60) cell 
lines 
Compound Colorectal Cancer Lines Breast Cancer Lines Leukemia Lines 
HT-29 Caco-2 MCF7 MDA-
MB231 
K562 HL-60 
Camptothecin 5.0 ± 0.7 11 ± 2 0.32 ± 0.01 0.33 ± 0.04 2.6 ± 0.2 
0.005 ± 
0.003 
 
88 
- - 35.4 ± 0.4 - 36 ± 4 - 
 
123 
8.0 ± 0.4 12.2 ± 0.6 0.62 ± 0.03 28 ± 2 1.9 ± 0.9 2.2 ± 0.5 
 
126 
- - - 49 ± 5 27 ± 2 - 
 
127 
- - - 90 ± 8   
 
128 
3.9 ± 0.6 9.6 ± 0.4 3.7 ± 0.5 30 ± 1 7.7 ± 0.5 6.5 ± 1 
 
131 
11 ± 1 6 ± 2 2.2 ± 0.1 29 ± 1 8.7 ± 0.8 3.8 ± 0.7 
 
132 
9.2 ± 0.5 12 ± 2 - 38.3 ± 0.5 - - 
 
133 
5.9 ± 0.8 - * * - - 
*Complex 133 was not found to be soluble enough for testing in the MCF7 and MDA-MB231 cell lines 
The compounds shown in Table 5 showed significantly better activity than those that of the first 
library (Table 2). Aside from 88 which only showed moderate activity in two anticancer cell lines, 
the only other imidazo[1,2-a]pyridine that showed any notable activity was 126. The platinum 
complexes tested (122 and 129) were highly insoluble and showed little activity against the 
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cancer cell lines. Of the zinc complexes tested, only 132 showed any activity. It was immediately 
evident that the most active compounds to date were the copper-containing complexes (123, 
128, 131 and 133) that showed activity comparable to that of camptothecin. The only difference 
between these imidazo[1,2-a]pyridines was the nature of the substituent at C-3, with different 
substituents showing slightly better activity in different cancer cell lines. Complex 128 showed 
the most significant activity in the colorectal cancer cell lines. Complex 123 showed the most 
significant activity in the leukemic and breast cancer cell lines. None of the complexes in this 
study showed activity comparable to camptothecin in the triple negative MDA-MB231 cell line. 
For the sake of comparison the raw metal salts that were used to make the complexes (Cu(OAc)2, 
Zn(OAc)2 and ZnCl2) were also tested against these cancer cell lines and found to show no 
significant activity.  
Given that these metal complexes were the first of their kind no toxicity data was available for 
them. As previously described, leucocytes were treated with the imidazo[1,2-a]pyridine 
complexes at a concentration of 20 µM for 24 hours and the results are shown in Figure 64. 
 
Figure 64 – Leucocyte viability when exposed to selected metal complexes at 20 µM for 24 
hours 
 
Unsurprisingly, from Figure 64, it can be seen that these metal complexes show significantly 
greater toxicity than that of the metal free imidazo[1,2-a]pyridines seen earlier. Complex 128 
showed toxicity comparable to that of camptothecin, while complexes 123 and 131 showed 
greater toxicity, with 131 showing the most significant toxicity of all. The toxicity of these 
compounds is an important feature to monitor as the greater the toxicity seen, the more harsh 
the side effects that can be expected from the ultimate treatment, going against the broader aim 
of this project.  
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Considering that the free metal salts did not show any significant activity in the cell lines and the 
imidazo[1,2-a]pyridine ligands only showed moderate activity, as well as the pK data obtained 
from the previous section, it can be concluded that the significant improvement in the IC50 values 
for these metal complexes compared to compounds previously tested is due to the hybrid effect 
of the compounds. This proved our initial project aims – albeit with a different metal than was 
initially envisaged and prompted further investigation. 
 
2.4.7. A more focused Structure-Activity study library 
Given the significant activity of 123 across several cell lines, it was fairly clear that the cyclohexyl 
substituent was important for activity. From there it was decided that the other substituents on 
the imidazo[1,2-a]pyridine ring needed to be investigated in order to further enhance our 
understanding of these compounds. Using the general procedure the imidazo[1,2-a]pyridines 
outlined in Figure 65 were synthesized. This series includes compounds where the halogen 
substituent was absent (134), the position of the bromine substituent has been changed (135 and 
136), the R1 substituent has been changed to a chlorine atom (137) as well as where the halogen 
substituent has been moved to the R2 pyridyl ring (138 and 139). 
  
 
134 (74 %) 135 (69 %) 136 (47 %) 
   
137 (89 %) 138 (82 %) 139 (86 %) 
Figure 65 – Pyridyl-containing imidazo[1,2-a]pyridines 134 to 139 
 
These compounds were characterised using 
1
H and 
13
C NMR spectroscopy where the 
characteristic chemical shifts for the compounds were as expected. The N-H signals for 
compounds 138 and 139 appeared as doublets, while for the other imidazo[1,2-a]pyridines 134 
to 137 they appeared as singlets.  Given the conformation of imidazo[1,2-a]pyridine 88, crystal 
structures were obtained for all the compounds in this new library (with the exception of 135 
which was collected as a golden oil) after growing crystals by slow evaporation from appropriate 
 
At the end of my tether 
 
 
Results and Discussion 
 
 
90 
 
solvents. These crystal structures are shown in Figure 66. In these structures, the same twisted 
conformation as that in 88 can be seen. This suggests that for these types of structures, this is the 
most energetically favourable conformation for this particular ring system, regardless of the 
substituents on the imidazo[1,2-a]pyridine. 
  
 
A - 134 B - 135 C - 137 
 
  
 
 D - 138 E - 139  
Figure 66 – The asymmetric units of 134, 135, 137, 138 and 139 
 
Using imidazo[1,2-a]pyridines 134 to 139, a series of copper acetate complexes were formed in a 
similar manner to those previously described. These complexes form the final series of 
compounds investigated in this study and the expected complexes are shown in Figure 67, along 
with copper chloride and copper nitrate complexes of 88 to investigate the effect of the counter 
ion on the anticancer activity of the complex. 
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140 (89 %) 141 (85 %) 142 (99 %) 
  
143 144 
 
 
145 (53 %) 146 (97 %) 
Figure 67 – Copper complexes (140 to 146) synthesized to for the SAR study 
 
This series of compounds highlighted the importance of using crystallography in this project. 
Suitable crystals of all of the complexes synthesized for this series were grown from the 
appropriate solvents. Figure 68 shows the ORTEP diagrams for complexes 140 to 142, showing 
the resulting complexes were as expected. Unfortunately the complexation reaction of 
imidazo[1,2-a]pyridine 136 with copper acetate was unsuccessful as determined by ESI mass 
spectroscopy where no ligand could be detected. 
 
At the end of my tether 
 
 
Results and Discussion 
 
 
92 
 
  
140 141 
 
142 
Figure 68 – The asymmetric units of 140, 141 and 142 (hydrogen atoms are omitted for clarity) 
 
While we expected that the complexes generated from 138 and 139 would form the monomer 
complexes 143 and 144 as all the previous metal complexes had, SCXRD showed that reactions 
do not always go as expected. The complexes generated were in fact 147 (A) and 148  (B) shown 
in Figure 69. 
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147 (35 %) A 
 
 
148 (47 %) B 
Figure 69 – The structures and asymmetric units of 147 and 148 (hydrogen atoms are omitted 
for clarity) 
 
Given that all the copper complexes had acetate moieties as counterions, it was deemed 
important to investigate other types of counterions, in this case chloride and nitrate. Preparation 
of the copper sulfate derivative of 88 was attempted, however this was found to be unsuccessful 
also using ESI mass spectroscopy. Complex 145 was crystallized by slow evaporation from a 
CDCl3/d4-MeOD mixture, explaining why one nitrate group was replaced by a chlorine atom. The 
resulting crystal structure for 145 is given in Figure 70. 
 
At the end of my tether 
 
 
Results and Discussion 
 
 
94 
 
 
145 
Figure 70 – The asymmetric unit of 145 (hydrogen atoms are omitted for clarity) 
 
2.4.8. Results from Biological Testing 
On the back of the success seen in the anticancer activity of copper complex 123, we hoped to 
gain some insight into the structurally important features in the complex, if not to further 
improve the anticancer activity of the copper complexes. Imidazo[1,2-a]pyridines 134 to 139 and 
copper complexes 140 to 146 were sent for testing at Wits School of Pharmacology with Dr 
Harmse and her team for the same testing that was done on the other small library. The results 
from these tests are shown in Table 6, where complex 123 has been included for ease of 
comparison. 
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Table 6 - IC50 values (µM) obtained for the active compounds in the SAR study in colorectal (HT-
29 and Caco-2), breast cancer (MCF7 and MDA-MB231) and leukemia (K562 and HL-60) cell 
lines 
Compound 
Colorectal Cancer Lines Breast Cancer Lines Leukemia Lines 
HT-29 Caco-2 MCF7 
MDA-
MB231 
K562 HL-60 
Camptothecin 5.0 ± 0.7 11 ± 2 0.32 ± 0.01 0.33 ± 0.04 2.6 ± 0.2 
0.005 ± 
0.003 
 
123 
8.0 ± 0.4 12.2 ± 0.6 0.62 ± 0.03 28 ± 2 1.9 ± 0.9 2.2 ± 0.5 
 
137 
67 ± 5 - 23 ± 3 - - 29.2 ± 0.7 
 
140 
3 ± 1 11 ± 1 1.1 ± 0.6  3 ± 1 3 ± 1 
 
141 
6 ± 1 10.94 ± 0.06 1.20 ± 0.08 2.4 ± 0.4 6.0 ± 0.4 2.1 ± 0.3 
 
142 
14 ± 2 48 ± 3 3.8 ± 0.9 19 ± 1 3.0 ± 0.4 5 ± 2 
 
145 
10 ± 3 1.6 ± 0.4 1.0 ± 0.5 14 ± 1 11.1 ± 0.8 3.6 ± 0.1 
 
146 
14 ± 4 24.6 ± 0.3 1.1 ± 0.3 19 ± 1 9 ± 1 12 ± 4 
 
147 
- - 8.2 ± 0.4 23 ± 4 4 ± 2 13 ± 3 
 
148 
14 ± 4 20 ± 1 9.2 ± 0.9 18 ± 2 10.6 ± 0.7 14 ± 2 
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All of the copper complexes (140 to 146) submitted for testing showed significant anticancer 
activity. In the colorectal cancer cell lines it can be seen that moving the bromine substituent 
from the 6-position to the 5-position (as in 141) significantly increases the activity of the 
compound. However, compound 142 also showed better activity than 123, suggesting that a 
chlorine substituent may be more favourable than the bromine atom in the same position. The 
activity of these compounds are comparable to and slightly better than that of the camptothecin 
standard. In the Caco-2 cell line, changing the counterion from the acetate groups in 123 to the 
chloride ions in 145 results in a ten-fold improvement in the activity of the compound. 
In the MCF7 breast cancer cell line all of the complexes showed good to excellent activity. In this 
study copper complex 123 continued to show the greatest activity in the library. Considering how 
low the IC50 value for camptothecin is, to have complexes showing similar activity is an excellent 
result. Copper complexes 140, 141, 145 and 146 also show excellent activity against this cancer 
cell line. This suggests that having a halogen substituent on the imidazo[1,2-a]pyridine ring 
improves the activity while the counterion has little effect on the overall activity. In the MDA-
MB231 cell line, only 141 showed any significant activity. Considering this showed good activity in 
the MCF7 cell lines as well, this makes complex 141 of particular interest for the possible 
treatment of breast cancer.  
The K562 leukemic cell line was also particularly susceptible to the imidazo[1,2-
a]pyridine―copper complexes. Again complex 123 had the best activity, showing a greater 
activity than that of camptothecin. Complexes 140, 142 and 143 also showed comparable activity 
to that of camptothecin. Changing the counterion from the acetate groups decreased the activity 
of the compounds substantially. Unfortunately none of the complexes tested showed any activity 
comparable to camptothecin, however, several complexes showed IC50 values below 3 µM in the 
HL-60 leukemic cell line - 123, 140, 141 and 145. Copper complexes 123 and 140 showed 
significant anticancer activity in both leukemic cell lines and could be developed further in the 
treatment of leukemia. 
The final series of compounds was used to test the toxicity of these compounds towards 
leucocytes. Leucocytes were dosed at 20 µM for 24 hours and analysed using an MTT assay as 
before. From Figure 71 it can be seen that the imidazo[1,2-a]pyridines 134 to 139 show little 
toxicity in the leucocytes. The copper complexes (140 to 146) in general showed a greater toxicity 
than that of the imidazo[1,2-a]pyridines and the camptothecin, with complex 145 exhibiting the 
most toxicity and complex 143 the least, being comparable to that of the imidazo[1,2-a]pyridines 
and camptothecin. 
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Figure 71 - Leucocyte viability when exposed to selected imidazo[1,2-a]pyridines and 
imidazo[1,2-a]pyridine-metal complexes at 20 µM for 24 hours 
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At the end of my tether: 
Conclusions and Future 
Work 
 
3.1. Imidazo[1,2-a]pyridine synthesis and biological activity 
Over the course of this project, the library of available imidazo[1,2-a]pyridines synthesized by our 
laboratory was expanded upon significantly (imidazo[1,2-a]pyridines 85 to 102). This was done 
using previously developed methodology,
91
 as well as modified methodology using ethanol as a 
solvent. The use of ethanol as a solvent resulted in reactions with fewer side products and were 
higher yielding overall. The yields for the Groebke-Blackburn-Bienaymé multicomponent coupling 
reaction were notoriously unpredictable and could potentially be further investigated to optimize 
each individual reaction. The type of acid catalyst used in the coupling reaction could be another 
avenue for further investigation. 
Testing this imidazo[1,2-a]pyridine library against leukemic (K562 and HL-60), breast (MCF-7 and 
MDA-MB231) and colorectal (Caco-2 and HT-29) cancer cell lines only resulted in one compound 
that showed significantly better activity than those previously investigated by de Koning and co-
workers.
91
 Imidazo[1,2-a]pyridine 102 (Figure 72) showed significant activity in the HT-29 
colorectal cancer cell line (IC50 = 4.1 ± 0.4 µM).
109
 Additionally, these compounds did verify that 
the imidazo[1,2-a]pyridines show significantly lower toxicity towards leucocytes than the 
camptothecin standard they were tested against (Figure 44 and Figure 71). 
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102 
Figure 72 – Imidazo[1,2-a]pyridine showing the greatest anticancer activity 
 
3.2. Attempts at modifying the imidazo[1,2-a]pyridines and 
attempted tether syntheses 
With the intention of synthesizing metal-imidazo[1,2-a]pyridine complexes, we initially envisaged 
that a tether (or linker) would have to be built onto the imidazo[1,2-a]pyridine in order to house 
the metal. This was to come from diethyl malonate or malononitrile directly or from the tether 
derivatives (103) being added to the imidazo[1,2-a]pyridine.  
The use of Suzuki-Miyaura coupling reactions in modifying the bromine-containing imidazo[1,2-
a]pyridine was found to be successful using a variety of substituted phenyl boronic acids, using 
both conventional and microwave conditions and using Pd(PPh3)4 as a catalyst.
105
 The reactions 
were successful regardless of the position of the bromine on the imidazo[1,2-a]pyridine. 
The addition of a vinyl group to the imidazo[1,2-a]pyridine was successful using Suzuki-Miyaura 
cross coupling, resulting in the formation of both 106 and 107. Unfortunately using a cross 
metathesis reaction to add 103 to the imidazo[1,2-a]pyridine was unsuccessful despite extensive 
investigation. A benzaldehyde substituent was also successfully added to the imidazo[1,2-
a]pyridine using 2- or 4-formylphenylboronic acid (108 to 110). Using 109 in a Knoevenagel 
reaction with diethyl malonate was successful under Dean Stark conditions to afford 111 (Figure 
73), however the compound was not successfully reduced to the diol required to house the 
metal. 
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111 
Figure 73 – The product from the successful Knoevenagel condensation reaction 
 
The imidazo[1,2-a]pyridines resulting from the Suzuki-Miyaura coupling reactions were very 
large. This made adding small molecules (like the tethers) onto the large imidazo[1,2-a]pyridine 
troublesome. The Heck reaction was then investigated to add a shorter, more flexible tether onto 
the imidazo[1,2-a]pyridine. Using a previously developed method for Heck coupling reactions,
107
 
ethyl acrylate was successfully coupled to the aromatic bromide containing imidazo[1,2-
a]pyridines 85 or 102 resulting in 114 and 113 respectively (as shown in Figure 74). The reaction 
was higher yielding when the bromide was on the R2 substituent (102) which went to completion, 
rather than directly on the ring itself (85) where starting material was recovered from the 
reaction. The ester (113) was reduced to the carboxylic acid using potassium hydroxide, however 
this resulted in a compound that was insoluble and could not be used in further chelation 
attempts.  
 
 
113 114 
Figure 74 – Products from the Heck coupling reactions 
 
To add diethyl malonate or malononitrile directly onto the molecule, arylation reactions were 
also investigated. Scheme 25 and Scheme 26 outline the attempts at the arylation reactions using 
a wide variety of catalysts and reaction conditions, however none of these reactions were 
successful.  
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Unfortunately no tethered complexes were successfully synthesized over the course of this 
project and could serve as an area for potential further development. 
 
3.3. Introducing metals to the imidazo[1,2-a]pyridines 
3.3.1. Introducing ferrocene to the imidazo[1,2-a]pyridine 
The first attempt to add metals to the imidazo[1,2-a]pyridine was made by using 
ferrocenecarbaldehyde to introduce it directly onto the imidazo[1,2-a]pyridine in the Groebke-
Blackburn-Bienaymé coupling reaction. This resulted in the formation of compounds 115 to 117 
in varying yields. These compounds were found to exhibit significant π stacking, making these 
compounds insoluble. Due to this insolubility, the anticancer activity of these compounds could 
not be determined.  
 
3.3.2. Synthesis of isocyanides to generate a wider variety of 
imidazo[1,2-a]pyridines 
In order to use the Groebke-Blackburn-Bienaymé coupling reaction to generate imidazo[1,2-
a]pyridines, substituted isocyanides are required. Over the course of this project it was noted 
that there were several limitations to the isocyanides that could be commercially obtained, 
leading to benzyl and adamantyl isocyanide being synthesized using methodology used 
extensively in our laboratory.
114
 Both the benzyl and adamantyl isocyanides were synthesized in 
good yields and used to generate imidazo[1,2-a]pyridines 124 and 126 along with a commercially 
available ethyl isocyanoacetate to form 124. 
 
3.3.3. Adding metals directly to the imidazo[1,2-a]pyridine 
Having been unsuccessful in adding a tether to the imidazo[1,2-a]pyridine, we attempted to add 
metals directly onto the imidazo[1,2-a]pyridine ring using imidazo[1,2-a]pyridine 88. This was 
found to be successful using a variety of metal salts (ZnCl2, Zn(OAc)2, Cu(OAc)2 and PtCl2), 
resulting in the formation of compounds 120 to 123. The general description for the types of 
metal complexes synthesized is given in Figure 75. It was found that the zinc acetate and 
platinum chloride complexes could be characterised using NMR spectroscopy; the imidazo[1,2-
a]pyridine signals could be identified in the 
1
H NMR spectrum even with the significant shifting 
and reduced signal splitting. All of the compounds could only be conclusively characterised using 
single crystal x-ray diffraction and elemental analysis.  
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Figure 75 – General scaffold for the metal complexes synthesized 
 
This library was expanded to include metal complexes generated from the imidazo[1,2-
a]pyridines 124-126. The resulting complexes were outlined in Figure 56 and were intended to 
investigate the biological importance of the nature of the R3 substituent. 
 
3.3.4. Complex Stability Studies 
Given that the types of complexes in Figure 50 and Figure 56 were novel, investigation into the 
stability of the compounds was paramount. Having ruled out the usual closed cell titration setup 
due to the imidazo[1,2-a]pyridines reacting with the silicone tubing (Figure 60), out-of-cell pK 
titrations in 50% methanol/water with a 1 mM MES and NaH2PO3 buffer system were performed. 
Imidazo[1,2-a]pyridines 88, 124, 125 and 126, zinc complexes 120, 121, 127, 130 and 132 and 
copper complexes 123, 128, 131 and 133 were investigated. The pK values were calculated using 
SigmaPlot and are summarised in Table 4. The imidazo[1,2-a]pyridines were found to exhibit only 
a single pK value instead of the 2 which were expected for each coordinating nitrogen, this was 
attributed to the significant hydrogen bonding that was seen in the crystal structures for the 
molecules (Figure 49 and Figure 55). This hypothesis was further supported by the hydrogen 
bond being preserved in a crystal grown from HBr (Figure 63). The metal complexes showed the 
expected 2 pK values. All of the compounds investigated in this study showed pK values below pH 
7.35 (except for 130) and thus can be expected to be stable under physiological conditions.  
 
3.3.5. Anticancer activity of the metal complexes 
Testing these compounds against leukemic, colorectal and breast cancer cell lines resulted in the 
copper-imidazo[1,2-a]pyridine complex 123 (Figure 76) showing the greatest activity in the 
leukemic and breast cancer cell lines and 128 in the colorectal cancer cell lines. The zinc and 
platinum complexes that were tested showed little to no significant activity in any of these lines. 
These results earmarked 123 as a potential lead compound that could be further developed. The 
copper complexes in this study were shown to have comparable toxicity to that of camptothecin 
in leucocytes, with 131 showing the greatest toxicity in the series (Figure 64).  
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123 
Figure 76 – Potential lead copper complex 123 
 
In general it was found that crystals suitable for SCXRD could be grown using d4-MeOD for zinc 
complexes and CDCl3 for the copper-containing compounds. 
 
3.3.6. Investigation into the Structure-Activity relationship  
In order to do a more detailed structure-activity study, the metal complex library was further 
expanded to investigate the importance of the halogen as well as position on the imidazo[1,2-
a]pyridine, as well as the effect of the counterion on the metal salt used. In order to investigate 
the significance of the halogen in this study imidazo[1,2-a]pyridines 134 to 139 were synthesized 
using the general procedure and copper complexes 140 to 144 were made from these 
compounds. Additionally compounds 145 and 146 were synthesized from 88 in order to 
investigate the counterion effect on the activity of the molecule. Testing the anticancer activity of 
these compounds resulted in significant activity being observed in all the copper complexes 
tested. In the colorectal cancer cell lines (HT-29 and Caco-2) complex 140 was found to be the 
most active complex, suggesting that the position of the halogen was significant. In the Caco-2 
cell line it was noted that changing the counterion from acetate groups to chloride ions (as in 
145) showed a significant change in activity. 
In the MCF7 breast cancer cell line, copper complex 123 showed the most significant activity of 
all the complexes tested. Complexes 140, 141, 145 and 146 showed excellent activity that should 
also be noted. The MDA-MB231 cell lines were mostly resistant to the imidazo[1,2-a]pyridines 
tested in this study, however complex 141 (Figure 77) showed the most significant activity. 
Combining this with the activity of 141 seen in MCF7 cells this compound should be further 
investigated for its use in the fight against breast cancer. 
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141 
Figure 77 – Most active compound in breast cancer cell lines 
 
In the K562 leukemic cell lines, copper complex 123 showed greater activity than that of 
camptothecin. In this cell line it was noted that changing the counterion from acetate groups to 
chloride or nitrate ions dramatically decreased the activity of the compounds. None of the 
complexes showed activity comparable to camptothecin in the HL-60 cancer cell line, however, 
several showed anticancer activity at concentrations below 3 µM. Copper complexes 123 and 140 
(Figure 78) showed notable activity in both the K562 and HL-60 cell lines which could be further 
developed as a treatment for leukemia.  
 
140 
Figure 78 – A copper complex showing significant anticancer activity in K562 and HL-60 cancer 
cell lines 
 
Having obtained these excellent anticancer results, further testing on these active compounds is 
required. Testing these compounds in an animal model would give far more information on how 
successful these compounds would be as potential drug candidates. It would also help us gain a 
better understanding of how these compounds behave in the body and what the potential side 
effects could be. Since the exact target of these molecules is not known, testing in an animal 
model could also help narrow down the exact target.  
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Plot Twist: 
Introduction 
 
The choice of reagent used to perform a particular reaction is invariably key in organic synthesis. 
The reaction conditions (solvent, temperature, atmosphere etc.) often govern the reaction that a 
particular reagent can mediate – especially when the reagent can facilitate multiple 
transformations. Two related reagents of particular importance to this section of this PhD are 
ceric ammonium nitrate (CAN) and ceric ammonium sulfate (CAS) and their novel use in organic 
synthesis. Before discussing their use in these novel reactions, it is important to revisit the 
existing uses of CAN and CAS. The review below details the previous transformations made 
possible by both CAN and CAS. 
 
4.1. The use of Ceric Ammonium Nitrate in Organic Synthesis 
Found on the shelves of nearly every organic chemistry lab is ammonium cerium(IV) nitrate, 
commonly referred to as ceric ammonium nitrate or CAN. Commercially available as dark orange 
crystals or a light orange powder, it is considered to be a typical example of a cerium salt in the 
4+ oxidation state. Smith et al. were of the first research groups to synthesize and make use of 
CAN in 1936. Before this point, ceric sulfate had been used as an oxidative standard in titrations. 
Obtaining analytically pure ceric sulfate proved problematic at the time with high concentrations 
of other lanthanide species remaining present in the salt. They reported a highly efficient 
synthesis of CAN in high purity even from the highly impure cerium sulfate starting material. 
Additionally this new salt showed significantly improved solubility and stability in water and 
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organic solvents and since then has been widely used in analytical testing and organic 
synthesis.
119
  
It wasn’t until 1968 that the crystal structure was reported by Beineke and Delgaudio that 
confirmed the structure proposed by Smith et al. – (NH4)2Ce(NO3)6.
120
 In the decades that have 
followed, CAN has been found to efficiently transfer a single electron, reducing the Ce
4+
 to the 
equally stable Ce
3+
 and as a result making it suitable for many different applications. It has also 
been noted that the solvent choice can influence the behaviour of the CAN in the reaction, 
allowing for a variety of different types of reactions to occur.
121
 
 
4.1.1. CAN as an oxidant 
One of the first reported uses of CAN for synthetic purposes was in the Physical Chemistry 
laboratories at Oxford by J. Shorter where it was found that alcohols and ketones containing α-
hydrogen atoms could be oxidized to carbon dioxide, formic acid or acetic acid.
122
 Shortly after 
Shorter’s findings were published Trahanovsky and Young further developed the methodology to 
make it more suitable for synthetic oxidations of organic molecules. Additionally they showed 
that these oxidations can be applied to the oxidation of benzyl alcohols to benzaldehydes in 
excellent yields. Scheme 25 outlines this synthesis that was performed in a 50% aqueous acetic 
acid solution containing a 0.5 M CAN solution at room temperature (or slightly warmed) for a few 
minutes before being extracted with ether and washed with 1.5 M potassium hydroxide 
solution.
123
 
 
   
 
    
    (92-94 %)     
Reaction conditions: 0.5 M CAN 50 % AcOH/H2O, rt. 
Scheme 25 – CAN-mediated oxidation of benzyl alcohols to benzaldehydes, where R = H, OMe, 
NO2 or Br 
 
A few years after, they extended their work to the oxidation of cyclopropylmethanol to 
cyclopropanecarbaldehyde in water at 75 °C. What made this work of particular importance was 
that it was a relatively high yielding reaction where all other reported yields for this oxidation 
with other oxidants tended to be low or as a by-product of another reaction.
124
 
Following these initial reports, the use of CAN as an oxidant became increasingly popular. The 
first review on the use of CAN in organic synthesis was published in 1973 by Ho. In this review he 
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highlighted that while exposing primary alcohols to CAN generates aldehydes (as in Scheme 25), 
similarly secondary alcohols could be oxidized to ketones.
125
 
Using CAN, Kurz et al. found that dicarbonates could be introduced to a toluene molecule from 
various peroxide sources (such as 149 in Scheme 26). They found that the carbonate could be 
added in a variety of different positions as shown in Scheme 26.
126
 
   
 
 
 
 
 
 
 
 
149 
 (58 %) : (31 %) 
 
 
  : (11 %) 
Reaction conditions: CAN (2.25 eq), MeCN, 60 °C, 24 h. 
Scheme 26 – Oxidative dicarbonate additions to toluene using CAN 
 
One of the most important examples of the use of CAN as an oxidant for this project was 
described by Jacob et al. where CAN was used to oxidize 1,4 dimethoxybenzenes to their 
corresponding quinones. These reactions were performed in acetonitrile with the addition of 2-3 
equivalents of CAN as an aqueous solution at room temperature for 30 minutes. During this study 
it was also noted that 1,4-dimethoxynaphthalene (150) could be oxidized to naphthoquinone 
(151) exclusively using the conditions shown in Scheme 27.
127
 This particular method can also be 
applied to 1,4-dihydroxybenzene systems as well as highly substituted 1,4-
dimethoxynaphthalene derivatives.
121
   
 
 
 
 
 
 150  151 (94 %)  
Reaction conditions: CAN aq (2-3 eq), MeCN, rt. 
Scheme 27 – CAN-mediated oxidation of 1,4-dimethoxynaphthalene to naphthoquinone 
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This reaction has since become a staple in the synthetic chemist’s handbook and is common 
practise in our laboratories.
128
 The oxidative abilities is not only limited to dimethoxy or 
dihydroxy substituents, but can also be applied to asymmetrical molecules. Butler et al. found 
that CAN could be used to oxidize N-p-anisylazoles to quinones and pyrazoles as shown in 
Scheme 28 where both products could be successfully isolated. Their study found similar results 
with triazoles, tetrazoles and pentazoles (which decomposes spontaneously to azide and nitrogen 
gas). Additionally it was found that the C‒O and C‒N bonds were oxidized preferentially to C‒C 
bonds.
129
  
 
 
 
 
 
         (19 %) 
Reaction conditions: CAN (2.1 eq), MeOH/H2O, rt, 24 h. 
Scheme 28 – Oxidation of N-p-anisylazole to quinone and pyrazole using CAN 
 
Aside from just a basic oxidation, it has been found that the oxidative conditions could prompt 
further reactions. Doyle et al. found that exposing substituted alkyl alcohol chains (such as 152) 
with a phenyl substituent to CAN resulted in the formation of furan type rings, such as 153 
outlined in Scheme 29 with minimal formation of side products (such as benzoic acid).
130
 
 
 
 
 
 
152  153 (77 %)  (10 %) 
Reaction conditions: CAN (2 eq), MeCN/H2O, 75 °C. 
Scheme 29 – CAN-mediated oxidation of alkyl alcohol to form a furan ring 
Horiuchi and Kiji found that in the presence of CAN, oxidative iodination could be performed on 
cyclic and acyclic ketones selectively at the α-position (Scheme 30A). They found that, given the 
choice, iodination occurs at the more highly substituted position as shown in Scheme 30 in high 
yields. 
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 A   (85 %) 
 
 
 
 B   (88 %) 
Reaction conditions: CAN (0.5 eq), I2 (0.5 eq), AcOH /H2O, 50 °C, 8 h. 
Scheme 30 – α-position iodination of cyclohexanones 
 
The research group of Baciocchi has done extensive investigations into the use of CAN as an 
oxidant. Amongst their substantial research was the 1,2- and 1,4-addition of aldehydes/ketones 
(154, Scheme 31) with alkenes enabled by CAN. In this report, a mechanism for the addition was 
proposed where CAN was used to generate an α-ketoalkyl radical on the aldehyde/ketone (155) 
which could add to the alkene (156) to generate radical 157. On exposure to a further equivalent 
of CAN, and the presence of a counterion (ONO2)
-
 three products would be possible – 
nitroketoalkane 158, the unsaturated adduct 159 and the dihydrofuran 160. They concluded 
surprisingly that 158 tended to be the major product out of the reactions, and the that R3 
substituent was unaffected by the reaction regardless of its degree of saturation. They made no 
mention of the resulting stereochemistry in nitroketoalkane 158.
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154        155 
 
   
 
 
158, 159  
or 160 
  156  157     
  
 
158 159 160 
Scheme 31 – 1,2- and 1,4-oxidative additions of alkenes to ketones 
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In molecules where there is no α-carbon, CAN can still be used to perform other vinylic and 
alcoholic coupling reactions with carbonyl-containing compounds (e.g. carbamates). A recent 
example of such a reaction was published by Bekkaye and Masson. They postulated a mechanism 
for the reaction where CAN oxidizes carbamate 161 to generate radical 162 (Scheme 32). This 
radical reacts with allyltrimethylsilane to form intermediate 163 which would be immediately 
oxidized by a further equivalent of CAN, in the process removing the trimethylsilyl (TMS) group to 
form 164. The alcohol (such as EtOH in the example given in Scheme 32) can then add 
nucleophillicly to the imine to form the desired product 165 in a single pot. Bekkaye and Masson 
generated a library of about 20 compounds using this method with other highly substituted 
carbamates, allyltrimethylsilanes and a few simple alcohols making this a method that could be 
widely used to generate β-allylated α-carbamido ethers under relatively mild conditions.
132
 
 
 
 
 
 
161  162  163 
 
 
 
 
 164  165 
Reaction conditions: CAN (2.5 eq), allyltrimethylsilane (1 eq), EtOH (1 eq), MeCN, -15 °C, 1 h. 
Scheme 32 – Multicomponent coupling reaction using CAN in the formation of complex vinyl 
carbamates 
 
Citterio et al. used CAN to add alkene and alkyne substituents to diethyl (pyridylmethyl)malonate 
(such as 166) as shown in Scheme 33. This resulted in the formation of cyclic products 167-170 in 
relatively high yields. Interestingly, for the alkene addition (Scheme 33A) the formation of the 
ortho product 167 and para product 168 was in a nearly equal ratio, with the para product being 
in slight excess when the reaction was performed in methanol. Conversely, the reaction with the 
alkyne (Scheme 33B) resulted in the substantial major product being the ortho product 169 under 
similar conditions.
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166   A 167  168 
 
 
 
 
 
 
 
166   B 169  170 
          Reaction conditions: CAN (2.2 eq), MeOH, N2, rt, 1-6 h. 
Scheme 33 – Alkene and alkyne addition to diethyl (pyridylmethyl)malonate facilitated by CAN 
oxidation 
 
In the presence of mole equivalents of CAN, benzylic alcohols could be oxidized to the 
corresponding benzaldehydes. Mehdi et al. investigated performing these reactions in ionic 
liquids. When substituted benzyl alcohols were exposed to 2 mol equivalents of CAN in 1-alkyl-3-
methylimidazolium triflate at 100-125 °C for 6-8 hours the alcohols were oxidized to their 
benzaldehyde in near quantitative yields. What was interesting to note was that no nitrated 
product or benzoic acid was collected when this ionic liquid was used.
134
  
Another use of CAN in an oxidative role is as an alternative to the Nef reaction in generating 
ketones and aldehydes from nitro compounds. Scheme 34 is an example of the reactions 
investigated by Olah and Gupta where the nitro alkane 171 was oxidized to heptaldehyde using a 
single equivalence of CAN (aqueous) in triethylamine and acetonitrile. In this study they found 
their method applicable to primary or secondary nitro alkyl (or alkyl aryl) compounds. A similar 
procedure can be performed on silyl nitronates as well as some unsaturated nitro compounds.
135
 
 
 
 
 
 
 171  (67 %)  
Reaction conditions: NEt3, aqueous CAN (1 eq), MeCN, 50 °C, 1.5 h. 
Scheme 34 – An example of the use of CAN to oxidize nitro compounds to aldehydes 
 
Of course the oxidation is not limited to ring forming reactions, but can also oxidize heterocycles 
into open ring analogues. Evans et al. provide an excellent example of this where they made use 
of CAN to oxidize oxazoles in moderate to good yields. They investigated this reaction with a wide 
variety of substituted oxazoles (such as 172 in Scheme 35) and found it to be widely applicable. 
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Performing the same reaction with other oxidants did not result in the same outcome. Only 
partial conversion was achieved using KMnO4 and Ce(OTf)4, however none to the excellent extent 
that was achieved with CAN. Interestingly, not all cerium based oxidants could be used for this 
transformation.
136
 
 
 
 
 
 
 
 
 172  (70 %)    
Reaction conditions: CAN (3.8 eq), MeCN/H2O, rt.  
Scheme 35 – Oxidation of oxazoles to form imides and carboxylic acids 
4.1.2. CAN as a nitrating agent 
Aside from oxidations, CAN has been used in the nitration of organic compounds. One of the first 
reports of this particular feature of CAN was by Ridd and his co-worker Dinçtürk where they 
nitrated several substituted benzene derivatives in acetonitrile. They compared their results to 
the standard method for nitration using concentrated nitric acid. Their results showed no 
significant difference between CAN and nitric acid in the ratio of the products (ortho or para) 
formed with the exception of with anisole where with CAS the major product formed was para 
product 174 (Scheme 36) while with nitric acid, ortho product 173 was the major resulting 
product. Additionally they found that the addition of water to the reaction suppressed nitration. 
The anisole reaction is shown in Scheme 36 outlining the differences in ratios between the nitric 
acid and the CAN-mediated reaction.
137
 
 
 
 
 
 
 
 
   173  174  
  CAN : 36.5 % ± 0.5 %  63.7 % ± 0.5 %  
  HNO3 : 65.9 % ± 0.6 %  34.1 % ± 0.6 %  
Reaction conditions: CAN or HNO3 (1 eq), MeCN, 84 °C, 2 min. 
Scheme 36 – Nitration of anisole using CAN and HNO3 
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Chawla and Mittal used CAN on a silica gel support to nitrate fused aromatic rings such as 
naphthalene, anthracene (used as an example in Scheme 37) and phenanthrene. They found that 
when only acetonitrile as a solvent was included in the reaction mononitrated (such as 175) and 
dinitrated products (such as 176) resulted. When the reaction was performed in acetic acid the 
resulting products were dinitrated aromatics (such as 176) as well as quinones (e.g. 177) further 
highlighting the importance of the role of the solvent in the nature of reactions that occur.
138
 
 
 
 
 
 
 
 
  175  176  177 
Yields in MeCN 55 %  27 %  0 
Yields in AcOH 0  35 %  65 % 
               Reaction conditions: CAN (1.1 eq), SiO2 (1 g), 60-65 °C, 1 h. 
Scheme 37 – CAN-mediated oxidation of anthracene under controlled conditions 
 
In the years that followed, the research group of Hwu et al. did extensive research into the use of 
CAN to generate α,β-unsaturated nitroalkenes. This can be done by the sonication of the alkene, 
sodium nitrite (10 eq) and CAN (2 eq) in acetic acid in a sealed tube. This methodology could be 
used on a wide variety of alkenes, including alkyl, cyclic and silyl and heterocyclic containing 
alkenes as shown in Scheme 38. They also proposed a mechanism for the nitration (Scheme 39) 
which again involves the generation of a radical on the alkene (178) after the nitro radical has 
attacked one end of the double bond. This radical can be transferred to the Ce
4+
 in the CAN, 
leaving a cation behind (179). Elimination of hydrogen then results in the regeneration of the 
alkene (180).
139, 140
  
 
 
 
Reaction conditions: CAN (2 eq), NaNO2 (10 eq), AcOH (12 eq)/CHCl3, 25-73 °C, 2.5 – 4 hours 
Scheme 38 – Nitration of benzofuran 
 
 
 
 
 
 
 
  178  179  180 
Scheme 39 – Proposed mechanism for the nitration of alkenes 
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Given the importance of the choice of solvent in nitration reactions with CAN, Deleersnyder et al. 
investigated using ionic liquids as the solvent. Their study focused on using 1-ethyl-3-
methylimidazolium triflate as the solvent as all of the substrates of interest were found to be 
soluble in this ionic liquid. When naphthalene was exposed to CAN in this particular ionic liquid, 
the major product from the reaction was 1-nitronaphthalene (90 %) with only trace amounts of 
2-nitronaphthalene (8 %), naphthoquinone (1 %) and phthalic acid (1 %) noted. The more water 
was introduced to the reaction the more naphthoquinone was formed, however significant 
quantities of 1-nitronaphthalene were isolated regardless of the volume of water added to the 
reaction.
141
 The use of ionic liquids in CAN based reactions is an interesting avenue of research 
and something that could be of potential use in other reactions. 
 
4.1.3. Removal and addition of protection groups using CAN 
4.1.3.1. Removal of protection groups 
Protection groups are widely used in organic synthesis, however once they have performed their 
function they can be problematic to remove. Methods for removal of protection groups often 
require harsh acidic conditions. CAN has been found to have substantial success removing a 
number of protection groups using mild catalytic conditions.
142
  
One of the first reported CAN-mediated deprotections was by the Hwu research group where 
they found that with CAN the trityl protection group could easily be removed from nucleotides 
and nucleosides. After stirring the protected nucleotide in an 
acetonitrile/dimethylformamide/water solvent mixture at room temperature for 1-15 hours with 
0.1 equivalents of CAN resulted in the formation of the deprotected nucleotide exclusively with 
no damage to the sugar moiety or phosphate chain. An example of this work is given in Scheme 
40. They also found that the mono p-methoxytrityl group could also be successfully removed 
under the proposed conditions.
143
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Reaction conditions: CAN (0.1 eq), MeCN/DMF/H2O, 25 °C, 10 h. 
Scheme 40 – Trityl protection group removal using catalytic amounts of CAN 
Not long after, the same research group found that the tert-butoxycarbonyl (or BOC) protection 
group could successfully be removed from nitrogen, oxygen or sulfur atoms and making it 
particularly useful for the removal of BOC groups from protected amino acids. Examples of the 
compounds that were successfully deprotected are shown in Figure 79. These reactions were 
performed in acetonitrile under reflux conditions with 0.2 equivalents of CAN.
144
 
 
 
 
A B C 
Figure 79 – N-protected (A), O-protected (B) and S-protected (C) BOC-containing compounds 
successfully deprotected using CAN 
 
Hwu proposed a mechanism for the protection group removal which accounted for how CAN 
could be used in catalytic amounts. Scheme 41 outlines the proposed mechanism for the removal 
of the BOC group from an amine, however a similar mechanism was proposed for the removal of 
the trityl group, in which the CAN oxidizes the heteroatom (O, N or S) and later the Ce
3+
 reduces 
the amide during the removal of the BOC protection group to regenerate the Ce
4+
, resulting in 
the formation of the alcohol/amine/thiol.
144
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Scheme 41 – Proposed mechanism for the catalytic deprotection of BOC from an amine 
 
Another research group – Markó et al. ‒ did extensive research into the use of CAN in the 
removal of ketals and acetals to regenerate alcohols. They also noted that while many methods 
exist for the removal of such groups, the typical acidic conditions could not be used for molecules 
containing sensitive moieties. The CAN procedure they developed allowed for the removal of the 
protecting groups using mild, neutral conditions with catalytic amounts of CAN (3 mol %) where 
no racemization or additional oxidation of the compounds they tested was noted. This procedure 
could be applied to a variety of acetals and ketals however was unsuccessful for the pinacol 
derived ketal. Figure 80 shows a selection of sensitive molecules that were successfully 
deprotected using their methodology in acetonitrile with a borate/hydrochloric acid buffer (pH 8) 
at 60 °C for 0.3 – 2.5 hours in excellent yields.
145
  
  
 
 
Figure 80 – Deprotection of ketals and acetals using mild, neutral conditions described by 
Markó et al.  
 
They also found that this methodology could be extended to the deprotection of 
tetrahydropyranyl (THP) and tetrahydrofuranyl (THF) ethers under the same conditions as 
described above. Again under these conditions the CAN was found to behave as a Lewis acid 
rather than an oxidant, resulting in only the removal of the ether moieties and no further 
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reactions occurred, allowing for the deprotection of highly sensitive alcohols. Examples of the 
types of molecules that were investigated and were successfully deprotected in good yields are 
depicted in Figure 81.
146
 
 
 
 
Figure 81 – A selection of compounds that were successfully deprotected using catalytic 
amounts of CAN 
 
Markó et al. found that this method was sensitive enough to be used in the deprotection of a 
single dioxolane moiety in bis protected sugars such as 181 in Scheme 42.
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 181    
Reaction conditions: CAN (3% mol), NaBrO3 (1.5 eq), MeCN/H2O, 60 °C, 1.2 h. 
Scheme 42 – Deprotection of a sensitive sugar using catalytic amounts of CAN 
 
Even when mole equivalents of CAN was added to the reaction mixture, the deprotection of 
ketals was still found to be favourable over the oxidation of other parts of the molecule. For 
example exposing 183 (Scheme 43) to CAN (2.5 eq) in acetonitrile/water could be expected to 
result in protected ketone 182 (given the significant oxidative ability of CAN), however the 
research group of Markó found that exclusively 184 was formed instead in a 79 % yield.
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182  183  184 (79 %) 
Reaction conditions: CAN (2.5 eq), MeCN/H2O, 70 °C. 
Scheme 43 – Selective acetal deprotection of 183 even when exposed to mole equivalents of 
CAN 
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Cotelle and Catteau investigated the use of CAN in the removal of benzylic acetal substituents. 
They found that CAN adsorbed onto SiO2 in dichloromethane resulted in the successful removal 
of the acetate groups, resulting in the regeneration of benzaldehydes. Interestingly, in diacetate-
protected benzaldehydes containing an aryl acetate functionality, the aryl acetate remained 
intact after the reaction. Particularly of interest was that 186 on exposure to CAN/Silica in 
dichloromethane formed benzaldehyde 185. When the same reaction was performed but with an 
addition of a small amount of water/methanol further oxidation to the quinone 187 was 
collected along with 185 (shown in Scheme 44). The acetal groups could not be removed from 
quinone 187 using this methodology.
148
 
 
 
 
 
 
 
 
 
185 (92 %)  186  187 (10 %)  185 (90 %) 
Reaction conditions: i) CAN/SiO2 (1 eq), DCM, rt, 92 %; ii) CAN/SiO2 (1eq), DCM/H2O, rt. 
Scheme 44 – Deacetylation and oxidation of diacetal protected aldehydes 
 
The use of CAN to remove the protection groups discussed up until now tends to be used more 
as an alternate method when the more conventional methods prove unsuccessful. Yoshimura et 
al. were amongst the first to discover that CAN could be used to remove the para-methoxybenzyl 
(or PMB) group. During the course of their research they found that PMB could be selectively 
removed from diketopiperazine derivatives (such as 188, Scheme 45), even in the presence of 
other methoxy substituents.
149
 On further development, it was discovered that PMB could be 
removed from a wide variety of analogues, such as 188 resulting in 189 in moderate to good 
yields. They investigated the use of CAN in 2-7.6 mol equivalents and in acetonitrile/water and 
methanol/water mixtures.
150
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 188  189 (99 %)  
Reaction conditions: CAN (3.8 eq), MeCN/H2O, rt, 2 h. 
Scheme 45 – CAN-mediated removal of PMB protection group from diketopiperazine 
 
When the reaction was performed without the addition of water, it was found that a methoxy 
substituent was introduced to the benzylic position of the PMB group and 190 (Scheme 46) was 
the major product isolated.
150
 
 
 
 
 
 
 188  190 (67 %)  
Reaction conditions: CAN (3.8 eq), MeOH, rt, 3 h. 
Scheme 46 – CAN-mediated addition of methanol to the benzylic position of the PMB group on 
diketopiperazine 188 
 
In the examples given by Yoshimura et al. the benzyl group appeared to remain intact after 
exposure to CAN. The research group of Davies at Oxford reported that on tertiary amines where 
both a benzyl group and a PMB group is present and exposed to CAN, two products were isolated 
(one where the PMB group was removed and one where the benzyl group was removed) in a 1:1 
ratio. In tertiary amines that contained two benzyl groups, they found that with 2.1 equivalents 
of CAN at room temperature in aqueous acetonitrile a single benzyl group could be removed. 
However, it was also noted that the third substituent in the tertiary amine impacted whether the 
benzyl group could be removed or not; the reactions were only successful with propyl, butyl, 
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hexyl and t-butyl amines. It was also possible with other, more highly substituted alkyl chains as 
shown in Scheme 47 below.
151
 
 
 
 
 
 
   (96 %)  
Reaction conditions: CAN (2.1 eq), MeCN/H2O; rt, 10 min. 
Scheme 47 – Benzyl deprotection from a tertiary amine using CAN 
 
A slightly different version of the PMB group – 3,4-dimethoxybenzyl group could also be removed 
using CAN. Davies and Ichihara made use of this in their synthesis of β-lactams and N-(α-
methylbenzyl)-β-amino esters, an example of which is shown in Scheme 48.
152
 
 
 
 
 
 
Reaction conditions: CAN, MeCN/H2O, rt. 
Scheme 48 – CAN-mediated removal of the 3,4-dimethoxybenzyl group from a tertiary amine 
 
Further highlighting the sensitivity and selectivity of this deprotection method, Wright et al. 
found that PMB groups could selectively be removed from monosaccharides in an acetone/water 
solution, even in the presence of other protection groups as shown in Scheme 49.
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   (72 %)  
Reaction conditions: CAN (4.2 eq), acetone/H2O, rt, 85 min. 
Scheme 49 – PMB removal from monosaccharides 
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The use of CAN in the removal of the PMB protection group has become widely accepted as the 
standard methodology because of its high efficiency and mild conditions. So much so that it has 
played a crucial role in the synthesis of several highly complex natural products such as the 
synthesis of (+)-18-epi-latrunculol A,
154
 lactacystin,
155
 (±)-lepadiformine A
156
 and latrunculin A
157
 
to name a few. Greater detail on the use of CAN in the removal of protection groups can be 
found in a review by Maulide et al.
142
  
 
4.1.3.2. Addition of protection groups 
Interestingly, CAN can also be used to add protecting groups to heteroatoms in selected 
examples. The research group of Roy et al. found that the addition of catalytic amounts of CAN 
could be used to chemoselectively protect aldehydes with 1,2-ethanedithiol in chloroform at 
room temperature as shown in Scheme 50. Additionally, under reflux conditions alicyclic ketones 
could also be selectively protected.
158
  
 
 
 
 
 
   (96 %)  
Reaction conditions: 1,2-ethanedithiol (2.1 eq), CAN (0.2 eq), CHCl3, rt, 18 h. 
Scheme 50 – Chemoselective thiolacetalization of aldehydes 
 
A wide variety of alcohols can also be protected using 3,4-dihydro-2H-pyran and CAN adsorbed 
on silica in acetonitrile at room temperature for 5-15 minutes. Pachamuthu and Vankar 
developed this method and found that it could be applied to highly sensitive molecules. A 
selection of sensitive molecules that were successfully THP protected are shown in Figure 82. It 
should be noted that the reaction was not enantioselective and both enantiomers of each 
product were isolated.
159
 
    
Figure 82 – A selection of alcohols that were successfully THP protected using CAN adsorbed on 
SiO2 
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4.1.4. Other uses of CAN in organic synthesis 
CAN has been used to facilitate a variety of other reactions. CAN has been used in a 
multicomponent coupling reaction, reported by Sridharan et al. where CAN was used in 
Friedländer and Friedländer-Borsche annulations for the synthesis of luotonin A. The reactions 
were performed in ethanol where CAN behaves as a Lewis Acid. Scheme 51 details one of the 
reactions investigated, where the substituted aniline 191 and  ethyl 3-oxobutanoate 192 
condense to form intermediate 193 in the presence of CAN that can then cyclize resulting in the 
formation of 194.
160
 
 
 
 
 
 
 
 
 191  192  193  
   
 
 
  
   194 (98 %)   
Reaction conditions: CAN (15 mol %), EtOH, reflux, 8 hours. 
Scheme 51 – Friedländer annulation catalysed using CAN 
 
Clark et al. reported the use of CAN as a radical initiator in the oxidative 5-endo cyclization of 
enamides in average yields. This was performed in methanol and the reaction proposed to 
proceed as outlined in Scheme 52. The choice of solvent was determined by the nature of the 
ester present in the molecule to prevent nucleophilic attack of the solvent at the ester.
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Scheme 52 – Proposed mechanism for the CAN-mediated cyclization of enamides 
 
An article was published by Tale in Organic Letters in 2002 that outlined the use of CAN to 
generate 2-arylbenzothiazoles from thiophenols and aromatic nitriles. The reaction was 
performed in acetonitrile with 2 equivalents of CAN and solid sodium bicarbonate as shown in 
Scheme 53.
162
 
 
 
 
 
 
 
 
     (95 %)  
Reaction conditions: CAN (2 eq), NaHCO3, MeCN, rt, 30 min. 
Scheme 53 – Reported CAN-mediated formation of 2-arylbenzothiazoles by Tale 
 
The following year Nair and Augustine found that the work published by Tale was irreproducible 
under the reported conditions and that the only product that was isolated from the reactions 
were disulfides (such as 195 in Figure 83) or thiosulfonates (such as 196). They achieved the same 
results even without the addition of the aromatic nitrile and rationalized what was seen by the 
generation of radicals on the thiols which can quench by reacting with themselves resulting in the 
disulfides (such as 195), the presence of more CAN could further oxidize the disulfides to 
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thiosulfonates (such as 196). Alternatively the thiol radical could be oxidized further with 
atmospheric oxygen which could then react further to give the thiosulfonates.
163
  
  
195 196 
Figure 83 – An example of the disulfides and thiosulfonates generated when thiols are exposed 
to CAN 
 
There have been several reports of diaryl sulfides oxidized by CAN to sulfoxides which supports 
this theory.
125,164
 A more recent example of this oxidation was by Hajipour et al. where sulfides 
were successfully oxidized to sulfoxides using CAN in 1-hexyl-3-methylimidazolium bisulfate (an 
ionic liquid) at 80 °C. This reaction was successful even without the addition of water to the 
reaction. Figure 84 shows some examples of some of the sulfides that were successfully oxidized 
using CAN.
165
  
  
  
Figure 84 – A selection of sulfides that can be oxidized to sulfoxides when exposed to CAN 
 
A more unusual example of the reactivity of CAN was published by Nair and Mathew where 
dihydrofurans were synthesized from 1,3-dicarbonyl compounds and alkenes. A mechanism for 
this unusual reaction was postulated and is outlined in Scheme 54. This methodology was applied 
to two 1,3-dicarbonyl compounds (dimedone and acetylacetone) and a variety of different 
alkenes and showed superior reactivity over a similar reaction being performed using manganese 
acetate. In order for this reaction to occur it was found that a methanolic solution of the 
dicarbonyl and the alkene (in a 2.5:3 ratio) needed to be cooled to 0 °C over an ice bath before 
CAN (4.6 mmol equivalents) dissolved in methanol was added. The reaction was deemed 
complete after 15 minutes. The reactions were less successful with dienes than with alkenes and 
there were no reports of regioisomers collected.
166
 
 
 
 
Plot Twist 
 
 
Introduction 
 
 
126 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 54 – Proposed mechanism for the synthesis of dihydrofurans from 1,3-dicarbonyls and 
alkenes 
 
The mild conditions required for reactions with CAN have allowed for its use in a variety of other 
unusual reactions; for example as a radical initiator for polymerization reactions
167
 or to modify 
protein residues.
168
 Greater detail on the use of CAN in organic synthesis can be found in one of 
several different reviews by Ho,
125
 Sridharan and Menéndez,
169
 Nair et al.
170
 and Hwu and King.
171
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4.2. The use of Ceric Ammonium Sulfate in Organic Synthesis 
Ceric ammonium sulfate (or CAS) is the significantly less famous older brother of CAN. It was 
initially developed to prevent the cumbersome fresh preparation of ceric sulfate from an impure 
ceric oxide (which was used as a reference standard in oxidimetry). In the report by Smith et al. 
that described the first proposed synthesis and use of CAN, they noted that while CAS was 
commercially available and readily soluble in dilute sulfuric acid, the solution composition of 
sulfate and ammonia was highly variable and formed a highly hydroscopic salt making it 
unsuitable for use as a reference standard.
119
 Physically, CAS ((NH4)4Ce(SO4)4.2H2O) is markedly 
similar in appearance to the better known CAN and is commercially available as orange 
powder/crystals. CAS also tends to behave as a single electron transfer agent. The major 
difference between the two being the solubility of the ceric salts in water and organic solvents – 
CAN is readily soluble in both while CAS is significantly less so. Perhaps consequently, very little 
literature exists on the use of CAS in synthetic reactions. The literature review below details the 
few reports of CAS in organic synthesis. 
 
4.2.1. CAS in polymerization reactions 
One of the first reports of the use of CAS was by Mino et al. in 1958 where they investigated the 
oxidation of pinacol using CAS. The use of CAS (in 1N sulfuric acid) was used to determine the 
effect of the presence of acrylamide in the reaction mixture would have on the oxidation of 
pinacol. When no acrylamide was added to the reaction, it was found that CAS successfully 
oxidizes pinacol to acetone as shown in Scheme 55.
172
  
 
  
 
 
    
  
Scheme 55 – CAS mediated oxidation of pinacol 
 
When acrylamide (a monomer) was introduced to the reaction, significantly less acetone was 
formed along with the appearance of a polymer. It was determined that the radical alcohol 
generated by the oxidation of pinacol served as an initiator for the polymerization of acrylamide. 
The polymerization was terminated when the radical polymer was quenched by a further 
equivalent of Ce
4+
.
172
 
Several years later, Subramanian and Santappa also used CAS as a radical initiator for the 
polymerization of acrylonitrile, methyl acrylate and methyl methacrylate using malonic acid or 
cyclohexanone to complete the redox systems. Their study confirmed that while the rate of 
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initiation was slower than what would be obtained using CAN, the chain length of the polymer 
that resulted was longer.
173
 
Since then, CAS has been used as a polymerization initiator. Due to CAS being a single electron 
transfer agent, it became vital that CAS be used as part of a redox pair to be able to use CAS in 
catalytic amounts and to prevent the formation of large amounts of homopolymer formation. An 
example of more recent polymerization work was published by Chowdhury et al. in 2001 where 
they used CAS and dextrose as a redox pair in the graft polymerization of methyl methacrylate 
onto guar gum. They investigated the optimal parameters for this particular reaction but found 
that polymethyl methacrylate could easily be found using the CAS/dextrose redox pair initiator in 
water.
174
 
 
4.2.2. CAS in the solid state 
Due to the tendency of the CAS to hydrolyse in an aqueous environment – growing crystals 
suitable for SCXRD analysis was found to be very difficult. Shan and Huang managed to use 
hydrothermal methods to grow crystals of CAS as a dimeric unit.
175
 CAS has also been used as a 
raw material to generate a variety of other cerium (IV) based complexes. Abrahams et al. used 
CAS and 2,5-dihydroxybenzoquinone (dhbq) in a 1:2 ratio to generate a Ce
3+
 complex 
(Ce2(dhbq)3.24H2O) regardless of ratio of reactants were added. The dhbq serves as a chelating 
bridge between two cerium metal centers which, along with the 8-coordinate geometry of the 
cerium metal centers, form cages that can trap large amounts of water molecules.
176
 
Singh and Singh investigated the complexation of coumarins to a variety of metals. It was thought 
that the hydroxyl group on coumarins was the main reason for the significant biological activity 
shown as it could form complexes. Singh and Singh took the opportunity to investigate how 
different metals (Mn
2+
, Fe
3+
, Cu
2+
, Ti
4+
, Zr
4+
, Ce
4+
, Th
4+
 and UO2
2+
) would coordinate to 4-methyl-
7,8-dihydroxycoumarin and 4-methyl-6,7-dihydroxycoumarin. CAS was dissolved in an aqueous 
ethanolic solution before the coumarins were added and once the solution was adjusted to pH 5 
the precipitates that were collected were found to be complexes 197 and 198 in Figure 85.
177 
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197 198 
Figure 85 – Ceric complexes generated from exposing CAS to coumarins 
 
4.2.3. Using CAS in Organic Synthesis 
In the 1950’s Tozer and Tuck used CAS to generate semiquinone free radicals in phenothiazines 
(Figure 86). Their aim was to investigate the lifetime (and hence stability) of the free radicals 
generated and was performed under acidic conditions allowing the CAS to be readily soluble 
throughout their experiment.
178
 
 
R = OMe, Me, Ph, Cl, Br or I 
Figure 86 – Phenothiazine scaffold that was oxidized to semiquinones using CAS 
 
As previously mentioned, Doyle et al. used CAN to generate furan rings from alkyl alcoholic 
chains containing an aryl substituent (Scheme 29). Included in their research, they investigated 
using CAS instead of CAN to mediate the reaction and found that only starting material was 
obtained from the reaction (Scheme 56). It was also noted that while the CAN formed the 
characteristic ceric-complex red colour when added to the alcohol, the same observation was not 
noted when CAS was used. Given that the reactions were performed in 7:1 acetonitrile : water it 
is possible that no reaction occurred due to a lack of solubility.
130
 
 
Plot Twist 
 
 
Introduction 
 
 
130 
 
 
  
 
 
Scheme 56 – Attempted CAS mediated oxidative cyclization of alkyl alcohols 
 
One of the first synthetic uses for CAS was by Periasamy and Bhatt. They found that CAS could be 
used to oxidize polycyclic aromatic hydrocarbons to quinones. Given that this was the first official 
report of the use of CAS and the general lack of literature surrounding using CAS in organic 
synthesis, a detailed investigation into their work is outlined in Scheme 57. The reactions were 
performed in acetonitrile with dilute sulfuric acid with 6 mol equivalents of CAS at temperatures 
ranging between 25-50 °C for 4-6 hours. The results of these reactions resulted in several 
surprises – the first of which being the formation of ortho-quinones 200 (B), 201 (C) and 206 (E). 
The naphthalene in Scheme 57D showed that either aromatic ring could be oxidized (202 and 
203), however the non-substituted aromatic ring oxidation (203) was produced in higher yields. 
Finally when 1-bromonaphthalene was exposed to CAS a variety of products were isolated. The 
first of which being the most predictable brominated naphthoquinone (204), surprisingly a 1,2-
bromine shift during the oxidation of the naphthalene affording 205, the formation of ortho-
quinone 206 as mentioned previously as well as the isolation of para-naphthoquinone (151) 
where the bromine atom was absent.
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  A 151 (90-95 %)  
 
 
 
 
 
 
 
   199 (15 %)  200 (60 %)  
B 
 
 
 
 
 
        C 201 (73 %)  
 
 
 
 
 
 
 
   202 (26 %)  203 (45 %)  
D 
 
 
  
 
 
 
 
   204 (15 %)  205 (10 %)  
   
 
 
 
 
    206 (30 %)  151 (18 %)  
E 
Reaction conditions: CAN (6 eq), 4N H2SO4, 25-50 °C, 4-6 h. 
Scheme 57 – CAS mediated oxidation of polycyclic aromatic hydrocarbons 
 
The 1,2-shift of the naphthalene substituent was highly unexpected and prompted further 
investigation by this research group. To confirm the oxidation products, they exposed 1,4-
d2naphthalene to CAS and found that at least 3 products (Scheme 58) were formed; 151 (where 
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the oxidation occurred at the deuterium atoms), 207 (where the alternate aromatic ring was 
oxidized) and 208 where a 1,2-shift occurs on oxidation. These products were determined by 
mass spectroscopy and no mention was made regarding yields.
180
 
 
 
 
 
 
 
 
 
 
 
 
   151  207  208  
Scheme 58 – Oxidation of deuterium labelled naphthalene using CAS 
 
In order to investigate the extent of the 1,2-shift Periasamy and Bhatt furthered their 
investigations to include the reactions outlined in Scheme 59 below. Exposing 1,5-
dibromonaphthalene to CAS resulted in the exclusive formation of the 1,2-shift oxidation 
product, 209 in a respectable yield of 66%. Perhaps more interestingly, when 210 was oxidized by 
CAS both the oxidation to quinone (211) had occurred in addition to the 1,2-shift oxidation 
product 212 in almost equal proportions.
180
 
 
 
 
 
 
   209 (66 %)  
 
 
 
 
 
 
 
 210  211 (28 %)  212 (24 %)  
Reaction conditions: CAN (4 eq), MeCN/4N H2SO4, 50-60 °C, 4-5 h. 
Scheme 59 – Investigation of the 1,2-substituent shift in other substituted naphthalenes 
 
The presence of 212 is highly significant as this was the first example of a C‒C bond shift that 
occurs exclusively in oxidation reactions using CAS – so much so that it was highlighted in a 
review on the effects of transition metal salts on hydrocarbons.
181
 A mechanism was proposed by 
Periasamy and Bhatt (Scheme 60), where the naphthalene is oxidized to radical cation 213 which 
would exist in equilibrium with 214. From there water can add to the carbocation to give 215. On 
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further oxidation of 215 a carbocation is generated (216) and from there the 1,2-shift occurs to 
give 217. Following the removal of a proton to give rise to 218 and the further oxidation and 
further addition of water affords the naphthoquinone 219.
180
 Decades later, they noted that the 
1,2-shift could occur after the first hydroxy group was introduced to the naphthalene. 
182
 
 
 
 
 
 
  213  214 
 
 
 
 
 
 215  216  
 
 
 
 
 
217  218  219 
Scheme 60 – Proposed mechanism for the 1,2-shift during the oxidation of naphthalenes 
 
The oxidation of 1-methyl naphthalene (220, Scheme 61) resulted in the formation of 1-
naphthaldehyde (221) and naphthoquinone (151). Furthermore, when 1-naphthaldehyde 221 (or 
1-naphthoic acid) was exposed to CAS under the same conditions the only product isolated from 
the reaction was naphthoquinone (151) in average yields of 42-50 %. A similar observation was 
noted with 1-naphthol, however naphthoquinone (151) was only isolated in a poor yield (20 %) 
and the remainder of the majority of the reaction produced polymeric, oxidative material.  
 
 
 
 
 
 
 
 220  221 (30 %)  151 (20 %)  
Reaction conditions: CAN (6 eq), MeCN/2M H2SO4, 25 °C, 24 h. 
Scheme 61 – CAS mediated oxidation of 1-methyl naphthalene 
 
They also exposed naphthalenes 222 and 224 (Scheme 62) to CAS under similar conditions 
resulting in 223 in a respectable yield (from 222) and in the formation of 205 and 206 (from 224). 
Interestingly, when 225 was exposed to CAS in a solution containing dilute acid two products 
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were isolated – an unexpected 226 being the major product along with a small amount of 227 
formed. In a reaction with more concentrated sulfuric acid, only 228 was isolated. This was the 
only example of a double 1,2-substituent shift in their research. Bhatt and co-workers also found 
that similar 1,2-substituent shifts during the oxidation of naphthalenes (such as those in Scheme 
62) could be achieved using manganese(III) sulfate.
182
 
 
 
 
 
 
 222  223 (60 %)  
 
 
 
 
 
 
 
 224  205 (60%)  206 (15 %)  
 
 
 
 
 
 
 
 225  226 (52 %)  227 (20 %)  
 
 
 
 
 
 225  228 (68 %)  
Reaction conditions: i) CAN (4 eq), MeCN/2M H2SO4, 25 °C, 2 h; ii) CAN (6 eq), MeCN/0.5M H2SO4, 50 °C, 3 h; 
iii) CAN (6 eq), MeCN/6M H2SO4, 50 °C, 4 h. 
Scheme 62 – CAS oxidation of 1,4-disubstituted naphthalenes 
 
In order to explain the results seen in Scheme 62, a new mechanism was proposed and this is 
outlined in Scheme 63.
182
 Similar to the mechanism in Scheme 60, the new mechanism also 
incorporates how naphthoquinone 151 is obtained from naphthalenes containing a methyl, 
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formyl or acid substituent (R1). The isolation of compound 226 showed a key intermediate in the 
1,2-shift of the substituents. 
       
 
 
 
 
 
       
 
R1 = CH3 
R2 = H 
221 
 
151 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 63 – Proposed mechanism for the oxidation and 1,2-substituent shifts of substituted 
naphthalenes 
 
In the early 80’s Skarżewski developed a redox system that would allow for the use of CAS in 
catalytic quantities. He reported that the addition of silver(I) nitrate, sodium dodecyl sulfate and 
ammonium persulfate added to the reaction with CAS in order to oxidize the cerium from Ce
3+
 
back to Ce
4+
 after it has oxidized the naphthalene. The reactions were successful even when the 
sodium dodecyl sulfate and ammonium persulfate were excluded from the reaction but resulting 
in a significantly lower yield. When the silver(I) nitrate was excluded from the reaction, the yield 
from the reaction was entirely dependent on the amount of CAS that was added. Skarżewski was 
concerned with the extent to which his methodology could be applied and found that the 
methodology was unsuccessful (or very poor yielding) in compounds where 1,4-dimethoxy 
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substituents were present as well as alcohol substituents anywhere in the molecule (the alcohol 
formed a complex with the ceric ion instead of reacting further). An example of the compounds 
investigated in this study is demonstrated in Scheme 64, where 2-methyl naphthalene (229) was 
oxidized by CAS to 230 as the major product and 231 as a minor product.
183
 
 
 
 
 
 
 
 
 229  230 (60 %)  231 (20 %)  
Reaction conditions: CAN (0.1 M), (NH4)2S2O8 (3.5 g), AgNO3 (0.03 M), SDS (0.001 M), 0.55 M H2SO4, 50 °C, 5 
h. 
Scheme 64 – An example of the oxidations investigated using the Skarżewski CAN redox 
method 
 
Inspired by the work done by Bhatt and co-workers, Balanikas et al. explored the oxidation of 
more polynuclear aromatic hydrocarbons using CAS. In acetonitrile/4N sulfuric acid, 2 mol 
equivalents of CAS was added to the relevant polyaromatic compound and stirred at room 
temperature for 5 hours (selected examples shown in Scheme 65). The oxidation of 
benzo[k]fluoranthene (232) resulted in the formation of para-quinone 233 and ortho-quinone 
234. Interestingly, when benzo[b]fluroranthene (235) was exposed to CAN, lactone 236 was 
formed exclusively in a mediocre yield. When there was a hydroxy substituent present on the 1-
position of benzo[b]fluoranthene (237) an ortho-quinone, 238 was formed instead. When 
chrysene (239) was oxidized using CAS, both lactone 240 (minor) and ortho-quinone 241 (major) 
were isolated in poor yields. The formation of lactones 236 and 240 are particularly noteworthy 
as one of the aromatic rings was oxidized and a ring closing cyclization occurred.
184
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232  233 (28 %)  234 (10 %) 
 
 
 
 
 
 235  236 (53 %)  
 
 
 
 
 
 
 237  238 (30 %)  
 
 
 
 
 
239  240 (8 %)  241 (23 %) 
Reaction conditions: CAN (2 eq), MeCN/4N H2SO4, rt, 5 h. 
Scheme 65 – Polyaromatic compounds oxidized using CAS 
 
The most recent example of the use of CAS in organic synthesis was by Lawrence et al. where 
instead of adding a reagent to oxidize the Ce
3+
 back to Ce
4+
, this was performed using electrolysis 
for the oxidation of alcohols to their corresponding benzaldehydes in a biphasic system. The 
relevant benzyl alcohol was dissolved in dichloromethane, the CAS (0.23 equivalents) was 
dissolved in a 1.3M solution of perchloric acid and carefully placed on top of the 
dichloromethane solution. Two types of experiments were performed; one where the 
dichloromethane layer was mixed exclusively and the electrodes (2.5 F/mol and 30 mA/cm
2
 
current density) were placed in the aqueous acidic layer close to the interface between the layers 
but without touching it and the second one where the two phases were stirred together for 90 
minutes. They found that the biphasic electrolysed method resulted in higher yields for the 
biphasic system than when the biphasic system was mixed. Figure 87 below shows the 
benzaldehydes that were successfully generated using their methodology.
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Figure 87 – Benzaldehydes generated using the electrolytic biphasic system by Lawrence et al. 
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4.3. The use of CAN/CAS in the WITS Laboratories 
4.3.1. Project Origin 
As previously stated, CAN is currently used in the WITS Laboratories to remove para-
methoxybenzyl protecting groups from heteroatoms, but mainly for the oxidation of aromatic 
para-dimethoxy ethers to quinones.
128
 It has also become of interest to our laboratories for the 
synthesis of xanthones where we developed novel methodology based on the use of CAN, as will 
be outlined later in this section.  
However, our interest in the synthesis of xanthones began in 1988 where my supervisor, Charles 
de Koning, and Giles developed methodology for the synthesis of the xanthone bikaverin (242) 
shown in Figure 88. The xanthone core is highlighted in green in Figure 88.
186
 
 
242 
Figure 88 – The structure of bikaverin with the xanthone ring core highlighted in blue 
 
Scheme 66 outlines the synthetic route used, where a Friedel Crafts reaction mediated by 
trifluoroacetic anhydride (TFAA) resulted in the formation of benzophenone 243. In this 
synthesis, it is also important to highlight the unexpected synthesis of spiroketal 245 which was 
formed from the 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) oxidation of 244, probably 
mediated by a radical process.
186
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    243 (51 %) 
 
 
 
 
 244 (80 %)  245 (61 %) 
 
 
 
 
 (94 %)  (93 %) 
Reaction conditions: i) TFAA, DCM, rt, 90 h; ii) 10 % Pd/C, H2, 5 bar, 1 h; iii) DDQ, benzene, rt, 68 h; iv) TFA (aq), 
CH2Cl2, rt, 5 min; v) 200 °C, 1.1 bar, 1 h. 
Scheme 66 – Synthetic route employed by de Koning and Giles in the synthesis of bikaverin 
 
More recently, an attempt was made to expand this methodology to other naturally occurring 
xanthones. However the use of this route proved to be unsuccessful, in part due to the Friedel 
Crafts reaction to form the benzophenone which resulted in products formed in very low yields. 
However, when Mondal et al. changed the synthetic approach a new method was reported. The 
key features of their synthesis is outlined in Scheme 67, where the benzophenone (247) was 
installed using a lithiation reaction; 1-bromo-2,3,5-trimethoxybenzene (246) was treated with n-
butyllithium (n-BuLi) and reacted with a benzyl protected ester at -78 °C. Following the removal 
of the benzyl groups from 247 using 10% palladium on carbon (Pd/C), the xanthone 249 was 
formed quantitatively by the treatment of 248 under basic conditions (potassium hydroxide at 
reflux in methanol) by means of an oxa-Michael addition followed by elimination to furnish 
249.
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 246  247 (100 %)  
 
 
 
 
 248 (100 %)  249 (100 %) 
Reaction conditions: i) n-BuLi (1 eq), THF, -78 °C, 75 min; ii) 10 % Pd/C, H2, MeOH, rt, 6 h; iii) KOH (5 eq), 
MeOH, reflux, 12h. 
Scheme 67 – Synthetic route employed by Mondal et al. to synthesize xanthones 
 
While the base catalysed oxa-Michael addition to form xanthones was successful for Mondal et 
al., it was not of interest to our research group. The n-butyl lithium facilitated formation of the 
substituted ketone was synthetic methodology we wished to utilize. In previous research in our 
laboratories, this formed a key step of Jeremy Naidoo’s MSc. Combining the synthetic 
methodologies by de Koning and Mondal, he attempted to form spirofuran 254 using the 
synthetic route outlined in Scheme 68. The lithiation reaction between 2-bromo-1,4-
dimethoxynaphthalene (250) and the benzyl protected ester (251) resulted in the successful 
formation of the benzophenone compound 252 in a good yield. The deprotection of 252 to form 
the phenol 253 was also high yielding. Unfortunately the formation of 254 using DDQ was 
unsuccessful regardless of the conditions used.
188
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250  251  252 (89 %) 
 
 
 
 
 
 
 
  253 (97 %)  254  
Reaction conditions: i) n-BuLi, THF, -78 C, 90 min; ii) 5 % Pd/C, H2, 5 atm, 18 h; iii) DDQ, benzene, rt, 72 h; iv) 
DDQ, benzene, reflux, 72 h; v) DDQ, CHCl3, rt, 72 h; vi) DDQ, CDCl3, reflux, 72 h. 
Scheme 68 – Synthetic route employed by Naidoo in an attempt to form the spirofuran 254 
 
Naidoo then had to change tack in the synthesis, they envisaged that 253 could be oxidized to 
255 which could then undergo a Michael addition reaction to form xanthone 256 – potentially all 
in a single step using CAN as shown in Scheme 69.
188
  
 
 
 
 
 
253  255  256 
                 Reaction conditions: CAN, MeCN/H2O, rt, 1.5 h. 
Scheme 69 – Proposed CAN oxidation of 253 
 
On exposure of 253 to CAN in acetonitrile/water the expected oxidation did not occur, however 
an unexpected product was isolated instead. The dione product (257) shown in Figure 89 was 
isolated in a reproducible yield of 72 %.
188
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257 
Figure 89 – Unexpected product when 253 was exposed to CAN 
 
There was some literature precedence for the generation of such diones under oxidative 
conditions – Franck and Zeidler reported the generation of similar diones as well as xanthones 
and spirofuran type compounds when exposing benzophenones which contain an alcohol 
substituent to potassium ferrocyanate (K3[Fe(CN)6]) and later by Ellis et al. using the same 
catalyst.
189,190
 
Given how unexpected this product was, Naidoo repeated this synthesis, this time using the 
substrate derived from 1,4-dimethoxybenzene. When this benzophenone (258) was exposed to 
CAN, two products resulted; dione 259 (15 %) and xanthone 260 (74 %) as shown in Scheme 
70.
188
 
 
 
 
 
 
 
 
 258  259 (15 %)  260 (74 %)  
Reaction conditions: CAN, MeCN, rt, 1.5 h.  
Scheme 70 – CAN oxidation of substituted benzophenone 258 
 
4.3.2. Development by Johnson 
These interesting results also formed the basis of Myron Johnson’s MSc at this university where 
he further investigated this CAN-mediated reaction. To confirm the results obtained by Naidoo, 
Johnson repeated the CAN oxidations of 253 and 258 and found the same products were 
generated in similar yields. Furthermore, when the trimethoxybenzophenone (261, Scheme 71) 
was exposed to CAN he found that only a single product, xanthone 262, was collected in an 
excellent yield (91 %).
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 261  262 (91 %)  
Scheme 71 – CAN oxidation of trimethoxybenzophenone 261 
 
In order to determine how general this CAN-mediated reaction was, it was further expanded to 
include the chlorine-containing substrates as shown in Scheme 72. The results obtained for 
Scheme 72A and B show similar results to that obtained without the chlorine; phenol 263 was 
oxidized exclusively to novel dione 264, while dimethoxybenzophenone 265 was oxidized 
afforded dione 266 and xanthone 267. When trimethoxybenzophenone 270 was exposed to CAN 
dione 268 and xanthone 269 resulted, along with trace amounts of unexpected spirofuran-
containing product, 271.
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 263  264 (93 %)  
A 
 
 
 
 
 
265  266 (17 %)  267 (63 %) 
B 
 
 
 
 
 
 
 
 268 (29 %)                269 (21 %) 
 
 
  
  
  
  
270   271 (9 %)    
C 
Reaction conditions: CAN (5 eq), MeCN/H2O/CHCl3, rt, 10 min. 
Scheme 72 – CAN-mediated oxidation of chlorine-containing benzophenones 
 
These results were novel and were published as a Note in the Journal of Organic Chemistry in 
2010, along with a proposed mechanism for the reaction (Scheme 73). We postulated that the 
substituted benzophenone (such as 258) could either be oxidized by CAN to generate a radical 
cation on the dimethoxybenzene ring as shown in intermediate 272 (Scheme 73) which could 
then succumb to nucleophilic attack from the phenol to give radical intermediate 273. 
Alternatively, CAN could generate an oxygen centered radical on the phenol (274) which could 
then add to the dimethoxybenzene ring, also generating radical intermediate 273. This radical 
can be stabilized by resonance and can then either be quenched by further oxidation of 273 
resulting in the formation of dione (such as 259) or could eliminate methanol resulting in 
xanthone 260.
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 272 
   
 
    259 
 
 
 
 
258  273  
 
 
 
 
         
                              260 
 
 
 
 274    
Scheme 73 – Proposed mechanism for the CAN oxidation of substituted benzophenones to 
form diones and xanthones 
 
4.3.3. Development of CAN reaction by Omolo 
From these results, and aiming to use this new methodology to synthesize naturally occurring 
xanthones, Justin Omolo during the course of his PhD at the University of the Witwatersrand 
explored this methodology further. He began by repeating Scheme 70 and Scheme 71, however 
this time in his hands he exclusively isolated 259 from 258 in a 72 % yield (no xanthone 260 was 
isolated) and 262 from 261 in a slightly lower yield of 63 %. 
It was completely unexpected that Scheme 70 would result exclusively in dione 259 – especially 
when it was previously only isolated as a minor product. Thus Omolo investigated methods to 
convert these diones into xanthones. He found that subjecting the dione 259 to microwave 
irradiation in DME resulted in the desired transformation. For example, Scheme 74 where 259 
was converted into 275 in a 50 % yield.
193
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 259  275 (50 %)  
Reaction conditions: DME, microwave, 10 min, 150 °C, 120 W. 
Scheme 74 – Conversion of dione to xanthone 
 
Omolo expanded the series of reactions performed by investigating the CAN-mediated reaction 
of benzophenones with aromatic bromides. He wished to obtain substrates containing aromatic 
bromides as these could be used in transition metal cross coupling reactions. The results from 
these reactions are reported in Scheme 75 where naphthalene 276 resulted in the formation of 
dione 277 in a mediocre yield of 48 %. The dimethoxybenzophenone substrate 278 resulted in 
the exclusive formation of 279 in a low yield and this could be converted to xanthone 280 in a 
poor yield. Following the same procedure, trimethoxybenzophenone 281 resulted in the 
formation of both dione 282 and spirofuran 283 in low yields when exposed to CAN.
193
 Although 
these reactions were novel, the outcome of the reactions in Scheme 75 was markedly different 
from what was obtained in the hands of Johnson and Naidoo.   
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 276  277 (48 %)  
A 
 
 
 
 
 
 278  279 (35 %)  
  
 
 
  280 (10 %)  
B 
 
 
281 
 
 
  
 
 
282 (18 %)   
 
 
 
 
   283 (22 %)  
C 
    Reaction conditions: i) CAN, MeCN/H2O/CHCl3, rt, 10 min; ii) DME, microwave, 10 min, 150 °C, 
    120 W. 
Scheme 75 – CAN-mediated oxidation reactions performed by Omolo 
 
The mechanism proposed by Omolo for the formation of spirofurans under the CAN oxidative 
conditions is outlined in Scheme 76 and follows the one proposed in the JOC 2010 paper.
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Scheme 76 – Proposed mechanism for the CAN-mediated formation of spirofurans 
 
Even though formed from low yielding reactions, the presence of the bromine atom on these 
diones, xanthones and spirofurans allowed further manipulation using the Suzuki-Miyaura cross 
coupling reaction – a well-developed reaction used extensively in the WITS laboratories. Initially 
attempted using dione 282, Omolo found that the Suzuki-Miyaura reaction (which was 
performed using microwave conditions) was unsuccessful, resulting in the formation of xanthone 
284 (Scheme 77).
193
 
 
 
 
 
 
 282  284 (34 %)  
Reaction conditions: 2-formyphenyl boronic acid, CsF, Pd(PPh3)4, DME, microwave, 10 min, 150 °C, 120 W. 
Scheme 77 – Resulting product from the attempted Suzuki-Miyaura coupling reaction under 
microwave conditions 
 
The Suzuki-Miyaura coupling reaction was then attempted using spirofuran compound 283 and 
was found to be successful using Pd(PPh3)4 under microwave conditions using a variety of 
aromatic boronic acids in moderate to good yields. A selection of the compounds formed and 
their yields are detailed in Figure 90.  
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(53 %) (67 %) 
 
(70 %) 
Figure 90 – Spirofuran compounds altered using Suzuki-Miyaura coupling reactions 
 
The spirofuran compounds synthesized bore a striking similarity to a commercial antifungal 
agent, griseofulvin (Figure 91) and so the spirofurans (and selected xanthones and diones from 
both Omolo and Johnson’s work) were tested for antimicrobial and antifungal activity. The 
results were published in Bioorganic and Medicinal Chemistry Letters in 2011 where the 
spirofurans showed good activity against the Cryptococcus neoformans yeast. Additionally, dione 
259 showed the best antifungal activity of all the compounds screened in both the Cryptococcus 
neoformans and the Candida albicans yeast cell lines and was comparable to the activity 
exhibited by the amphotericin B standard.
194
 This suggested that the use of this novel synthetic 
methodology could be useful in the development of new antifungal agents. 
 
Figure 91 – The structure of commercially available antifungal griseofulvin 
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4.4. Aims of this project 
Given the potential of developing new synthetic methodology for new antifungal agents as well 
as the discrepancy between the results obtained by Johnson and Omolo, it was deemed that 
further exploration of the novel CAN reaction was necessary. This aim formed one of the major 
objectives for this PhD project. 
In the paper published by Johnson et al. in 2010 a mechanism was proposed that relied on the 
fact that a para-methoxy substituent was necessary to stabilize the radical cation. The proposed 
radical generated, once cyclisation has occurred (273), has the potential to be resonance 
stabilized as shown in Scheme 78.
192
 From the proposed mechanism, the presence of methoxy 
groups in these positions would stabilise the radical intermediate and hence allow for the 
formation of xanthones or diones. However, no experiments had been conducted to support this 
hypothesis. 
 
 
 
 
 
  273   
Scheme 78 – Resonance stabilization of the radical intermediate of 273 
 
This project aimed at probing this mechanism by using the methodology developed by Johnson 
to generate benzophenone derivatives with methoxy substituents in other varying positions on 
the benzene rings that could be exposed to CAN. We were also interested in the effect of 
removing or adding additional methoxy groups to these substrates.  
An additional aim of this project is to determine if this novel synthetic methodology could be 
adapted to the synthesis of the nitrogen-containing derivatives, the biologically active acridones. 
Figure 92 shows examples of acridones isolated from the root of Thamnosma rhodesica.
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1-hydroxy-10-methylacridone (285) Rutacridone (286) 
 
 
Gravacridonediol (287) Rhodesiacridone (288) 
Figure 92 – Examples of naturally occurring acridones showing biological activity 
 
We hypothesised that the synthesis of the acridone ring core could be achieved by using the 
CAN-mediated ring closure methodology as outlined in Scheme 79 from commercially available 
anthranilic acid and 1,4-dimethoxybenzene. After a series of transformations akin to the 
xanthone methodology we would obtain benzophenone 291. Following deprotection of 291, 292 
could then be exposed to CAN to hopefully obtain either 293 or 294 (or a combination of both). 
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 289  290   
 
 
 
 
291  292  
 
 
 
                          293                   294 
Scheme 79 – Proposed synthesis of acridones using the CAN-mediated methodology 
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Plot Twist: 
Results and Discussion 
 
5.1. Repetition of work by Johnson 
Given the promising antifungal testing results obtained previously, some of the xanthones and 
related compounds needed to be resynthesized to conduct further biological assays. Following 
literature precedent, salicylic acid was easily converted to the corresponding O-benzyl protected 
ester 251 as shown in Scheme 80. 
 
 
 
 
 
 295  251 (99 %)  
Reaction conditions: Benzyl bromide (2.1 eq), K2CO3 (3 eq), acetone, reflux, 18 h. 
Scheme 80 – Benzyl protection of salicylic acid 
 
Since the following reactions were repeated exactly as described in Johnson’s MSc,
191
 the 
reactions are summarized in Scheme 81 below. 1,4-Dimethoxynaphthalene 150 was easily 
converted into 253 via the intermediates of 250 and 252. 
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251 
150  250 (50 %)  252 (58 %) 
 
 
 
 
 
 
  253 (74 %)  257 (86 %)  
Reaction conditions: i) NBS (1 eq), CHCl3, reflux, 2 h; ii) n-BuLi (1.28 M, 1 eq), 251 (0.9 eq), THF, -78 °C, 2 h; 
iii) 5 % Pd/C (10 mass %), MeOH, rt, 18 h; iv) CAN (5 eq), MeCN/H2O/CHCl3, rt, 18 h. 
Scheme 81 – Synthesis of dione 257 
 
The final step of this synthesis involved the key CAN-mediated oxidative cyclization of 253, which 
occurred as expected resulting in the formation of 257 in a similar yield to what was previously 
obtained. The structure of dione 257 was confirmed by 
1
H and 
13
C NMR spectroscopy and, along 
with COSY and HSQC experiments, the spectra were fully assigned. 
Similarly, dione 259 and xanthone 260 were synthesized using the same methodology employed 
by Johnson as shown in Scheme 82. Commercially available 1,4-dimethoxybenzene could be 
brominated to afford 289, subjected to lithiation and reacted with 251 to generate 
benzophenone compound 296. Finally, debenzylation to produce 258 resulted in a substituted 
benzophenone that could be used in the CAN-mediated cyclization reaction. All of these 
reactions occurred in good yields and the NMR spectra obtained matched Johnson’s results.
191
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      251 
  289 (77 %)  
 
 
 
 
 
 296 (71 %)  258 (76 %)  
 
 
 
 
 259 (44 %)  260 (32 %) 
Reaction conditions: i) NBS (1 eq), CHCl3, reflux, 3 d; ii) n-BuLi (1.4 M, 1 eq), 251 (0.9 eq), THF, -78 °C, 2 h; iii) 
5 % Pd/C (10 mass  %), MeOH, rt, 18 h; iv) CAN (5 eq), MeCN/H2O/CHCl3, rt, 18 h. 
Scheme 82 – Synthetic route utilized in the synthesis of dione 259 and xanthone 260 
 
While both 259 and 260 were isolated from the oxidation of 258 with CAN, a disturbing aspect 
was that they were isolated in markedly different yields to those reported by both Johnson and 
Naidoo (259 in a 15 % yield and 260 in a 74 % yield).
191
 As the purpose of the synthesis was to 
generate more xanthones and diones for biological testing it was performed on a significantly 
larger scale than that performed by Johnson. We initially attributed the difference in yields to the 
difference in reaction scale. As will be discussed later, this was not the case. 
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5.2. Initial attempts towards the synthesis of acridones 
With more confidence gained in the synthetic methodology to be used in this project, the 
synthesis of acridones was then attempted, as outlined in Scheme 79, using the same synthetic 
methods. Starting from commercially available anthranilic acid, we began with the benzyl 
protection as before. As detailed in Scheme 83, the combination of anthranilic acid, potassium 
carbonate and benzyl bromide with heating under reflux conditions, resulted in the formation of 
a sticky cream oil of 290 after purification by column chromatography. The 
1
H NMR spectrum of 
the product collected showed the presence of methylene benzyl groups which would be 
indicative of what we assumed were three benzyl groups attached to the anthranilic acid.  
 
 
 
 
 
   290  
Reaction conditions:  Benzyl bromide (3.1 eq), K2CO3 (3.5 eq), acetone, reflux, 12 h. 
Scheme 83 – First attempted benzyl protection of anthranilic acid 
 
The presumed 290 was used in the lithiation reaction (Scheme 84), and this resulted in the 
formation of a luminous yellow reaction mixture. Purification of this yellow product resulted in a 
yellow solid that was determined to be mono-N-benzylated benzophenone 297 (Figure 93) in a 
very low yield (12 %). The structure was determined from the 
1
H and 
13
C NMR spectra, where the 
benzylic CH2 signal was evident at 4.53 ppm and the N-H signal at 9.40 ppm in the 
1
H NMR 
spectrum and the ketone carbonyl signal at 198.5 ppm and the benzylic methylene carbon at 46.9 
ppm in the 
13
C NMR spectrum. This suggested that the sticky cream coloured oil which we 
assumed to be 290 was actually a mixture of benzylated products. 
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Cream oil 290 
 
 
 
 
 
 289  291  
Reaction conditions: n-BuLi (1.4 M, 1 eq), 290 (0.9 eq), THF, -78 °C, 2 h. 
Scheme 84 – Lithiation reaction using the sticky cream oil thought to be 290 
 
 
297 
Figure 93 – Product isolated from the lithium mediated coupling of 1,4-dimethoxybenzene and 
the sticky cream oil 
 
While 297 was not the desired product, it could potentially be a suitable candidate for 
attempting the CAN-mediated ring closure reaction and Scheme 85 outlines our first attempt at 
the formation of acridones using this method. The reaction was performed as before in an 
acetonitrile/water/chloroform solvent system at room temperature overnight. After purification 
by column chromatography, mostly starting material was isolated from the reaction (50 %), 
although acridone 298 was isolated in a 10 % yield as a yellow solid. Characterisation was made 
primarily using NMR spectroscopy where only a single methoxy signal was noted at 3.95 ppm, 
along with the presence of the benzylic CH2 at 5.61 ppm in the 
1
H NMR spectrum. Furthermore, 
the absence of the N-H signal suggested that the ring closure had in fact occurred. The 
13
C NMR 
spectrum (and relevant 2D experiments) along with high resolution ESI-MS further supported this 
structure ([M+H]
+
 for C21H18NO2 calculated 316.1338 and found to be 316.1338). It was also 
observed that the solution of 298 fluoresced blue under natural light – another characteristic 
feature of acridones.
196
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 297  298 (10 %)  
Reaction conditions: CAN (5 eq), MeCN/H2O/CHCl3, rt, 18h. 
Scheme 85 – The first attempt at acridone formation using the CAN-mediated methodology 
 
While wondering about the discrepancy in yields between our work and that of Johnson in our 
labs, it is of significance to highlight that up until this point, the CAN used was the same container 
of CAN that Johnson had used in his project. This container was hand-labelled, contained both 
orange and yellow crystals and was almost finished at this point of the project (shown in Figure 
94 and Figure 95).  
  
Figure 94 – The ‘Old CAN’ container with the faded labels 
 
Figure 95 – The physical appearance of the ‘Old CAN’ 
 
Given that a large amount of starting material was returned from Scheme 85, the reaction was 
repeated with the collected 297 but this time with the addition of CAN from a new bottle 
obtained from Sigma-Aldrich. After leaving the repeated reaction overnight (as previously done) 
no starting material remained. Unfortunately, no acridone 298 was isolated either. Albeit an 
accidental synthesis, this was a promising start for this project and was proof of concept that at 
least one acridone could be synthesized using the CAN methodology. Unfortunately, despite 
numerous attempts to repeat this synthesis using the Sigma-Aldrich CAN, no acridone was 
formed.  
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5.3. Irreproducible results and confusing catalysts 
5.3.1. Irreproducibility of Johnson’s results 
After the disappointment of not being able to reproduce the synthesis of acridones, we returned 
to the work performed in Johnson’s MSc dissertation to test if we could reproduce the results 
obtained using the new CAN obtained from Sigma-Aldrich. 
Bromination of 1,2,5-trimethoxybenzene was found to be spontaneous at room temperature 
when it was added to a stirring suspension of recrystallized N-bromosuccinimide in 
dichloromethane. The lithiation of 246 and subsequent reaction with ester 251 was successful, 
although in a mediocre yield (also noted by Johnson
191
). Debenzylation of 299 was quantitative 
using 5 % Pd/C under a hydrogen atmosphere, resulting in the formation of 261 as shown in 
Scheme 86. The NMR spectroscopic data matched well with Johnson’s reports for compounds 
246, 299 and 261. When Johnson exposed 261 to CAN he isolated xanthone 262 in a 91 % 
yield,
191
 however, repetition of the same reaction (as shown below in Scheme 86) resulted in the 
isolation of an unexpected spirofuran 300 albeit in a low yield. No starting material or any other 
products were isolated from this reaction and 300 was isolated even after repeating the reaction 
numerous times.  
 
 
 
 
251 
 
 
  246 (87 %)  299 (58 %) 
 
 
 
 
 261 (99 %)  300 (35 %) 
Reaction conditions: i) NBS (1 eq), DCM, rt, 20 min %; ii) n-BuLi (1.2 M, 1 eq), 251 (0.9 eq), THF, -78 °C, 2 h; 
iii) 5 % Pd/C (10 mass %), MeOH, rt, 18 h; vi) CAN (3 eq), MeCN/H2O, rt, 10 min. 
Scheme 86 – Synthetic route utilized in the repeated synthesis of the trimethoxy series 
 
Concerned that there was a contaminant in the new bottle of CAN purchased from Sigma-Aldrich 
that was resulting in the difference in the products obtained we recrystallized the CAN purchased 
from Sigma-Aldrich following the methodology prescribed by Perrin in the Purification of 
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Laboratory Chemicals.
197
 Scheme 81 and Scheme 82 were repeated using the recrystallized CAN. 
This time CAN was added portion-wise to a solution of substrate 253 and the reaction monitored 
by TLC. After the addition of only 2 equivalents of the new CAN (and after only about 10 minutes) 
no further starting material could be visualized on the TLC plate. After purification of the reaction 
mixture, dione 257 was collected, unfortunately in a very poor yield. Table 7 shows a comparison 
between the results obtained using the old hand-labelled bottle of CAN and the new bottle 
purchased from Sigma-Aldrich, as well as in comparison with results previously obtained. 
 
 
 
 
 
 253  257  
Scheme 87 – Repeated synthesis of 257 using the recrystallized CAN 
Table 7 – Comparison of the attempted synthesis of 257 using two different sources of CAN 
Experiment Catalyst Reaction conditions Yield of 257 
Naidoo
188
 Old CAN (5 eq) MeCN/H2O/CHCl3, r.t., overnight 72 % 
Johnson
191
 Old CAN (5 eq) MeCN/H2O/CHCl3, r.t., overnight 72 % 
Dam Old CAN (5 eq) MeCN/H2O/CHCl3, r.t., overnight 86 % 
Dam New CAN (2 eq) MeCN/H2O, r.t., 10 min 26 % 
 
As concerned as we were by this outcome, even more concerning results were obtained when 
the reaction was repeated using substrate 258 (Scheme 88). With the new bottle of CAN no 
xanthone 260 was isolated, and only dione 259 was isolated in a very poor yield. Using fewer 
equivalents of the new CAN and changing the temperature of the reaction (to reflux or to 0 °C) 
did not affect the outcome of the reaction. Changing the solvent mixture to a methanol/water 
solution resulted in the same observation – all the starting material was consumed almost 
immediately and only 259 was isolated in a poor yield. These results are outlined in Table 8.  
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258  260  259 
Scheme 88 – Repeated oxidation of 258 using the new CAN 
Table 8 – Comparison of the results obtained when 258 was exposed to different CAN sources 
Experiment Catalyst Reaction Conditions Yield of 260 Yield of 259 
Johnson
191
 Old CAN (5 eq) MeCN/H2O/CHCl3, r.t., overnight 74 % 15 % 
Dam Old CAN (5 eq) MeCN/H2O/CHCl3, r.t., overnight 32 % 44 % 
Dam New CAN (5 eq) MeCN/H2O, r.t., 10 min 0 3 % 
Dam New CAN (2.5 eq) MeCN/H2O, reflux, 10 min 0 30 % 
Dam New CAN (2.5 eq) MeCN/H2O, 0 °C, 10 min 0 24 % 
Dam New CAN (5 eq) MeOH/H2O, r.t., 10 min 0 16 % 
 
Even when the reaction was performed with a single equivalent of new CAN, the starting material 
was consumed within 10 minutes and only dione 259 formed in a poor yield. Since, from the 
proposed mechanism (Scheme 73), two equivalents of CAN were required to generate the dione 
species and dione was exclusively formed even with the addition of 1 equivalent of CAN, it was 
thought that the Ce
4+
 ion was being regenerated during the reaction. Repeating this reaction 
under completely inert conditions where CAN was added in 0.1 mol equivalents and monitoring 
the reaction by TLC showed some interesting results. On the TLC plate the xanthone 260 
appeared as a fluorescent blue spot at a higher Rf than the starting material 258 (which was a 
dark spot), the dione 259 also appeared as a dark spot on the TLC plate but at a similar Rf value 
(just slightly higher than the starting material). After the addition of the 0.2 equivalents of CAN, 
the TLC showed the presence of a fluorescent blue spot at the same Rf as xanthone 260 along 
with starting material. This fluorescence spot increased in sized as the reaction proceeded with 
further additions of CAN and the starting material spot decreased in size slowly. After 0.6 
equivalents of CAN had been added, the appearance of a third spot – with the same Rf as dione 
259 – was observed. As more equivalents of CAN were slowly added the dione spot increased 
dramatically and the fluorescent blue spot, as well as the starting material spot, reduced slowly 
until only trace amounts were found by the time a full equivalent of CAN had been added. These 
traces had completely disappeared after the reaction had been worked up. Figure 96 below is a 
graphical representation of what was noted on the TLC plate. Although not a quantitative 
representation, the graph is given for clarity. 
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Figure 96 – TLC observations of the addition of CAN in 0.1 mol equivalents under inert 
conditions 
 
5.3.2. Analysis of the CAN samples 
Hence, it was proposed that there must be a contaminant present either in the old CAN that 
facilitated the reaction or in the new CAN preventing the reaction from occurring. Therefore, the 
contents of the two bottles of CAN needed to be investigated.  
Powder X-ray diffraction (PXRD) analysis was performed on both the old CAN used by Johnson 
(and the author at the start of this project) and the new CAN obtained from Sigma-Aldrich. PXRD 
analysis was performed by Dr Stuart Miller at the University of the Witwatersrand on a Bruker D2 
diffractometer on a silicon wafter zero background sample holder with a cobalt X-ray source 
(step size 0.16°). The powder patterns that were obtained were compared with the files for CAN 
(and variations thereof) in the Joint Committee on Powder Diffraction Standards (JCPDS) 
database using the search/match algorithm on the EVA Bruker X-ray data evaluation package. 
The PXRD pattern of the CAN obtained from Sigma-Aldrich agreed well with a monoclinic CAN 
powder pattern from the database (Figure 97). The recrystallized CAN showed a similar pattern 
to that of the commercially available CAN (Figure 98) and also fitted well with the monoclinic 
CAN pattern in the JCPDS database. 
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Figure 97 – PXRD pattern for the CAN purchased from Sigma-Aldrich with the database CAN 
superimposed in red 
 
 
Figure 98 – PXRD pattern for the recrystallized Sigma-Aldrich CAN and its match from the 
database overlayed in red 
 
The sample from the old CAN container gave a PXRD pattern that did not match with any cerium 
nitrate or any cerium oxide salt present in the database. This wasn’t completely surprising as the 
old container appeared to contain a mixture of yellow and orange crystals. It was found that the 
orange crystals were soluble in water while the yellow crystals were insoluble and thus could be 
Sigma_CAN
00-033-0049 (*) - Ammonium Cerium Nitrate - (NH4)2Ce(NO3)6 - Y: 4.87 % - d x by: 1. - WL: 1.78897 - Monoclinic - a 13.06900 - b 6.84610 - c 8.17320 - alpha 90.000 - beta 91.360 - gamma 90.000 - Primitive - P21/n
Operations: Import
Sigma_CAN - File: d2_15_1056.raw - Type: Locked Coupled - Start: 10.000 ° - End: 90.006 ° - Step: 0.026 ° - Step time: 37. s - Temp.: 25 °C (Room) - Time Started: 0 s - 2-Theta: 10.000 ° - Theta: 5.000 ° - Chi: 0.00 °
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00-033-0049 (*) - Ammonium Cerium Nitrate - (NH4)2Ce(NO3)6 - Y: 15.03 % - d x by: 1. - WL: 1.78897 - Monoclinic - a 13.06900 - b 6.84610 - c 8.17320 - alpha 90.000 - beta 91.360 - gamma 90.000 - Primitive - P21/
Operations: Import
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separated by filtration after the orange crystals were dissolved in the water. The filtrate was 
concentrated in vacuo to furnish the orange crystals. Both the yellow and orange crystals were 
dried separately in a desiccator overnight before attempting any further analysis. The PXRD of 
the yellow crystals showed a more amorphous structure that appeared to be a mixture of cerium 
oxides (Figure 99).  
 
Figure 99 – PXRD pattern of the insoluble yellow crystals from the Old CAN container 
 
The water soluble orange crystals on the other hand gave a good diffraction pattern that 
indicated the presence of a single compound. This pattern did not match any of the powder 
patterns in the JCPDS database for any ceric ammonium nitrate compound – even with different 
hydration or varying the oxides of CAN as shown in Figure 100. 
Insol_CAN
00-018-0322 (I) - Cerium Sulfate Hydrate - Ce2(SO4)3·8H2O - Y: 5.31 % - d x by: 1. - WL: 1.78897 - Orthorhombic - a 9.93000 - b 9.51000 - c 17.33000 - alpha 90.000 - beta 90.000 - gamma 90.000 - Base-centered - 
00-040-1485 (*) - Sodium Cerium Sulfate Hydrate - NaCe(SO4)2·H2O - Y: 5.47 % - d x by: 1. - WL: 1.78897 - Hexagonal - a 7.01500 - b 7.01500 - c 12.90300 - alpha 90.000 - beta 90.000 - gamma 120.000 - Primitive 
00-052-0336 (I) - Ammonium Cerium Phosphate Hydrate - (NH4)2Ce(PO4)2·H2O - Y: 8.36 % - d x by: 1. - WL: 1.78897 - Orthorhombic - a 12.72000 - b 14.00000 - c 16.10000 - alpha 90.000 - beta 90.000 - gamma 90
Operations: Y Scale Mul  2.000 | Smooth 0.186 | Smooth 0.150 | Smooth 0.150 | Background 1.000,1.000 | Import
Insol_CAN - File: d2_15_1171.raw - Type: Locked Coupled - Start: 10.000 ° - End: 90.006 ° - Step: 0.026 ° - Step time: 37. s - Temp.: 25 °C (Room) - Time Started: 0 s - 2-Theta: 10.000 ° - Theta: 5.000 ° - Chi: 0.00 ° -
Operations: Y Scale Add 292 | Import
Insol_CAN - File: d2_15_1171.raw - Type: Locked Coupled - Start: 10.000 ° - End: 90.006 ° - Step: 0.026 ° - Step time: 37. s - Temp.: 25 °C (Room) - Time Started: 0 s - 2-Theta: 10.000 ° - Theta: 5.000 ° - Chi: 0.00 ° -
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Figure 100 – PXRD pattern of the orange crystals from the old CAN compared to the CAN (and 
CAN variation) patterns from the PXRD database 
 
Thankfully Dr Miller expanded the search of the database to include any cerium based 
compounds and an exact match was found. Figure 101 shows the PXRD pattern for the water 
soluble orange crystals compared with the PXRD pattern of ammonium cerium sulfate (or CAS). 
The spectra were almost identical. This meant that the catalyst in the old CAN container which 
was responsible for the ring closure reaction that resulted in xanthones and diones was in fact 
CAS not CAN. Considering that the physical properties of CAN and CAS are very similar, and that 
CAS is hardly ever used in organic synthesis while the use of CAN is common practice, it is easy to 
see how the container was mislabelled. Figure 102 shows the distinct physical similarity between 
the water soluble orange crystals (which is CAS), commercially obtained CAS and recrystallized 
CAN. The commercially obtained CAN appears as a darker orange, however is still not very 
different from the orange crystals of CAS analysed.   
soluable_CAN
00-048-1108 (*) - Ammonium Cerium Nitrate Hydrate - Ce(NH4)2(NO3)5·2H2O - Y: 13.76 % - d x by: 1. - WL: 1.78897 - Monoclinic - a 10.60400 - b 9.00500 - c 17.19100 - alpha 90.000 - beta 104.610 - gamma 90.000
00-047-0811 (*) - Ammonium Cerium Nitrate - (NH4)3Ce2(NO3)9 - Y: 13.19 % - d x by: 1. - WL: 1.78897 - Cubic - a 13.83580 - b 13.83580 - c 13.83580 - alpha 90.000 - beta 90.000 - gamma 90.000 - Primitive - P413
00-033-0049 (*) - Ammonium Cerium Nitrate - (NH4)2Ce(NO3)6 - Y: 13.87 % - d x by: 1. - WL: 1.78897 - Monoclinic - a 13.06900 - b 6.84610 - c 8.17320 - alpha 90.000 - beta 91.360 - gamma 90.000 - Primitive - P21/
00-045-0589 (*) - Cerium Oxide Nitrate Hydrate - Ce2O(NO3)6·3H2O - Y: 12.47 % - d x by: 1. - WL: 1.78897 - Triclinic - a 7.93700 - b 8.45200 - c 7.08300 - alpha 103.610 - beta 104.160 - gamma 83.010 - Primitive - 
00-047-0809 (*) - Ammonium Cerium Nitrate Hydrate - (NH4)2Ce(NO3)5·4H2O - Y: 12.54 % - d x by: 1. - WL: 1.78897 - Monoclinic - a 11.09000 - b 8.93400 - c 17.92700 - alpha 90.000 - beta 101.750 - gamma 90.000
00-048-1107 (*) - Ammonium Cerium Nitrate Hydrate - Ce(NH4)2(NO3)5·3H2O - Y: 12.05 % - d x by: 1. - WL: 1.78897 - Monoclinic - a 10.86900 - b 8.98000 - c 17.34500 - alpha 90.000 - beta 100.150 - gamma 90.000
Operations: Y Scale Add -958 | Y Scale Add 833 | Y Scale Add 333 | Import
soluable_CAN - File: d2_15_1172.raw - Type: Locked Coupled - Start: 10.000 ° - End: 90.006 ° - Step: 0.026 ° - Step time: 37. s - Temp.: 25 °C (Room) - Time Started: 0 s - 2-Theta: 10.000 ° - Theta: 5.000 ° - Chi: 0.0
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Figure 101 – PXRD pattern of the orange crystals from the old CAN and the comparison to 
ammonium cerium sulfate from the database superimposed in red 
 
 
Figure 102 – Ceric ammonium sulfate, the water soluble portion of the ‘Old CAN’, recrystallized 
CAN and ceric ammonium nitrate obtained from Sigma-Aldrich (left to right) showing the 
distinct similarities in physical properties of CAS and recrystallized CAN. 
  
soluable_CAN
00-053-0642 (I) - Ammonium Cerium Sulfate - (NH4)2Ce(SO4)3 - Y: 108.14 % - d x by: 1. - WL: 1.78897 - Monoclinic - a 9.41200 - b 16.41700 - c 23.04100 - alpha 90.000 - beta 114.710 - gamma 90.000 - 12 - 3234.2
Operations: Y Scale Add -958 | Y Scale Add 833 | Y Scale Add 333 | Import
soluable_CAN - File: d2_15_1172.raw - Type: Locked Coupled - Start: 10.000 ° - End: 90.006 ° - Step: 0.026 ° - Step time: 37. s - Temp.: 25 °C (Room) - Time Started: 0 s - 2-Theta: 10.000 ° - Theta: 5.000 ° - Chi: 0.0
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5.4. When life gives you CAS 
This surprising turn of events sparked new interest in the novel xanthone forming reaction that 
was developed in our labs. The first step going forward was to confirm that the results published 
by our group in the Journal of Organic Chemistry were in fact correct, just with a change in 
reagent (and hence catalyst ratio). Johnson reported the addition of 5 equivalents of ‘CAN’ to the 
reactions, which when recalculated this was found to be 4.3 equivalents of CAS. The synthesis 
(Scheme 89) was repeated with known amounts of CAS. Additionally we decided to change the 
reaction conditions to fully understand the effects of the different components in the reaction. 
When the reaction was performed with 4 equivalents of CAS in an acetonitrile/water/chloroform 
solution at room temperature both dione 259 and xanthone 260 were isolated after column 
chromatography – after repeating this reaction in triplicate it was found that dione 259 formed in 
an average yield of 30 % and 260 in an average yield of 45 %. This ratio was significantly different 
than the ratio obtained by Johnson, however since the reaction showed a similar product ratio 
every time it was repeated, we deemed these results reliable.  It was found that under these 
conditions, at least 3 equivalents of CAS was required for the reaction to go to completion. When 
the chloroform was not included in the solvent mixture the reaction went to completion, 
however the two products were isolated in very low yields even when performed under reflux 
conditions. Changing the solvent system to a methanol/water solution resulted in the exclusive 
formation of xanthone 260 in low to average yields, depending on the temperature at which the 
reaction was performed. These results – along with the corrected results previously obtained – 
are detailed in  
Table 9. The reaction was also performed in a chloroform/water solvent system and it was found 
that despite the formation of some of 259 (determined by TLC) the reaction did not go to 
completion regardless of how much CAS was added to the reaction or the temperature at which 
the reaction was performed. 
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258  259  260 
Scheme 89 – CAS mediated oxidation of 258 
Table 9 – Results from the CAS mediated cyclization of 258 as well as the corrected results 
obtained previously 
Author Catalyst Reaction Conditions Yield 259 Yield 260 
Johnson
191
 CAS (4.3 eq) MeCN/H2O/CHCl3, r.t., overnight 15 % 74 % 
Dam CAS (4.3 eq) MeCN/H2O/CHCl3, r.t., overnight 44 % 32 % 
Dam CAN (5 eq) MeOH/H2O, r.t., 10 min 16 % 0 
Dam CAS (5 eq) MeCN/H2O, r.t., overnight 32 % 10 % 
Dam CAS (4 eq) MeCN/H2O/CHCl3, r.t., overnight Ave = 45 % Ave = 30 % 
Dam CAS (3 eq) MeCN/H2O, r.t., overnight 8 % 21 % 
Dam CAS (2 eq) MeOH/H2O, reflux, 1 hour  54 % 
Dam CAS (5 eq) MeOH/H2O, reflux, 1 hour  31 % 
Dam CAS (5 eq) MeCN/H2O, reflux, 1 hour  20 % 
 
Excited by these results we determined that the optimal reaction conditions were 4 equivalents 
of CAS in an acetonitrile/water/chloroform solvent system combined in a 4:2:1 ratio, stirring at 
room temperature for 18 hours. Based on these results, we repeated the reaction on the other 
substrates reported in the JOC paper using these conditions and the results are shown in Table 
10. These results matched well with what was reported in the JOC note.
192
 
Table 10 – CAS reaction performed on benzophenones previously reacted with CAN 
Starting Benzophenone Product Johnson Yield
191
 Product Yield 
 
253 
 
257 
72 % 81 % 
 
261 
 
262 
91 % 70 % 
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5.4.1. Repetition of the chlorine-containing reactions performed by 
Johnson using CAS 
Realising that we needed to correct the JOC note, the rest of the reactions on all the substrate 
precursors needed to be repeated to ensure that the correct products were obtained in the 
yields reported in the JOC paper. Given that the synthesis was reported in detail by Johnson, the 
reaction schemes will only briefly be discussed. Commercially available 5-chlorosalicylic acid was 
successfully O-benzylated to obtain 301 as shown in Scheme 90.  
 
 
 
 
 
   301 (99 %)  
Reaction conditions: Benzyl bromide (2.1 eq), K2CO3 (3 eq), acetone, reflux, 18 h. 
Scheme 90 – Benzyl protection of 5-chlorosalicylic acid 
 
5.4.1.1. The chlorine-containing dimethoxynaphthalene series 
As before, 250 was lithiated using n-BuLi and reacted with the benzyl protected salicylic acid 301 
to generate benzophenone 302 (Scheme 91). Benzophenone 302 was significantly insoluble in 
methanol and so the debenzylation reaction needed to be performed in ethyl acetate. The 
reaction needed to be closely monitored to make sure that the reaction was stopped before the 
chlorine atom was reduced after the removal of the benzyl group (accounting for the relatively 
low yielding reaction). The debenzylated compound 263 was then exposed to CAS resulting in the 
formation of dione 264 in a high yield. The spectroscopic data obtained for these compounds 
concurred with the data reported by Johnson.
191
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 301  
 250 (50 %)  302 (32 %)  
 
 
 
 
 263 (42 %)  264 (ave 84 %) 
Reaction conditions: i) n-BuLi (1.28 M, 1 eq), 301 (0.9 eq), THF, -78 °C, 2 h; ii) H2, 5 % Pd/C (10 mass %), 
EtOAc, rt, 1 h; iii) CAS (4 eq), MeCN/H2O/CHCl3, rt, 18 h. 
Scheme 91 – Synthesis of dione 264 
 
5.4.1.2. The chlorine-containing 1,4-dimethoxybenzene series 
Following the synthesis outlined in Scheme 92, benzophenone 303 was isolated in a 76 % yield. 
Debenzylation of 303 under a hydrogen atmosphere was successful to afford 265. The reaction 
had to be closely monitored to prevent the removal of the chlorine substituent as well under the 
reductive conditions. Finally, the CAS reaction resulted in the formation of both dione 266 and 
xanthone 267 from benzophenone 265. Repetition of the reaction in triplicate resulted in the 
formation of dione 266 in an average yield of 50 % and 28 % xanthone 267. This too is markedly 
different from the ratio reported by Johnson (17 % 266 and 63 % 267).
191
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301 
  289 (77 %)  303 (76 %) 
 
 
 
 
 
  265 (79 %)   
 
 
 
 
 
 266 (Ave 50 %)  267 (Ave 28 %)  
Reaction conditions: i) NBS (1 eq), CHCl3, reflux, 3 d; ii) n-BuLi (1.28 M, 1 eq), 301 (0.9 eq), THF,     
-78 °C, 2 h; iii) 5 % Pd/C (10 mass %), MeOH, rt, 4 h; iv) CAS (4 eq), MeCN/H2O/CHCl3, rt, 18 h. 
Scheme 92 – Synthetic route utilized in the synthesis of dione 266 and xanthone 267 
 
5.4.1.3. The chlorine-containing trimethoxybenzene series 
The synthetic route as outlined in Scheme 93 was successful. The lithiation of 246 and 
subsequent reaction with 301 resulted in the furnishing of 304 in a reasonable yield. Removal of 
the benzyl group resulted in 270 being isolated in a good yield. This reaction occurred fast and 
was complete after an hour with dechlorinated compound 261 isolated also. The CAS mediated 
oxidation of 270 resulted in the visualization of three new spots on the TLC plate. These products 
were isolated using flash column chromatography and found to be dione 268, xanthone 269 and 
spirofuran 271. This reaction was repeated in triplicate and the yields reported are reported as 
average yields. Again, the ratio of the products collected was somewhat different to that 
obtained by Johnson (268 reported yield 28 %, 269 21 % and 271 9 %).
191
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301 
  246 (87 %)  304 (61 %) 
  
 
  
  270 (70 %)   
 
 
 
 
 
268 (Ave 23 %)  269 (Ave 46 %)  271 (Ave 4 %) 
Reaction conditions: i) NBS (1 eq), DCM, rt, 20 min; ii) n-BuLi (1.2 M, 1 eq), 301 (0.9 eq), THF, -78 °C, 2 h; iii) 5 % 
Pd/C (10 mass %), MeOH, rt, 2 h; iv) CAS (4 eq), MeCN/H2O, rt, 18 h. 
Scheme 93 – Synthetic route employed in the synthesis of the chloro-trimethoxy series 
 
Overall, these reactions show that the outcomes published in the JOC Note were indeed true. 
Given that the oxidant that Johnson used contained a mixture of cerium oxides in addition to 
CAS, this could explain the difference in ratios between the products obtained in this project and 
what was previously determined. It also confirms the PXRD findings that the initial catalyst used 
was CAS and not CAN. 
 
5.4.2. Conversion of diones to xanthones 
Amongst the results reported by Omolo, he noted that diones could successfully be converted to 
xanthones using microwave irradiation. Using this procedure, Omolo obtained xanthone 275 
(Scheme 74) from dione 259.
193
 When the same reaction was repeated by the author no 
conversion was found to occur and only starting material (259) was recovered from the reaction. 
Increasing the temperature, reaction time or wattage applied to the reaction did not have any 
influence on the reaction. 
Hoping to find another method for the conversion of diones to the naturally occurring xanthones, 
we considered that the structure of the diones contained a quinone acetal functionality. Since 
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sodium dithionite is used to reduce quinones to their aromatic-hydroquinone equivalents,
128
 we 
postulated that in applying similar conditions to diones, the dione could be reduced to its 
hydroxy-aromatic equivalent, as shown in Scheme 94. 
 
 
 
 
 
Reaction conditions: Na2S2O4 (3 eq), THF/H2O, rt, 10 min. 
Scheme 94 – Conversion of diones to xanthones using sodium dithionite 
 
This reaction was found to be remarkably successful under the given conditions and diones 257, 
259, 264 and 266 were successfully converted to novel hydroxy-containing xanthones (305 to 
308) shown in Scheme 95. As soon as the sodium dithionite was added to the rapidly stirring 
yellow dione/THF/water mixture the solution turned bright green, when the solution returned to 
a yellow colour (or a light yellow precipitate formed) the reaction was deemed over. These 
reactions were performed on a small scale (under 100 mg) so the addition of a phase transfer 
catalyst (such as TBAI) was not beneficial, however on a larger scale it may be advisable to add 
TBAI to the reaction. Purification of the reaction mixture was performed without the need for 
column chromatography as the phenolic-xanthone could be deprotonated under strongly basic 
conditions during the work up (making it soluble in the aqueous layer) while any unreacted 
starting material remained in the organic layer. After adjusting the pH of the aqueous layer to 
near neutral with solid ammonium chloride, the xanthone precipitated out of solution and was 
filtered off, washed with water and dried in a desiccator. Characterisation of these compounds 
showed significant shifting of the signals in the 
1
H NMR spectrum in the aromatic region in 
comparison to the dione precursors. The xanthones generated were also significantly less soluble 
than the dione precursors and hence NMR samples had to be made up in d4-MeOD and d-DMSO 
preventing the O-H signal from being observed in the 
1
H NMR spectrum. Moreover, only a single 
carbonyl carbon was observed for each of the compounds (where the starting diones contained 
two) in the 
13
C NMR spectrum along with a new aromatic C‒O type signal around 150 ppm. The 
IR spectra for these compounds revealed the tell-tale O‒H stretches between 3300-3400 cm
-1 
confirming the presence of a phenol in the xanthones. 
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R = H, 259 
R = Cl, 266 
 
R = H, 305 (90 %) 
R = Cl, 306 (75 %) 
 
 
 
 
 
 
 
R = H, 257 
R = Cl, 264 
 
R = H, 307 (64 %) 
R = Cl, 308 (68 %) 
 
Reaction conditions: Na2S2O4 (3 eq), THF/H2O, rt, 10 min. 
Scheme 95 – Conversion of dione compounds to hydroxy-containing xanthones 
  
The successful development of this method meant that regardless of whether diones or 
xanthones were obtained from the reaction or the ratio they were obtained in, xanthones could 
still be generated in good yields – albeit with a hydroxy substituent rather than the methoxy 
substituent present in previous xanthones. 
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5.5. Investigation of the mechanism of the CAS-mediated ring 
closure reactions 
Having optimized the reaction conditions for the CAS-mediated oxidation reaction, the next focus 
was to probe the mechanism of the reaction. Johnson et al. proposed a mechanism for the 
reaction (Scheme 73) which relied on the stabilization effects from the dimethoxy substituents 
arranged para to each other to stabilize the radical intermediate 273. This radical intermediate 
could further be resonance stabilized as previously shown in Scheme 78.  
To investigate this, we needed to synthesize suitable benzophenones containing methoxy 
substituents in a variety of positions. We were also interested in the effects of the second 
methoxy substituent, so a benzophenone with only a single methoxy substituent was also 
deemed necessary. In this section the synthesis of the various benzophenone precursor 
substrates will be discussed individually and then the results from subjecting these 
benzophenones to CAS discussed together at the end of the section. 
 
5.5.1. Synthesis of (2-hydroxyphenyl)(2-methoxyphenyl)methanone 
312 
As detailed in Scheme 96, O-benzyl protection of salicylaldehyde was performed in the same 
manner as that for the salicylic acids however with the addition of only 1.1 equivalents of benzyl 
bromide resulting in aldehyde 309. 
 
 
 
 
 
   309 (73 %)  
Reaction conditions: Benzyl bromide (1.1 eq), K2CO3 (2 eq), acetone, reflux, 18 h. 
Scheme 96 – Benzyl protection of salicylaldehyde 
 
Exposure of the Grignard reagent of 289 (Scheme 97) to 309 afforded alcohol 310. PCC oxidation 
of 310 resulted in benzophenone 311, which after debenzylation furnished the desired substrate 
312. 
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 309 
289    310 (99 %)  
 
 
 
 
 
 311 (77 %)  312 (85 %)  
Reaction conditions: i) Mg (eq), THF, rt, 1 h; ii) 309 ( eq), THF, 0 °C, 2 h; iii) PCC ( eq), silica, DCM, rt, 1 h; iv) 5 
% Pd/C (10 mass %), MeOH, rt, 18 h. 
Scheme 97 – Synthetic scheme employed to synthesize substituted benzophenone 312 
 
5.5.2. Synthesis of dimethoxybenzophenone substrates 
5.5.1. Bromination of dimethoxybenzenes 313, 315 and 317  
The first step in attempting to generate a variety of di- and tri-methoxysubstituted 
benzophenones was the bromination of dimethylresorcinol (313), veratrole (315) and 1,3,5-
trimethoxybenzene (317) as shown in Scheme 98. The brominations occurred exclusively to 
afford the monobrominated benzenes 314 and 316. For benzene 314, the aromatic region in the 
1
H NMR spectrum contained three signals – a doublet at 7.73 ppm with a coupling constant (J) of 
8.7 Hz, a doublet (J = 2.7 Hz) at 6.46 ppm and a doublet of doublets (J = 8.7 and 2.7 Hz). These 
signals were indicative of the structure of 314. Similar splitting patterns were observed in the 
1
H 
NMR spectrum of 316; a doublet of doublets (J = 8.5 and 2.3 Hz) at 6.99 ppm and two doublets at 
6.94 ppm (J = 2.3 Hz) and 6.68 ppm (J = 8.5 Hz). From the coupling constants, both meta and 
ortho coupling were indicated, confirming the structure of 316. 
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 313 A 314 (96 %)  
 
 
 
 
 
 315 B 316 (87 %)  
 
 
 
 
 
 317 C 318 (80 %)  
Reaction conditions: NBS (1 eq), CHCl3, rt, 20 min. 
Scheme 98 – Bromination of di- and tri-methoxybenzenes 
 
5.5.2. Lithiation reactions 
All the bromine-lithium exchange reactions were performed under similar reaction conditions to 
those reported previously, and reaction of the lithiated species generated from the 
bromobenzenes in Scheme 98 with ester 251 afforded the substituted benzophenone 
compounds (319 – 321) in acceptable yields as outlined in Figure 103. 
   
319 (92 %) 320 (44 %) 321 (45 %) 
Figure 103 – Substituted benzophenones generated from lithiation reactions with substituted 
bromobenzenes in Scheme 98 
 
Characteristic features of these compounds were noted on the 
1
H and 
13
C NMR spectra and 
included the distinctive methoxy signals, the benzyl CH2 signals as well as the ketone.  
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5.5.3. Directed Ortho-metalation Reactions 
In order to access more benzophenones that would contain methoxy substituents on the 
benzene ring we considered using directed-orthometalation reactions (or DOM reactions) using 
dimethoxyresorcinol (313) and veratrole (315) as starting materials. The same lithiation 
procedure (using n-BuLi and the same reaction conditions) as previously mentioned was used, 
except with lithiation occurring on the benzene rings without being positioned by the presence of 
the bromine atom. The reactions and resulting products are outlined in Scheme 99. The 
preferential position for the DOM lithiation was between the two methoxy substituents on 313, 
and hence 322 was furnished as a peach coloured solid in a good yield. The tell-tale symmetry of 
this compound was seen on the 
1
H NMR spectrum; there was a single methoxy signal integrating 
for 6 protons at 3.55 ppm and a distinct doublet integrating for 2 protons at 6.42 ppm. This 
symmetry was also seen in the 
13
C NMR spectrum. The structure of 323 was less easily 
determined due to the number of aromatic signals present in the 
1
H NMR spectrum. This 
spectrum did look significantly different to that of 320, suggesting that the proposed structure 
was correct. 
 
 
 
 
 
 313  322 (81 %)  
 
 
 
 
 
 315  323 (43 %)  
Reaction conditions: n-BuLi (1 eq), ester (0.9 eq), THF, -78 °C, 90 min. 
Scheme 99 – Products from DOM reactions with substituted benzenes 
 
5.5.4. Debenzylation of the protected benzophenones 
Using the 5 % Pd/C catalysed debenzylation reactions under a hydrogen atmosphere as 
previously outlined, the five benzophenones 324 - 328 were successfully synthesized as shown in 
Figure 104. 
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 324 (71 %) 325 (62 %) 326 (74 %)  
 
 
 
 
 
  
  327 (60 %)  328 (66 %)   
Figure 104 – Substituted benzophenones generated after debenzylation 
 
5.5.3. Subjection of substituted benzophenones to CAS 
Having synthesized a series of substituted benzophenones, we were then in a position to expose 
each one to CAS under the optimized reaction conditions. Since we were exploring the scope of 
this novel reaction, the reactions were closely monitored by TLC, and any new spots that were 
identified were isolated and where possible characterised. Each reaction was repeated in 
triplicate (or more) to ensure that any result obtained was reproducible.  
When monomethoxybenzophenone 312 (Scheme 100) was exposed to CAS no starting material 
was noted. Unfortunately no compound could be successfully isolated from the reaction. This 
result tentatively suggested that the presence of the second methoxy substituent on the anisole 
benzene was necessary for the cyclization to occur. 
 
 
 
?  
 312    
Reaction conditions: CAS (2-4 eq), MeCN/H2O/CHCl3,rt, 18 hours. 
Scheme 100 – Exposure of 312 to CAS 
 
The next step was to conduct the CAS-mediated reactions on the dimethoxy-benzophenones 324 
- 328. An interesting result was obtained when 324 was exposed to CAS. Multiple spots were 
observed on the TLC plate, however only a single compound isolated could be characterised. We 
were surprised to find that in the 
1
H NMR spectrum of this compound the phenolic signal 
remained present at 12.15 ppm along with both methoxy signals at 3.91 and 3.61 ppm. 
Additionally, only six aromatic signals were present where the starting material (312) contained 
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seven. From the NMR spectral data it was determined that substitution had occurred para to the 
phenol. One possible explanation for this result was that the benzophenone 324 had dimerized 
as shown in Scheme 101. The same product was isolated with each repetition of the reaction, 
and this was the major product isolated from the reaction – despite the relatively low yield. 
 
 
 
 
 
 324  329 (24 %)  
Reaction conditions: CAS (2-4 eq), MeCN/H2O/CHCl3,rt, 18 hours. 
Scheme 101 – Proposed dimerization of 324 when exposed to CAS 
 
High resolution mass spectroscopy agreed with the dimer structure. Crystals suitable for SCXRD 
were grown from diethyl ether, and the structure of 329 confirmed, as shown in Figure 105. 
 
Figure 105 – The asymmetric unit of 329 (hydrogen atoms are omitted for clarity) 
 
Of course we could not rule out the possibility that other dimeric products could be formed in 
the reaction, however we were unable to isolate and characterise any other products. This 
reaction does show that CAS has the potential to form biaryl C‒C bonds through an oxidative 
process. A report by Chwala found that when selected phenols (with at least one methyl group 
positioned ortho to the hydroxyl group) were exposed to CAN in acetic acid and hydrogen 
peroxide, similar dimer-type compounds were isolated in minor quantities. Their particular work 
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focused on the synthesis of phenol derivatives using CAN, however these unexpected dimer 
products were noted – the new biaryl bond forming in the para-position to the hydroxyl group.
198
 
When benzophenone 327 was subjected to the same conditions as 324 a similar observation was 
made as shown in Scheme 102. The structure of 330 was elucidated from the 
1
H and 
13
C NMR 
spectra (along with supporting 2D experiments) which again suggested that substitution occurred 
at a position that was para to the phenol substituent. 
 
 
 
 
 
 327  330 (18 %)  
Reaction conditions: CAS (2-4 eq), MeCN/H2O/CHCl3,rt, 18 hours. 
Scheme 102 – CAS-mediated oxidation of benzophenone 327 
 
Interestingly, exposing compound 325 to CAS also furnished the dimer 331 (Scheme 103). The 
structure of 331 was determined using NMR spectroscopy as before, as well as by high resolution 
ESI mass spectroscopy. This result suggests that for the CAS-mediated ring closure reaction to 
occur, a methoxy substituent in an ortho-position to the ketone is essential.  
 
 
 
 
 
 325  331 (15 %)  
Reaction conditions: CAS (2-4 eq), MeCN/H2O/CHCl3,rt, 18 hours. 
Scheme 103 – CAS-mediated oxidation of benzophenone 325 
 
Benzophenone 328 contained two methoxy substituents ortho to each other. When 328 was 
subjected to CAS oxidation (Scheme 104), xanthone 332 was formed in a 60 % yield.  
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 328  332 (60 %)  
Reaction conditions: CAS (4 eq), MeCN/H2O/CHCl3,rt, 18 hours. 
Scheme 104 – CAS mediated oxidation of benzophenone 328 
 
Characterisation of the compound showed the presence of only a single methoxy signal at 4.04 
ppm and the absence of the phenol signal in the 
1
H NMR spectrum. The 
13
C NMR spectrum 
further supported the ring closed structure. Conclusive proof was obtained from SCXRD, where 
suitable crystals for analysis were grown from methanol and the results are shown in Figure 106. 
 
Figure 106 – The asymmetric unit of 332 
 
Finally, the trimethoxybenzophenone 326 was subjected to CAS. This compound was of interest 
as the compound has a methoxy substituent ortho to the ketone as well as two additional 
methoxy substituents that could theoretically be able to stabilize the radical intermediate. As 
shown in Scheme 105, spirofuran 333 was isolated in a 50 % yield when 326 was exposed to CAS. 
 
 
 
 
 
 326  333 (59 %)  
Reaction conditions: CAS (2-4 eq), MeCN/H2O/CHCl3,rt, 18 hours. 
Scheme 105 – CAS mediated formation of spirofuran 333 
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The structure of 333 was determined by NMR spectroscopy. From the 
1
H NMR spectrum it could 
be seen that the hydroxyl signal as well as one methoxy signal was no longer present. The 
presence of four aromatic ring protons showed that the phenol side of the benzophenone 
remained intact. Two more singlet signals were present – one at 5.64 integrating for 2H and one 
at 3.64 integrating for 6H. This suggested that there was symmetry in the molecule and that the 
aromaticity of the second aromatic ring had been disrupted. Additionally from the 
13
C NMR 
spectrum two carbonyl signals were evident in the product (at 194.4 and 186.8 ppm), but most 
distinctively a quaternary carbon at 84.3 ppm (determined along with HSQC). The presence of the 
two carbonyls and the quaternary carbon around 80 ppm was a feature characteristic to 
spirofurans and hence structure 333 was proposed. Crystals suitable for SCXRD analysis were 
grown and after analysis, the structure of 333 confirmed as shown in Figure 107. 
 
Figure 107 – The asymmetric unit of 333 
 
5.5.4. A deeper look at the proposed mechanisms 
The JOC paper outlined general proposed mechanism (Scheme 73). Using the results previously 
obtained as well as the new results outlined above a more detailed mechanism could be 
proposed. An important distintinction that needed to be made was the site for the first oxidation 
– was the first radical generated on an aromatic ring or on one of the oxygen atoms (and if so 
which one)? Since it has been established that phenol’s preferentially coordinate strongly to 
cerium atoms,
176,177
 it would be safe to assume this would also happen with these phenolic-
containing benzophenones with the result of generating a radical on the phenol rather than 
elsewhere on the molecule. Depending on the nature of the other benzene ring several different 
pathways leading to the products would then be possible. For example as shown in Scheme 106, 
the phenol radical can add to the adjacent benzene ring which would generate radical 334 that 
would be stabelized by the methoxy substituents at positions R1 and R2.  
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258, R1 = OMe and R2 = H 
328, R1 = H and R2 = OMe 
   
 
 
 
 
 
334     
Scheme 106 – Radical generation on the phenol and how it is stabilized once addition has 
occurred 
 
From the intermediate 334 shown in Scheme 106, both xanthones and diones could 
then be generated. Xanthones could be generated as shown in Scheme 107 where the 
driving force of rearomatization would force the elimination of a methanol radical which 
would be quenched as the reaction proceeds. 
 
 
 
 
334    
 
 
 
 
 
Scheme 107 – Proposed mechanism for the formation of xanthones 
 
The resonance stabilization of the radical intermediate 334 as shown in Scheme 106 
could result in the formation of intermediate 335 (Scheme 108) which is further stabilized 
by the methoxy oxygen. A further oxidation at this position would facilitate the 
elimination of methanol generating the diones as are formed in some of the reactions 
and shown in Scheme 108. 
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334  335  
 
 
 
 
 
   
 
 
Scheme 108 – Proposed mechanism for the formation of diones 
 
The phenolic radical addition to the benzene ring in Scheme 106 saw the addition of the phenol 
to the carbon attached to a methoxy substituent. Theoretically the phenol radical could add to 
the other side of the double bond of the benzene ring as shown in 336 (Scheme 109). In this 
scenario the methoxy substituent would stabilize the radical intermediate. This could be further 
stabilized as shown by pathway A (Scheme 109) especially where substituent R2 is an electron 
dontating substituent such as a methoxy group. Pathway B would also serve in stabelizing the 
radical intermediate however 337 could further be oxidized by the CAS, eliminating methanol to 
form the spirofuran product. It is interesting to note that spirofuran proucts were only isolated 
where at least 3 methoxy substituents (i.e. R1 or R2 = OMe) were present on the starting 
benzophenone. While benzophenone 324 would also fit this proposed mechanism no spirofuran 
product was isolated when exposed to CAS suggesting that for this particular mechanism to apply 
the stabilization through pathway A is crucial and that R1 and/or R2 needs to contain an electron 
dontating groups. 
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   336  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 337  
  
 
 
 
 
 
 
 
   
 
 
   
 
 
Scheme 109 – Proposed mechanism for the formation of spirofurans 
 
Finally the generation of the phenolic radical can also be used to explain the formation of the 
oxidative dimers 329, 330 and 331. In benzophenones where the radical intermediates in Scheme 
106 to Scheme 109 were not stabilized the phenolic radical would be able to perform other 
reactions. Scheme 110 outlines the proposed mechanism for the formation of the novel dimers 
where the phenolic radical is stabilized as shown by pathway A, however two molecules with 
radicals in the para position to the phenol could combine as shown in pathway B. With the 
driving force of aromaticity, the molecule can rearrange to form the dimers that were isolated. 
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Scheme 110 – Proposed mechanism for the formation of dimers 
 
Pathway A in Scheme 110 outlines that in the stabilization of the phenol radical there are several 
different positions at which the the radical monomers could combine. Depending on how these 
radicals combine different products are theoretically possible (Figure 108) however only the 
para-substituted dimers were isolated in this work. 
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A B 
Figure 108 – Other theoretically possible dimers where A represents the coupling of two 
benzophenones at the ortho positions while B represents the coupling at the para position of 
one benzophenone and the ortho position of the other 
 
These new proposed mechanisms differ from what was previously proposed, however 
the generation of a single phenolic radical performing different reactions depending on 
the electronics of the system far better explains the results the results detailed in this 
work than several seemingly isolated reactions as previously proposed. 
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5.6. Revisiting the acridone synthesis 
The noticeable difference between CAN and CAS as a reagent for synthesis was one explanation 
for why the synthesis of acridone 298 was only successful once (when unknowingly CAS was 
used) and then never again (when CAN was used). Therefore we wished to attempt the synthesis 
with commercial CAS to confirm this result. 
Revisiting the benzyl protection of anthranilic acid, a paper by González-Morales et al. reported 
that anthranilic acid could be protected in a similar manner as we had performed however in a 
5:1 methanol:water ratio.
199
 Using the González-Morales methodology anthranilic acid was 
successfully tri-benzyl protected to generate 290 in a 72 % yield (Scheme 111 with the new 
reaction conditions). 
 
 
 
 
 
   290 (72 %)  
Reaction conditions: Benzyl bromide (3.1 eq), K2CO3 (3.8 eq), 5:1 MeOH:H2O, reflux, 18 h. 
Scheme 111 – Successful benzyl protection of anthranilic acid 
 
Coupling of 290 with brominated compound 289 using n-BuLi (as shown in Scheme 112) resulted 
in benzophenone 291 in a very low yield of 31 %. Unfortunately subsequent attempts to remove 
the benzyl protection groups from the amine proved unsuccessful.  
 
 
 
 
 
 
 
 289  290  291 (31 %)  
Reaction conditions: n-BuLi (1.6 M, 1 eq), THF, -78 °C, 2 h. 
Scheme 112 – Lithiation reactions to generate amine-containing benzophenone 291 
 
Having had trouble with forming the desired benzophenone we searched for a different method 
to construct the desired 2-aminobenzophenones. Frye et al. reported a one-pot procedure for 
the synthesis of a variety of substituted 2-aminobenzophenones using n-BuLi, substituted 
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bromobenzenes and unprotected Weinreb amides. They found that the addition of n-BuLi 
dropwise to a cold (-78 °C) rapidly stirring solution of the substituted bromobenzenes and 
Weinreb amides in THF resulted in the formation of 2-aminobenzophenones in average yields.
200
  
In order to apply the Frye methodology, we first needed to synthesize Weinreb amide 339. This 
methodology had been well developed in our labs
113
 and involved the reaction of an acid with 
1,1’-carbonyldiimidazole (CDI) followed by the addition of N-O-dimethylhydroxylamine 
hydrochloride to generate the Weinreb amide such as 339 illustrated in Scheme 113. While these 
reactions are typically performed in dichloromethane, the poor solubility of the CDI-anthranilic 
acid complex 338 prevented the addition of the hydroxylamine hydrochloride. It was found that 
the reaction could either be performed in dry dimethylformamide or in a dichloromethane 
solution with the addition of small quantities of dimethylformamide to ensure solubility at each 
stage of the reaction. The sole use of dimethylformamide allowed for complete solubility of the 
compound throughout the synthesis but it was difficult to remove during the work up. 
Performing the reaction in dichloromethane with additional dimethylformamide meant that each 
stage of the reaction needed to be monitored and additional dimethylformamide added if 
necessary to solubilize the reaction mixture. The brown oil resulting from the reaction was 
determined to be 339 by NMR spectroscopy. 
 
 
 
 
 
 
 
   338  339 (96 %)  
Reaction conditions: i) CDI (1.2 eq), DMF, rt, 1 h; ii) N-O-dimethylhydroxylamine HCl (1.2 eq), rt, 18 h. 
Scheme 113 – Synthesis of Weinreb amide 339 
 
Following the Frye approach, bromo-dimethoxybenzene 289 (Scheme 114) and Weinreb amide 
339 were condensed using n-BuLi, and 2-aminobenzophenone 292 was synthesized in a 55 % 
yield. 
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339 
 
 
   
 289  292 (55 %)  
Reaction conditions: n-BuLi (2 eq), ester 339 (1 eq), THF, -78 °C, 90 min. 
Scheme 114 – Synthesis of 2-aminobenzopheone 292 using Frye methodology 
 
Since we had previously achieved some success with the CAS reaction using a single benzyl group 
on the amine (as in compound 297), we decided to return to this approach. Using reductive 
amination with benzaldehyde, it was found that 297 (Scheme 115) could be formed from 292 
under microwave conditions using sodium cyanoborohydride (NaCNBH4) in ethanol. Irradiation of 
292 with benzaldehyde in ethanol allowed for the formation of an imine (facilitated by the 
presence of anhydrous sodium sulfate) before the reduction by NaCNBH4, resulting in 297 in a 70 
% yield. The NMR spectra obtained for 297 corresponded with the previously obtained spectra 
using the alternative synthetic methodology. Exposure of benzophenone 297 to 4 equivalents of 
CAS resulted in the visualization of a fluorescent blue spot on the TLC plate along with the 
starting material (297) spot. After purification by column chromatography, the fluorescent blue 
spot was separated from the starting material (36 % collected) and determined to be acridone 
298 in a yield of 8 %. Returning the collected started material to the CAS reaction under reflux 
conditions resulted in the decomposition of the starting material.  
 
 
 
 
 
292  297 (70 %)  298 (8 %) 
Reaction conditions: i) benzaldehyde (1 eq), Na2SO4, EtOH, µW, 100 °C, 150 W, 10 min; ii) NaCNBH4 (2 eq), 
EtOH, µW, 100 °C, 150 W, 25 min; iii) CAS (4 eq), MeCN/H2O/CHCl3, rt, 18 h. 
Scheme 115 – Reductive amination and CAS mediated ring closure reaction to form acridone 
298 
 
A potential reason for the low yield of the reaction could be due to the significant hydrogen 
bonding present in 297 (shown in Figure 109). The N-H proton in the 
1
H NMR spectrum was a 
broad triplet at 9.40 ppm. This downfield chemical shift further supports the hypothesis of 
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hydrogen bonding, especially since without the benzyl protection group (i.e. 292) the amine NH2 
showed a chemical shift of 6.39 ppm. 
 
Figure 109 – The hydrogen bonding present in 297 
 
Unfortunately due to time constraints, this project could not be further investigated. However, 
this result shows a proof of concept – that the CAS mediated ring closure methodology could be 
applied to the formation of acridones. 
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6.1. CAN vs. CAS 
6.1.1. Conclusion 
Perhaps the most significant outcome of this project was the discovery that the oxidant reported 
for the formation of xanthones and diones in JOC was in fact ceric ammonium sulfate (CAS) and 
not ceric ammonium nitrate (CAN). CAS is significantly less soluble in the 
acetonitrile/water/chloroform solvent system than CAN and this may play a role in why the 
reaction works preferentially with CAS rather than CAN. However, we cannot ignore the role the 
counterion could be playing in the reaction as the nitrate (being a softer ligand than the sulfate) 
would dissociate from the cerium metal centre faster than the sulfate ion in CAS. 
Regardless of this, when hydroxy-containing benzophenones such as 253, 258 and 261  are 
exposed to CAN only dione and/or spirofuran compounds (Figure 110) were obtained in very low 
yields. This correlates well with what was observed by Omolo.
193
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257 259 300 
Figure 110 – Dione and spirofuran compounds that resulted from the CAN-mediated reactions 
 
When the reactions were performed using CAS, the results reported by Johnson et al. were 
verified. The same products isolated by Johnson were also obtained in this project, however the 
ratio of products (when multiple products were collected) were different. We are confident in 
the ratio of the products reported here as the reactions were performed under controlled 
conditions in triplicate (or more) and reported as average yields. 
Extensive investigation has found that an acetonitrile/water/chloroform solvent system in a 4:2:1 
ratio was essential for this novel xanthone or dione reaction to occur and temperature plays no 
role in the rate of, or the type of products formed during, the reaction. When chloroform was 
excluded from the reaction, the products were isolated in low yields. When acetonitrile was 
excluded from the reaction, the reaction did not go to completion (regardless of CAS equivalents 
or temperature). Changing the solvent system to a methanol/water solution resulted in the 
exclusive formation of xanthone 260 when benzophenone 258 was subjected to the CAS 
conditions. 
A reliable, quick method for the conversion of dione compounds to xanthones was also 
developed over the course of this project (Scheme 94). Novel xanthones 305, 306, 307 and 308 
were generated in good yields using this methodology to show the versatility of this reaction. 
 
6.1.2. Future work 
While extensive work has gone into understanding the novel CAS reaction, the exclusive 
formation of xanthone 260 from benzophenone 258 under the aqueous methanol conditions 
serves as an interesting result that could further be developed. For example it would be 
interesting to see if naphthalene 253 in Scheme 116 (which forms dione 257 exclusively under 
‘normal’ conditions) would still result in dione 257 exclusively in an aqueous methanol 
environment or if a xanthone (such as 340) could be generated from the reaction. 
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 253  340  
Proposed reaction conditions: CAS (4 eq), MeOH/H2O, rt. 
Scheme 116 – Proposed xanthone formation using CAS in a methanol solution 
 
Furthermore, in the reactions presented in this thesis CAS was used in mole equivalents to 
facilitate the reaction. Since there have been a few reports of using CAS under catalytic 
conditions by the addition of compounds (such as silver(I) nitrate, sodium dodecyl sulfate and 
ammonium persulfate as used by Skarżewski)
183
 to reoxidize the cerium, future work could 
include the development of the reaction further to be performed under catalytic conditions. 
 
6.2. Mechanistic investigations 
6.2.1. Conclusions from the mechanistic investigations 
In order to further understand the mechanisms behind this novel reaction, a series of substituted 
benzophenones were synthesized. When methoxybenzophenone 312 was exposed to CAS no 
compounds were successfully isolated from the reaction. This suggests that a second substituent 
with electron donation abilities was necessary for any reactions to occur.  
A variety of different products were isolated depending on the electronic nature of the 
benzophenone starting material. The exposure of benzophenones that contained ortho or para 
dimethoxy substituents (253, 258, 261, 263, 265, 270 and 328) to CAS resulted in the formation 
of xanthone and/or dione products. Benzophenones that had a meta dimethoxy substitution 
pattern (324 and 327) or where no methoxy substituent ortho to the keto-bridge was present 
(325) resulted in the formation of novel dimers under similar conditions. These compounds were 
characterised by NMR spectroscopy and the structure confirmed by obtaining a crystal structure 
for dimer 329. This result highlights the importance of the position of the electron donting 
methoxy substituents on the benzophenones in directing the type of reaction which occurs. 
Furthermore, when trimethoxy-containing substituent 326 was exposed to CAS a spirofuran 333 
was isolated and trace amounts of spirofuran 271 was isolated from trimethoxy-containing 270 
further highlighting this finding. Curiously when benzophenone 261 was exposed to CAN was a 
spirofuran product, 300, was isolated where with CAS exclusively xanthone 262 was formed.  
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The previously proposed mechanisms did not adequately account for all the results obtained in 
this work and hence more detailed mechanisms have been proposed. Scheme 106 to Scheme 110 
outline the proposed mechanisms for the synthesis of xanthones, diones, spirofurans and dimers 
respectively. These new proposed mechanisms detail how all of the products were generated 
from the simple oxidation of the phenol substituents on the benzophenones as shown in Scheme 
117. 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
  
 
 
   
Scheme 117 – General scheme for the potential outcomes of exposing hydroxy-containing 
benzophenones to CAS 
 
6.2.2. Future work from the results from the mechanistic investigations 
The formation of dimers 329, 330 and 331 were unexpected and unprecedented with CAS. Since 
we were only interested in the outcome of the reaction, this project did not include optimization 
of the dimerization reaction conditions and this could serve as an interesting extension to this 
research. Other procedures to form similar dimers require harsh conditions or complicated 
catalysts, and optimization of this reaction could result in a procedure that requires mild, near 
neutral conditions. 
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Of course we cannot rule out the possibility that dimerization could occur in different positions 
(particularly in the ortho position) or that further oxidation could occur as well and this could also 
serve as a point for further investigation. 
 
6.3. Extension of the methodology to the formation of 
Acridones 
6.3.1. Conclusions 
The initial aim of the project was to extend the novel methodology to the synthesis of acridones. 
Due to the unforeseen use of CAS and not CAN we did not fully explore the potential for the 
application of this novel reaction to the synthesis of acridones. A proof of concept resulted in the 
formation of a single acridone, 298, in a poor yield. The poor yield may be attributed to 
significant hydrogen bonding in the starting material (297) – and the reaction did not go to 
completion regardless of how much CAS was added to the reaction. No products were 
successfully isolated when the reaction was performed using CAN.  
Reported herein are a selection of synthetic routes which could be used to generate suitable 2-
aminobenzophenone precursors that could be used to investigate the potential of the CAS 
mediated acridone reaction, the most beneficial being the one-pot lithiation reaction with 
Weinreb amide 339 and bromobenzenes.
200
 Following this a single benzyl protection of the 
amine needs to occur before the CAS reaction can be successful. 
 
6.3.2. Future work 
Extending the CAS methodology to the synthesis of acridones serves as the largest avenue of 
future research from this project. The issue of the hydrogen bonding in the precursor for the CAS 
reaction needs to be addressed. A suggestion would be to protect the ketone as the 
corresponding acetal to remove/weaken the hydrogen bonding as shown in Scheme 118. 
Alternatively, the ketone could be reduced to the alcohol before the ring closure is attempted. 
No research has been done into the necessity of the ketone in the CAS reaction and perhaps this 
should be investigated with the more established xanthone synthetic series before being applied 
to the acridone synthesis. 
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Scheme 118 – Proposed protection of the ketone to facilitate acridone formation 
 
No attempts at removing the benzyl group from acridone 298 were made as only small amounts 
of the acridone were collected. Once the CAS-mediated ring closure for the formation of 
acridones has been optimized then methods for the removal of this protection group used needs 
to be investigated. From there the methodology could be applied in the synthesis of naturally 
occurring acridones such as those outlined in Figure 91. 
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7.1. General Experimental Procedures 
7.1.1. Purification of solvents and reagents 
The solvents and reagents used for this project were purchased from ACE Chemicals or Sigma-
Aldrich and used without purification unless otherwise stated. Dichloromethane (DCM) and 
acetonitrile (MeCN) were distilled over calcium hydride under nitrogen gas. Tetrahydrofuran 
(THF) was distilled over sodium wire and benzophenone under nitrogen gas. Deuterated solvents 
used for growing suitable crystals for single crystal X-ray diffraction were purchased from Merck. 
7.1.2. General laboratory techniques and equipment 
During the course of this project, thin layer chromatography (TLC) was performed on aluminium-
backed Macherey-Nagel ALUGRAM Sil G/UV254 plates that are pre-coated with 0.25 mm silica gel 
60. The compounds were detected using ultraviolet light and stained if necessary, using iodine 
(for the imidazo[1,2-a]pyridines) or vanillin (for the acridone synthesis). 
Evaporation of solvent under reduced pressure was performed on a Büchi Rotavopor R-3 with a 
Büchi R-3 heating bath at approximately 50 °C. This is referred to as evaporation/concentration in 
vacuo. Final drying was done using a high vacuum pump at 1 mm/Hg. 
Microwave reactions were carried out on a commercial CEM Discover microwave oven. 
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7.1.3. Chromatographic Separations 
Mixtures of products were separated by routine column chromatography, where the silica used 
was Macherey-Nagel 60, silica gel 60 (particle size 0.063 - 0.200 mm). Flash column 
chromatography was also performed, using Merck silica gel (particle size 0.035-0.070 mm). In an 
appropriately sized column, silica of mass approximately 30 times that of the product was packed 
and the product loaded onto the silica surface and covered with acid washed sand. Elution was 
achieved using the indicated solvent mixtures that were hexane and ethyl acetate based. 
7.1.4. Spectroscopic Techniques 
7.1.4.1. NMR Spectroscopy 
1
H NMR spectra were recorded using Bruker Advance-500 and Bruker Advance-300 
spectrometers operating at 500 MHz and 300 MHz respectively. All spectra were recorded in 
deuterated chloroform (CDCl3), deuterated methanol (d4-MeOD) or deuterated dimethylsulfoxide 
(d6-DMSO) with all chemical shift values reported in parts per million referenced against 0.03% 
tetramethylsilane (TMS) as an internal standard. Coupling constants, J, are reported in Hertz (Hz). 
Commonly used abbreviations in assignments include: s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet.  
75.47 MHz and 125 MHz 
13
C NMR (
1
H decoupled) spectra were recorded on Bruker Advance-300 
and Bruker Advance-500 Spectrophotometers. All spectra were recorded in CDCl3, d4-MeOD or 
d6-DMSO and the chemical shifts are reported on the δ scale in parts per million (ppm) relative to 
the central signal of CDCl3 taken as 77.0 ppm, d4-MeOD as 49.0 ppm and d6-DMSO as 39.5 ppm.  
All NMR spectroscopic data was processed using the MestReNova software suite licenced to the 
University of the Witwatersrand.
201
 The 
1
H and 
13
C NMR spectra were recorded for all 
compounds. Additional 2D experiments (COSY, HSQC, HMBC etc.) were recorded for final 
compounds, novel compounds and for any other compounds where it was deemed necessary. 
The compounds synthesized in this project were characterised as definitively as the spectra 
collected would allow, however *,’,
#
,
~
 and 
^
 were symbols used to denote interchangeable 
assignments. 
7.1.4.2. Infrared Spectroscopy 
Infrared spectra were recorded on a Bruker Tensor 27 Spectrophotometer and all samples were 
loaded directly onto a diamond cell. All predominant absorptions are reported in terms of 
wavenumbers (ν/cm
-1
). IR spectra were obtained only for compounds where no IR data was 
available and for final compounds. 
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7.1.4.3. High Resolution Mass Spectroscopy 
High resolution mass spectra (HRMS) were recorded on a Waters Synapt G2. All data was quoted 
in relative abundance (m/z). HRMS was performed only on novel compounds where no MS data 
was available as well as for final compounds. The author would like to thank the Mass 
Spectroscopy Unit at Stellenbosch University for their analysis of the compounds synthesized in 
this work. 
7.1.5. Melting Points 
Melting points were recorded using a Stuart SMP10 melting point apparatus. Capillary tubes that 
were sealed at one end were loaded with small amounts of sample and loaded into the melting 
point apparatus and observed. The point at which the entire sample had uniformly melted was 
considered to be the melting point. Melting points are reported without correction.  
7.1.6. Elemental Analysis 
The author would like to thank the analysis units at the University of Stellenbosch and University 
of Johannesburg for their elemental analysis of selected samples from this work. 
7.1.7. Single Crystal X-ray Diffraction 
Single crystal X-ray diffraction was made use of extensively over the course of this project. 
Suitable crystals were grown and diffraction intensity data collection, crystal structure solution 
and refinement were conducted by the author of this PhD. The intensity data were collected on a 
Bruker APEX II CCD area detector diffractometer with graphite monochromated Mo K α-radiation 
(50kV, 30mA) using the APEX 2 data collection software. The collection method involved ω-scans 
of width 0.5° and 512x512 bit data frames. Data reduction was carried out using the program 
SAINT+ version 6.02.6 software and SADABS was used to make empirical absorption 
corrections.
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SHELXS-97 was used to solve crystal structures by direct methods.
203
 After initial isotropic 
refinements of non-hydrogen atoms, further anisotropic refinements were done by full matrix 
least-squares calculations based on F
2
 using SHELXL-97.
203
 C-bound H atoms were first located in 
the difference map, then positioned geometrically and allowed to ride on their respective parent 
atoms, with thermal displacement parameters 1.2 times of the parent C atom. Where possible, 
the coordinates and isotropic displacement parameters of the N‒bound and O‒bound H atoms 
involved in the hydrogen bonding interactions were allowed to refine freely. Diagrams and 
publication material were generated using WinGX
204
 and ORTEP-3 and the displacement 
ellipsoids shown at a 50% probability level.
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An example of the crystallographic information along with the ORTEP diagrams for selected 
compounds can be found in the Appendices, while the crystallographic information for each of 
the crystal structures obtained in this thesis are available in the Digital Appendix.  
7.1.8. pH measurements 
A Metrohm High-precision 780 pH meter and Metrohm Unitrode combination pH electrode was 
used for all pH measurements in the stability study. The electrode was calibrated by means of a 3 
buffer calibration at pH 4, 7 and 9 using Metrohm ready-to-use buffer solutions. 
7.1.9. UV-vis Spectroscopy 
The stability studies were performed using UV-vis spectra that were recorded on either a Cary 
100 UV-vis Spectrophotometer or Cary 300 Bio UV-vis Spectrophotometer, fitted with cuvette 
holders for 1 cm path length cuvettes. Matched Helma standard quartz cuvettes with Teflon 
stoppers were used for the pK experiments, one of which was used as a reference cell containing 
a 50% MeOH/H2O solution. Each spectrum was recorded with a spectral band width of 2 nm, 
signal averaging time of 0.1 s, data interval of 0.5 nm and a scan rate of 300 nm.min
-1
. 
The scan application of the Cary WinUV software suite was used to facilitate the collection of 
absorbance spectra.
206
 
7.1.10. Data Analysis 
The spectroscopic data collected from the stability study was analysed using SigmaPlot
118
 to 
determine the pK of selected compounds. Two models were used to fit the data using equations 
1 and 2 below. 
    
  [ 
 ]      
     
  
     Equation 1 
    
    
         [ 
 ]        
          
       
    Equation 2 
The free ligands that showed a single pK were successfully fitted using equation 1. The zinc 
complexes that showed two distinct pK values were successfully fitted using equation 2. While 
the copper complexes also showed two pK values, due to the significant spectroscopic 
differences between pK1 and pK2, each pK was fitted separately using equation 1. The derivation 
of these equations can be found in the Digital Appendix. 
The pK values determined by SigmaPlot was then further analysed in Microsoft Excel to 
determine the K value for each experiment, the average K value(s) for each compound and the 
standard deviation. The pK value(s) for each compound was determined using the average K 
values and the error calculated from the sum of weighted relative percentage error reciprocals. 
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The raw absorbance data and the reports generated from SigmaPlot are available in the Digital 
Appendix. An example of the results obtained for one compound is given in Appendix A3. 
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7.2. Experimental Procedures for At the End of My Tether 
7.2.1. General Procedure and Experimental details for the Groebke-
Blackburn-Bienaymé MCR reactions 
The general procedure for the MCR of imidazo[1,2-a]pyridines involved the combination of the 
appropriate 2-aminopyridine, isocyanide and aldehyde in equal mol ratio’s in a round bottomed 
flask. To this Montmorillonite K10 clay was added (same mass as the 2-aminopyridine that was 
added) followed by the solvent (dioxane or ethanol). The mixture was stirred under reflux 
conditions for 4-48 hours, in some cases with additional stirring at room temperature for a 
further 12 hours. The clay was filtered off through Celite and washed with hot EtOAc or DCM. The 
filtrate was then concentrated in vacuo and the product purified by recrystallization or by column 
chromatography before being successfully characterised by NMR spectroscopy. 
 
The general procedure was followed using 2-amino-5-
bromopyridine (2.00 g, 11.56 mmol), 3,4-
dimethoxybenzaldehyde (1.92 g, 11.56 mmol, 1 eq), 
cyclohexyl isocyanide (1.26 g, 11.56 mmol, 1 eq) and 
Montmorillonite K10 clay (2.00 g). The product was 
recrystallized from a large volume of hot ether. 
Imidazo[1,2-a]pyridine 85 was collected as yellow cubes 
and white crystals (2.94 g, 59 %). Rf = 0.47 (50 % 
EtOAc/Hexane). m.p. = 158-159 ˚C. 
1
H NMR (300 MHz, CDCl3): δH =  8.19 (1H, dd, J = 2.0 and 0.9 
Hz, H-5), 7.65 (1H, d, J = 2.0 Hz, H-11), 7.52 (1H, dd, J = 8.3 and 2.0 Hz, H-15), 7.40 (1H, dd, J = 9.4 
and 0.9 Hz, H-8), 7.15 (1H, dd, J = 9.4 and 1.9 Hz, H-7), 6.93 (1H, d, J = 8.4 Hz, H-14), 3.97 (3H, s, 
H-16*), 3.92 (3H, s, H-17*), 3.04 (1H, d, J = 4.4 Hz, H-24), 2.97 (1H, m, H-18), 1.78 (2H, d, J = 9.8 
Hz, H-19a and H-23a), 1.69 (2H, q, J = 3.8 Hz, H-20a and H-22a), 1.58 (1H, d, J = 5.7 Hz, H-21a), 
1.31 – 1.10 (5H, m, H-19b, H-20b, H-21b, H-22b and H-23b). 
13
C NMR (75 MHz, CDCl3): δC = 149.2 
(C-12*), 148.8 (C-13*), 139.9 (C-9), 137.8 (C-3), 127.2 (C-7), 127.1 (C-10), 124.5 (C-2), 122.9 (C-5), 
119.5 (C-15), 117.9 (C-8), 111.2 (C-11), 110.6 (C-14), 106.5 (C-6), 56.9 (C-18), 56.1 (C-16
#
), 56.0 (C-
17
#
), 34.3 (C-19 and C-23), 25.8 (C-21), 24.9 (C-20 and C-22). IR (νm.cm
-1
) = 3298, 2928, 2853, 
1585, 1504, 1448, 1406, 1361, 1319, 1255, 1224, 1168, 1134, 1026, 941, 891, 862, 798, 760, 715, 
671. ESI-MS (m/z) calculated for C21H25N3O2Br, [M+H]
+
, 430.3380, found 430.1141. 
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 The general procedure was followed using 2-amino-5-bromopyridine (2.00 g, 11.56 mmol), 3,4-
dimethoxybenzaldehyde (1.92 g, 11.56 mmol, 1 
eq), xylyl isocyanide (1.52 g, 11.56 mmol, 1 eq) 
and Montmorillonite K10 clay (2.00 g). The 
product was recrystallized from hot ether. 86 
was collected as a cream powder (1.38 g, 26 %). 
Rf = 0.39 (50 % EtOAc/Hexane). m.p. = 202 ˚C. 
1
H 
NMR (300 MHz, CDCl3): δH = 7.85 (1H, dd, J = 1.9 
and 0.9 Hz, H-5), 7.54 (1H, dd, J = 8.4 and 2.0 Hz, 
H-15), 7.42 (1H, dd, J = 9.4 and 0.9 Hz, H-8), 7.38 
(d, J = 2.0 Hz, H-11), 7.17 (1H, dd, J = 9.4 and 1.9 Hz, H-7), 6.95 (2H, d, J = 7.5 Hz, H-20 and H-22), 
6.81 – 6.73 (2H, m, H-14 and H-21), 5.36 (1H, s, H-26), 3.86 (3H, s, H-16*), 3.67 (3H, s, H-17*), 
1.97 (6H, s, H-24 and H-25). 
13
C NMR (75 MHz, CDCl3): δC = 148.8 (C-12 and C-13), 140.4 (C-18*), 
139.7 (C-9*), 139.2 (C-3*), 130.1 (C-19 and C-23), 127.6 (C-7), 125.9 (C-2), 124.6 (C-20 and C-22), 
122.4 (C-5), 120.9 (C-10), 119.9 (C-21), 119.7 (C-15), 117.8 (C-8), 110.9 (C-11), 109.9 (C-14), 106.9 
(C-6), 55.8 (C-12
#
), 55.6 (C-13
#
), 18.5 (C-24 and C-25). IR (νm.cm
-1
) = 3363, 3091, 3059, 3045, 3001, 
2960, 2947, 2835, 1583, 1504, 1469, 1409, 1375, 1327, 1261, 1259, 1170, 1134, 1026, 947, 850, 
806, 756, 730, 678, 642. ESI-MS (m/z) calculated for C23H23N3O2Br, [M+H]
+
, 452.0974, found 
452.0976. 
 
The general procedure was followed using 2-amino-5-
bromopyridine (1.50 g, 8.67 mmol), 3,4-
dimethoxybenzaldehyde (1.44 g, 8.67 mmol, 1 eq), t-
butyl isocyanide (0.72 g, 8.67 mmol, 1 eq) and 
Montmorillonite K10 clay (1.50 g). The mixture was 
purified by recrystallization from hot EtOAc. 
Imidazo[1,2-a]pyridine 87 was collected as a cream 
powder (2.57 g, 73 %). Rf = 0.31 (50 % EtOAc/Hexane). m.p. = 148 ˚C. 
1
H NMR (300 MHz, CDCl3): 
δH = 8.34 – 8.28 (1H, m, H-5), 7.53 (1H, 1H, d, J = 2.0 Hz, H-8), 7.42 (1H, d, J = 1.8 Hz, H-11), 7.41 – 
7.37 (1H, m, H-15), 7.16 (1H, dd, J = 9.4 and 2.0 Hz, H-7), 6.91 (1H, d, J = 8.3 Hz, H-14), 3.97 (3H, s, 
H-16*), 3.92 (3H, s, H-17*), 3.08 (1H, s, H-22), 1.05 (9H, s, H-19, H-20 and H-21). 
13
C NMR (75 
MHz, CDCl3): δC = 149.0 (C-12*), 148.8 (C-13*), 140.5 (C-9), 140.3 (C-3), 127.7 (C-10), 127.3 (C-7), 
123.6 (C-2), 123.4 (C-5), 120.7 (C-15), 117.9 (C-8), 111.5 (C-11), 110.9 (C-14), 106.3 (C-6), 56.6 (C-
18), 56.1 (C-16
#
), 55.9 (C-17
#
), 30.5 (C-19, C-20 and C-21). IR (νm.cm
-1
) = 3308, 3005, 2966, 2837, 
1682, 1584, 1504, 1464, 1386, 1313, 1251, 1209, 1140, 1024, 951, 853, 795, 760, 671. ESI-MS 
(m/z) calculated for C19H23N3O2Br, [M+H]
+
, 404.0974, found 404.0980. 
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2-Amino-5-bromopyridine (2.00 g, 11.56 mmol), 
2-pyridinecarboxaldehyde (1.24 g, 11.56 mmol, 1 
eq), cyclohexyl isocyanide (1.26 g, 11.56 mmol, 1 
eq) and Montmorillonite K10 clay (2.00 g) were 
combined and the general procedure followed. 
The resulting mixture was purified by 
recrystallization from an ether/methanol mixture 
to afford imidazo[1,2-a]pyridine 88 as yellow 
needles (1.4 g, 33 %). Rf = 0.50 (50 % EtOAc/Hexane). m.p. = 135 - 136 ˚C. 
1
H NMR (500 MHz, 
CDCl3): δH =  8.55 (1H, ddd, J = 4.9, 1.9 and 0.9 Hz, H-12), 8.15 (1H, dt, J = 8.1 and 1.1 Hz, H-15), 
8.09 (1H, dd, J = 1.9 and 0.9 Hz, H-5), 7.75 (1H, td, J = 7.8 and 1.8 Hz, H-14), 7.41 (1H, dd, J = 9.5 
and 0.9 Hz, H-8), 7.17 – 7.09 (2H, m, H-7 and H-13), 6.21 (1H, d, J = 9.9 Hz, H-22), 3.07 (1H, tt, J = 
9.6 and 5.7 Hz, H-16), 1.93 – 1.84 (2H, m, H-17a and H-21a), 1.76 – 1.66 (2H, m, H-18a and H-
20a), 1.57 (1H, dd, J = 9.7 and 4.4 Hz, H-19a), 1.37 – 1.17 (5H, m, H-17b, H-18b, H-19b, H-20b and 
H-21b). 
13
C NMR (126 MHz, CDCl3): δC = 154.8 (C-12), 148.5 (C-9), 139.2 (C-3), 136.7 (C-14), 131.5 
(C-2*), 131.4 (C-10*), 126.7 (C-7), 123.1 (C-5), 121.5 (C-13), 120.5 (C-15), 118.6 (C-8), 106.7 (C-6), 
55.6 (C-16), 34.2 (C-17 and C-21), 25.9 (C-19), 25.0 (C-18 and C-20). IR (νm.cm
-1
) = 3338, 2925, 
2918, 2858, 2856, 1612, 1554, 1506, 1456, 1390, 1303, 1298, 1247, 1205, 1159, 1126, 1085, 
1024, 912, 887, 844, 779, 736, 702, 667, 634. ESI-MS (m/z) calculated for C18H20BrN4, [M+H]
+
, 
371.0871, found 371.0874.  
 
2-Amino-5-bromopyridine (2.00 g, 11.56 mmol), 2,4-
dimethoxybenzaldehyde (1.92 g, 11.56 mmol, 1 eq), 
cyclohexyl isocyanide (1.26 g, 11.56 mmol, 1 eq) and 
Montmorillonite K10 clay (2.00 g) were used and the 
general procedure followed. The product was 
recrystallized from an ether/methanol mixture resulting 
in a yellow powder that was found to be imidazo[1,2-
a]pyridine 89 (3.50 g, 70 %). Rf = 0.48 (50 % 
EtOAc/Hexane). m.p. = 164 ˚C. 
1
H NMR (300 MHz, 
CDCl3): δH = 8.20 (1H, d, J = 1.3 Hz, H-5), 7.73 (1H, d, J = 8.5 Hz, H-15), 7.40 (1H, d, J = 9.4 Hz, H-8), 
7.13 (1H, dd, J = 9.4 Hz and J = 1.9 Hz, H-7), 6.66 (1H, dd, J = 8.5 Hz and J = 2.4 Hz, H-14), 6.57 (1H, 
d, J = 2.3 Hz, H-12), 3.87 (3H, s, H-16*), 3.86 (3H, s, H-17*), 3.85 (1H, s, N-H), 2.67 – 2.59 (1H, m, 
H-18), 1.69 (2H, d, J = 12.6 Hz, H-19), 1.59 (2H, dd, J = 9.8 Hz and J = 3.3 Hz, H-20), 1.49 (1H, dd, J 
= 8.8 Hz and J = 3.6 Hz, H-21a), 1.16 – 0.96 (5H, m, H-21b, H-22 and H-23). 
13
C NMR (75 MHz, 
CDCl3): δC = 160.8 (C-13*), 156.9 (C-11*), 140.0 (C-9), 134.7 (C-3), 132.3 (C-15), 127.0 (C-7), 126.1 
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(C-2), 122.7 (C-5), 117.9 (C-8), 116.7 (C-10), 106.1 (C-6), 105.8 (C-14), 99.2 (C-12), 56.4 (C-18), 
56.1 (C-16
#
), 55.4 (C-17
#
), 34.1 (C-19 and C-23), 25.7 (C-21), 24.8 (C-20 and C-22). IR (νm.cm
-1
) = 
3340, 2925, 2918, 2858, 2856, 1612, 1558, 1506, 1454, 1392, 1325, 1298, 1247, 1207, 1159, 
1126, 1085, 1024, 912, 889, 844, 821, 781, 702, 669, 632. ESI-MS (m/z) calculated for 
C21H25N3O2Br, [M+H]
+
, 430.1130, found 430.1125. 
Following the general procedure, 2-amino-5-
bromopyridine (1.00 g, 5.78 mmol), 2-trifluoro-
methylbenzaldehyde (1.01 g, 5.78 mmol, 1 eq), cyclohexyl 
isocyanide (0.63 g, 5.78 mmol, 1 eq) and Montmorillonite 
K10 clay (1.00 g) were combined and a cream powder 
resulted after recrystallization from hot EtOAc which was 
found to be 90 (1.34 g, 53 %). Rf = 0.72 (50 % 
EtOAc/Hexane). m.p. = 160-163 ˚C. 
1
H NMR (300 MHz, 
CDCl3): δH = 8.24 (1H, dd, J = 1.9 and 0.9 Hz, H-5), 7.79 (1H, 
dd, J = 7.8 and 1.4 Hz, H-12), 7.61 (1H, td, J = 7.5 and 1.5 Hz, H-14), 7.55 (1H, d, J = 7.7 Hz, H-13), 
7.50 (1H, dd, J = 7.4 and 1.4 Hz, H-15), 7.42 (1H, dd, J = 9.4 and 0.9 Hz, H-8), 7.20 (1H, dd, J = 9.5 
and 1.9 Hz, H-7), 3.00 (1H, d, J = 5.9 Hz, H-23), 2.66 (1H, m, H-17), 1.76 – 1.44 (5H, m, H-18a, H-
19a, H-20a, H-21a and H-22a), 1.04 (5H, m, H-18b, H-19b, H-20b, H-21b and H-22b). 
13
C NMR (75 
MHz, CDCl3): δC = 139.5 (C-9), 136.2 (C-3), 133.2 (t, C-11), 132.7 (C-15), 131.4 (C-14), 129.9 (t, C-
2), 129.5 (C-10), 129.1 (C-16), 128.5 (C-13), 127.2 (C-7), 126.4 (t, C-12), 123.1 (C-5), 118.4 (C-8), 
106.8 (C-6), 56.3 (C-17), 33.8 (C-18 and C-22), 25.6 (C-20), 24.5 (C-19 and C-21). IR (νm.cm
-1
) = 
3248, 2928, 2855, 1555, 1495, 1448, 1408, 1406, 1312, 1231, 1188, 1138, 1107, 1051, 1034, 957, 
887, 856, 796, 768, 690, 667, 646. ESI-MS (m/z) calculated for C20H20BrF3N3, [M+H]
+
, 438.0793, 
found 438.0799. 
 
2-Amino-5-bromopyridine (1.50 g, 8.67 mmol), hexanal (0.87 g, 8.67 mmol, 1 eq), cyclohexyl 
isocyanide (0.95 g, 8.67 mmol, 1 eq) and 
Montmorillonite K10 clay (1.50 g) were 
combined and the general procedure followed. 
The product was purified by column 
chromatography in a 50 % EtOAc/Hexane eluent 
solution. Imidazo[1,2-a]pyridine 91 was collected 
as a yellow viscous liquid (1.10 g, 35 %). Rf = 0.69 
(50 % EtOAc/Hexane). 
1
H NMR (300 MHz, CDCl3): 
δH = 8.13 (1H, d, J = 1.8 Hz, H-5), 7.31 (1H, d, J = 
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9.3 Hz, H-8), 7.08 (1H, dd, J = 9.4 and 2.0 Hz, H-7), 2.94 – 2.82 (2H, m, H-15 and H-21), 2.74 – 2.64 
(2H, m, H-10), 1.91 – 1.82 (2H, m, H-16a and H-20a), 1.82 – 1.70 (4H, m, H-11, H-17a and H-19b), 
1.65 – 1.58 (1H, m, H-18a), 1.36 (4H, m, H-12 and H-13), 1.30 – 1.16 (5H, m, H-16b, H-17b, H-18b, 
H-19b and H-20b), 0.95 – 0.86 (3H, m, H-14). 
13
C NMR (75 MHz, CDCl3): δC = 140.8 (C-9), 139.6 (C-
3), 126.0 (C-7), 124.8 (C-2), 122.5 (C-5), 117.3 (C-8), 105.7 (C-6), 57.1 (C-15), 34.1 (C-16 and C-17), 
31.9 (C-13), 29.1 (C-11), 27.3 (C-10), 25.7 (C-18), 24.8 (C-17 and C-19), 22.5 (C-12), 14.0 (C-14). IR 
(νm.cm
-1
) = 3280, 2928, 2855, 1653, 1564, 1499, 1450, 1402, 1396, 1321, 1261, 1132, 1090, 891, 
795, 735. ESI-MS (m/z) calculated [M+H]
+
 for C18H27N3Br, 364.1388, found 364.1380. 
 
Following the general procedure, 2-amino-5-bromopyridine (1.50 g, 8.67 mmol), 2-
chlorobenzaldehyde (1.22 g, 8.67 mmol, 1 eq), 
cyclohexyl isocyanide (0.95 g, 8.67 mmol, 1 eq) 
and Montmorillonite K10 clay (1.50 g) were 
combined and the mixture purified by 
recrystallization from hot methanol to afford 92 
as a cream powder (1.34 g, 38 %). Rf = 0.62 (50 % 
EtOAc/Hexane). m.p. = 151 - 152 ˚C. 
1
H NMR 
(300 MHz, CDCl3): δH = 8.26 (1H, d, J = 1.7 Hz, H-
5), 7.67 – 7.61 (1H, m, H-15), 7.49 – 7.40 (2H, m, 
H-8 and H-12), 7.38 – 7.31 (2H, m, H-13 and H-14), 7.19 (1H, dd, J = 9.5, 1.9 Hz, H-7), 3.25 (1H, d, J 
= 7.1 Hz, H-22), 2.64 (1H, dq, J = 6.4 and 3.3 Hz, H-16), 1.65 (2H, m, H-17a and H-21a), 1.55 (2H, d, 
J = 4.6 Hz, H-18a and H-20a), 1.52 – 1.41 (1H, m, H-19a), 1.13 – 0.94 (5H, m, H-17b, H-18b, H-19b, 
H-20b and H-21b). 
13
C NMR (75 MHz, CDCl3): δC = 140.0 (C-3), 136.2 (C-9), 133.6 (C-2), 132.6 (C-
11), 132.5 (C-12), 129.5 (C-14), 129.4 (C-15), 127.1 (C-17), 127.0 (C-7), 126.6 (C-10), 123.0 (C-5), 
118.3 (C-8), 106.7 (C-6), 56.4 (C-16), 33.8 (C-17 and C-21), 25.6 (C-19), 24.6 (C-18 and C-20). IR 
(νm.cm
-1
) = 3354, 2933, 2851, 1557, 1508, 1479, 1448, 1391, 1323, 1261, 1227, 1180, 1109, 1082, 
1045, 1029, 931, 889, 831, 785, 734, 711, 652, 601. ESI-MS (m/z) calculated [M+H]
+
 for 
C19H20N3ClBr 404.0529, found 404.0529. 
 
2-Amino-5-bromopyridine (0.628 g, 1.55 mmol), 
2,4-dimethoxybenzaldehyde (0.258 g, 1.55 
mmol, 1 eq), adamantyl isocyanide (0.250 g, 
11.56 mmol, 1 eq) and Montmorillonite K10 clay 
(0.628 g) were used and the general procedure 
followed. The mixture was purified by column 
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chromatography using a 40 % EtOAc/Hex eluent. The product, 93, was collected as a peach foam 
(0.694 g, 93 %). Rf = 0.69 (50 % EtOAc/Hexane). m.p. = 95 - 97 ˚C. 
1
H NMR (300 MHz, CDCl3): δH = 
8.43 (1H, dd, J = 2.0 and 0.9 Hz, H-5), 7.72 (1H, d, J = 8.5 Hz, H-15), 7.38 (1H, dd, J = 9.4 and 0.9 
Hz, H-8), 7.12 (1H, dd, J = 9.4 and 1.9 Hz, H-7), 6.65 (1H, dd, J = 8.5 and 2.4 Hz, H-14), 6.54 (1H, d, 
J = 2.4 Hz, H-12), 3.86 (3H, s, H-16*), 3.85 (3H, s, H-17*) 3.71 (1H, s, H-28), 1.96 – 1.84 (3H, m, H-
22, H-23 and H-24), 1.44 (12H, m, H-19, H-20, H-21, H-25, H-26 and H-27). 
13
C NMR (75 MHz, 
CDCl3): δC = 160.8 (C-11*), 156.9 (C-13*), 140.6 (C-9), 137.3 (C-3), 132.3 (C-15), 126.4 (C-7), 124.8 
(C-2), 123.7 (C-5), 117.7 (C-8), 117.5 (C-10), 105.8 (C-6), 105.7 (C-14), 99.2 (C-12), 56.1 (C-16
#
), 
55.9 (C-17
#
), 55.4 (C-18), 43.5 (C-19, C-20 and C-21), 36.2 (C-25, C-26 and C-27), 29.6 (C-25, C-26 
and C-27). IR (νm.cm
-1
) = 3346, 2905, 2847, 1614, 1503, 1456, 1391, 1306, 1285, 1207, 1159, 
1163, 1090, 1030, 916, 829, 791, 671, 561. ESI-MS (m/z) calculated [M+H]
+
 for C25H29N3O2Br 
482.1443, found 482.1460. 
 
2-Amino-6-bromopyridine (1.50 g, 8.67 mmol), 3,4-dimethoxybenzaldehyde (1.44 g, 8.67 mmol, 1 
eq), cyclohexyl isocyanide (0.95 g, 8.67 mmol, 1 
eq) and Montmorillonite K10 clay (1.50 g) were 
combined and the general procedure followed. 
The product was purified by column 
chromatography using an eluent of 20-80 % 
EtOAc/Hexane. After concentration in vacuo, 94 
was collected as a viscous brown oil (2.73 g, 73 
%). Rf = 0.64 (50 % EtOAc/Hexane). 
1
H NMR (300 
MHz, CDCl3): δH =  7.96 (1H, d, J = 2.0 Hz, H-11), 
7.85 (1H, dd, J = 8.4 and 2.0 Hz, H-15), 7.51 (1H, 
dd, J = 7.2 and 2.8 Hz, H-8), 6.98 – 6.89 (3H, m, H-6, H-7 and H-14), 3.98 (3H, s, H-16*), 3.93 (3H, 
s, H-17*), 3.63 (1H, s, H-24), 3.05 – 2.87 (1H, m, H-18), 1.70 (2H, d, J = 11.5 Hz, H-19a and H-23a), 
1.62 (2H, dd, J = 7.8 and 2.9 Hz, H-20a and H-22a), 1.54 (1H, d, J = 4.3 Hz, H-21a), 1.21 – 1.01 (5H, 
m, H19b, H-20b, H-21b, H-22b and H-23b). 
13
C NMR (75 MHz, CDCl3): δC = 148.6 (C-12 and C-13), 
144.1 (C-9), 139.4 (C-3), 127.4 (C-7), 126.4 (C-10), 124.1 (C-2), 120.6 (C-5), 118.5 (C-15), 117.2 (C-
8), 111.7 (C-6), 111.1 (C-11), 110.9 (C-14), 59.0 (C-18), 56.0 (C-16*), 55.9 (C-17*), 33.1 (C-19 and 
C-23), 26.0 (C-21), 25.0 (C-20 and C-22). IR (νm.cm
-1
) = 3352, 2931, 2856, 1708, 1635, 1510, 1452, 
1419, 1371, 1311, 1257, 1176, 1139, 1026, 979, 850, 808, 763. ESI-MS (m/z) calculated [M+H]
+
 
for C21H25N3O2Br 430.1130, found 430.1132.  
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2-Amino-6-bromopyridine (1.50 g, 8.67 mmol), 
2,4-dimethoxybenzaldehyde (1.44 g, 8.67 mmol, 
1 eq), cyclohexyl isocyanide (0.947 g, 8.67 mmol, 
1 eq) and Montmorillonite K10 clay (1.50 g) were 
combined and the general procedure followed. 
The mixture was purified by column 
chromatography using an eluent of 30 % 
EtOAc/Hexane. The product was further purified 
by recrystallization from an ether/methanol 
mixture. Imidazo[1,2-a]pyridine 95 was collected as a brown solid (1.498 g, 40 %). Rf = 0.40 (50 % 
EtOAc/Hexane). m.p = 80 – 81 °C. 
1
H NMR (300 MHz, CDCl3): δH =  
1
H NMR (300 MHz, CDCl3) δ = 
7.63 (1H, d, J = 8.5 Hz, H-11), 7.50 (1H, dd, J = 8.5 and 1.4 Hz, H-8), 6.92 (2H, m, H-6 and H-7), 6.66 
(1H, dd, J = 8.5 and 2.3 Hz, H-12), 6.58 (1H, d, J = 2.3 Hz, H-14), 3.87 (3H, s, H-16*), 3.86 (3H, s, H-
17*), 3.63 (1H, d, J = 9.1 Hz, H-24), 2.88 – 2.72 (1H, m, H-18), 1.73 (2H, d, J = 12.4 Hz, H-19a and 
H-23a), 1.52 (2H, dt, J = 10.9 and 5.5 Hz, H-20a and H-22a), 1.47 (1H, s, H-21a), 1.16 – 0.72 (5H, 
m, H-19b, H-20b, H-21b, H-22b and H-23b). 
13
C NMR (75 MHz, CDCl3): δC = 160.9 (C-15
#
), 157.2 
(C-13
#
), 143.8 (C-9), 136.5 (C-3), 132.6 (C-5), 129.0 (C-7), 123.2 (C-11), 118.5 (C-8), 116.8 (C-2), 
116.7 (C-6), 112.0 (C-10), 105.6 (C-12), 99.1 (C-14), 58.9 (C-18), 56.0 (C-16*), 55.4 (C-17*), 50.2, 
33.0 (C-19 and C-23), 25.8 (C-21), 25.0 (C-20 and C-22). IR (νm.cm
-1
) = 3418, 3341, 2937, 2934, 
2843, 1614, 1557, 1506, 1454, 1441, 1400, 1298, 1285, 1259, 1205, 1161, 1123, 1074, 1028, 937, 
921, 889, 824, 770, 719, 667, 630. ESI-MS (m/z) calculated [M+H]
+
 for C21H25N3O2Br 430.1130, 
found 430.1137. 
 
2-Amino-3-bromopyridine (1.00 g, 5.78 mmol), 
2,4-dimethoxybenzaldehyde (0.961 g, 5.78 
mmol, 1 eq), cyclohexyl isocyanide (0.631 g, 5.78 
mmol, 1 eq) and Montmorillonite K10 clay (1.00 
g) were combined and the general procedure 
followed. The mixture was purified by column 
chromatography using an eluent of 40 % 
EtOAc/Hexane. 96 was found to be the product 
and was collected as a sticky brown oil (1.866 g, 
75 %). Rf = 0.51 (75 % EtOAc/Hexane), 
1
H NMR (300 MHz, CDCl3): δH =  8.07 (1H, dd, J = 6.8, 0.8 
Hz, H-5), 7.83 (1H, d, J = 8.5 Hz, H-15), 7.31 (1H, dd, J = 7.2 and 0.8 Hz, H-7), 6.66 (1H, dd, J = 8.5 
and 2.3 Hz, H-14), 6.63 – 6.58 (1H, m, H-6), 6.57 (1H, d, J = 2.3 Hz, H-12), 3.96 – 3.87 (1H, m, H-
24), 3.84 (3H, s, H-16*), 3.82 (3H, s, H-17*), 2.64 (1H, s, H-18), 1.68 (2H, d, J = 10.0 Hz, H-19a and 
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H-23a), 1.54 (2H, s, H-20a and H-22a), 1.45 (1H, s, H-21a), 1.01 (5H, m, H-19b, H-20b, H-21b, H-
22b and H-23b). 
13
C NMR (75 MHz, CDCl3): δC = 160.8 (C-11*), 156.9 (C-13*), 139.1 (C-9), 134.6 
(C-3), 132.7 (C-15), 128.2 (C-2), 125.1 (C-7), 122.0 (C-5), 116.7 (C-8), 111.2 (C-6), 111.1 (C-10), 
105.9 (C-14), 99.0 (C-12), 56.3 (C-16
#
), 56.1 (C-18), 55.4 (C-17
#
), 34.0 (C-19 and C-23), 25.6 (C-21), 
24.7 (C-20 and C-22). IR (νm.cm
-1
) = 3368, 2932, 2855, 1614, 1580, 1503, 1454, 1447, 1348, 1304, 
1263, 1207, 1159, 1088, 1030, 939, 833, 733, 702, 664, 582.  ESI-MS (m/z) calculated [M+H]
+
 for 
C21H25N3O2Br 430.1130, found 430.1136. 
 
Following the general procedure 2-
aminopyridine (1.50 g, 15.9 mmol), 2-bromo-4,5-
dimethoxybenzaldehyde (3.91 g, 15.9 mmol, 1 
eq), cyclohexyl isocyanide (1.74 g, 15.9 mmol, 1 
eq) and Montmorillonite K10 clay (1.50 g) were 
combined. The mixture was purified by column 
chromatography using an eluent of 50 % 
EtOAc/Hexane. 97 was collected as a mustard 
foam (4.22 g, 62 %). Rf = 0.31 (50 % EtOAc/Hexane). m.p. = 110-112 °C. 
1
H NMR (300 MHz, 
CDCl3): δH =  8.13 (1H, d, J = 6.8 Hz, H-5), 7.51 (1H, d, J = 9.1 Hz, H-8), 7.16 – 7.08 (2H, m, H-7 and 
H-15*), 7.08 (1H, s, H-12*), 6.78 (1H, td, J = 6.8 and 0.9 Hz, H-6), 3.90 (3H, s, H-16*), 3.88 (3H, s, 
H-17*), 3.27 (1H, d, J = 6.8 Hz, H-24), 2.64 (1H, s, H-18), 1.72 – 1.61 (2H, m, H-19a and H-23a), 
1.61 – 1.51 (2H, m, H-20a and H-22a), 1.46 (1H, s, H-21a), 1.15 – 0.96 (5H, m, H-19b, H-20b, H-
21b, H-22b and H-23b). 
13
C NMR (75 MHz, CDCl3): δC = 149.5 (C-13*), 148.5 (C-14*), 141.4 (C-9), 
136.8 (C-3), 128.5 (C-2), 125.9 (C-5), 123.8 (C-7
#
), 123.0 (C-10), 117.5 (C-12
#
), 115.2 (C-11), 114.9 
(C-6), 113.0 (C-8), 111.6 (C-15
#
), 56.5 (C-18), 56.2 (C-16 and C-17), 34.0 (C-19 and C-23), 25.8 (C-
21), 24.7 (C-20 and C-22). IR (νm.cm
-1
) = 3346, 2930, 2856, 1657, 1606, 1604, 1503, 1452, 1411, 
1342, 1246, 1205, 1169, 1028, 860, 760, 623. ESI-MS (m/z) calculated [M+H]
+
 for C21H25N3O2Br 
430.1130, found 430.1133. 
 
Following the general procedure 2-
aminopyridine (2.00 g, 21.25 mmol), 2-
bromobenzaldehyde (3.93 g, 21.25 mmol, 1 eq), 
cyclohexyl isocyanide (2.320 g, 21.25 mmol, 1 eq) 
and Montmorillonite K10 clay (2.00 g) were 
combined. The mixture was purified by column 
chromatography using an eluent of 50 % 
 
97 
 
 
98 
 
 
At the end of my tether 
 
Experimental 
 
213 
 
EtOAc/Hexane. Imidazo[1,2-a]pyridine 98 was collected as a viscous brown oil (5.222 g, 66 %). Rf 
= 0.28 (50 % EtOAc/Hexane). 
1
H NMR (300 MHz, CDCl3): δH = 8.14 (1H, dt, J = 6.9 and 1.2 Hz, H-5), 
7.65 (1H, dd, J = 8.0 and 1.2 Hz, H-15), 7.61 (1H, dd, J = 7.7 and 1.8 Hz, H-12), 7.53 (1H, dt, J = 9.1 
and 1.1 Hz, H-8), 7.39 (1H, td, J = 7.5 and 1.3 Hz, H-13), 7.28 – 7.20 (1H, m, H-14), 7.14 (1H, ddd, J 
= 9.1, 6.7 and 1.3 Hz, H-7), 6.80 (1H, td, J = 6.8 and 1.2 Hz, H-6), 3.25 (1H, d, J = 7.0 Hz, H-22), 2.67 
(1H, m, H-16), 1.73 – 1.61 (2H, m, H-17a and H-21a), 1.61 – 1.52 (2H, m, H-18a and H-20a), 1.46 
(1H, m, H-19a), 1.15 – 0.94 (5H, m, H-17b, H-18b, H-19b, H-20b and H-21b). 
13
C NMR (75 MHz, 
CDCl3): δC = 141.5 (C-9), 136.8 (C-3), 136.2 (C-2), 132.9 (C-15*), 132.7 (C-12*), 129.5 (C-13), 127.5 
(C-14), 126.0 (C-10), 123.9 (C-7), 123.03 (C-5), 123.00 (C-11), 117.7 (C-8), 111.8 (C-6), 56.5 (C-16), 
34.0 (C-17 and C-21), 25.8 (C-19), 24.7 (C-18 and C-20). IR (νm.cm
-1
) = 3383, 3086, 2930, 2855, 
1634, 1564, 1504, 1450, 1350, 1265, 1258, 1194, 1024, 923, 733, 646. ESI-MS (m/z) calculated 
[M+H]
+
 for C19H21N3Br 370.0919, found 370.0925. 
 
2-Aminopyridine (2.00 g, 21.25 mmol), 2-
bromobenzaldehyde (3.93 g, 21.25 mmol, 1 eq), 
t-butyl isocyanide (1.766 g, 21.25 mmol, 1 eq) 
and Montmorillonite K10 clay (2.00 g) were 
combined and the general procedure followed. 
The resulting mixture was purified by 
recrystallization from hot ether to afford 99 as 
cream crystals (2.919 g, 40 %). Rf = 0.57 (50 % EtOAc/Hexane). m.p. = 184 - 185 ˚C. 
1
H NMR (300 
MHz, CDCl3): δH =  8.28 (1H, dt, J = 6.8 and 1.3 Hz, H-5), 7.62 (2H, m, H-15 and H-12), 7.51 (1H, d, J 
= 9.0 Hz, H-8), 7.37 (1H, td, J = 7.5 and 1.3 Hz, H-14*), 7.19 (1H, td, J = 7.7 and 1.8 Hz, H-13*), 7.12 
(1H, ddd, J = 8.7, 6.7 and 1.3 Hz, H-7), 6.76 (1H, td, J = 6.8 and 1.2 Hz, H-6), 3.19 (1H, s, H-20), 0.90 
(9H, s, H-17, H-18 and H-19). 
13
C NMR (75 MHz, CDCl3): δC = 142.1 (C-9), 139.3 (C-3), 137.0 (C-2), 
133.1 (C-15*), 132.6 (C-12*), 129.4 (C-13), 127.5 (C-14), 124.6 (C-10), 124.2 (C-7), 123.7 (C-5), 
122.7 (C-11), 117.5 (C-8), 111.4 (C-6), 55.8 (C-16), 30.0 (C-17, C-18 and C-19). IR (νm.cm
-1
) = 3236, 
2968, 1630, 1554, 1503, 1470, 1431, 1385, 1339, 1273, 1222, 1219, 1024, 947, 918, 812, 752, 
700, 650, 609. ESI-MS (m/z) calculated M+H for C17H19N3Br, [M+H]
+
, 344.0762, found 344.0770. 
 
Following the general procedure 2-
aminopyridine (0.717 g, 7.62 mmol), 2-
bromobenzaldehyde (1.41 g, 7.62 mmol, 1 eq), 
xylyl isocyanide (1.00 g, 7.62 mmol, 1 eq) and 
Montmorillonite K10 clay (1.00 g) were 
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combined. The mixture was purified by column chromatography using an eluents of 30-80 % 
EtOAc/Hexane to afford 100 which was collected as a bottle green powder (1.768 g, 59 %). Rf = 
0.31 (50 % EtOAc/Hexane). m.p. = 60 °C. 
1
H NMR (300 MHz, CDCl3): δH = 7.70 (1H, dt, J = 6.9 and 
1.2 Hz, H-5), 7.63 – 7.60 (1H, m, H-12), 7.58 (1H, q, J = 1.3 Hz, H-8), 7.40 (1H, dd, J = 7.6, 1.9 Hz, H-
15), 7.30 – 7.23 (1H, m, H-14), 7.21 – 7.12 (2H, m, H-7 and H-13), 6.85 (2H, d, J = 7.4 Hz, H-18 and 
H-20), 6.73 (2H, m, J = 8.3, 6.8 Hz, H-6 and H-19), 5.50 (1H, s, H-24), 1.91 (6H, s, H-22 and H-
23).
13
C NMR (75 MHz, CDCl3): δC = 141.1 (C-9), 140.3 (C-3), 137.9 (C-16), 135.3 (C-2), 132.3 (C-12), 
132.0 (C-15), 129.6 (C-13), 129.3 (C-18 and C-20), 127.2 (C-14), 126.6 (C-17 and C-21), 123.8 (C-
10), 123.8 (C-13), 122.6 (C-11), 122.4 (C-5), 121.4 (C-19), 117.9 (C-8), 112.3 (C-6), 18.3 (C-22 and 
C-23). IR (νm.cm
-1
) = 3209, 2945, 1634, 1572, 1499, 1474, 1466, 1421, 1350, 1269, 1222, 1152, 
1099, 1024, 918, 840, 839, 762, 745, 648. ESI-MS (m/z) calculated [M+H]
+
 for C21H19N3Br 
392.0762, found 392.0769. 
 
2-Aminopyridine (1.50 g, 15.94 mmol), 3-bromobenzaldehyde (2.95 g, 15.94 mmol, 1 eq), 
cyclohexyl isocyanide (1.74 g, 15.94 mmol, 1 eq) 
and Montmorillonite K10 clay (2.00 g) were 
combined and the general procedure followed. 
The mixture was purified by recrystallization 
from hot ether, resulting in a white powder that 
was found to be 101 (2.188 g, 37 %). Rf = 0.34 (50 
% EtOAc/Hexane). m.p. = 139 – 140 °C. 
1
H NMR 
(300 MHz, CDCl3): δH = 8.29 (1H, t, J = 1.8 Hz, H-
11), 8.07 (1H, dt, J = 6.9 and 1.2 Hz, H-5), 8.00 
(1H, dt, J = 7.8, 1.4 Hz, H-15), 7.52 (1H, dt, J = 9.1 and 1.1 Hz, H-8), 7.43 (1H, ddd, J = 8.0, 2.0 and 
1.1 Hz, H-13), 7.30 (1H, t, J = 7.9 Hz, H-14), 7.13 (1H, ddd, J = 9.1, 6.7 and 1.3 Hz, H-7), 6.78 (1H, 
td, J = 6.7 and 1.2 Hz, H-6), 3.03 (1H, d, J = 4.9 Hz, H-22), 3.01 – 2.90 (1H, m, H-16), 1.82 (2H, d, J = 
11.2 Hz, H-17a and H-21a), 1.70 (2H, d, J = 6.9 Hz, H-18a and H-20a), 1.58 (1H, s, H-19a), 1.21 (5H, 
m, H-17b, H-18b, H-19b, H-20b and H-21b).
13
C NMR (75 MHz, CDCl3): δC = 141.7 (C-9), 136.7 (C-
3), 135.2 (C-2), 130.1 (C-11), 131.0 (C-13 and C-14), 130.0 (C-10), 125.4 (C-15), 125.3, 124.2 (C-7), 
122.8 (C-12), 122.7 (C-5), 117.6 (C-8), 111.8 (C-6), 57.0 (C-16), 34.3 (C-17 and C-21), 25.7 (C-19), 
24.8 (C-18 and C-20). IR (νm.cm
-1
) = 3258, 2922, 2851, 1634, 1595, 1572, 1508, 1447, 1362, 1335, 
1225, 1219, 1070, 995, 970, 889, 851, 783, 735, 681. ESI-MS (m/z) calculated [M+H]
+
 for 
C19H21N3Br 370.0919, found 370.0928. 
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Following the general procedure, 2-
aminopyridine (1.00 g, 10.627 mmol), 3-
bromobenzaldehyde (1.97 g, 10.627 mmol, 1 eq), 
t-butyl isocyanide (1.16 g, 10.627 mmol, 1 eq) 
and Montmorillonite K10 clay (1.00 g) were 
combined in ethanol. The resulting mixture was 
purified by recrystallization from hot ether. The 
product was collected as yellow crystals and found to be 102 (2.301 g, 63 %). Rf = 0.40 (50 % 
EtOAc/Hexane). m.p. = 153 – 155 ˚C. 
1
H NMR (300 MHz, CDCl3): δH = 8.21 (1H, t, J = 1.8 Hz, H-11), 
8.15 (1H, dt, J = 6.9 and 1.2 Hz, H-5), 7.90 (1H, dt, J = 7.7, 1.3 Hz, H-15), 7.50 (1H, dt, J = 9.0 and 
1.1 Hz, H-8), 7.41 (1H, ddd, J = 8.0, 2.1 and 1.1 Hz, H-13), 7.25 (1H, t, J = 7.9 Hz, H-14), 7.11 (1H, 
ddd, J = 9.0, 6.7, 1.3 Hz, H-7), 6.74 (1H, td, J = 6.8 and 1.2 Hz, H-6), 3.02 (1H, s, H-20), 1.04 (9H, s, 
H-17, H-18 and H-19). 
13
C NMR (75 MHz, CDCl3): δC = 142.2 (C-9), 138.0 (C-3), 137.4 (C-2), 131.0 
(C-11), 130.2 (C-13), 129.7 (C-14), 126.5 (C-15), 124.4 (C-7), 123.8 (C-10), 123.4 (C-5), 122.4 (C-
12), 117.4 (C-8), 111.6 (C-6), 56.5 (C-16), 30.5 (C-17, C-18 and C-19). IR (νm.cm
-1
) = 3305, 2972, 
2922, 1629, 1595, 1560, 1541, 1504, 1471, 1442, 1386, 1190, 1068, 993, 929, 891, 856, 781, 754, 
734, 719, 673, 605. ESI-MS (m/z) calculated [M+H]
+
 for C17H19N3Br 344.0762, found 344.0770. 
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7.2.2. Tether synthesis 
 
Diethyl malonate (5.00g, 31.217 mmol) was dissolved in 
50 ml THF in a dry 2-necked round bottomed flask 
under and inert atmosphere. The solution was cooled to 
0 °C in an ice bath before NaH (1.373 g, 34.339 mmol, 
1.1 eq) was added portionwise. The solution was left 
stirring for 40 min at 0 °C before allyl bromide (5.665 g, 
46.826 mmol, 1.5 eq) was added dropwise. The solution was allowed to warm to room 
temperature and stirred overnight. The resulting opaque yellow solution was extracted using 
brine, washed with ether (3 x 30 ml) and dried over anhydrous Na2SO4 before being concentrated 
in vacuo. The crude product was purified by distillation under reduced pressure and 103 was 
collected as a colourless oil (4.187 g, 67 %). 
1
H NMR (300 MHz, CDCl3): δH = 5.87 – 5.58 (1H, m, H-
9), 5.19 – 5.02 (2H, m, H-10), 4.27 – 4.14 (4H, m, H-4 and H-6), 3.49 – 3.34 (1H, m, H-2), 2.64 (2H, 
m, H-8), 1.34 – 1.19 (6H, m, H-5 and H-7). 
13
C NMR (75 MHz, CDCl3): δC = 168.9 (C-1 and C-3), 
134.2 (C-9), 117.5 (C-10), 61.4 (C-4 and C-6), 51.7 (C-2), 32.9 (C-8), 14.1 (C-5 and C-7). IR (νm.cm
-1
) 
= 3086, 2986, 2941, 1730, 1643, 1447, 1369, 1286, 1215, 1194, 1144, 1128, 1036, 1024, 920, 858, 
642. ESI-MS (m/z) calculated for C10H17O4, [M+H]
+
, 201.1127, found 201.1121. 
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7.2.3. Suzuki-Miyaura Cross Coupling reactions 
Both the use of conventional heating and microwave irradiation was used to perform the Suzuki-
Miyaura cross coupling reactions. Two general procedures are described that detail each method 
of reaction. The general procedure is described followed by the characterisation for the 
compounds synthesized using that method. 
7.2.3.1. General Procedure for the Microwave assisted Suzuki-Miyaura 
coupling reactions 
In a clean, unscratched microwave tube, the bromine-containing imidazo[1,2-a]pyridine (1 eq), 3-
vinylphenylboronic acid (1.5 eq), CsF (2.5 eq) and Pd(PPh3)4 (10 mol %) were added and diluted 
with DME (3 ml). After adding a microwave stirrer bar and sealing the microwave tube, the 
mixture was reacted in a CEM Discover microwave oven at 150 °C, 150 W for 20 minutes. Once 
cooled, the contents were extracted with water and washed with EtOAc (3 x 30 ml). The organic 
layer was dried over anhydrous Na2SO4, concentrated in vacuo and purified by column 
chromatography with an appropriate eluent and the structure confirmed by 
1
H NMR, 
13
C NMR, 
infrared and mass spectrophotometry. 
 
Imidazo[1,2-a]pyridine 85 (0.250 g, 0.581 
mmol), 3-vinylphenylboronic acid (0.129 
g, 0.871 mmol, 1.5 eq), Pd(PPh3)4 (0.0671 
g, 0.0581 mmol, 10 mol %) and CsF (0.220 
g, 1.452 mmol, 2.5 eq) were combined in 
a microwave tube and reacted using the 
microwave assisted general procedure. 
The product was purified by column 
chromatography with an eluent mixture 
of 50-80 % EtOAc/Hexane. After concentration in vacuo, the yellow solid collected was found to 
be 106 (0.258 g, 97 %). Rf = 0.41 (50 % EtOAc/Hexane). m.p. = 142-143 ˚C. 
1
H NMR (300 MHz, 
CDCl3): δH = 8.28 (1H, dd, J = 1.8 and 1.0 Hz, H-5), 7.78 (1H, d, J = 8.5 Hz, H-14), 7.66 – 7.57 (2H, m, 
H-8 and H-26), 7.50 (1H, m, H-28*), 7.48 – 7.42 (2H, m, H-29* and H-30*), 7.37 (1H, dd, J = 9.3, 
1.9 Hz, H-7), 6.81 (1H, dd, J = 17.6 and 10.9 Hz, H-31), 6.68 (1H, dd, J = 8.5 and 2.4 Hz, H-15), 6.59 
(1H, d, J = 2.4 Hz, H-11), 5.91 – 5.79 (1H, m, H-32trans), 5.33 (1H, d, J = 10.9 Hz, H-32cis), 3.89 (3H, s, 
H-16
#
), 3.87 (3H, s, H-17
#
), 2.65 (1H, m, H-19), 1.71 (2H, dd, J = 10.5 and 4.2 Hz, H-20a and H-24a), 
1.59 (2H, q, J = 4.4, 3.7 Hz, H-21a and H-23a), 1.54 – 1.44 (1H, m, H-22a), 1.06 (5H, m, H-20b, H-
21b, H-22b, H-23b and H-24a). 
13
C NMR (75 MHz, CDCl3): δC = 160.8 (C-12’), 157.0 (C-13’), 141.2 
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(C-9), 138.7 (C-3), 138.5 (C-27), 136.7 (C-31), 134.30 (C-2), 132.4 (C-14), 129.4 (C-29*), 127.2 (C-
25), 126.6 (C-28*), 125.6 (C-10), 125.4 (C-30*), 125.1 (C-26), 123.8 (C-7), 120.0 (C-5), 117.2 (C-8), 
114.8 (C-32), 105.9 (C-15), 99.4 (C-11), 56.7 (C-16), 56.2 (C-16
#
), 55.6 (C-17
#
), 34.3 (C-20 and C-
24), 25.8 (C-22), 24.9 (C-21 and C-23). IR (νm.cm
-1
) = 3298, 2928, 2853, 1585, 1510, 1464, 1418, 
1409, 1325, 1244, 1180, 1138, 1109, 1026, 908, 885, 798, 760, 721, 709, 627. ESI-MS (m/z) 
calculated for C29H32N3O2, [M+H]
+
, 454.2495, found 454.2517. 
 
89 (0.250 g, 0.581 mmol), 3-
vinylphenylboronic acid (0.129 g, 0.871 
mmol, 1.5 eq), Pd(PPh3)4 (0.0671 g, 0.0581 
mmol, 10 mol %) and CsF (0.220 g, 1.452 
mmol, 2.5 eq) were combined and reacted 
according to the general procedure for 
microwave assisted reactions. The product 
was purified by column chromatography 
with an eluent mixture of 80 % EtOAc/Hexane. After concentration in vacuo, the yellow solid that 
was collected was found to be 107 (0.215 g, 82 %). Rf = 0.75 (50 % EtOAc/Hexane). m.p. = 107 ˚C. 
1
H NMR (500 MHz, CDCl3) δH = 8.30 (1H, t, J = 1.3 Hz, H-5), 7.78 (1H, d, J = 8.5 Hz, H-15), 7.64 (1H, 
d, J = 9.3 Hz, H-8), 7.60 (1H, d, J = 2.0 Hz, H-26), 7.50 – 7.45 (1H, m, H-28
#
), 7.45 – 7.40 (2H, m, H-
29
#
 and H-30
#
), 7.38 (1H, dd, J = 9.2 and 1.8 Hz, H-7), 6.78 (1H, dd, J = 17.6 and 10.9 Hz, H-31), 
6.65 (1H, dd, J = 8.5 and 2.4 Hz, H-14), 6.57 (1H, d, J = 2.4 Hz, H-12), 5.87 – 5.78 (1H, m, H-32trans), 
5.31 (1H, d, J = 10.9 Hz, H-32cis), 3.92 (1H, d, J = 7.78 Hz, H-18), 3.85 (3H, s, H-16*), 3.83 (3H, s, H-
17*), 2.74 – 2.65 (1H, m, H-19), 1.76 – 1.67 (2H, m, H-20a and H-24a), 1.62 – 1.54 (2H, m, H-21a 
and H-23a), 1.50 – 1.43 (1H, m, H-22a), 1.07 (5H, m, H-20b, H-21b, H-22b, H-23b, H-24b). 
13
C 
NMR (126 MHz, CDCl3) δC = 160.6 (C-11’), 156.8 (C-13’), 140.5 (C-9), 138.2 (C-3), 138.1 (C-25), 
136.4 (C-31), 133.5 (C-27), 132.1 (C-15), 129.1 (C-29
#
), 127.0 (C-2), 126.3 (C-28
#
), 125.7 (C-6), 
125.2 (C-30
#
), 124.8 (C-26), 124.1 (C-7), 119.7 (C-5), 116.6 (C-8), 116.1 (C-10), 114.5 (C-32), 105.6 
(C-14), 99.1 (C-12), 56.3 (C-19), 55.9 (C-16*), 55.2 (C-17*), 33.9 (C-20 and C-24), 25.5 (C-22), 24.6 
(C-21 and C-23). IR (νm.cm
-1
) = 3346, 2930, 2855, 1738, 1614, 1599, 1504, 1452, 1394, 1327, 
1304, 1258, 1207, 1155, 1150, 1078, 1030, 1018, 918, 833, 800, 716, 632. ESI-MS (m/z) 
calculated for C29H32N3O2, [M+H]
+
, 453.2495, found 454.2495. 
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7.2.3.2. General Procedure for the Conventional Suzuki-Miyaura Cross 
Coupling Reactions 
The boronic acid (1.5 eq), Pd(PPh3)4 (10 mol %) and brominated imidazo[1,2-a]pyridine (1 eq) was 
added  to a 2-neck round bottomed flask with a stirrer bar. To this a condenser was fitted to one 
neck and a rubber septum to the other neck and the set up evacuated and filled with N2. This 
evacuation process was repeated 3 times, followed by the addition of DME and freshly prepared 
Na2CO3 (2M, 5 eq). The mixture was heated to reflux and stirred under a N2 atmosphere 
overnight. After cooling, the reaction was filtered through Celite, washed with EtOAc, extracted 
with water and washed further with EtOAc. The organic layer was dried over anhydrous Na2SO4 
and concentrated in vacuo. The product was then purified by column (or flash column) 
chromatography using EtOAc/Hexane as the eluent. 
 
Using the general procedure for the 
conventionally heated Suzuki-Miyaura coupling 
reactions, 85 (0.250 g, 0.581 mmol), 2-
formylphenylboronic acid (0.131 g, 0.871 mmol, 
1.5 eq), Pd(PPh3)4 (0.0671 g, 0.0581 mmol, 10 
mol %) and CsF (0.220 g, 1.452 mmol, 2.5 eq) 
were combined and reacted. The product was 
purified by column chromatography with an 
eluent mixture of 50-80 % EtOAc/Hexane and 
again using flash column chromatography with an eluent of 40 % EtOAc/Hexane. After 
concentration in vacuo, the green solid that was collected was found to be 108 (0.266 g, 99 %). Rf 
= 0.18 (50 % EtOAc/Hexane). m.p. = 170-173 ˚C. 
1
H NMR (500 MHz, CDCl3): δH = 10.09 (1H, d, J = 
0.8 Hz, H-31), 8.09 (1H, dd, J = 1.8 and 1.0 Hz, H-5), 8.07 (1H, dd, J = 7.9 and 1.4 Hz, H-27), 7.73 – 
7.68 (2 H, m, H-11 and H-29), 7.61 (1 H, dd, J = 9.2 and 1.0 Hz, H-8), 7.60 – 7.58 (1H, m, H-15), 
7.56 (1 H, dt, J = 7.8 and 1.1 Hz, H-28), 7.52 (1H, dd, J = 7.7 and 1.1 Hz, H-30), 7.19 (1H, dd, J = 9.1 
and 1.8 Hz, H-7), 6.97 (1H, d, J = 8.4 Hz, H-14), 4.01 (3H, s, H-16*), 3.95 (3H, s, H-17*), 3.16 – 3.09 
(1H, m, H-18), 3.01 (1H, s, H-19), 1.82 (2H, dt, J = 12.2 and 3.0 Hz, H-20a and H-24a), 1.70 (2H, dt, 
J = 10.5 and 3.0 Hz, H-21a and H-23a), 1.58 (1H, dd, J = 10.8 and 4.1, H-22a), 1.24 – 1.10 (5H, m, 
H-20b, H-21b, H-22b, H-23b and H-24b). 
13
C NMR (125 MHz, CDCl3): δC = 191.5 (C-31), 149.1 (C-
12’), 148.7 (C-13’), 141.9 (C-25), 140.6 (C-9), 137.8 (C-3), 134.3 (C-2), 133.9 (C-11*), 131.0 (C-30), 
128.4 (C-28), 128.3 (C-27), 127.2 (C-10), 126.1 (C-7), 124.6 (C-6), 122.6 (C, 122.2 (C-5), 119.4 (C-
15), 116.8 (C-8), 111.1 (C-14), 110.5 (C-29*), 57.0 (C-19), 56.0 (C-16
#
), 55.9 (C-17
#
), 34.2 (C-20 and 
C-24), 25.7 (C-22), 24.8 (C-21 and C-23). IR (νm.cm
-1
) = 3316, 2936, 2857, 1691, 1589, 1508, 1464, 
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1408, 1404, 1323, 1252, 1225, 1130, 1020, 883, 812, 764, 716, 638. ESI-MS (m/z) calculated for 
C28H30N3O3, [M+H]
+
, 456.2287, found 456.2289. 
 
The general procedure was followed using 102 (1.00 
g, 2.91 mmol), 2-formylphenyl boronic acid (0.653 g, 
4.357 mmol, 1.5 eq), Pd(PPh3)4 (0.336 g, 0.291 
mmol, 10 mol %) and Na2CO3 (2M, 7.26 ml, 5 eq). 
The reaction was heated under reflux for 18 hours 
and the product was purified by column 
chromatography using 50-60 % EtOAc/Hexane as 
the eluent. The product, 109, was collected as a 
golden foam (1.109 g, 99 %). Rf = 0.47 (50 % EtOAc/Hexane). m.p. = 76-78 ˚C. 
1
H NMR (300 MHz, 
CDCl3): δH =  10.04 (1H, s, H-26), 8.22 (1H, d, J = 6.9 Hz, H-5), 8.06 – 8.02 (1H, m, H-11), 8.01 (2H, 
dd, J = 3.5, 1.7 Hz, H-22 and H-25), 7.68 – 7.60 (1H, m, H-14), 7.56 – 7.46 (4H, m, H-8, H-15, H-23 
and H-24), 7.33 – 7.28 (1H, m, H-13), 7.17 – 7.09 (1H, m, H-7), 6.78 (1H, td, J = 6.8 Hz and J = 1.0 
Hz, H-6), 3.08 (1H, s, N-H), 1.06 (9H, s, H-17, H-18 and H-19). 
13
C NMR (75 MHz, CDCl3): δC = 192.5 
(C-26), 146.1 (C-21), 142.2 (C-9), 139.0 (C-3), 137.9 (C-12), 135.8 (C-2), 133.8 (C-20), 133.5 (C-14), 
130.9 (C-23*), 129.6 (C-10), 129.2 (C-13), 128.3 (C-25
#
), 127.9 (C-22
#
), 127.8 (C-24*), 127.4 (C-11), 
124.2 (C-7), 123.8 (C-15), 123.5 (C-5), 117.4 (C-8), 111.5 (C-6), 56.5 (C-16), 30.4 (C-17, C-18 and C-
19). IR (νm.cm
-1
) = 3367, 3055, 2968, 2843, 2754, 1681, 1593, 1546, 1504, 1473, 1444, 1390, 
1365, 1340, 1284, 1218, 1197, 1093, 1026 906, 829, 808, 760, 706, 676, 640, 615, 607. ESI-MS 
(m/z) calculated for C24H24N3O, [M+H]
+
, 370.1919, found 370.1929. 
 
Compound 102 (1.00 g, 2.91 mmol), 4-formylphenyl 
boronic acid (0.653 g, 4.357 mmol, 1.5 eq), Pd(PPh3)4 
(0.336 g, 0.291 mmol, 10 mol %) and Na2CO3 (2M, 7.26 
ml, 5 eq) were combined according to the general 
conventional heating procedure. The reaction was 
purified by flash column chromatography using 0-60 % 
EtOAc/Hexane as the eluent. 110 was collected as a 
yellow powder (0.931 g, 87 %). Rf = 0.4 (50 % 
EtOAc/Hexane). m.p. = 73-76˚C. 
1
H NMR (500 MHz, 
CDCl3): δH = 10.03 (1H, s, H-26), 8.32 (1H, 1H, s, H-15), 8.19 (1H, d, J = 6.8 Hz, H-5), 8.00 (1H, d, J = 
7.6 Hz, H-8), 7.93 (2H, d, J = 8.1 Hz, H-21 and H-25), 7.82 (1H, d, J = 8.1 Hz, H-22 and H-24), 7.54 
(1H, t, J = 7.7 Hz, H-11 and H-13), 7.48 (1H, t, J = 7.7 Hz, H-7), 7.14 – 7.08 (1H, m, H-12), 6.74 (1H, 
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t, J = 6.7 Hz, H-6), 1.05 (s, 9H). 
13
C NMR (126 MHz, CDCl3): δC = 191.9 (C-26), 147.2 (C-20), 142.1 
(C-9), 139.6 (C-3), 139.0 (C-14), 136.1 (C-23), 135.1 (C-2), 130.2 (C-22 and C-24), 128.8 (C-12), 
128.1 (C-13), 127.7 (C-21 and C-25), 127.1 (C-11), 126.2 (C-7), 124.1 (C-5), 123.7 (C-10), 123.4 (C-
15), 117.3 (C-8), 111.4 (C-6), 56.4 (C-16), 30.4 (C-17, C-18 and C-19). IR (νm.cm
-1
) = 3362, 2972, 
2926, 1711, 1632, 1605, 1504, 1476, 1445, 1366, 1356, 1259, 1209, 1186, 1065, 1026, 910, 835, 
799, 754, 748, 702. ESI-MS (m/z) calculated for C24H24N3O, [M+H]
+
, 370.1919, found 370.1924. 
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7.2.4. Knoevenagel condensation reaction 
 
The general reaction for the Knoevenagel 
condensation was adapted from work by Gu and 
Holland.
106
 In a 50 ml round bottomed flask, the 
imidazo[1,2-a]pyridine containing an aldehyde 109 
(1.109g, 3.010 mmol), diethyl malonate (0.271 g, 
0.258 ml, 4.515 mmol, 1.5 eq), piperidine (0.051 g, 
0.060 ml, 0.602 mmol, 0.2 eq) and benzoic acid 
(0.037 g, 0.301 mmol, 0.1 eq) were combined and 
a Dean-Stark apparatus was fitted. To this set up 
toluene (25 ml) was added and the system was heated under reflux under an N2 atmosphere 
overnight. After cooling the reaction mixture was washed with water, 1M HCl, saturated NaHCO3 
and brine sequentially. The organic layer was then dried over anhydrous Na2SO4, concentrated in 
vacuo and purified by flash column chromatography using flash column chromatography using 80 
% EtOAc/Hexane as the eluent. The product was collected as a yellow oil (1.06 g, 69 %). Rf = 0.72 
(80 % EtOAc/Hexane). 
1
H NMR (300 MHz, CDCl3): δH =  8.19 (1H, d, J = 6.8 Hz, H-5), 8.00 (1H, s, H-
26), 7.97 (1H, d, J = 3.8 Hz, H-25), 7.79 – 7.65 (1H, m, H-15), 7.53 – 7.19 (7H, m, H-8, H-11, H-13, 
H-14, H-22, H-23 and H-24), 7.08 (1H, t, J = 7.4 Hz, H-7), 6.71 (1H, t, J = 6.5 Hz, H-6), 4.28 (2H, q, J 
= 7.1 Hz, H-29*), 4.23 – 4.12 (2H, m, H-32*), 3.19 (1H, s, N-H), 1.27 – 1.14 (6H, m, H-30 and H-33), 
1.04 (9H, d, J = 2.1 Hz, H-17, H-18 and H-19). 
13
C NMR (75 MHz, CDCl3): δC = 166.4 (C-28
#
), 163.8 
(C-31
#
), 143.4 (C-26), 142.7 (C-9), 142.0 (C-3), 139.8 (C-12), 139.1 (C-2), 135.7 (C-10), 132.1 (C-21), 
130.1 (C-14*), 129.9 (C-24*), 129.1 (C-13*), 128.9 (C-23*), 128.3 (C-22*), 128.1 (C-15), 127.6 (C-
27), 127.4 (C-11*), 127.3 (C-21), 124.0 (C-7), 123.8 (C-20), 123.5 (C-5), 117.2 (C-8), 111.3 (C-6), 
61.4 (C-29’), 61.3 (C-32’), 56.3 (C-16), 30.3 (C-17, C-18 and C-19), 14.0 (C-30
~
), 13.9 (C-33
~
).  IR 
(νm.cm
-1
) = 3364, 2976, 2872, 1726, 1632, 1618, 1599, 1506, 1472, 1445, 1366, 1248, 1198, 1113, 
1065, 1026, 920, 862, 808, 756, 706, 671, 623. ESI-MS (m/z) calculated for C31H34N3O4, [M+H]
+
, 
512.2549, found 512.2550. 
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7.2.5. General Procedure for Heck Reactions 
The Heck reaction was adapted from Riaan Petersen’s thesis.
107
 A 2-necked round bottom flask, 
fitted with a condenser and a dropping funnel, containing Pd(OAc)2 (0.4 eq) and P(o-tolyl)3 (1.6 
eq) and a stirrer bar was evacuated and charged with N2 repeatedly. Following this, a mixture of 
DMF (3 ml), MeCN (4 ml) and H2O (2 ml) was added. The solution was stirred at 40 ˚C for 
approximately 30 min until the solution formed the catalyst complex (a yellow precipitate). The 
imidazo[1,2-a]pyridine (1 eq) was dissolved in 4 ml MeCN and added to the dropping funnel 
along with ethyl acrylate (1.5 eq) and NEt3 (10 eq) and added to the catalyst solution. The 
dropping funnel was washed with 3 ml of DMF to ensure that all the starting materials had been 
successfully transferred to the dropping funnel removed from the flask and stoppered. The 
reaction mixture was heated to 78 ˚C and stirred under these conditions overnight. The mixture 
was extracted with water (30 ml) and washed with ether (30 ml). The organic phase was then 
washed with 6M HCl (2 x 30 ml). The acid layers were combined and neutralised with solid 
NaHCO3 and, after being placed in a separating funnel, extracted with ether (2 x 30 ml) before 
being dried over anhydrous Na2SO4 and concentrated in vacuo. 
 
The catalyst was formed from Pd(OAc)2 (0.078g, 
0.350 mmol, 0.4 eq) and P(o-tolyl)3 (0.426 g, 1.340 
mmol, 1.6 eq). To this 102 (0.300 g, 0.874 mmol), 
ethyl acrylate (0.131 g, 1.311 mmol, 1.5 eq) and 
NEt3 (0.944 g, 9.264 mmol, 10 eq) were added. After 
extraction and concentration in vacuo, the product 
113 was collected as a yellow solid (0.297 g, 94 %). 
Rf = 0.5 (50 % EtOAc/Hexane). m.p. = 135 – 136 ˚C. 
1
H NMR (300 MHz, CDCl3): δH = 8.21 (1H, d, J = 1.8 Hz, H-11), 8.16 (1H, dt, J = 6.9 and 1.3 Hz, H-5), 
7.99 (1H, dt, J = 7.3 and 1.7 Hz, H-15), 7.76 (1H, d, J = 16.0 Hz, H-21), 7.51 (1H, dt, J = 9.1 and 1.1 
Hz, H-8), 7.46 – 7.34 (2H, m, H-13 and H-14), 7.09 (1H, ddd, J = 9.1, 6.6 and 1.3 Hz, H-7), 6.72 (1H, 
td, J = 6.8 and 1.2 Hz, H-6), 6.54 (1H, d, J = 16.0 Hz, H-22), 4.27 (2H, q, J = 7.1 Hz, H-24), 3.17 (1H, 
s, H-20), 1.33 (3H, t, J = 7.1 Hz, H-25), 1.02 (9H, s, H-17, H-18 and H-19). 
13
C NMR (75 MHz, CDCl3): 
δC = 167.0 (C-23), 144.7 (C-21), 142.1 (C-9), 138.6 (C-3), 136.1 (C-12), 134.4 (C-2), 129.9 (C-15), 
128.6 (C-13*), 127.8 (C-11), 126.8 (C-14*), 124.1 (C-7), 123.7 (C-10), 123.4 (C-5), 118.3 (C-22), 
117.3 (C-8), 111.4 (C-6), 60.4 (C-24), 56.3 (C-16), 30.4 (C-17, C-18 and C-19), 14.3 (C-25). IR 
(νm.cm
-1
) = 3300, 3067, 2974, 1709, 1636, 1449, 1366, 1275, 1275, 1086, 1038, 986, 910, 868, 
806, 754, 731, 689, 567. ESI-MS (m/z) calculated [M+H]
+
 for C22H26N3O2 364.2025, found 
364.2033. 
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Imidazo[1,2-a]pyridine 85 (0.250 g, 
0.581 mmol), ethyl acrylate 
(0.0582 g, 0.581 mmol, 1 eq) were 
added to the freshly formed 
catalyst from Pd(OAc)2 (0.0521, 
0.232 mmol, 0.4 eq) and P(o-tolyl)3 
(0.283 g, 0.930 mmol, 1.6 eq) with 
Et3N (0.627 g, 6.159 mmol, 10.6 
eq). After purification using the 
acid extraction method, 114 was collected as a sticky red oil (0.143 g, 55 %). Rf = 0.36 (50 % 
EtOAc/Hexane). 
1
H NMR (500 MHz, CDCl3): δH = 8.18 – 8.14 (1H, m, H-5), 7.70 – 7.65 (2H, m, H-11 
and H-25), 7.56 (1H, dd, J = 8.3 and 2.0 Hz, H-15), 7.51 – 7.48 (1H, m, H-8), 7.33 (1H, dd, J = 9.4 
and 1.8 Hz, H-7), 6.94 (1H, d, J = 8.4 Hz, H-14), 6.40 (1H, d, J = 15.8 Hz, H-26), 4.29 (2H, q, J = 7.1 
Hz, H-28), 3.99 (3H, s, H-16*), 3.93 (3H, s, H-17*), 3.11 (1H, s, H-18), 3.03 – 2.94 (1H, m, H-19), 
1.86 – 1.77 (2H, m, H-20a and H-24a), 1.70 (2H, m, H-21a and H-23), 1.64 – 1.56 (1H, m, H-22a), 
1.36 (3H, t, J = 7.1 Hz, H-29), 1.30 – 1.10 (5H, m, H-20b, H-21b, H-22b, H-23b and H-24b). 
13
C NMR 
(126 MHz, CDCl3): δC = 166.8 (C-27), 149.0 (C-12
#
), 148.7 (C-13
#
), 141.22 (C-9), 141.17 (C-25), 
137.7 (C-2), 127.0 (C-10), 124.9 (C-3), 124.6 (C-5), 121.0 (C-7), 119.8 (C-6), 119.4 (C-15), 117.8 (C-
8), 117.4 (C-26), 111.1 (C-14), 110.4 (C-11), 60.7 (C-28), 56.9 (C-19), 56.0 (C-16*), 55.9 (C-17*), 
34.2 (C-20 and C-24), 25.7 (C-22), 24.8 (C-21 and -23), 14.4 (C-29). IR (νm.cm
-1
) = 3339, 2928, 
2851, 2363, 1707, 1634, 1508, 1462, 1418, 1312, 1256, 1235, 1174, 1140, 1032, 979, 852, 806, 
764, 733. ESI-MS (m/z) calculated for C26H32N3O4, [M+H]
+
, 450.2393, found 450.2400. 
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7.2.6. Synthesis of ferrocene-containing imidazo[1,2-a]pyridines 
The synthesis of ferrocene-containing imidazo[1,2-a]pyridines 115 to 117 were synthesized 
according to the general procedure for Groebke-Blackburn-Bienaymé Multicomponent Reactions 
(Section 7.2.1.) using ferrocenecarbaldehyde. 
 
2-Amino-5-bromopyridine (1.5 g, 8.67 mmol), 
ferrocenecarboxaldehyde (1.86 g, 8.67 mmol, 1 eq), 
cyclohexyl isocyanide (0.945 g, 8.67 mmol, 1 eq) and 
Montmorillonite K10 clay (1.5 g) were combined and 
the general procedure followed. The product purified by 
recrystallization in an ether/methanol mixture. Orange 
crystals and salmon powder were collected and found 
to be 115 (2.42 g, 55 %). Rf = 0.77 (50 % EtOAc/Hexane), m.p. = 197-199 ˚C, 
1
H NMR (300 MHz, 
CDCl3): δH = 8.19 (1H d, J = 1.1 Hz, H-5), 7.38 (1H, d, J = 9.4 Hz, H-8), 7.14 (1H, dd, J = 9.4 and J = 
1.8 Hz, H-7), 4.92 – 4.87 (2H, m, H-11 and H-14), 4.38 – 4.34 (2H, m, H-12 and H-13), 4.08 (5H, s, 
H-15, H-16, H-17, H-18 and H-19), 3.14 (1H, d, J = 3.7 Hz, H-20), 2.92 (1H, d, J = 4.0 Hz, H-26), 1.88 
(2H, d, J = 9.7 Hz, H-21a and H-25a), 1.79 (2H, d, J = 6.5 Hz, H-22a and H-24a), 1.67 (1H, d, J = 6.5 
Hz, H-23a), 1.42 – 1.16 (5H, m, H-21b, H-22b, H-23b, H-24b and H25b). 
13
C NMR (75 MHz, CDCl3): 
δC = 140.0 (C-9), 137.7 (C-3), 126.6 (C-7), 124.0 (C-2), 122.5 (C-5), 117.3 (C-8), 106.1 (C-6), 78.3 (C-
10), 69.3 (C-15, C-16, C-17, C-18, C-19), 68.8 (C-12 and C-13), 66.9 (C-11 and C-14), 57.2 (C-20), 
34.2 (C-21 and C-25), 25.7 (C-23), 25.0 (C-22 and C-24). IR (νm.cm
-1
) = 3315, 3099, 2922, 2852, 
1573, 1446, 1392, 1340, 1315, 1236, 1176, 1120, 1103, 1001, 943, 823, 783, 732, 667. ESI-MS 
(m/z) calculated for C23H25FeN3Br, [M+H]
+
, 478.0581, found 478.0592. 
 
The general procedure was followed using 2-amino-5-
bromopyridine (2.00 g, 11.56 mmol), 
ferrocenecarboxaldehyde (2.47 g, 11.56 mmol, 1 eq), 
xylyl isocyanide (1.52 g, 11.56 mmol, 1 eq) and 
Montmorillonite K10 clay (2.00 g). The product purified 
by recrystallization from hot EtOAc. Brown crystals were 
collected and found to be 116 (0.17 g, 3 %). Rf = 0.62 (50 
% EtOAc/Hexane). m.p. = >300 ˚C. 
1
H NMR (300 MHz, CDCl3): δH =  7.93 (1H, s, H-5), 7.46 (1H, d, J 
= 9.5 Hz, H-8), 7.20 (1H, d, J = 9.1 Hz, H-7), 7.06 (2H, d, J = 7.3 Hz, H-22 and H-24), 6.87 (1H, t, J = 
7.4 Hz, H-23), 5.12 (1H, s, H-28), 4.70 (2H, s, H-11 and H-14), 4.27 (2H, s, H-12 and H-13), 4.03 
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(5H, s, H-15, H-16, H-17, H-18 and H-19), 2.06 (6H, s, H-26 and H-27). 
13
C NMR not available due 
to a lack of solubility. IR (νm.cm
-1
) = 3315, 3099, 2922, 2852, 1573, 1446, 1392, 1340, 1315, 1236, 
1176, 1120, 1103, 1001, 943, 823, 783, 732, 667. ESI-MS (m/z) calculated for C25H23FeN3Br, 
[M+H]
+
, 500.0425, found 500.0428. 
 
Following the general procedure 2-Amino-5-
bromopyridine (1.50 g, 8.67 mmol), 
ferrocenecarboxaldehyde (1.86 g, 8.67 mmol, 1 eq), t-
butyl isocyanide (0.72 g, 8.67 mmol, 1 eq) and 
Montmorillonite K10 clay (1.50 g) were combined, 
reacted and then purified by recrystallization from hot 
ether. Beige crystals were collected and found to be 117 
(3.01 g, 72 %). Rf = 0.69 (50 % EtOAc/Hexane). m.p. = 201 - 202 ˚C. 
1
H NMR (300 MHz, CDCl3): δH = 
8.28 (1H, d, J = 1.2 Hz, H-5), 7.40 (1H, d, J = 9.4 Hz, H-8), 7.14 (1H, dd, J = 9.4 and 1.9 Hz, H-7), 4.92 
– 4.80 (2H, m, H-11 and H-14), 4.38 – 4.29 (2H, m, H-12 and H-13), 4.10 (5H, s, H-15, H-16, H-17, 
H-18 and H-19), 2.89 (1H, s, H-24), 1.13 (9H, s, H-21, H-22 and H-23). 
13
C NMR (75 MHz, CDCl3): δC 
= 140.5 (C-9), 139.6 (C-3), 126.7 (C-7), 123.3 (C-5), 123.1 (C-2), 117.4 (C-8), 105.7 (C-6), 79.3 (C-
10), 69.4 (C-15, C-16, C-17, C-18 and C-19), 68.4 (C-12 and C-13), 68.0 (C-11 and C-14), 56.2 (C-
20), 30.5 (C-21, C-22 and C-23). IR (νm.cm
-1
) = 3315, 3103, 2972, 2950, 2895, 1573, 1469, 1402, 
1388, 1323, 1224, 1124, 1105, 1022, 939, 819, 796, 717, 671, 628. ESI-MS (m/z) calculated for 
C21H23N3FeBr, [M+H]
+
, 452.0425, found 452.0443. 
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7.2.7. General procedure for the synthesis of isocyanides used in the 
Groebke-Blackburn-Bienaymé multicomponent coupling reaction 
General procedure for involves a two-step synthesis where the desired amine is formylated and 
then dehydrated resulting in the formation of the substituted isocyanide. 
7.2.7.1. Step One: formylation of the amine 
The appropriate amine is stirred in excess acetic anhydride in a round bottomed flask with 2 
equivalents of formic acid under an inert atmosphere for 18 hours. Following which the contents 
of the flask were emptied into a 100 ml beaker and washed with water. The solution was 
neutralized by a slow addition of solid NaHCO3 before being washed with EtOAc three times in a 
separation funnel. The organic layer was dried over anhydrous Na2SO4, concentrated in vacuo 
and continued to the next step without further purification. 
7.2.7.2. Step Two: dehydration to form the isocyanide 
In a large two necked round bottomed flask fitted with a dropping funnel, the formylated amine 
was dissolved in dry DCM under an inert atmosphere. To this 10 equivalents of NEt3 was added 
and the solution cooled to 0 °C in an ice bath. POCl3 (3 eq) was added dropwise to this solution at 
0 °C. The solution was then allowed to warm to room temperature and stirred under N2 for a 
further 2 hours. The reaction was quenched by the slow addition of saturated NaHCO3, 
transferred to a separating funnel and washed three times with DCM. The organic layer was dried 
over anhydrous Na2SO4, concentrated in vacuo and purified by column chromatography. It was 
noted that some decomposition occurs with the isocyanide on silica so purification methods need 
to be highly optimised to obtain the maximum yield. 
 
The general procedure was followed using benzyl amine 
(3.00 g, 28.00 mmol), formic acid (2.58 g, 56.00 mmol, 2 
eq), NEt3 (24.66 g, 0.244 mol, 10 eq) and POCl3 (11.21 g, 
73.11 mmol 3 eq). Following purification by column 
chromatography with 0 – 50 % EtOAc/Hexane as the 
eluent, benzyl isocyanide was collected as a pungent 
yellow oil (1.56 g, 55 %). 
1
H NMR (300 MHz, CDCl3) δH = 
7.44 – 7.27 (5H, m, H-5, H-6, H-7, H-8 and H-9), 4.74 – 4.45 (2H, m, H-3). 
13
C NMR (75 MHz, CDCl3) 
δC = 157.7 (t, C-1), 132.4 (C-4), 129.0 (C-5 and C-9), 128.4 (C-6 and C-8), 126.6 (C-7), 45.6 (t, C-3). 
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Adamantylamine (1.00 g, 6.61 mmol), formic acid (0.608 
g, 13.22 mmol, 2 eq), NEt3 (6.21 g, 61.4 mmol, 10 eq) 
and POCl3 (2.82 g, 5.94 mmol, 3 eq) were used following 
the general procedure. The adamantyl isocyanide was 
collected as a white powder (0.696 g, 97 %) after 
purification by column chromatography with 10 % 
EtOAc/Hexane as the eluent and concentration in vacuo. 
1
H NMR (300 MHz, MeOD) δH = 3.32 
(3H, p, J = 1.6 Hz, H-7, H-8 and H-9), 1.78 – 1.61 (12H, m, H-4, H-5, H-6, H-10, H-11 and H-12). 
13
C 
NMR (75 MHz, MeOD) δC = 184.8 (C-1), 49.1 (C-3), 45.3 (C-4, C-5 and C-6), 37.2 (C-10, C-11 and C-
12), 31.0 (C-7, C-8 and C-9). 
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7.2.8. Synthesis of pyridyl-containing imidazo[1,2-a]pyridines for metal 
complexation reactions 
The general procedure for the Groebke-Blackburn-Bienaymé multicomponent reactions (section 
7.2.1) to synthesize the pyridyl-containing imidazo[1,2-a]pyridines. Reactions were performed in 
ethanol under reflux conditions overnight. The compounds were purified by recrystallization or 
column chromatography as appropriate. Spectroscopic characterisation for these compounds is 
outlined below. 
 
Combining 5-bromo-2-aminopyridine (2.304 g, 13.317 
mmol), benzyl isocyanide (1.56 g, 13.317 mmol, 1 eq) 
and pyridinecarbaldehyde (1.27 ml, 13.317 mmol, 1 eq) 
with Montmorillonite K10 clay (2.30 g) and following 
the general procedure with EtOH as the solvent resulted 
in 124 (2.037 g, 40 %), which was collected as a mustard 
yellow powder after recrystallization from ether. Rf = 
0.57 (50 % EtOAc/Hexane). m.p. = 121 ˚C. 
1
H NMR (500 
MHz, CDCl3) δ 8.53 – 8.48 (1H, m, H-12), 8.13 (1H, d, J = 8.0 Hz, H-15), 8.10 (1H, d, J = 1.0 Hz, H-5), 
7.74 (1H, td, J = 7.8 and 1.8 Hz, H-14), 7.41 (1H, dd, J = 9.5 and 0.9 Hz, H-8), 7.40 – 7.36 (2H, m, H-
19 and H-23), 7.33 – 7.28 (2H, m, H-20 and H-22), 7.28 – 7.23 (1H, m, H-21), 7.16 – 7.11 (2H, m, 
H-7 and H-13) 6.53 (1H, t, J = 7.1 Hz, H-16), 4.24 (2H, d, J = 6.8 Hz, H-17). 
13
C NMR (126 MHz, 
CDCl3) δ 154.5 (C-10), 148.6 (C-12), 140.1 (C-9), 136.6 (C-14), 131.9 (C-3), 131.3 (C-2), 128.5 (C-20 
and C-22), 128.1 (C-19 and C-23), 127.5 (C-7*), 126.9 (C-18), 122.8 (C-5), 121.5 (C-13*), 120.3 (C-
15), 118.5 (C-8), 106.8 (C-6), 51.4 (C-17). IR (νm.cm
-1
) = 3302, 3028, 2930, 2856, 1589, 1516, 1477, 
1429, 1396, 1352, 1317, 1290, 1251, 1226, 1110, 1037, 995, 931, 790, 733, 798, 663, 628, 617. 
ESI-MS (m/z) calculated [M+H]
+
 for C19H16N4Br 379.0558, found 379.0544.  
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2-Amino-5-bromopyridine (1.835 g, 10.609 mmol), 2-
pyridinecarboxaldehyde (1.01 ml, 10.609 mmol, 1 eq), 
ethyl isocyanoacetate (1.20 g, 10.609 mmol, 1 eq) and 
Montmorillonite K10 clay (1.80 g) were combined and 
the general procedure followed. The resulting mixture 
was purified by recrystallization from a DCM/Hexane 
mixture to afford 125 as mustard flakes (1.763 g, 44 %). 
Rf = 0.23 (50 % EtOAc/Hexane). m.p. = 142 - 144 ˚C. 
1
H 
NMR (300 MHz, CDCl3): δH =  8.59 (1H, ddd, J = 4.9 Hz, J 
= 1.8 Hz and J = 0.9 Hz, H-12), 8.23 (1H, dd, J = 1.9 Hz and J = 0.9 Hz, H-15), 8.15 (1H, dt, J = 8.0 Hz 
and J = 1.1 Hz, H-5), 7.80 – 7.72 (1H, m, H-7), 7.43 (1H, dd, J = 9.5 Hz and J = 0.8 Hz, H-14), 7.21 – 
7.12 (2H, m, H-8 and H-13), 6.50 (1H, t, J = 6.5 Hz, N-H), 4.18 (2H, q, J = 7.2 Hz, H-19), 3.89 (2H, d, 
J = 6.6 Hz, H-17), 1.25 – 1.19 (3H, m, H-20). 
13
C NMR (75 MHz, CDCl3): δC = 170.6 (C-18), 154.2 (C-
10), 148.8 (C-12), 139.3 (C-9), 136.7 (C-7), 131.9 (C-3), 130.5 (C-2), 127.1 (C-13*), 122.8 (C-15), 
121.7 (C-8*), 120.5 (C-5), 118.6 (C-14), 107.0 (C-6), 61.2 (C-17), 48.6 (C-19), 14.1 (C-20). IR (νm.cm
-
1
) = 3199, 3087, 2976, 2927, 2904, 1735, 1591, 1548, 1481, 1431, 1396, 1371, 1340, 1317, 1238, 
1207, 1110, 1097, 1024, 995, 958, 871, 794, 746, 696, 632. ESI-MS (m/z) calculated for 
C16H16N4O2Br, [M+H]
+
, 375.0458, found 375.0449.  
 
The general procedure was followed using 2-amino-5-
bromopyridine (0.322 g, 1.863 mmol), 2-
pyridinecarboxaldehyde (0.177 ml, 1.863 mmol, 1 eq), 
adamantyl isocyanide (0.300 g, 1.863 mmol, 1 eq) and 
Montmorillonite K10 clay (0.50 g). The resulting mixture 
was purified by flash column chromatography using 30-
50 % EtOAc/Hexane as an eluent. The product, 126 was 
collected as a yellow powder (0.738 g, 94 %). Rf = 0.50 
(50 % EtOAc/Hexane). m.p. = 159 - 162 ˚C. 
1
H NMR (500 MHz, CDCl3): δH =  8.57 (1H, ddd, J = 4.9 
Hz, J = 1.8 Hz and J = 1.0 Hz, H-12), 8.44 (1H, dd, J = 1.9 Hz and J = 0.9 Hz, H-5), 8.16 – 8.12 (1H, m, 
H-15), 7.76 (1H, td, J = 7.7 Hz and J = 1.8 Hz, H-14), 7.40 (1H, dd, J = 9.5 Hz and J = 0.9 Hz, H-8), 
7.18 (1H, ddd, J = 7.6 Hz, J =4.9 and J = 1.2 Hz, H-13), 7.14 (1H, dd, J = 9.5 Hz and J = 1.9 Hz, H-7), 
5.39 (1H, s, N-H), 2.00 – 1.96 (3H, m, H-21, H-22 and H-23), 1.71 (6H. d, J = 2.9 Hz, H-18, H-19 and 
H-20), 1.58 (3H, d, J = 12.7 Hz, H-24, H-25a), 1.55 – 1.49 (3H, m, H-25b and H-26). 
13
C NMR (126 
MHz, CDCl3) δC = 154.7 (C-10), 148.3 (C-12), 140.0 (C-9), 136.5 (C-14), 135.7 (C-3), 128.2 (C-2), 
127.2 (C-7), 124.4 (C-5), 121.9 (C-13), 121.3 (C-15), 118.1 (C-8), 106.2 (C-6), 57.7 (C-17), 43.5 (C-
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18, C-19 and C-20), 36.2 (C-24, C-25 and C-26), 29.8 (C-21, C-22 and C-23). IR (νm.cm
-1
) = 3303, 
2904, 2849, 1591, 1568, 1476, 1425, 1395, 1321, 1288, 1229, 1199, 1103, 1088, 1045, 920, 842, 
787, 743, 696, 603. ESI-MS (m/z) calculated for C22H24N4Br, [M+H]
+
, 423.1184, found 423.1180.  
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7.2.9. General procedure for the synthesis of metal-imidazo[1,2-
a]pyridine complexes 
 
The general procedure for metal co-ordination was loosely based off of a procedure by Steffen 
and Palenik.
112
 This procedure initially was performed in ethanol, however the copper-containing 
complexes were too soluble in ethanol so this procedure was adapted accordingly. In an 
appropriately sized round bottom flask, the relevant imidazo[1,2-a]pyridine was dissolved in 
ether. Metal salt (1 eq) was added to the solution and the reaction stirred overnight at room 
temperature. With time a precipitate forms and is collected by gravity filtration and washed with 
ether and recrystallized using an appropriate method. This method was used unless otherwise 
stated. 
 
89 (0.100 g, 0.232 mmol), zinc(II) chloride (0.015 g, 
0.116 mmol, 1 eq) and triethyl orthoformate (0.138 g, 
0.929 mmol, 4 eq) were combined and refluxed in 
ethanol overnight resulting in the formation of a cream 
powder that was collected by gravity filtration and 
dried. After vapour diffusion recrystallization from 
EtOAc/hexane, the structure of 119 was confirmed by 
single crystal X-ray crystallography (0.117 g, 99 %). IR 
(νm.cm
-1
) = 3289, 3090, 2932, 2855, 1603, 1528, 1503, 
1474, 1412, 1331, 1294, 1238, 1092, 1049, 843, 789, 
758, 712, 648, 546.  
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88 (0.250 g, 0.673 mmol), zinc(II) chloride (0.092g, 0.673 
mmol, 1 eq) and triethyl orthoformate (0.200 g, 1.346 
mmol, 4 eq) were combined and refluxed overnight in 3 
ml of ethanol. The zinc complex, 120, was collected as a 
cream powder. After vapour diffusion recrystallization 
from DCM/hexane, the structure of the complex was 
confirmed by single crystal X-ray crystallography (0.283 
g, 83 %). IR (νm.cm
-1
) = 3289, 3092, 2932, 2858, 1742, 
1634, 1604, 1528, 1503, 1474, 1450, 1412, 1331, 1240, 
1144, 1097, 1047, 1042, 843, 789, 806, 758, 711, 685, 648, 546.  
* The complex was not significantly soluble in CDCl3 or d4-MeOD to obtain a good NMR. The complex was 
soluble in d6-DMSO however, significant exchange occurred between the d6-DMSO and the complex so the 
NMR could not be sufficiently resolved. 
 
Using the general procedure, 88 (0.200 g, 0.539 mmol) 
and zinc(II) acetate monohydrate (0.099g, 0.539 mmol, 
1 eq) were combined in ether with a few drops of EtOH 
resulting in a white powder. After recrystallization by 
slow evaporation from isopropyl alcohol, the structure 
of the complex 121 was confirmed by single crystal X-
ray crystallography and NMR spectroscopy (0.149 g, 50 
%). 
1
H NMR (500 MHz, CDCl3) δH = 8.87 (1H, d, J = 5.1 
Hz, H-12), 8.22 (1H, s, H-5), 8.01 (1H, d, J = 8.0 Hz, H-15), 
7.93 (1H, d, J = 9.0 Hz, H-8), 7.89 (1H, t, J = 7.8 Hz, H-14), 
7.40 (1H, t, J = 6.4 Hz, H-13), 7.31 (1H, d, J = 9.5 Hz, H-7), 3.80 (1H, s, H-22), 2.82 (1H, s, H-16), 
2.10 (6H, s, H-25 and H-26), 1.85 – 1.70 (5H, m, H-17a, H-18a, H-19a, H-20a and H-21a), 1.32 (2H, 
q, J = 11.1 Hz, H-18b and H-20b), 1.17 (3H, t, J = 9.8 Hz, H-17b, H-19b and H-21b). 
13
C NMR (126 
MHz, CDCl3) δC = 180.6 (C-23 and C-24), 149.8 (C-12), 147.2 (C-9), 139.6 (C-3), 139.4 (C-14), 131.9 
(C-7), 130.4 (C-10), 127.8 (C-2), 124.3 (C-13), 123.3 (C-5), 121.2 (C-15), 118.5 (C-8), 109.4 (C-6), 
57.8 (C-16), 34.4 (C-18 and C-20), 25.4 (C-19), 25.0 (C-17 and C-21), 22.1 (C-25 and C-26). IR 
(νm.cm
-1
) = 3259, 3074, 2923, 2854, 1581, 1406, 1332, 1236, 1092, 1047, 1015, 822, 798, 758, 
674, 618.  
 
 
120 
 
 
121 
 
 
At the end of my tether 
 
Experimental 
 
234 
 
In a 10 ml round bottomed flask, 88 (0.100 g, 0.269 
mmol, 1.1 eq) and PtCl2 (0.065 g, 0.245 mmol) were 
combined with 2 ml DMF and triethyl orthoformate 
(0.199 g, 1.345 mmol, 5 eq) and refluxed overnight. This 
resulted in the formation of a mustard yellow powder 
that following characterisation by NMR spectroscopy 
was determined to be 122 (0.190 g, 99 %). 
1
H NMR (500 
MHz, DMSO-d6) δH =  9.39 (1H, d, J = 6.0 Hz, H-12), 8.82 
(1H, d, J = 2.0 Hz, H-5), 8.77 – 8.71 (1H, m, H-8), 8.31 
(1H, td, J = 7.7 and 1.7 Hz, H-14), 8.15 (1H, d, J = 8.0 Hz, H-15), 7.73 (1H, dd, J = 9.8 and 2.0 Hz, H-
7), 7.58 (1H, td, J = 6.9, 6.2 and 1.7 Hz, H-13), 5.59 (1H, d, J = 8.0 Hz, H-16), 3.04 – 2.91 (1H, m, H-
17), 1.88 (2H, d, J = 12.1 Hz, H-18a and H-22a), 1.68 (2H, J = 12.1 Hz, H, H-19a and H-21a), 1.55 
(1H, d, J = 10.7 Hz, H-20a), 1.38 (2H, q, J = 11.7 Hz, H-18b and H-22b), 1.16 (3H, h, J = 12.7 Hz, H-
19b, H-20b and H-21b). 
13
C NMR (126 MHz, DMSO) δC = 152.6 (C-9), 148.2 (C-12), 141.4 (C-3), 
139.9 (C-14), 134.0 (C-10), 132.9 (C-7), 130.5 (C-2), 125.1 (C-5), 124.4 (C-13), 121.8 (C-15), 116.3 
(C-8), 108.5 (C-6), 57.7 (C-17), 33.5 (C-18 and C-22), 25.1 (C-20), 24.7 (C-19 and C-21). 
 
88 (0.200 g, 0.539 mmol) and copper(II) acetate 
monohydrate (0.106g, 0.539 mmol, 1 eq) were 
combined following the general procedure. The product 
purified by recrystallization from DCM to afford 123. 
The structure of the complex was confirmed by single 
crystal X-ray crystallography (0.708 g, 99 %). IR (νm.cm
-1
) 
= 3444, 3252, 3076, 2925, 2856, 1571, 1500, 1389, 
1329, 1245, 1098, 1047, 1020, 784, 755, 674, 619.  
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124 (0.500 g, 1.319 mmol) and zinc(II) acetate 
monohydrate (0.290 g, 1.319 mmol, 1 eq) were 
combined according to the general procedure with the 
addition of a few drops of EtOH. The complex 127 was 
collected as a light yellow powder. After vapour 
diffusion recrystallization from d4-MeOD and ether, the 
structure of the complex was confirmed by single crystal 
X-ray crystallography (0.483 g, 65 %). 
1
H NMR (500 
MHz, CDCl3) δH = 8.80 (1H, s, H-12), 7.90 – 7.80 (2H, m, 
H-5 and H-15), 7.75 (1H, s, H-8), 7.70 (1H, td, J = 7.8, 1.7 
Hz, H-14), 7.30 (1H, d, J = 6.5 Hz, H-13), 7.26 – 7.22 (3H, 
m, H-7, H-19 and H-23), 7.16 (3H, td, J = 9.1, 3.5 Hz, H-
20, H-21 and H-22), 4.88 (1H, s, N-H), 4.07 (2H, d, J = 6.1 
Hz, H-17), 2.06 (6H, s, H-26 and H-27). 
13
C NMR (126 MHz, CDCl3) δC = 180.7 (C-24 and C-25), 
149.5 (C-12), 146.7 (C-9), 139.4 (C-14), 138.3 (C-3), 131.9 (C-18 and C-10), 129.9 (C-17), 128.9 (C-
19
 
and C-23), 128.8 (C-21), 128.1 (C-20 and C-22), 124.2 (C-13), 123.5 (C-8), 121.0 (C-5*), 118.0 
(C-15*), 109.0 (C-6), 52.6 (C-17), 22.1 (C-26 and C-27). IR (νm.cm
-1
) = 3271, 3072, 3018, 1577, 
1407, 1329, 1232, 1038, 1016, 810, 781, 740, 675, 619.  
 
The general procedure was followed using 124 (0.200 g, 
0.527 mmol) and copper(II) acetate monohydrate 
(0.116 g, 0.570 mmol, 1.1 eq). After collection of the 
green powder, the product 128 (0.320 g, 99 %) was 
recrystallized by vapour diffusion from CDCl3 and ether. 
The structure of the complex was confirmed by single 
crystal X-ray crystallography. IR (νm.cm
-1
) = 3428, 3246, 
3084, 3029, 2999, 2925, 1577, 1564, 1526, 1498, 1482, 
1391, 1330, 1244, 1204, 1166, 1124, 1096, 1045, 1018, 
975, 930, 842, 813, 785, 750, 704, 675, 647, 617.  
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In a 25 ml round bottomed flask, 123 (0.300 g, 0.791 
mmol, 2 eq) and PtCl2 (0.105 g, 0.396 mmol) were 
combined in 10 ml DMF and refluxed for 18 hours. A 
yellow solid precipitated out of solution and this was 
collected by filtration and washed with MeOH. The 
yellow solid was characterised by NMR spectroscopy 
and SCXRD and determined to be 129 (0.170 g, 67 %). 
1
H NMR (500 MHz, d-DMSO) δH = 9.37 (1H, dd, J = 6.0 
and 1.6 Hz, H-12), 8.71 (1H, d, J = 9.8 Hz, H-5), 8.51 (1H, 
d, J = 1.7 Hz, H-8), 8.18 (1H, td, J = 7.8 and 1.6 Hz, H-14), 
8.03 (1H, dd, J = 8.2 and 1.5 Hz, H-15), 7.70 (1H, dd, J = 9.8 and 1.9 Hz, H-7), 7.56 (1H, ddd, J = 7.5, 
6.0 and 1.5 Hz, H-13), 7.34 – 7.21 (5H, m, H-19, H-20, H-21, H-22, H-23),  6.18 (1H, t, J = 6.3 Hz, H-
16), 4.26 (2H, d, J = 6.3 Hz, H-17). 
 
Zinc (II) acetate monohydrate (0.108 g, 0.108 mmol, 1.1 
eq) and 125 (0.200 g, 0.533 mmol) were combined 
according to the general procedure with additional 
EtOH added. 130 was collected as a mustard powder 
(0.226 g, 76 %). After vapour diffusion recrystallization 
from CDCl3 and ether, the structure of the complex was 
confirmed by SCXRD. 
1
H NMR (500 MHz, CDCl3) δH = 
8.85 (1H, d, J = 5.1 Hz, H-12), 8.54 – 8.50 (1H, m, H-5), 
8.08 (1H, d, J = 8.0 Hz, H-15), 8.01 (1H, s, H-8), 7.90 (1H, 
td, J = 7.8, 1.7 Hz, H-14), 7.45 – 7.40 (1H, m, H-13), 7.38 
(1H, d, J = 9.5 Hz, H-7), 4.20 (2H, q, J = 7.2 Hz, H-19), 
3.83 (2H, d, J = 5.8 Hz, H-17), 2.09 (6H, s, H-23 and H-
24), 1.89 (1H, s, N-H), 1.25 (3H, t, J = 7.1 Hz, H-20). 
13
C NMR (126 MHz, CDCl3) δ = 180.6 (C-21 and 
C-22), 171.3 (C-18), 149.5 (C-12), 146.5 (C-9), 139.8 (C-10), 139.6 (C-14), 132.2 (C-13), 127.5 (C-2 
and C-3), 124.5 (C-7), 124.1 (C-5), 121.2 (C-15), 118.3 (C-8), 109.3 (C-6), 61.9 (C-19), 49.1 (C-17), 
22.7 (C-23 and C-24), 14.1 (C-20). IR (νm.cm
-1
) = 3273, 3080, 2980, 2922, 2845, 1730, 1582, 1474, 
1416, 1337, 1296, 1238, 1198, 1105, 1028, 928, 820, 792, 727, 677, 673, 619.  
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The general procedure was followed using 125 (0.200 g, 
0.533 mmol) and copper(II) acetate monohydrate 
(0.106 g, 0.533 mmol, 1 eq). In order to confirm the 
structure of the collected green powder 131, the 
product (0.271 g, 91 %) was recrystallized by vapour 
diffusion from d4-MeOD and ether. IR (νm.cm
-1
) = 3443, 
3269, 3082, 2907, 2851, 1572, 1528, 1503, 1481, 1389, 
1358, 1334, 1242, 1159, 1121, 1090, 1047, 1018, 928, 
860, 829, 792, 760, 738, 706, 673, 619.  
 
 
126 (0.161 g, mmol) and zinc(II) acetate monohydrate 
(0.077 g, 0.419 mmol, 1.1 eq) were combined following 
the general procedure with an additional few drops of 
EtOH. A white powder was collected (0.161 g, 70 %). 
After recrystallization by vapour diffusion from CDCl3 
and ether, the structure of the white powder was found 
to be 132 by single crystal X-ray crystallography. 
1
H 
NMR (500 MHz, CDCl3) δH = 8.93 – 8.88 (1H, m, H-12), 
8.43 (1H, d, J = 8.0 Hz, H-15), 8.37 (1H, s, H-5), 8.01 (1H, 
d, J = 9.5 Hz, H-8), 7.88 (1H, t, J = 7.8 Hz, H-14), 7.44 – 
7.36 (2H, m, H-7 and H-13), 3.34 (1H, s, N-H), 2.09 (6H, 
s, H-29 and H-30), 2.06 (3H, s, H-21, H-22 and H-23), 1.77 – 1.72 (6H, m, H-18, H-19 and H-20), 
1.66 – 1.51 (6H, m, H-24, H-25 and H-26). 
13
C NMR (126 MHz, CDCl3) δ = 180.6 (C-27 and C-28), 
149.8 (C-12), 147.5 (C-9), 140.3 (C-10), 138.9 (C-14), 133.3 (C-3), 132.2 (C-7*), 125.0 (C-2), 124.6 
(C-13*), 124.1 (C-5), 121.9 (C-15), 118.6 (C-8), 109.2 (C-6), 58.2 (C-17), 44.3 (C-18, C-19 and C-20), 
35.9 (C-24, C-25 and C-26), 29.7 (C-21, C-22 and C-23), 22.1 (C-29 and C-30). IR (νm.cm
-1
) = 3271, 
3074, 3018, 2907, 2855, 1585, 1530, 1503, 1472, 1412, 1393, 1323, 1234, 1088, 1049, 1013, 922, 
824, 797, 760, 706, 671, 617. 
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The general procedure was followed using 126 (0.150 g, 
0.355 mmol) and copper(II) acetate monohydrate 
(0.078 g, 0.390 mmol, 1.1 eq). The product was 
collected as a turquoise solid (0.144 g, 67 %) and after 
recrystallization from MeOD and ether was found to be 
133 from SCXRD. IR (νm.cm
-1
) = 3257, 3086, 2905, 2845, 
1585, 1558, 1530, 1506, 1476, 1412, 1385, 1360, 1327, 
1250, 1186, 1151, 1117, 1088, 1047, 1018, 924, 853, 
806, 791, 762, 735, 706, 675, 646, 619.  
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7.2.10. Synthesis of pyridyl imidazo[1,2-a]pyridines for the SAR study 
 
The synthesis of the following imidazo[1,2-a]pyridines were synthesized according to the general 
procedure outlined in Section 7.2.1 by heating the reactants under reflux conditions in ethanol 
overnight. The products were purified by recrystallization or flash column chromatography. 
 
2-Aminopyridine (1.00 g, 10.626 mmol), 2-
pyridinecarboxaldehyde (1.14 g, 10.626 mmol, 1 eq), 
cyclohexyl isocyanide (1.16 g, 10.626 mmol, 1 eq) and 
Montmorillonite K10 clay (1.2 g) were combined and 
the general procedure followed. The resulting mixture 
was purified by recrystallization from an ether/DCM 
mixture to afford imidazo[1,2-a]pyridine 134 as yellow 
crystals (2.31 g, 74 %). Rf = 0.40 (50% EtOAc/Hexane), 
m.p. = 123 - 124 ˚C, 
1
H NMR (300 MHz, CDCl3): δH =  8.54 (1H, ddd, J = 5.0 Hz, J = 1.8 Hz and J = 
0.9 Hz, H-12), 8.18 (1H, dt, J = 8.1 Hz and J = 1.1 Hz, H-15), 8.01 – 7.94 (1H, m, H-5), 7.73 (1H, td, J 
= 7.7 and J = 1.7 Hz, H-14), 7.52 (1H, d, J = 9.1 Hz, H-8*), 7.18 – 6.98 (2H, m, H-13 and H-7), 6.73 
(1H, td, J = 6.7 Hz and J = 1.1 Hz, H-6), 6.25 (1H, s, H-16), 3.10 (1H, d, J = 9.9 Hz, H-17), 1.89 (2H, 
dd, J = 10.2 Hz and J = 4.5 Hz, H-18), 1.77 – 1.65 (2H, m, H-19), 1.55 (1H, d, J = 3.9 Hz, H-20a), 1.39 
– 1.14 (5H, m, H-20b, H-21, H-22). 
13
C NMR (75 MHz, CDCl3): δC = 155.1 (C-10), 148.3 (C-12), 140.7 
(C-9), 136.4 (C-14), 131.2 (C-3), 130.2 (C-2), 123.2 (C-7), 123.0 (C-5), 121.0 (C-13), 120.2 (C-15), 
117.8 (C-8*), 111.6 (C-6), 55.5 (C-17), 34.0 (C-18 and C-22), 25.8 (C-20), 25.0 (C-19 and C-21). IR 
(νm.cm
-1
) = 3262, 2925, 2848, 1590, 1555, 1477, 1403, 1346, 1229, 1095, 1073, 892, 792, 760, 
734, 694, 639. ESI-MS (m/z) calculated for C18H21N4, [M+H]
+
, 293.1766, found 293.1765.  
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2-Amino-6-bromopyridine (2.00 g, 11.56 mmol), 2-
pyridinecarboxaldehyde (1.238 g, 11.56 mmol, 1 eq), 
cyclohexyl isocyanide (1.262 g, 11.65 mmol, 1 eq) and 
Montmorillonite K10 clay (1.0 g) were combined and 
the general procedure followed. The resulting mixture 
was purified by column chromatography with 20 % 
EtOAc/Hexane as an eluent to afford a sticky golden oil, 
135 (2.976 g, 69 %). Rf = 0.54 (50 % EtOAc/Hexane).
 1
H 
NMR (500 MHz, CDCl3) δ = 8.56 (1H, ddd, J = 4.9, 1.9 and 0.9 Hz, H-12), 8.18 (1H, dt, J = 8.0 and 
1.1 Hz, H-15), 7.73 (1H, td, J = 7.7 and 1.8 Hz, H-14), 7.48 (1H, dd, J = 8.9 and 1.2 Hz, H-8), 7.14 
(1H, ddd, J = 7.5, 4.8 and 1.2 Hz, H-13), 6.93 (1H, dd, J = 7.1 and 1.1 Hz, H-6), 6.87 (1H, dd, J = 8.8 
and 7.1 Hz, H-7), 4.96 (1H, s, H-16), 3.15 – 3.02 (1H, m, H-17), 1.92 (2H, dt, J = 8.8 and 3.1 Hz, H-
18a and H-22a), 1.64 (2H, dt, J = 6.8 and 3.3 Hz, H-19a and H-21a), 1.58 – 1.50 (1H, m, H-20a), 
1.20 – 1.03 (5H, m, H-18b, H-19b, H-20b, H-21b and H-22b). 
13
C NMR (126 MHz, CDCl3) δ = 158.8, 
154.5 (C-10), 148.1 (C-12), 142.8 (C-9), 139.6, 136.5 (C-14), 133.1 (C-3), 132.9 (C-2), 123.6 (C-6), 
121.5 (C-13), 121.0 (C-15), 118.8 (C-7), 117.2 (C-8), 112.2 (C-5), 60.2 (C-17), 32.7 (C-18 and C-22), 
25.9 (C-20), 25.5 (C-19 and C-21). IR (νm.cm
-1
) = 3268, 2928, 2852, 1589, 1552, 1470, 1428, 1400, 
1298, 1225, 1144, 1074, 976, 891, 768, 721. EIS-MS (m/z) calculated for C18H20BrN4, [M+H]
+
, 
371.0871, found 371.0866.  
 
Following the general procedure, 2-amino-3-
bromopyridine (1.00 g, 5.78 mmol), 2-
pyridinecarboxaldehyde (0.619 g, 5.78 mmol, 1 eq), 
cyclohexyl isocyanide (0.631 g, 5.78 mmol, 1 eq) and 
Montmorillonite K10 clay (1.0 g) were combined in 
ethanol. The resulting mixture was purified by flash 
column chromatography with 20 % EtOAc/Hexane as 
yellow crystals, 136 (1.00 g, 47 %). Rf = 0.45 (50 % 
EtOAc/Hexane). m.p. = 136 - 137 ˚C. 
1
H NMR (300 MHz, CDCl3): δH =  8.54 (1H, dt, J = 4.8 Hz and J 
=1.8 Hz, H-12), 8.29 (1H, dt, J = 8.0 Hz and J = 1.4 Hz, H-15), 7.96 (1H, dd, J = 6.9 Hz and J = 2.7 Hz, 
H-5), 7.74 (1H, tq, J = 7.9 Hz and J = 1.8 Hz, H-14), 7.34 (1H, dt, J = 7.2 Hz and J = 2.2 Hz, H-7), 7.14 
(1H, m, H-13), 6.63 (1H, td, J = 7.1 Hz and J = 4.7 Hz, H-6), 6.29 (s, 1H), 3.07 (1H, s, H-17), 1.87 (2H, 
d, J = 12.8 Hz, H-18), 1.71 (2H, s, H-19), 1.55 (1H, s, H-20a), 1.25 (5H, m, H-20b, H-21, H-22). 
13
C 
NMR (75 MHz, CDCl3): δC = 154.7 (C-10), 151.5 (C-9), 148.2 (C-12), 138.2 (C-10), 136.4 (C-14), 
132.5 (C-3), 131.1 (C-2), 125.4 (C-7), 122.5 (C-5), 121.3 (C-13), 120.9 (C-15), 112.1 (C-8), 111.5 (C-
6), 55.6 (C-17), 34.0 (C-18 and C-22), 25.8 (C-19 and C-21), 24.9 (C-20). IR (νm.cm
-1
) = 3262, 2926, 
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2849, 1591, 1573, 1475, 1436, 1370, 1349, 1293, 1251, 1236, 1209, 1143, 1071, 992, 936, 895, 
836, 791, 758, 722, 662. ESI-MS (m/z) calculated for C18H20N4Br, [M+H]
+
, 371.0871, found 
371.0869. 
 
Following the general procedure, 2-amino-5-
chloropyridine (1.00 g, 7.78 mmol), 2-
pyridinecarboxaldehyde (0.833 g, 7.78 mmol, 1 eq), 
cyclohexyl isocyanide (0.857 g, 7.78 mmol, 1 eq) and 
Montmorillonite K10 clay (1.0 g) were combined in 
ethanol. Column chromatography was used to purify 
the compound with 20 % EtOAc/Hexane as an eluent to 
afford a yellow powder, 137 (2.27 g, 89 %). Rf = 0.57 (50 
% EtOAc/Hexane). m.p. = 118 - 119 ˚C. 
1
H NMR (300 MHz, CDCl3): δH =  8.60 – 8.52 (1H, m, H-12), 
8.15 (1H, dt, J = 8.0 Hz and J =, 1.1 Hz, H-15), 7.98 (1H, dd, J = 2.0 Hz and J = 0.9 Hz, H-5), 7.74 (1H, 
dd, J = 8.7 Hz and J = 6.8 Hz, H-14), 7.46 (1H, d, J = 9.5 Hz, H-8), 7.13 (1H, ddd, J = 8.6 Hz, J = 4.1 Hz 
and J = 2.7 Hz, H-13), 7.08 – 6.91 (1H, m, H-7), 6.21 (1H, s, H-16), 3.07 (1H, s, H-17), 1.88 (2H, d, J 
= 11.1 Hz, H-18), 1.78 – 1.62 (2H, m, H-19), 1.56 (1H, d, J = 6.0 Hz, H-20a), 1.45 – 1.13 (5H, m, H-
20b, H-21 and H-22).
13
C NMR (75 MHz, CDCl3): δC = 154.7 (C-10), 148.3 (C-12), 139.0 (C-9), 136.5 
(C-14), 131.5 (C-3), 131.5 (C-2), 124.5 (C-7), 121.3 (C-6), 120.7 (C-13), 120.3 (C-5), 120.0 (C-15), 
118.2 (C-8), 55.4 (C-17), 34.0 (C-18 and C-22), 25.8 (C-20), 24.9 (C-19 and C21). IR (νm.cm
-1
) = 
3305, 2930, 2853, 1590, 1476, 1400, 1324, 1287, 1232, 1201, 1184, 1115, 1085, 1046, 943, 891, 
807, 786, 740, 702, 626. ESI-MS (m/z) calculated for C18H20ClN4, [M+H]
+
, 327.1376, found 
327.1369.  
 
2-Aminopyridine (0.253 g, 2.688 mmol), 5-bromo-2-
pyridinecarboxaldehyde (0.500 g, 2.688 mmol, 1 eq), 
cyclohexyl isocyanide (0.293 g, 2.688 mmol, 1 eq) and 
Montmorillonite K10 clay (0.500 g) were combined and 
the general procedure followed. The resulting mixture 
was purified by column chromatography with 20 % 
EtOAc/Hexane as an eluent to afford 138 as a yellow 
solid (0.816 g, 82 %). Rf = 0.63 (50 % EtOAc/Hexane). 
m.p. = 144 ˚C. 
1
H NMR (300 MHz, CDCl3): δH =  8.60 (1H, dt, J = 2.4 and 0.8 Hz, H-12), 8.08 (1H, dt, 
J = 8.6 and 0.8 Hz, H-15), 7.96 (1H, dq, J = 6.9 and 1.1 Hz, H-5), 7.85 (1H, ddd, J = 8.6, 2.4 and 0.9 
Hz, H-14), 7.50 (1H, dq, J = 9.1 and 1.1 Hz, H-8), 7.09 (1H, ddt, J = 9.1, 6.6 and 1.1 Hz, H-7), 6.76 
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(1H, tt, J = 6.8 and 1.0 Hz, H-6), 5.93 (1H, d, J = 9.8 Hz, H-16), 3.14 – 3.00 (1H, m, H-17), 1.89 (2H, 
d, J = 11.7 Hz, H-18a and H-19a), 1.72 (2H, q, J = 5.2 Hz, H-19a and H-21a), 1.57 (1H, s, H-20a), 
1.40 – 1.15 (5H, m, H-18a, H-19a, H-20a, H-21a and H-22a). 
13
C NMR (75 MHz, CDCl3): δC = 153.6 
(C-9), 149.3 (C-12), 140.9 (C-3), 139.1 (C-14), 131.3 (C-10), 129.5 (C-2), 123.6 (C-7), 123.1 (C-5), 
121.6 (C-15), 117.9 (C-8), 117.4 (C-13), 111.8 (C-6), 55.6 (C-17), 34.1 (C-18 and C-22), 25.8 (C-20), 
25.0 (C-19 and C-21). IR (νm.cm
-1
) = 3302, 2922, 2848, 1580, 1537, 1471, 1444, 1413, 1359, 1292, 
1265, 1230, 1197, 1139, 1120, 1086, 1047, 1002, 922, 889, 841, 752, 702, 636, 617. ESI-MS (m/z) 
calculated for C18H20BrN4, [M+H]
+
, 371.0871, found 371.0855.  
 
The combination of 2-aminopyridine (0.332 g, 3.532 
mmol), 5-chloro-2-pyridinecarboxaldehyde (0.500 g, 
3.532 mmol, 1 eq), cyclohexyl isocyanide (0.386 g, 3.532 
mmol, 1 eq) and Montmorillonite K10 clay (0.500 g) 
according to the general procedure resulted in the 
formation of  139 (0.997 g, 86 %) as a yellow powder 
following purification by column chromatography with a 
20 % EtOAc/Hexane eluent. Rf = 0.54 (50 % 
EtOAc/Hexane). m.p. = 139 - 140 ˚C. 
1
H NMR (300 MHz, CDCl3): δH =  8.50 (1H, dt, J = 2.5 and 0.8 
Hz, H-12), 8.13 (1H, dt, J = 8.6 and 0.8 Hz, H-15), 7.96 (1H, dq, J = 6.9 and 1.1 Hz, H-5), 7.71 (1H, 
ddd, J = 8.6, 2.5 and 0.8 Hz, H-14), 7.50 (1H, dq, J = 9.1 and 1.0 Hz, H-8), 7.09 (1H, ddt, J = 9.0, 6.6 
and 1.1 Hz, H-7), 6.75 (1H, tt, J = 6.8 and 1.0 Hz, H-6), 5.93 (1H, d, J = 9.8 Hz, H-16), 3.06 (1H, m, 
H-17), 1.94 – 1.83 (2H, m, H-18a and H-22b), 1.73 (2H, d, J = 7.8 Hz, H-19a and H-21a), 1.57 (1H, s, 
H-20), 1.40 – 1.15 (5H, m, H-18b, H-19b, H-20b, H-21b and H-22b). 
13
C NMR (75 MHz, CDCl3): δC = 
153.5 (C-9), 147.3 (C-12), 141.0 (C-3), 136.4 (C-14), 131.4 (C-13), 129.7 (C-2), 129.1 (C-10), 123.7 
(C-7), 123.2 (C-5), 121.3 (C-15), 118.0 (C-8), 111.9 (C-6), 55.8 (C-17), 34.3 (C-18 and C-22), 25.9 (C-
20), 25.1 (C-19 and C-21). IR (νm.cm
-1
) = 3303, 2925, 2850, 1579, 1541, 1471, 1446, 1363, 1346, 
1288, 1230, 1199, 1139, 1107, 1089, 1008, 923, 891, 842, 798, 752, 738, 704, 638, 621. ESI-MS 
(m/z) calculated for C18H20ClN4, [M+H]
+
, 327.1376, found 327.1379.  
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7.2.11. Synthesis of Copper Complexes 
 
Following the general procedure outlined in Section 7.2.9. the following copper complexes were 
synthesized in diethyl ether, the resulting powders collected by gravity filtration and 
recrystallized from acetone unless otherwise stated. Crystals suitable for SCXRD were grown from 
appropriate solvents. 
 
Combining 134 (0.300 g, 1.074 mmol) and Cu(OAc)2.H2O 
(0.214 g, 1.074 mmol, 1 eq) according to the general 
procedure resulted in the formation of a green powder 
(0.455 g, 89 %). After vapour diffusion recrystallization 
from d4-MeOD and ether and characterisation by SXCRD 
the green powder was found to be 140. IR (νm.cm
-1
) = 
3302, 3265, 3107, 3082, 3049, 2930, 2857, 1582, 1506, 
1479, 1381, 1327, 1292, 1247, 1151, 1091, 1047, 1010, 
941, 926, 850, 775, 758, 673, 646, 621.  
 
The general procedure was followed using 135 (1.776 g, 
4.784 mmol) and Cu(OAc)2.H2O (0.955 g, 4.784 mmol, 1 
eq). A green powder, 141 resulted. The structure of the 
complex was confirmed by single crystal X-ray 
crystallography (2.238 g, 85 %) following suitable crystal 
formation by slow evaporation from d4-MeOD. IR 
(νm.cm
-1
) = 3414, 3287, 3080, 2924, 2855, 1576, 1485, 
1391, 1334, 1306, 1256, 1159, 1099, 1047, 1022, 964, 
930, 785, 758, 679, 648, 621.  
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137 (0.500 g, 1.530 mmol) and Cu(OAc)2.H2O (0.305 g, 
1.530 mmol, 1 eq) were combined following the general 
procedure. A dark green powder precipitated from the 
reaction and this was collected by gravity filtration and 
washed with ether to afford 142. The structure of the 
complex was confirmed by single crystal X-ray 
crystallography (0.789 g, 99 %). IR (νm.cm
-1
) = 3379, 
3282, 3282, 3067, 2930, 2858, 1610, 1568, 1528, 1502, 
1477, 1400, 1331, 1292, 1242, 1151, 1128, 1097, 1078, 
1047, 1022, 877, 822, 787, 756, 725, 679, 621. 
 
The combination of 138 (0.300 g, 0.808 mmol) with 
Cu(OAc)2.H2O (0.161 g, 0.808 mmol, 1 eq) according to 
the general procedure resulted in the formation of a 
green solid (0.408 g, 35 %). Following slow evaporation 
recrystallization from isopropyl alcohol the structure of 
147 was confirmed. IR (νm.cm
-1
) = 3294, 3250, 3105, 
3043, 2928, 2855, 1570, 1508, 1479, 1389, 1377, 1331, 
1248, 1146, 1105, 1030, 1013, 949, 928, 841, 779, 752, 
673, 619.  
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The general procedure was followed using 139 (0.300 g, 
0.918 mmol) and Cu(OAc)2.H2O (0.183 g, 0.918 mmol, 1 
eq). The resulting green powder (0.408 g, 47 %) was 
found to be 148 following recrystallization by slow 
evaporation from d4-MeOD. IR (νm.cm
-1
) = 3510, 3221, 
3111, 3053, 2930, 2855, 1595, 1504, 1483, 1423, 1375, 
1325, 1246, 1146, 1121, 1097, 1069, 1032, 1013, 928, 
854, 826, 756, 681, 667, 617.  
 
 
 
 
 
The general procedure was followed using 88 (0.300 g, 
0.808 mmol) and CuCl2.H2O (0.138 g, 0.808 mmol, 1 eq) 
in ether resulting in the formation of a light green solid, 
145 (0.215 g, 53 %) after filtration. The structure of the 
green solid was confirmed by SCXRD following 
recrystallization from a MeOH/H2O solution (although 
this structure could not be solved satisfactorily). IR 
(νm.cm
-1
) = 3283, 3101, 3067, 2928, 2849, 1628, 1605, 
1582, 1522, 1497, 1450, 1408, 1367, 1333, 1300, 1258, 
1238, 1167, 1128, 1096, 1016, 947, 870, 804, 787, 752, 706, 671, 642, 602.  
* Acetone could not be used to recrystallize this compound – it exchanges with the counterion 
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The combination of an ethereal solution of 88 (0.300 g, 
0.808 mmol) with Cu(NO3)2 (0.188 g, 0.808 mmol, 1 eq) 
according to the general procedure resulted in the 
formation of a lime green powder (0.439 g, 97 %) that 
was collected by filtration. A slow evaporation 
recrystallization from a MeOH/DCM solution provided 
suitable crystals for SCXRD which confirmed the 
structure of 146. IR (νm.cm
-1
) = 3327, 3094, 2924, 2854, 
1610, 1568, 1479, 1452, 1410, 1302, 1275, 1246, 1161, 
1113, 1097, 1069, 1009, 970, 893, 872, 808, 783, 750, 
708, 675, 652.  
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7.3. Experimental Procedures for the preparation of 
xanthones and related compounds. 
7.3.1. General procedure for the benzyl protection of salicylic acids and 
salicylaldehyde 
 
 
 
 
 
To a solution containing the relevant salicylic acid or aldehyde (1 eq) in dry acetone, K2CO3 (3 eq) 
was added and the mixture heated under reflux for 15 minutes. Benzyl bromide (2.1 eq for 
salicylic acids or 1.1 eq for salicylaldehyde) was added to the resulting cloudy solution and the 
reaction left to reflux overnight. On completion of the reaction, the K2CO3 was filtered off and 
concentrated in vacuo. The products were purified by column chromatography. 
 
Salicylic acid (5.00g, 56.20 mmol), K2CO3 (15.00 g, 0.108 
mol, 3 eq) and benzyl bromide (18.57 g, 0.108 mol, 3 
eq) were combined according to the general procedure 
in acetone (120 ml). Following purification, 251 was 
collected as a white solid (11.36 g, 99 %). Rf = 0.77 (10 % 
EtOAc/Hexane). m.p. = 49-51 °C, lit 48-50 °C.
191
 
1
H NMR 
(300 MHz, CDCl3): δH = 7.84 (1H, dd, J = 7.6 and 1.8 Hz, 
H-3), 7.45 – 7.34 (6H, m, H-5, H-10, H-12, H-14, H-17 
and H-21), 7.29 (5H, m, H-11, H-13, H-18, H-19 and H-20), 7.00 – 6.90 (2H, m, H-4 and H-6), 5.32 
(2H, s, H-15), 5.10 (2H, s, H-8). 
13
C NMR (75 MHz, CDCl3): δC = 166.2 (C-1), 158.2 (C-7), 136.6 (C-9), 
136.1 (C-16), 133.4 (C-5), 131.8 (C-3), 128.6 (C-2), 128.5 (C-10* and C-14*), 128.4 (C-17* and C-
21*), 128.1 (C-11* and C-13*), 128.0 (C-12*), 127.7 (C-19*), 127.0 (C-18* and C-20*), 120.5 (C-4’), 
113.7 (C-6’), 70.6 (C-8), 66.6 (C-15). 
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5-chlorosalicylic acid (10.00 g, 58.29 mmol), benzyl 
bromide (20.94 g, 0.1224 mol, 2.1 eq) and K2CO3 (24.17 
g, 0.1749 mol, 3 eq) were combined following the 
general procedure. The product (301) was purified by 
column chromatography in 10 % EtOAc/Hexane and 
collected as a white solid (20.10 g, 99 %). Rf = 0.65 (20 % 
EtOAc/Hex). m.p. = 63-64 °C; 64-66 °C.
191
 
1
H NMR (300 
MHz, CDCl3) δH = 7.79 (1H, d, J = 2.8 Hz, H-3), 7.45 – 7.22 
(11H, m, H-5, H-10, H-11, H-12, H-13, H-14, H-17, H-18, H-19, H-20 and H-21), 6.87 (1H, d, J = 8.9 
Hz, H-6), 5.31 (2H, s, H-15), 5.07 (2H, s, H-8). 
13
C NMR (75 MHz, CDCl3) δC = 164.9 (C-1), 156.7 (C-
7), 136.1 (C-9*), 135.7 (C-16*), 133.0 (C-11
#
, C-12
#
 and C-13
#
), 131.4 (C-18
#
, C-19
#
 and C-20
#
), 
128.5 (C-17
~
 and C-21
~
), 128.2 (C-3), 127.9 (C-5), 127.0 (C-10
~
 and C-14
~
), 125.5 (C-4), 122.0 (C-2), 
115.2 (C-6), 70.9 (C-8), 67.0 (C-15). 
 
Salicylaldehyde (2.00 g, 16.38 mmol), K2CO3 (2.49 g, 
18.02 mmol, 1.1 eq) and benzyl bromide (3.08 g, 18.02 
mmol, 1.1 eq) were combined as outlined in the general 
procedure. Following purification by column 
chromatography using 10 % EtOAc/Hexane and the 
resulting viscous colourless oil was found to be 309 
(2.73 g, 73 %). Rf = 0.44 (10 % EtOAc/Hexane). 
1
H NMR 
(300 MHz, CDCl3): δH = 10.55 (1H, d, J = 0.7 Hz, H-1), 
7.88 – 7.82 (1H, m, H-3), 7.54 – 7.49 (1H, m, H-5), 7.46 – 7.29 (1H, m, H-10, H-11, H-12, H-13 and 
H-14), 7.05 (1H, s, H-6), 7.01 (1H, d, J = 7.1 Hz, H-4), 5.17 (1H, s, H-8). 
13
C NMR (75 MHz, CDCl3): δC 
= 189.65 (C-1), 161.05 (C-7), 136.09 (C-9), 135.86 (C-5), 128.71 (C-11 and C-13), 128.43 (C-3), 
128.25 (C-6), 127.27 (C-10 and C-14), 125.24 (C-2), 121.00 (C-4), 113.07 (C-6), 70.49 (C-8). IR 
(νm.cm
-1
) = 3071, 3034, 2867, 1685, 1597, 1470, 1452, 1379, 1286, 1237, 1188, 1159, 1102, 1004, 
852, 832, 756, 733, 696, 659. 
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7.3.2. Reduction of naphthoquinone 
 
 
 
 
 
 
 
This procedure was modified from work originally done 
by Johnson.
128
 Naphthoquinone 151 (1 eq) was 
dissolved in 250 ml of THF in a 1 litre round bottomed 
flask. Water (50 ml) was added to the flask along with 
sodium dithionite (16.51 g, 94.9 mmol, 3 eq) and TBAI 
(1.051 g, 2.85 mmol, 0.09 eq) and the reaction stirred 
under a nitrogen atmosphere for 30 minutes. During 
this time KOH (17.74 g, 0.316 mol, 10 eq) was dissolved in 100 ml of water and allowed to cool. 
The basic solution was added to the reaction mixture and stirred for a further 1 hour. Finally 
dimethyl sulfate (39.86 g, 0.316 mol, 10 eq) was added to the reaction mixture and the reaction 
stirred for 18 hours. Ammonia solution was added to quench the reaction and the organic layer 
extracted with EtOAc. This layer was then washed sequentially with water, 5 % HCl and brine in a 
separation funnel. The organic layer was then dried over MgSO4, concentrated in vacuo and 
purified by column chromatography using 10 % EtOAc/Hexane as the eluent. The product 150 
was collected as white crystals (4.76 g, 80 %). Rf = 0.70 (10 % EtOAc/Hexane). m.p. = 88-90 °C, lit 
86-88 °C.
207
 
1
H NMR (300 MHz, CDCl3) δH = 8.20 (2H, dd, J = 6.4 and 3.3 Hz, H-4), 7.49 (2H, dd, J = 
6.4 and 3.3 Hz, H-5), 6.68 (2H, s, H-1), 3.94 (6H, s, H-6). 
13
C NMR (75 MHz, CDCl3) δC = 149.5 (C-2), 
126.4 (C-3), 125.8 (C-4), 121.8 (C-5), 103.2 (C-1), 55.7 (C-6). IR (νm.cm
-1
) = 3078, 3046, 2947, 2849, 
1690, 1614, 1489, 1464, 1414, 1389, 1288, 1263, 1238, 1163, 1088, 1013, 962, 912, 837, 812, 
787, 762, 738, 712, 687, 662, 611. 
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7.3.3. General procedure for the bromination of substituted benzenes 
and naphthalenes 
 
 
 
 
 
 
 
Freshly recrystallized N-Bromosuccinimide* (NBS) (1 eq) was weighed out in a 100 ml round 
bottomed flask and 50 ml of DCM added to this with a stirrer bar. To this the appropriate 
methoxy-substituted benzene (1 eq) was added. Depending on the nature of the substituted 
benzene the reaction was either stirred at room temperature for 30 minutes or heated under 
reflux conditions for 2 hours (or longer). Once the reaction was deemed complete (as determined 
by TLC) the reaction mixture was poured into a separation funnel and the reaction quenched with 
saturated sodium sulfite. After a further two washes with the saturated sodium sulfite (Na2SO3) 
and a wash with brine, the DCM layer was dried over anhydrous Na2SO4 and concentrated in 
vacuo. The product was then purified by column chromatography with a 0-10 % EtOAc/Hexane 
eluent mixture and characterised by NMR Spectroscopy. 
* NBS was recrystallized from boiling water. On cooling white crystals precipitated out of the solution which 
were collected by filtration and dried in a desiccator overnight. The recrystallized NBS was stored in the 
fridge in a container that blocked out light. 
 
Previously prepared 1,4-dimethoxynaphthelene 150 
(3.00 g, 15.94 mmol, 1 eq) was added to NBS (2.84 g, 
15.94 mmol, 1 eq) in CHCl3 (30 ml). The reaction was 
heated under reflux for 2 hours before being quenched 
as described by the general procedure. Following 
purification, 250 was collected as a colourless oil (2.13 
g, 50 %). Rf = 0.65 (10 % EtOAc/Hexane). 
1
H NMR (300 
MHz, CDCl3) δH = 8.18 – 8.11 (1H, m, H-4), 8.05 – 7.97 (1H, m, H-7), 7.45 (2H, m, H-5 and H-6), 
6.81 (1H, d, J = 2.0 Hz, H-10), 3.90 (3H, d, J = 2.2 Hz, H-11*), 3.84 (3H, d, J = 2.2 Hz, H-12*). 
13
C 
NMR (75 MHz, CDCl3) δC = 152.2 (C-2*), 146.7 (C-9*), 128.9 (C-8), 127.3 (C-5
#
), 125.7 (C-3), 125.7 
(C-6
#
), 122.5 (C-7
~
), 121.7 (C-4
~
), 111.9 (C-1), 107.8 (C-10), 61.3 (C-11’), 55.7 (C-12’). 
*This compound was found to be unstable and so was used immediately after purification in the next step. 
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Following the general procedure, 1,4-
dimethoxybenzene (10.00 g, 72.38 mmol) and NBS 
(12.90 g, 72.38 mmol, 1 eq) were combined and heated 
under reflux in CHCl3 (60 ml) for 3 days. After 
purification, a light brown oil resulted and determined 
to be 289 (12.05 g, 77 %). Rf = 0.51 (10 % 
EtOAc/Hexane). 
1
H NMR (300 MHz, CDCl3) δH = 7.11 
(1H, dd, J = 2.3 and 0.9 Hz, H-6), 6.83 – 6.78 (2H, m, H-3 
and H-4), 3.81 (3H, s, H-7*), 3.73 (3H, s, H-8*). 
13
C NMR (75 MHz, CDCl3) δC = 154.1 (C-2*), 150.3 
(C-5*), 119.0 (C-6), 114.6 (C-1), 113.6 (C-4), 113.0 (C-3), 56.8 (C-7
#
), 55.9 (C-8
#
). 
 
On the slow addition of 1,2,4-trimethoxybenzene (5.00 
g, 29.73 mmol) to the stirring NBS (5.30 g, 29.73 mmol) 
DCM suspension, the reaction heated up significantly, 
dissolving the NBS. After 20 minutes the reaction had 
cooled and the NBS crashed out of solution. No starting 
material could be visualised on the TLC plate and so the 
reaction was quenched and purified. The white crystals 
that resulted were determined to be 246 (6.40 g, 87 %). Rf = 0.32 (10 % EtOAc/Hex). m.p. 52-54 
°C; lit 51-52 °C.
208
 
1
H NMR (300 MHz, CDCl3) δH = 7.04 (1H, s, H-6), 6.56 (1H, s, H-3), 3.89 (3H, s, H-
7), 3.87 (3H, s, H-8), 3.83 (3H, s, H-9). 
13
C NMR (75 MHz, CDCl3) δC = 150.4 (C-2*), 149.2 (C-4*), 
143.9 (C-5*), 116.6 (C-6), 101.2 (C-1), 99.0 (C-3), 57.3 (C-8), 56.7 (C-9), 56.3 (C-3). IR (νm.cm
-1
) = 
2990, 2955, 2851, 1593, 1512, 1458, 1431, 1377, 1323, 1269, 1215, 1161, 1053, 1026, 945, 864, 
837, 783, 702. 
 
1,3-Dimethoxybenzene (10.00 g, 72.38 mmol, 1 eq) and 
NBS (12.90 g, 72.38 mmol, 1 eq) were reacted according 
to the general procedure. The product 314 was 
collected after purification as a dark liquid (15.14 g, 96 
%). Rf = 0.67 (20 % EtOAc/Hex). 
1
H NMR (300 MHz, 
CDCl3) δH = 7.37 (1H, d, J = 8.7 Hz, H-6), 6.46 (1H, d, J = 
2.7 Hz, H-3), 6.36 (1H, dd, J = 8.7 and 2.7 Hz, H-5), 3.83 
(3H, s, H-7*), 3.76 (3H, s, H-8*). 
13
C NMR (75 MHz, CDCl3) δC = 160.3 (C-2*), 156.5 (C-4*), 133.1 
(C-6), 106.2 (C-1), 106.0 (C-5), 100.0 (C-3), 56.1 (C-7
#
), 55.5 (C-8
#
). IR (νm.cm
-1
) = 3009, 2947, 2824, 
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1589, 1464, 1439, 1414, 1313, 1288, 1263, 1138, 1113, 1063, 1038, 1012, 937, 912, 837, 812, 
786, 762, 687, 636. 
 
Veratrole (10.00 g, 72.38 mmol, 1 eq) was added to a 
NBS (12.90 g, 72.38 mmol, 1 eq)/DCM slurry. Following 
purification by column chromatography resulted in a 
dark oil that was determined to be 316 (13.65 g, 87 %) 
by NMR spectroscopy. Rf = 0.69 (20 % EtOAc/Hex) 
1
H 
NMR (300 MHz, CDCl3) δH = 6.99 (1H, dd, J = 8.5 and 
2.3Hz, H-6), 6.94 (1H, d, J = 2.3Hz, H-2), 6.68 (1H, d, J = 
8.5 Hz, H-5), 3.81 (3H, s, H-7*), 3.80 (3H, s, H-8*). 
13
C NMR (75 MHz, CDCl3) δC = 149.7 (C-3*), 
148.3 (C-4*), 123.3 (C-6), 120.8 (C-5), 114.8 (C-1), 112.5 (C-2), 56.0 (C-7
#
), 55.9 (C-8
#
). IR (νm.cm
-1
) 
= 3040, 2980, 2920, 2860, 1605, 1577, 1498, 1466, 1435, 1404, 1323, 1242, 1215, 1161, 1134, 
1026, 864, 810, 756, 729, 621. ESI-MS (m/z) calculated [M+H]
+
 for C8H10O2Br 216.9864, found 
216.9860. 
 
The reaction between 1,3,5-trimethoxybenzene (10.00 
g, 59.46 mmol, 1 eq) and NBS (10.60 g, 59.46 mmol, 1 
eq) resulted in the brominated compound 318 (11.71 g, 
80 %) as white crystals. Rf = 0.50 (20 % EtOAc/Hexane). 
m.p. = 90-92 °C, lit 93-95 °C. 
1
H NMR (300 MHz, CDCl3) 
δH = 6.17 (2H, s, H-3 and H-5), 3.87 (6H, s, H-7 and H-9), 
3.81 (3H, s, H-8). 
13
C NMR (75 MHz, CDCl3) δC = 160.5 (C-
4), 157.5 (C-2 and C-6), 92.1 (C-1), 91.7 (C-3 and C-5), 56.4 (C-7 and C-9), 55.5 (C-8). IR (νm.cm
-1
) = 
2970, 2933, 2824, 1578, 1468, 1431, 1395, 1321, 1219, 1190, 1161, 1132, 1074, 1016, 959, 930, 
814, 785, 669, 640. ESI-MS (m/z) calculated [M+H]
+
 for C9H12O3Br 246.9970, found 246.9972. 
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7.3.4. Grignard Reaction for the synthesis of 310 
 
 
 
 
309 
 
 
 
In a 2-neck round bottomed flask, dry magnesium 
(0.183g, 7.54 mmol, 1.6 eq) was weighed out and a 
stirrer bar added, followed by a rubber septum and 
condenser. The entire chamber was then 
evacuated, further dried under evacuation and the 
chamber filled with nitrogen. This process was 
repeated a further 3 times. Once filled with 
nitrogen for the final time, THF (5 ml) was injected 
followed by the 2-bromoanisole (1.32 g, 7.07 mmol, 1.5 eq). Heat was applied as necessary to 
initiate the Grignard reagent formation and then the reaction left to stir until all the magnesium 
was consumed (approximately 30 min) under a nitrogen atmosphere. To the brown solution, a 
further 5 ml of THF was added and cooled to 0 °C. The protected salicylaldehyde 309 (1.00 g, 4.71 
mmol) was dissolved in THF (5 ml) and injected dropwise into the cooled Grignard solution. An 
immediate colour change is observed and a bright yellow colour developed while the reaction 
was left to stir at 0 °C for 2 hours. 1M HCl (10 ml) was added to the reaction with vigorous stirring 
for 10 min, the suspension transferred to a separation funnel and the aqueous layer removed. 
The organic layer was further washed with brine before being dried with anhydrous MgSO4 and 
concentrated in vacuo. The product was then purified by column chromatography with using 10-
20 % EtOAc/Hexane as the eluent and 310 was collected as a yellow oil (1.48 g, 99 %). Rf = 0.31 
(10 % EtOAc/Hexane). 
1
H NMR (300 MHz, CDCl3): δH = 7.38 – 7.20 (7H, m, H-3, H-6, H-10, H-11, H-
12, H-13 and H-14), 7.18 (1H, dd, J = 7.5 and 1.7 Hz, H-20), 7.00 – 6.90 (2H, m, H-4 and H-5), 6.87 
(2H, d, J = 7.7 Hz, H-18 and H-19), 6.43 (1H, d, J = 5.5 Hz, H-1), 5.05 (2H, d, J = 3.8 Hz, H-8), 3.77 
(3H, s, H-21), 3.35 (d, J = 5.4 Hz, 1H). 
13
C NMR (75 MHz, CDCl3): δC = 156.91 (C-7), 155.82 (C-16), 
136.91 (C-9), 131.57 (C-2), 131.21 (C-15), 128.47 (C-11 and C-13), 128.30 (C-20), 127.94 (C-5), 
127.85 (C-18), 127.79 (C-12), 127.33 (C-10 and C-14), 120.83 (C-4), 120.56 (C-19), 111.72 (C-6*), 
110.50 (C-17*), 70.07 (C-8), 67.25 (C-1), 55.38 (C-21). IR (νm.cm
-1
) = 3560, 3442, 3030, 2940, 
2839, 1601, 1488, 1449, 1381, 1287, 1238, 1105, 1015, 870, 745, 695, 651. ESI-MS (m/z) 
calculated [M+H]
+
 for C21H20O3Na 343.1310, found 343.1302.  
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7.3.5. Method for Pyridinium Chlorochromate (PCC) oxidation 
 
 
 
 
 
 
In a round bottomed flask, alcohol 310 (1.00 g, 4.71 mmol, 1 eq) was dissolved in 20 ml DCM. To 
this solution 1.00 g of flash chromatography silica was added followed by PCC (1.49 g, 6.92 mmol, 
1.5 eq) in portions. This reaction mixture was stirred under nitrogen for 2 hours, a thick brown by 
product results as the reaction progresses. Once the reaction is completed (as determined by 
TLC) the reaction was filtered through a glass fritted funnel lined with Celite and flash silica and 
this plug washed with EtOAc. The filtrate was concentrated in vacuo and the resulting product 
311 collected as a viscous yellow oil (1.131 g, 77 %) used with no further purification. 
 Rf = 0.22 (10 % EtOAc/Hexane). 
1
H NMR (300 
MHz, CDCl3): δH = 7.60 (1H, dd, J = 7.6, 1.8 Hz, H-
7), 7.52 (1H, dd, J = 7.6, 1.8 Hz, H-20), 7.40 (2H, 
m, H-5 and H-18), 7.22 – 7.17 (3H, m, H-11, H-12 
and H-13), 7.07 – 7.00 (1H, m, H-6), 7.00 – 6.90 
(4H, m, H-4, H-10, H-14 and H-19), 6.82 (1H, dd, J 
= 8.4 and 0.9 Hz, H-17), 4.93 (2H, s, H-8), 3.59 
(3H, d, J = 0.6 Hz, H-21). 
13
C NMR (75 MHz, 
CDCl3): δC = 195.5 (C-1), 158.3 (C-3
#
), 157.2 (C-
16
#
), 136.4 (C-9), 132.6 (C-18*), 132.5 (C-5*), 130.9 (C-2
~
), 130.6 (C-15
~
), 130.4 (C-7), 130.3 (C-20), 
128.2 (C-11 and C-13), 127.4 (C-12), 126.7 (C-10 and C-14), 120.8 (C-6), 120.3 (C-4’), 112.4 (C-19’), 
111.6 (C-17), 70.1 (C-8), 55.6 (C-21). IR (νm.cm
-1
) = 3027, 2944, 2837, 1642, 1596, 1484, 1446, 
1382, 1308, 1248, 1161, 1103, 1022, 924, 853, 750, 695, 638. ESI-MS (m/z) calculated [M+H]
+
 for 
C21H19O3 319.1334, found 319.1340. 
* Care should be taken when disposing of the silica plug as PCC contains toxic chromium.  
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7.3.6. General procedure for the lithiation reactions to form 
benzophenones 
 
 
 
 
251 or 301 
 
 
 
After drying a 2-necked flask and stirrer bar in an oven overnight, a rubber septum was fitted to 
one neck of the flask and a nitrogen line attached to the other. The flask was evacuated, heated 
and filled with nitrogen several times before the addition of the relevant substituted 
bromobenzene (1.1 eq) and dry THF. Once the substituted bromobenzene had completely 
dissolved, the solution was cooled to -78 °C and n-BuLi (1.1 eq) added dropwise with high stirring. 
This solution was left to stir for 30 min at -78 °C. During this time, the protected salicylic acid (251 
or 301) (1 eq) was added to another dry 2-necked flask also fitted with a stirrer bar, rubber 
septum and nitrogen line. This flask was then evacuated and filled with nitrogen repeatedly 
before the addition of dry THF injected through the rubber septum. Once the ester had 
completely dissolved, it was cooled to -78 °C with high stirring. The lithiated solution was added 
to the ester solution dropwise over several minutes. The mixture was left to react at -78 °C for 1-
2 hours under nitrogen, saturated NH4Cl added to quench the solution and warmed to room 
temperature. The suspension was extracted with water and brine and washed with EtOAc, dried 
over anhydrous Na2SO4 and concentrated in vacuo. The resulting products were purified by flash 
column chromatography with 10-20 % EtOAc/Hexane as the eluent and characterised by NMR 
spectroscopy. 
 
Following the general procedure, brominated 
dimethoxynaphthalene 250 (1.964 g, 7.353 mmol, 1.1 
eq), n-BuLi (5.74 ml, 7.353 mmol, 1.28 M, 1.1 eq) and 
ester 251 (2.128 g, 6.685 mmol, 1 eq) were reacted. 
Following purification by flash column chromatography, 
the product 252 (1.541 g, 58 %) was collected as a green 
oil. Rf = 0.56 (20 % EtOAc/Hexane). 
1
H NMR (300 MHz, 
CDCl3) δH = 8.28 – 8.21 (1H, m, H-18), 8.11 – 8.03 (1H, 
m, H-21), 7.72 – 7.65 (1H, m, H-3), 7.59 – 7.51 (2H, m, 
H-19 and H-20), 7.50 – 7.41 (1H, m, H-5), 7.13 – 7.04 (2H, m, H-4 and H-6), 7.03 – 6.97 (1H, m, H-
12), 6.96 – 6.86 (3H, m, H-10, H-14 and H-24), 6.79 – 6.72 (2H, m, H-11 and H-13), 4.90 (2H, s, H-
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8), 3.92 (3H, s, H-25*), 3.59 (3H, s, H-26*). 
13
C NMR (75 MHz, CDCl3) δC = 196.2 (C-1), 157.5 (C-7*), 
151.7 (C-16*), 150.3 (C-23*), 135.9 (C-9), 132.9 (C-5), 130.2 (C-3), 128.8 (C-17), 128.4 (C-2), 127.9 
(C-10  and C-24), 127.5 (C-4
#
), 127.2 (C-22), 126.8 (C-11, C-13, C-19 and C-20), 123.1 (C-21), 122.4 
(C-18), 120.7 (C-6
#
), 112.4 (C-12), 103.1 (C-24), 96.8 (C-15), 70.3 (C-8), 63.6 (C-26’), 55.8 (C-25’).  
 
2-Bromo-1,4-dimethoxybenzene 289 (2.50 g, 11.5 
mmol, 1 eq), n-BuLi (8.2 ml, 11.5 mmol, 1.4 M, 1 eq) and 
ester 251 (3.66 g, 11.5 mmol, 1 eq) were reacted 
following the general procedure. The product, 296, was 
collected as a yellow oil (2.83 g, 71 %) after purification 
by flash column chromatography. Rf = 0.17 (10 % 
EtOAc/Hexane). 
1
H NMR (300 MHz, CDCl3) δH = 7.58 
(1H, dd, J = 7.6 and 1.8 Hz, H-7), 7.41 (1H, ddd, J = 8.3, 
7.4 and 1.8 Hz, H-5), 7.35 – 7.31 (1H, m, H-12), 7.23 – 
7.17 (2H, m, H-10 and H-14), 7.08 (1H, d, J = 3.2 Hz, H-20), 7.02 (1H, td, J = 7.5 and 1.0 Hz, H-6), 
6.98 – 6.89 (4H, m, H-4, H-18, H-11 and H-13), 6.74 (1H, d, J = 9.0 Hz, H-17), 4.92 (2H, s, H-8), 3.73 
(3H, s, H-21*), 3.50 (3H, s, H-22*). 
13
C NMR (75 MHz, CDCl3) δC = 195.3 (C-1), 157.2 (C-3*), 153.5 
(C-16*), 152.7 (C-19*), 136.4 (C-5), 132.6 (C-7), 131.2 (C-9), 130.8 (C-15
#
), 130.3 (C-2
#
), 128.2 (C-
10 and C-14), 127.5 (C-12), 126.9 (C-6), 126.7 (C-11 and C-13), 120.7 (C-4), 118.5 (C-18), 114.5 (C-
17), 112.3 (C-20), 70.1 (C-8), 56.4 (C-21’), 55.8 (C-22’). 
 
Following the general procedure, 1-bromo-2,4,5-
trimethoxybenzene 246 (0.500 g, 2.023 mmol, 1.1 eq) 
and n-BuLi (1.84 ml, 2.208 mmol, 1.2 M, 1.2 eq) were 
reacted, with a yellow colour observed on the 
formation of the lithiated species. This was further 
reacted with ester 251 (0.586 g, 1.840 mmol, 1 eq) and 
the resulting product 299 collected as a yellow liquid 
(0.404 g, 58 %) after purification by flash column 
chromatography. Rf = 0.20 (20 % EtOAc/Hexane). 
1
H 
NMR (500 MHz, CDCl3): δH =  7.50 (1H, dd, J = 7.5 and 1.8 Hz, H-3), 7.39 (1H, ddd, J =  8.3, 7.4 and 
1.8 Hz, H-5), 7.26 (1H, s, H-20), 7.21 (3H, dt, J = 4.4 and 1.6 Hz, H-10, and H-12 H-14), 7.03 (1H, td, 
J = 7.5 and 1.0 Hz, H-4), 7.01 – 6.98 (2H, m, H-11 and H-13), 6.95 (1H, dd, J = 8.3 and 0.9 Hz, H-6), 
6.34 (1H, s, H-17), 4.98 (2H, s, H-8), 3.87 (3H, s, H-21), 3.86 (3H, s, H-22), 3.50 (3H, s, H-23). 
13
C 
NMR (75 MHz, CDCl3): δC = 194.0 (C-1), 156.5 (C-7
#
), 155.1 (C-16
#
), 153.4 (C-19
#
), 143.2 (C-18), 
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303 
 
136.6 (C-9), 132.4 (C-2), 131.6 (C-5), 129.6 (C-3), 128.1 (C-10 and C-14), 127.5 (C-12), 126.5 (C-11 
and C-13), 121.6 (C-15), 120.8 (C-4), 113.3 (C-20), 112.1 (C-6), 97.3 (C-17), 70.1 (C-8), 56.7 (C-
21*), 56.5 (C-22*), 56.0 (C-23*). 
 
Brominated 250 (2.94 g, 10.99 mmol, 1.1 eq) was 
lithiated using n-BuLi (8.6 ml, 1.28 M, 10.99 mmol, 1.1 
eq) and combined with ester 301 (3.53 g, 9.99 mmol) 
following the general procedure. The product was 
collected as a cream solid (1.54 g, 32 %). Rf = 0.53 (20 % 
EtOAc/Hexane). m.p. = 165-167 °C, lit 160-162 °C.
191
 
1
H 
NMR (300 MHz, CDCl3): δH = 8.29 – 8.21 (1H, m, H-18), 
8.11 – 8.03 (1H, m, H-21), 7.69 (1H, dd, J = 7.5 and 1.8 
Hz, H-5), 7.58 – 7.50 (2H, m, H-19 and H-20), 7.50 – 7.45 
(1H, m, H-3), 7.09 (1H, dt, J = 8.0 and 1.4 Hz, H-12), 7.07 – 6.97 (1H, m, H-6), 6.95 – 6.87 (3H, m, 
H-10, H-14 and H-24), 6.78 – 6.72 (2H, m, H-11 and H-13), 4.90 (2H, s, H-8), 3.92 (3H, s, H-25*), 
3.59 (3H, s, H-26*).
13
C NMR (75 MHz, CDCl3): δC =196.2 (C-1), 157.5 (C-7*), 151.7 (C-16*), 150.3 
(C-23*), 135.9 (C-9), 132.9 (C-3), 130.2 (C-5), 129.0 (C-4’), 128.4 (C-17’), 127.9 (C-10 and C-14), 
127.5 (C-2
~
), 127.2 (C-22
~
), 126.8 (C-11, C-13, C-19 and C-20), 123.1 (C-21), 122.4 (C-18), 120.7 (C-
6), 112.4 (C-12), 103.0 (C-24), 100.0 (C-15) 70.3 (C-8), 63.6 (C-26
#
), 55.8 (C-25
#
).  
 
Following the general procedure, ester 301 (1.343 g, 
3.807 mmol), brominated 289 (0.909 g, 4.188 mmol, 1.1 
eq) and n-BuLi (3.35 ml, 4.188 mmol, 1.25 M, 1.1 eq) 
were combined at -78 °C. The product 303 was 
collected as a yellow solid after purification by column 
chromatography (1.103 g, 76 %). Rf = 0.37 (20 % 
EtOAc/Hexane). m.p. = 76-78 °C, lit 70-72 °C.
191
 
1
H NMR 
(300 MHz, CDCl3): δH =  7.52 (1H, d, J = 2.7 Hz, H-3), 7.39 
– 7.32 (1H, m, H-5), 7.21 (3H, dd, J = 5.0 and 1.9 Hz, H-
11, H-12 and H-13), 7.11 (1H, d, J = 3.2 Hz, H-20), 6.94 (3H, m, H-10, H-14 and H-18), 6.88 (1H, d, J 
= 8.8 Hz, H-6), 6.76 (1H, d, J = 9.0 Hz, H-17), 4.91 (2H, s, H-8), 3.76 (3H, s, H-21*), 3.52 (3H, s, H-
22*).
13
C NMR (75 MHz, CDCl3): δC = 193.8 (C-1), 155.6 (C-7
#
), 153.6 (C-16
#
), 152.9 (C-19
#
), 136.0 
(C-9), 132.4 (C-4), 131.8 (C-5), 130.2 (C-15), 129.7 (C-3), 128.3 (C-11 and C-13), 127.7 (C-12), 126.7 
(C-10 and C-14), 125.9 (C-2), 119.2 (C-18), 114.4 (C-20), 113.7 (C-6), 113.4 (C-17), 70.5 (C-8), 56.3 
(C-21*), 55.9 (C-22*).  
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Combining brominated 246 (5.00 g, 20.23 mmol, 1.1 
eq), n-BuLi (15.8 ml, 1.28 M, 20.23 mmol, 1.1 eq) and 
ester 301 (5.99 g, 18.39 mmol, 1 eq) according to the 
general procedure resulted in the formation of a yellow 
oil that was determined to be 304 (5.08g, 61 %). Rf = 
0.21 (10 % EtOAc/Hexane). 
1
H NMR (500 MHz, CDCl3): 
δH = 7.42 (1H, d, J = 2.7 Hz, H-7), 7.30 (1H, dd, J = 8.7 
and 2.7 Hz, H-5), 7.26 (1H, s, H-20), 7.22 – 7.18 (3H, m, 
H-11, H-12 and H-13), 6.99 – 6.94 (2H, m, H-10 and H-
14), 6.86 (1H, d, J = 8.8 Hz, H-4), 6.32 (1H, s, H-17), 4.92 (2H, s, H-8), 3.86 (3H, s, H-21*), 3.84 (3H, 
s, H-22*), 3.48 (3H, s, H-23). 
13
C NMR (125 MHz, CDCl3): δC = 192.3 (C-1), 155.4 (C-7), 154.9 (C-
16
#
), 154.0 (C-19
#
), 143.3 (C-18
#
), 136.1 (C-9), 133.9 (C-4), 130.9 (C-5), 128.9 (C-3), 128.2 (C-11 
and C-13), 127.6 (C-12), 126.5 (C-10 and C-14), 125.8 (C-2), 120.5 (C-15), 113.5 (C-6), 113.1 (C-20), 
96.9 (C-17), 70.4 (C-8), 56.4 (C-21*), 56.3 (C-22*), 56.0 (C-23*).  
 
Combining brominated 314 (3.77 g, 17.30 mmol, 1.1 
eq), n-BuLi (13.5 ml, 17.30 mmol, 1.28 M, 1.1 eq) and 
ester 251 (5.00 g, 15.73 mmol, 1 eq) according to the 
general procedure resulted in the formation of a yellow 
oil that was determined to be 319 (5.03 g, 92 %). Rf = 
0.44 (20 % EtOAc/Hexane). 
1
H NMR (300 MHz, CDCl3): 
δH = 7.58 (1H, dd, J = 8.7 and 1.3 Hz, H-17), 7.50 (1H, dd, 
J = 7.5 and 1.8 Hz, H-3), 7.42 – 7.34 (1H, m, H-5), 7.24 – 
7.17 (3H, m, H-10, H-12 and H-14), 7.06 – 6.96 (3H, m, 
H-4, H-11 and H-13), 6.94 (1H, dd, J = 8.4 and 1.0 Hz, H-6), 6.48 (1H, dd, J = 8.6 and 2.3, H-19), 
6.33 (1H, d, J = 2.2 Hz, H-20), 4.95 (2H, s, H-8), 3.81 (3H, s, H-21*), 3.57 (3H, s, H-22*). 
13
C NMR 
(75 MHz, CDCl3): δC = 194.1 (C-1), 164.1 (C-7*), 160.7 (C-16*), 156.6 (C-18*), 136.6 (C-9), 133.0 (C-
17), 132.0 (C-2’), 131.7 (C-5), 129.8 (C-3), 128.1 (C-10 and C-14), 127.4 (C-12), 126.6 (C-11 and C-
13), 123.2 (C-15’), 120.8 (C-4), 112.3 (C-6), 104.7 (C-19), 98.6 (C-20), 70.1 (C-8), 55.6 (C-21
#
), 55.4 
(C-22
#
). IR (νm.cm
-1
) = 3013, 2947, 2843, 1624, 1601, 1504, 1483, 1433, 1333, 1306, 1285, 1242, 
1209, 1150, 1144, 1030, 945, 826, 758. ESI-MS (m/z) calculated [M+H]
+
 for C22H21O4 349.1140, 
found 349.1438. 
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Combining brominated 316 (3.78 g, 17.30 mmol, 1.1 
eq), n-BuLi (13.5 ml, 17.30 ml, 1.1 eq) and ester 251 
(5.00 g, 15.73 mmol, 1 eq) according to the general 
procedure resulted in the formation of a yellow oil that 
was determined to be 320 (2.41 g, 44 %). Rf = 0.36 (20 % 
EtOAc/Hexane). 
1
H NMR (300 MHz, CDCl3): δH = 7.58 
(1H, d, J = 8.6 Hz, H-19), 7.50 (1H, dd, J = 7.5 and 1.8 Hz, 
H-4*), 7.43 – 7.32 (1H, m, H-7*), 7.23 – 7.16 (3H, m, H-
10, H-12 and H-14), 7.05 – 6.93 (4H, m, H-5*, H-6*, H-11 
and H-13), 6.48 (1H, dd, J = 8.6 and 2.3 Hz, H-20), 6.33 (1H, d, J = 2.3 Hz, H-16), 4.95 (2H, s, H-8), 
3.81 (3H, s, H-21’), 3.57 (3H, s, H-22’). 
13
C NMR (125 MHz, CDCl3): δC = 194.1 (C-1), 164.0 (C-3
#
), 
160.7 (C-18
#
), 156.6 (C-17
#
), 136.6 (C-9), 133.0 (C-19), 132.0 (C-15
~
), 131.7 (C-7*), 129.8 (C-4*), 
128.1 (C-10 and C-14), 127.4 (C-12), 126.6 (C-11 and C-13), 123.2 (C-2
~
), 120.8 (C-5*), 112.3 (C-
6*), 104.7 (C-20), 98.5 (C-16), 70.1 (C-8), 55.6 (C-21’), 55.4 (C-22’). IR (νm.cm
-1
) = 3024, 2943, 
2862, 2376, 1647, 1593, 1521, 1485, 1458, 1431, 1296, 1269, 1107, 1053, 1026, 918, 729, 702. 
ESI-MS (m/z) calculated [M+H]
+
 for C22H21O4 349.1140, found 349.1441. 
 
Combining brominated 318 (4.27 g, 17.28 mmol, 1.1 
eq), n-BuLi (13.5 ml, 17.28 mmol, 1.28 M, 1.1 eq) and 
ester 251 (5.00 g, 15.71 mmol, 1 eq) according to the 
general procedure resulted in the formation of a yellow 
oil that was determined to be 321 (2.65 g, 45 %). Rf = 
0.18 (20 % EtOAc/Hexane). 
1
H NMR (300 MHz, CDCl3): 
δH = 7.72 (1H, dd, J = 7.7 and 1.9 Hz, H-7), 7.35 (1H, ddd, 
J = 8.3, 7.3 and 1.9 Hz, H-5), 7.24 (3H, dd, J = 5.0 and 1.9 
Hz, H-10, H-12 and H-14), 7.12 (2H, dd, J = 6.7 and 2.9 
Hz, H-11 and H-13), 7.00 – 6.88 (2H, m, H-4 and H-6), 5.96 (2H, s, H-17 and H-19), 4.89 (2H, s, H-
8), 3.72 (3H, s, H-22), 3.52 (6H, s, H-21 and H-23). 
13
C NMR (75 MHz, CDCl3): δC = 193.3 (C-1), 
162.1 (C-3), 158.8 (C-16 and C-20), 157.9 (C-18), 136.5 (C-9), 133.1 (C-5), 131.3 (C-7), 130.3 (C-2), 
128.1 (C-10 and C-14), 127.5 (C-12), 127.3 (C-11 and C-13), 120.5 (C-4*), 114.8 (C-15), 113.0 (C-
6*), 90.8 (C-17 and C-19), 70.3 (C-8), 55.8 (C-21 and C-23), 55.2 (C-22). IR (νm.cm
-1
) = 3001, 2978, 
2931, 2862, 2839, 1659, 1485, 1458, 1431, 1377, 1296, 1242, 1161, 1107, 1026, 999, 918, 891, 
849, 802, 779, 756, 733, 687, 640, 617. ESI-MS (m/z) calculated [M+H]
+
 for C23H23O5 379.1545, 
found 379.1546. 
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A directed ortho-metalation was performed using 1,3-
dimethoxybenzene 313 (2.39 g, 17.30 mmol, 1.1 eq) 
and n-BuLi (13.5 ml, 1.28 M, 17.30 mmol, 1.1 eq) at -78 
°C in dry THF. This solution was added to ester 251 (5.00 
g, 15.73 mmol, 1 eq) also at -78 °C and the reaction 
mixture stirred for 2 hours. The reaction was quenched 
and purified as outlined in the general procedure and 
322 was collected as a peach solid (4.41 g, 81 %). Rf = 
0.26 (20 % EtOAc/Hexane). m.p. = 85-87 °C. 
1
H NMR 
(300 MHz, CDCl3): δH = 7.77 (1H, dd, J = 7.7 and 1.8 Hz, 
H-7), 7.37 (1H, ddd, J = 8.4, 7.3 and 1.9 Hz, H-5), 7.30 (2H, d, J = 4.6 Hz, H-10 and H-14), 7.24 (2H, 
dd, J = 5.2 and 1.8 Hz, H-11 and H-13), 7.15 (1H, d, J = 8.5 Hz, H-18), 7.13 – 7.09 (1H, m, H-12), 
6.96 (1H, dd, J = 7.6 and 1.0 Hz, H-4*), 6.94 – 6.87 (1H, m, H-6*), 6.42 (2H, d, J = 8.4 Hz, H-17 and 
H-19), 4.90 (2H, s, H-8), 3.55 (6H, s, H-21 and H-22). 
13
C NMR (75 MHz, CDCl3): δC = 194.1 (C-1), 
158.3 (C-3), 157.3 (C-16 and C-20), 136.4 (C-9), 133.6 (C-5), 131.7 (C-7), 130.1 (C-18), 128.2 (C-10 
and C-14), 127.4 (C-2), 127.2 (C-11 and C-13), 126.9 (C-12), 120.5 (C-18), 113.2 (C-15), 104.2 (C-17 
and C-19), 70.3 (C-8), 55.8 (C-21 and C-22). IR (νm.cm
-1
) = 2943, 2889, 2835, 2376, 1674, 1593, 
1485, 1458, 1431, 1296, 1269, 1242, 1161, 1107, 1026, 999, 945, 918, 864, 783, 756, 729, 702, 
621. ESI-MS (m/z) calculated [M+H]
+
 for C22H21O4 349.1140, found 349.1440. 
 
A directed ortho-metalation reaction was performed in 
order to synthesize 323. Veratrole 315 (2.39 g, 17.30 
mmol, 1.1 eq) was lithiated using n-BuLi (13.5 ml, 
1.28M, 17.30 mmol, 1.1 eq) at -78 °C in dry THF. This 
solution was added to ester 251 (5.00 g, 15.73 mmol, 1 
eq) and the general procedure followed. After 
purification by flash column chromatography, 323 was 
collected as a liquid (2.35 g, 43 %). Rf = 0.38 (20 % 
EtOAc/Hexane). 
1
H NMR (500 MHz, CDCl3): δH = 7.62 
(1H, dd, J = 7.6 and 1.8, H-7), 7.43 (1H, ddd, J = 8.3, 7.4 and 1.8 Hz, H-5), 7.19 (3H, dd, J = 5.1 and 
2.0 Hz, H-10, H-12 and H-14), 7.07 (1H, dd, J = 7.7 and 1.7 Hz, H-19), 7.03 (2H, t, J = 7.8 Hz, H-6 
and H-20), 6.96 (4H, ddd, J = 7.9, 5.2 and 1.2 Hz, H-4, H-11, H-13 and H-18), 4.93 (2H, s, H-8), 3.80 
(3H, s, H-21*), 3.52 (3H, s, H-22*). 
13
C NMR (125 MHz, CDCl3): δC = 195.7 (C-1), 157.4 (C-3), 152.7 
(C-16*), 148.0 (C-17*), 136.3 (C-9
~
), 135.8 (C-2
~
), 132.9 (C-5), 130.5 (C-7), 130.3 (C-15
~
), 128.2 (C-
10 and C-14), 127.5, 126.8 (C-11 and H-13), 123.6 (C-6’), 121.1 (C-19), 120.7 (C-20’), 115.1 (C-4
#
), 
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112.5 (C-18
#
), 70.1 (C-8), 61.3 (C-21’), 56.0 (C-22’). IR (νm.cm
-1
) = 2943, 2889, 2835, 1647, 1593, 
1566, 1485, 1458, 1431, 1377, 1296, 1269, 1242, 1161, 1107, 1080, 1053, 1026, 999, 972, 837, 
756, 702, 621. ESI-MS (m/z) calculated [M+H]
+
 for C22H21O4 349.1140, found 349.1442. 
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7.3.7. General procedure for the debenzylation of organic compounds 
using palladium on carbon 
 
 
 
 
 
 
 
10 % Palladium on activated carbon (10 mass %) was added to the desired benzylated ketone and 
dissolved in MeOH (30 ml). The resulting suspension was then exposed to a H2 atmosphere at 
ambient pressure, stirring at room temperature for 12 hours and then filtered through a 
Celite/flash silica plug, washed with EtOAc and concentrated in vacuo. If all the palladium was 
successfully removed the product was used with no further purification, if not the product was 
cleaned using column chromatography. 
 
Following the general procedure for debenzylation, 
ketone 311 (1.131 g, 3.716 mmol) and 10 % Pd/C (0.113 
g, 10 mass %) in 30 ml of MeOH resulted in the 
formation of 312 (0.717 g, 85 %) as a yellow solid after 
filtration and concentration was used with no further 
purification. Rf = 0.42 (10 % EtOAc/Hexane). m.p. = 74-
75 °C. 
1
H NMR (300 MHz, CDCl3): δH = 12.19 (1H, s, H-
15), 7.51 – 7.41 (2H, m, H-7 and H-13), 7.33 (1H, dd, J = 8.0 and 1.8 Hz, H-11), 7.28 (1H, dd, J = 7.5 
and 1.8 Hz, H-5), 7.08 – 6.98 (3H, m, H-6, H-10 and H-12), 6.79 (1H, ddd, J = 8.1, 7.2 and 1.2 Hz, H-
4), 3.76 (3H, s, H-14). 
13
C NMR (75 MHz, CDCl3): δC = 202.10 (C-1), 162.90 (C-3), 156.55 (C-9), 
136.44 (C-5), 133.75 (C-11), 131.85 (C-7), 128.79 (C-13), 127.83 (C-8), 120.52 (C-6), 120.22 (C-2), 
118.68 (C-12), 118.03 (C-4), 111.48 (C-10), 55.64 (C-14). IR (νm.cm
-1
) = 3026, 2968, 2939, 2835, 
1601, 1483, 1463, 1447, 1333, 1306, 1279, 1244, 1146, 1117, 1101, 1020, 932, 824, 793, 748, 
698, 640. ESI-MS (m/z) calculated [M+H]
+
 for C14H13O3 229.0865, found 229.0866. 
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Protected ketone 134 (0.610 g, 1.53 mmol) and 5 % 
Pd/C (0.031 g, 10 mass %) were reacted according to 
the general procedure under a hydrogen atmosphere. 
After purification by column chromatography in 10 % 
EtOAc/Hexane, 253 was collected as yellow crystals 
(0.349 g, 74 %). Rf = 0.22 (10 % EtOAc/Hexane). m.p. = 
117-119 °C, lit 116-118 °C.
191
 
1
H NMR (500 MHz, CDCl3): 
δH = 12.22 (1H, s, H-20), 8.35 – 8.27 (1H, m, H-11), 8.20 
– 8.12 (1H, m, H-14), 7.60 (2H, td, J = 6.5, 5.9 and 3.4 Hz, H-12 and H-13), 7.53 – 7.43 (2H, m, H-5 
and H-7), 7.06 (1H, dd, J = 8.3 and 1.1 Hz, H-4), 6.81 (1H, ddd, J = 8.3, 7.1 and 1.2 Hz, H-6), 6.68 
(1H, s, H-17), 3.97 (3H, s, H-18*), 3.82 (3H, s, H-19*). 
13
C NMR (125 MHz, CDCl3): δC = 202.4 (C-1), 
163.0 (C-3), 151.8 (C-9
~
), 147.5 (C-16
~
), 136.8 (C-5*), 134.1 (C-7*), 128.4 (C-2), 127.7 (C-10), 127.3 
(C-12
#
), 127.1 (C-13
#
), 126.3 (C-15), 122.7 (C-14), 122.6 (C-11), 119.9 (C-8), 119.0 (C-17), 118.1 (C-
6), 102.3 (C-17), 63.7 (C-18’), 55.8 (C-19’). 
 
Benzophenone 296 (2.00 g, 5.74 mmol) and 5 % Pd/C 
(0.100 g, 10 mass %) were reacted according to the 
general procedure and collected as a white solid (258) 
after purification (1.12 g, 76 %). Rf = 0.33 (10 % 
EtOAc/Hexane). m.p. = 86-87 °C, lit 96-98 °C.
191
 
1
H NMR 
(300 MHz, CDCl3): δH = 12.12 (1H, s, H-16), 7.47 (1H, 
ddd, J = 8.6, 7.1 and 1.7 Hz, H-5), 7.36 (1H, dd, J = 8.0, 
1.7, H-3), 7.06 – 6.99 (2H, m, H-6 and H-11), 6.94 (1H, d, 
J = 9.0 Hz, H-10), 6.85 (1H, d, J = 3.0 Hz, H-13), 6.81 (1H, ddd, J = 8.2, 7.2 and 1.2, H-4), 3.79 (3H, s, 
H-14*), 3.72 (3H, s, H-15*). 
13
C NMR (75 MHz, CDCl3): δC = 201.7 (C-1), 162.9 (C-7), 153.5 (C-9’), 
150.6 (C-12’), 136.5 (C-5), 133.8 (C-3), 128.4 (C-2), 120.1 (C-8), 118.7 (C-4), 118.1 (C-6*), 117.1 (C-
11*), 114.0 (C-13), 113.0 (C-10), 56.4 (C-14
#
), 55.9 (C-15
#
).  
 
Following the general procedure, 299 (0.404 g, 1.067 
mmol) and 5 % Pd/C (0.080 g, 20 mass %) was dissolved 
in methanol under a hydrogen atmosphere. The 
product 261 was collected as a yellow oil that solidified 
on standing (3.04 g, 99 %). Rf = 0.23 (20 % 
EtOAc/Hexane). m.p. = 105-107 °C, lit 107-110 °C.
191
 
1
H 
NMR (500 MHz, CDCl3): δH = 12.16 (1H, s, H-16), 7.46 
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(1H, ddd, J = 8.6, 7.2 and 1.7 Hz, H-5), 7.42 (1H, dd, J = 8.0 and 1.7 Hz, H-7), 7.03 (1H, dd, J = 8.4 
and 1.2 Hz, H-4), 6.89 (1H, s, H-13), 6.82 (1H, ddd, J = 8.1, 7.1 and 1.1 Hz, H-6), 6.59 (1H, s, H-10), 
3.97 (3H, s, H-13*), 3.85 (3H, s, H-14*), 3.75 (3H, s, H-15*). 
13
C NMR (125 MHz, CDCl3): δC = 201.0 
(C-1), 162.8 (C-3*), 152.2 (C-9*), 152.0 (C-11*), 143.1 (C-12*), 136.2 (C-5), 133.8 (C-7), 120.4 (C-
2’), 119.0 (C-8’), 118.5 (C-6), 118.0 (C-4), 112.7 (C-13), 97.4 (C-10), 56.6 (C-13
#
), 56.6 (C-14
#
), 56.2 
(C-15
#
). 
 
The general procedure was followed by combining 302 
(1.54 g, 3.548 mmol) and 5 % Pd/C (0.152 g, 10 mass %) 
in 20 ml EtOAc for 1 hour under a hydrogen 
atmosphere. The product 263 was purified as outlined 
in the general procedure (0.511 g, 42 %) and collected 
as a yellow solid. Rf = 0.71 (20 % EtOAc/Hexane). m.p. = 
165-167 °C, lit 109-111 °C.
191
 
1
H NMR (500 MHz, CDCl3): 
δH = 12.12 (1H, s, H-20), 8.37 – 8.27 (1H, m, H-11), 8.21 
– 8.12 (1H, m, H-14), 7.69 – 7.58 (2H, m, H-12 and H-13), 7.49 – 7.40 (2H, m, H-7 and H-5), 7.03 
(1H, dd, J = 8.5 and 0.8 Hz, H-4), 6.65 (1H, s, H-17), 4.00 (3H, s, H-18*), 3.83 (3H, s, H-19*). 
13
C 
NMR (126 MHz, CDCl3): δC = 201.6 (C-1), 161.5 (C-3), 158.6 (C-9
~
), 152.0 (C-16
~
), 136.7 (C-5*), 
132.9 (C-7*), 128.5 (C-10), 127.9 (C-15), 127.5 (C-12’), 127.4 (C-13’), 125.7 (C-6), 123.8 (C-8), 
122.8 (C-14), 122.7 (C-11), 120.6 (C-2), 119.8 (C-4), 102.0 (C-17), 63.8 (C-18
#
), 55.9 (C-19
#
).  
 
Following the general procedure, protected 
benzophenone 303 (1.013 g, 2.646 mmol) and 5 % Pd/C 
(0.100 g, 10 mass %) were combined in EtOAc (50 ml) 
for 4 hours. Following purification by flash column 
chromatography with an eluent consisting of 20 % 
EtOAc/Hexane, the product 265 was collected as a 
yellow solid (0.664 g, 79 %) Rf = 0.56 (20 % 
EtOAc/Hexane). m.p. = 96-98 °C, lit 74-76 °C.
191
 
1
H NMR 
(300 MHz, CDCl3): δH = 12.02 (1H, s, H-16), 7.41 (1H, dd, J = 8.9 and 2.7 Hz, H-5), 7.31 (1H, d, J = 
2.6 Hz, H-7), 7.04 (1H, dd, J = 9.0 and 3.0 Hz, H-11), 6.97 (2H, t, J = 8.7 Hz, H-4 and H-10), 6.84 (1H, 
d, J = 3.0 Hz, H-13), 3.80 (3H, s, H-14*), 3.74 (3H, s, H-15*). 
13
C NMR (75 MHz, CDCl3): δC = 200.8 
(C-1), 161.3 (C-16*), 153.6 (C-9*), 150.6 (C-12*), 136.4 (C-5), 132.6 (C-7), 127.6 (C-6’), 123.4 (C-
2’), 120.7 (C-8’), 119.7 (C-4*), 117.7 (C-11), 114.0 (C-13), 113.1 (C-10*), 56.3 (C-16
#
), 55.9 (C-15
#
).  
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When exposed to 5 % Pd/C (0.490 g, 10 % mass eq) 
under a hydrogen atmosphere, 304 (4.90 g, 10.87 
mmol) was reduced to 270 (2.67 g, 70 %) as a yellow 
solid. Rf = 0.17 (10 % EtOAc/Hexane).  m.p. = 158-160 
°C, lit 161-163 °C.
191
 
1
H NMR (300 MHz, CDCl3): δH = 
12.18 (1H, s, H-17), 7.48 – 7.40 (1H, m, H-4), 7.03 – 6.97 
(1H, m, H-7), 6.90 (1H, s, H-10), 6.81 (1H, td, J = 7.3 Hz, 
1.2 = H-5), 6.60 (1H, s, H-13), 3.96 (3H, s, H-14*), 3.83 (3H, s, H-15*), 3.73 (3H, s, H-16*). 
13
C NMR 
(75 MHz, CDCl3): δC = 201.0 (C-1), 162.7 (C-3’), 152.3 (C-9’), 152.0 (C-12’), 143.1 (C-11’), 136.2 (C-
6), 133.8 (C-7), 120.3 (C-2), 119.0 (C-8), 118.5 (C-5), 117.9 (C-7), 112.7 (C-10), 97.5 (C-13), 56.5 (C-
14*), 56.5 (C-15*), 56.2 (C-16*). 
 
Ketone 319 (4.86 g, 13.99 mmol) and 5 % Pd/C (0.486 g, 
10 mass %) were combined according to the general 
procedure. A yellow oil was collected after purification 
and confirmed to be 324 (2.58 g, 71 %). Rf = 0.46 (20 % 
EtOAc/Hexane). 
1
H NMR (300 MHz, CDCl3): δH = 12.24 
(1H, s, H-16), 7.42 (2H, m, J = 8.3, 7.9, 1.7, H-7 and H-5), 
7.27 (1H, d, J = 8.1 Hz, H-13), 7.00 (1H, dd, J = 8.4 and 
1.2 Hz, H-12), 6.79 (1H, ddd, J = 8.1, 7.2 and 1.1 Hz, H-6), 6.59 – 6.46 (2H, m, H-4 and H-10), 3.86 
(3H, s, H-14*), 3.74 (3H, s, H-15*). 
13
C NMR (125 MHz, CDCl3): δC = 201.2 (C-1), 163.2 (C-3*), 162.8 
(C-9*), 158.6 (C-11*), 136.1 (C-5), 133.8 (C-7), 131.0 (C-13), 120.7 (C-2’), 120.5 (C-8’), 118.5 (C-6), 
118.0 (C-4), 104.6 (C-12), 98.9 (C-10), 55.6 (C-14
#
), 55.5 (C-15
#
). IR (νm.cm
-1
) = 2936, 2839, 1605, 
1508, 1470, 1412, 1335, 1315, 1277, 1238, 1200, 1161, 1123, 1026, 949, 949, 910, 949, 910, 833, 
795, 756, 737, 698, 640, 621. ESI-MS (m/z) calculated [M+H]
+
 for C15H15O4 259.0970, found 
259.0974. 
 
Benzyl protected benzophenone 320 (2.21 g, mmol) was 
reduced using 5 % Pd/C (0.221 g, 10 mass %) under a 
hydrogen atmosphere. After purification by flash 
column chromatography, 325 was collected as a yellow 
solid (1.01 g, 62 %). Rf = 0.35 (20 % EtOAc/Hexane). 
m.p. = 86-89 °C, 76-78 °C.
209
 
1
H NMR (300 MHz, CDCl3): 
δH = 11.97 – 11.82 (1H, s, H-16), 7.70 – 7.64 (1 H, m, H-7), 7.50 (1H, ddd, J=  8.6, 7.1 and 1.6 Hz, H-
5), 7.36 – 7.30 (2H, m, H-13 and H-9), 7.10 – 7.05 (1H, m, H-4), 6.94 (1H, d, J = 7.9 Hz, H-12), 6.92 
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– 6.85 (1H, m, H-6), 3.97 (3H, d, J = 1.1 Hz, H-14*), 3.94 (3H, d, J = 1.1 Hz, H-15*). 
13
C NMR (75 
MHz, CDCl3): δC = 199.9 (C-1), 162.9 (C-16), 152.7 (C-10*), 149.1 (C-11*), 135.8 (C-5), 133.3 (C-7), 
130.5 (C-8), 124.3 (C-9
#
), 119.5 (C-2), 118.5 (C-6), 118.4 (C-4), 112.2 (C-13
#
), 110.1 (C-12), 56.1 (C-
14’), 56.1 (C-5’). IR (νm.cm
-1
) = 3424, 3007, 2972, 2936, 2833, 1618, 1584, 1514, 1479, 1462, 1447, 
1410, 1358, 1323, 1306, 1254, 1219, 1167, 1132, 1115, 1063, 1028, 976, 889, 854, 820, 802, 768, 
750, 698, 646, 611. ESI-MS (m/z) calculated [M+H]
+
 for C15H15O4 259.0970, found 259.0974. 
 
The benzyl group on 321 (2.342 g, 6.19 mmol) was 
removed using 5 % Pd/C (0.234 g, 10 mass %) under a 
hydrogen atmosphere as described in the general 
procedure. After filtration the product was 
recrystallized from isopropyl alcohol resulting in the 
collection of light yellow crystals of 326 (1.322 g, 74 %). 
Rf = 0.32 (20 % EtOAc/Hexane). m.p. = 144-146 °C. 
1
H 
NMR (300 MHz, CDCl3): δH = 12.23 (1H, s, H-17), 7.44 (1H, ddd, J = 8.6, 7.1 and 1.8 Hz, H-5), 7.32 
(1H, dd, J = 8.0 and 1.8, H-7), 7.00 (1H, dd, J = 8.4 and 1.2 Hz, H-4), 6.78 (1H, ddd, J = 8.2, 7.2 and 
1.1 Hz, H-6), 6.17 (2H, s, H-12 and H-10), 3.86 (3H, s, H-15), 3.71 (6H, s, H-14 and H-16). 
13
C NMR 
(75 MHz, CDCl3): δC = 201.1 (C-1), 162.8 (C-17*), 162.6 (C-11*), 158.4 (C-9 and C-13), 136.2 (C-5), 
133.2 (C-7), 121.4 (C-2), 118.7 (C-6), 117.8 (C-4), 109.7 (C-8), 90.7 (C-10 and C-12), 55.9 (C-14 and 
C-16), 55.5 (C-15). IR (νm.cm
-1
) = 3686, 2970, 2943, 2930, 2862, 2862, 2849, 1607, 1580, 1485, 
1404, 1337, 1296, 1242, 1229, 1202, 1188, 1148, 1121, 1053, 1026, 1013, 959, 932, 824, 797, 
756, 716. ESI-MS (m/z) calculated [M+H]
+
 for C16H17O5 289.1076, found 289.1082. 
 
Following the general procedure, benzophenone 322 
(4.08 g, 11.71 mmol) and 5 % Pd/C (0.41 g, 10 mass %) 
was used to remove the benzyl group resulting in the 
collection of a yellow solid that was confirmed to be 
327 (1.82 g, 60 %). Rf = 0.41 (20 % EtOAc/Hexane). m.p. 
= 104-107°C. 
1
H NMR (300 MHz, CDCl3): δH = 12.15 (1H, 
s, H-16), 7.44 (1H, ddd, J = 8.7, 7.2 and 1.8 Hz, H-5), 7.36 
(1H, t, J = 8.4 Hz, H-11), 7.28 (1H, dd, J = 7.9 and 1.7 Hz, H-7), 7.01 (1H, dd, J = 8.4 and 1.1 Hz, H-
4), 6.77 (1H, ddd, J = 8.1, 7.2 and 1.1 Hz, H-6), 6.62 (2H, d, J = 8.4 Hz, H-10 and H-12), 3.71 (6H, s, 
H-14 and H-15). 
13
C NMR (75 MHz, CDCl3): δC = 201.3 (C-1), 162.5 (C-3), 157.3 (C-9 and C-13), 
136.4 (C-5), 133.0 (C-7), 131.3 (C-11), 121.0 (C-2), 118.9 (C-6), 117.9 (C-4), 116.5 (C-8), 104.0 (C-
10 and C-12), 55.9 (C-14 and C-15). IR (νm.cm
-1
) = 3699, 2978, 2936, 2851, 1620, 1578, 1472, 
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1450, 1366, 1344, 1302, 1281, 1238, 1132, 1111, 1069, 1026, 941, 835, 793, 772, 750, 729, 623. 
ESI-MS (m/z) calculated [M+H]
+
 for C15H15O4 259.0970, found 259.0571. 
 
Methanol was used to dissolve benzylated 323 (2.35 g, 
6.76 mmol) and 5 % Pd/C (0.24 g, 10 mass %) added. 
After stirring under a hydrogen atmosphere and 
purification according to the general procedure, 328 
was collected as a white solid (1.16 g, 66 %). Rf = 0.56 
(10 % EtOAc/Hexane). m.p. = 75-77 °C. 
1
H NMR (300 
MHz, CDCl3): δH = 12.16 (1H, s, H-16), 7.45 (1H, ddd, J = 
8.7, 7.2 and 1.8 Hz, H-5), 7.35 (1H, dd, J = 8.0 and 1.7 Hz, H-7), 7.11 (1H, d, J = 7.5 Hz, H-12), 7.03 
(2H, m, H-6 and H-13), 6.85 (1H, dd, J = 7.4 and 1.7 Hz, H-11), 6.79 (1H, ddd, J = 8.2, 7.2 and 1.2 
Hz, H-4), 3.90 (3H, s, H-14*), 3.77 (3H, s, H-15*). 
13
C NMR (75 MHz, CDCl3): δC = 201.8 (C-1), 162.9 
(C-3), 152.8 (C-9*), 146.2 (C-10*), 136.7 (C-5), 133.9 (C-3), 133.0 (C-2), 124.1 (C-12), 120.1 (C-8), 
119.8 (C-11), 118.8 (C-6), 118.0 (C-4
#
), 114.4 (C-13
#
), 61.7 (C-14’), 55.9 (C-15’). IR (νm.cm
-1
) = 
3678, 2984, 2868, 2839, 2810, 1624, 1595, 1566, 1479, 1450, 1422, 1335, 1306, 1248, 1161, 
1074, 1045, 1016, 959, 843, 814, 785, 756, 698, 669, 611. ESI-MS (m/z) calculated [M+H]
+
 for 
C15H15O4 259.0970, found 259.0972. 
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7.3.8. General Procedure for the novel CAS-mediated ring closure 
A CHCl3 and MeCN solution in a 1:4 ratio was used to dissolve the hydroxy-containing 
benzophenone derivatives. Once the benzophenone had completely dissolved, water (double the 
volume than that of the CHCl3) was added and a suspension resulted. Ceric Ammonium Sulfate (4 
eq) was added slowly and the suspension stirred at room temperature overnight. The mixture 
was then transferred to a separating funnel and EtOAc and water added. The water layer was run 
off and the organic layer was washed further with sat NaHCO3 and brine, dried over anhydrous 
Na2SO4 concentrated in vacuo and purified by column chromatography. In some cases several 
products resulted from the reaction and so the reaction schemes as well as the products are 
given for each reaction below. 
 
 
 
 
 
 
Benzophenone 253 (0.120 g, 0.434 mmol, 1 eq) in a 
4:2:1 MeCN:H2O:CHCl3 solvent mixture was exposed to 
CAS (0.824 g, 1.303 mmol, 3 eq) overnight. After 
purification by flash column chromatography in 20 % 
EtOAc/Hexane, an orange solid resulted. NMR 
spectroscopy was used to confirm the identity of 257 
(0.092 g, 73 %).Rf = 0.46 (20 % EtOAc/Hexane). m.p. = 
139-140 °C, lit 162-165 °C.
191
 
1
H NMR (500 MHz, CDCl3): δH = 8.15 (1H, dd, J = 7.9 and 1.4 Hz, H-
12), 8.03 (2H, m, H-7 and H-15), 7.80 (1H, td, J = 7.6 and 1.4 Hz, H-14), 7.62 (2H, m, H-5 and H-13), 
7.19 (1H, d, J = 1.4 Hz, H-9), 7.19 – 7.16 (2H, m, H-4 and H-6), 3.03 (3H, s, H-18). 
13
C NMR (75 
MHz, CDCl3): δC = 184.0 (C-1
#
), 180.9 (C-10
#
), 157.7 (C-3), 143.7 (C-8), 137.0 (C-5*), 136.6 (C-16), 
133.9 (C-14), 130.8 (C-11), 130.6 (C-9’), 130.2 (C-13*), 127.5 (C-15
~
), 126.9 (C-12), 126.5 (C-7
~
), 
123.2 (C-4’), 121.5 (C-2), 118.6 (C-6’), 96.4 (C-17), 51.3 (C-18). IR (νm.cm
-1
) = 3069, 2936, 2833, 
1726, 1691, 1666, 1607, 1458, 1387, 1294, 1267, 1219, 1134, 1103, 1067, 1016, 943, 870, 756, 
737, 702, 660. ESI-MS (m/z) calculated [M+H]
+
 for C18H13O4 293.0814, found 293.0811. 
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The general procedure was followed using benzophenone 258 (0.400 g, 1.688 mmol, 1 eq) and 
CAS (3.350 g, 5.296 mmol, 3 eq). Purification using flash column chromatography 10-20 % 
EtOAc/Hexane resulted in a white solid and yellow crystals being collected. Using NMR 
spectroscopy, the white powder was determined to be 260 (0.142 g, 36 %) and the yellow 
crystals to be 259 (0.153 g, 36 %). 
 
Rf = 0.33 (10 % EtOAc/Hexane). m.p. = 127-128 °C, lit 
131-133 °C.
191
 
1
H NMR (300 MHz, CDCl3): δH = 8.36 (1H, 
dd, J = 8.0 and 1.7 Hz, H-7), 7.76 – 7.68 (2H, m, H-5 and 
H-9), 7.49 (1H, dd, J = 8.5 and 1.2 Hz, H-11), 7.45 (1H, d, 
J = 9.1 Hz, H-12), 7.41 – 7.37 (1H, m, H-6), 7.37 – 7.33 
(1H, m, H-4), 3.93 (3H, s, H-14). 
13
C NMR (75 MHz, 
CDCl3): δC = 177.1 (C-1), 156.1 (C-10*), 156.0 (C-13*), 151.0 (C-3*), 134.6 (C-5), 126.7 (C-7), 124.9 
(C-6), 123.7 (C-2
#
), 122.2 (C-8
#
), 121.3 (C-11), 119.4 (C-12), 118.0 (C-4), 105.9 (C-9), 55.9 (C-14). IR 
(νm.cm
-1
) = 2972, 2938, 2868, 2851, 1670, 1636, 1601, 1462, 1288, 1236, 1219, 1202, 1150, 1097, 
1045, 1028, 1011, 959, 941, 854, 820, 785, 750, 698, 629. ESI-MS (m/z) calculated [M+H]
+
 for 
C14H11O3 227.0708, found 227.0708. 
 
Rf = 0.19 (10 % EtOAc/Hexane). m.p. = 108-110 °C, 110-
112 °C.
191
 
1
H NMR (300 MHz, CDCl3): δH = 8.02 (1H, dd, J 
= 7.9 and 1.8 Hz, H-7), 7.60 (1H, ddd, J = 8.3, 7.3 and 1.7 
Hz, H-5), 7.18 (1H, ddd, J = 8.0, 7.3 and 1.1 Hz, H-6), 7.14 
– 7.07 (2H, m, H-4 and H-12), 6.89 (1H, d, J = 2.0 Hz, H-
9), 6.44 (1H, dd, J = 10.4 and 2.0 Hz, H-11), 3.35 (3H, s, 
H-14). 
13
C NMR (75 MHz, CDCl3): δC = 185.0 (C-10), 
180.9 (C-1), 157.0 (C-3), 144.5 (C-8), 140.1 (C-12*), 137.0 (C-5), 130.7 (C-11), 128.5 (C-9), 127.5 
(C-7), 123.3 (C-6), 121.7 (C-2), 118.5 (C-4*), 95.1 (C-13), 51.3 (C-14). IR (νm.cm
-1
) = 2972, 2938, 
2868, 2851, 1670, 1636, 1601, 1462, 1288, 1236, 1219, 1202, 1150, 1097, 1045, 1028, 1011, 959, 
941, 854, 820, 785, 750, 698, 629. ESI-MS (m/z) calculated [M+H]
+
 for C14H11O4 243.0657, found 
247.1680.  
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Following the general procedure, benzophenone 261 (0.167 
g, 0.579 mmol, 1 eq) exposed to CAS (1.466 g, 2.317 mmol, 
4 eq) resulted in a single product that was determined to be 
262. This was collected as yellow crystals (0.122 g, 69 %). Rf 
= 0.43 (20 % EtOAc/Hexane). m.p. = 153-155 °C, lit 170-172 
°C.
191
 
1
H NMR (300 MHz, CDCl3): δH = 8.35 (1H, ddd, J = 8.0, 
1.8 and 0.5 Hz, H-7), 7.74 – 7.65 (2H, m, H-5 and H-9), 7.47 (1H, ddd, J = 8.5, 1.1 and 0.5 Hz, H-4), 
7.38 (1H, ddd, J = 8.2, 7.1 and 1.1 Hz, H-6), 6.93 (1H, s, H-12), 4.03 (3H, s, H-14*), 4.01 (3H, s, H-
15*). 
13
C NMR (75 MHz, CDCl3): δC = 176.1 (C-1), 156.1 (C-3
#
), 155.5 (C-13
#
), 152.5 (C-10
#
), 146.8 
(C-11
#
), 134.0 (C-5), 126.6 (C-7), 123.8 (C-6), 121.6 (C-2), 117.7 (C-4), 115.0 (C-8), 105.5 (C-9), 99.7 
(C-12), 56.5 (C-14*), 56.4 (C-15*). IR (νm.cm
-1
) = 2972, 2938, 2868, 2833, 1653, 1601, 1514, 1462, 
1427, 1306, 1271, 1236, 1201, 1132, 1063, 1028, 1011, 941, 854, 820, 785, 750, 698, 646. ESI-MS 
(m/z) calculated [M+H]
+
 for C15H13O4 257.0814, found 257.0816. 
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The general procedure was followed using 263 (0.183 g, 
0.534 mmol) and CAS (1.351 g, 2.136 mmol) resulting in 
the formation of 264. This was collected as a yellow 
solid (0.146 g, 84 %). Rf = 0.65 (20 % EtOAc/Hexane). 
m.p. = 158-160 °C, lit 162-165 °C.
191
 
1
H NMR (300 MHz, 
CDCl3): δH = 8.16 (1H, ddd, J = 7.8, 1.4 and 0.6 Hz, H-12), 
8.03 – 7.97 (2H, m, H-7 and H-15), 7.81 (1H, ddd, J = 7.9, 
7.4 and 1.4 Hz, H-13*), 7.63 (1H, td, J = 7.6 and 1.3 Hz, 
H-14*), 7.56 (1H, dd, J = 8.8 and 2.7 Hz, H-5), 7.21 (1H, s, H-9), 7.19 – 7.13 (1H, m, H-4), 3.02 (H, s, 
C-18). 
13
C NMR (75 MHz, CDCl3): δC = 183.7 (C-10), 180.1 (C-1), 156.2 (C-3), 143.0 (C-8), 136.7 (C-
5), 136.2 (C-16), 134.0 (C-13*), 131.1 (C-9), 130.8 (C-11), 130.4 (C-14*), 128.9 (C-6), 127.0 (C-12’), 
126.9 (C-7’), 126.5 (C-15’), 122.4 (C-2), 120.2 (C-4), 96.7 (C-17), 51.4 (C-18). IR (νm.cm
-1
) = 3109, 
2974, 2936, 2820, 1682, 1663, 1624, 1605, 1470, 1412, 1258, 1200, 1142, 1123, 1065, 1026, 987, 
949, 891, 833, 775, 737, 718, 679, 660, 621. ESI-MS (m/z) calculated [M+H]
+
 for C18H12O4Cl 
327.0424, found 327.0415. 
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When exposed to CAS (2.644 g, 4.180 mmol, 4 eq), benzophenone 265 (0.306 g, 1.045 mmol, 1 
eq) was transformed into two products. The two products were separated by flash column 
chromatography and collected as a light pink solid that was found to be 267 (0.027 g, 26 %) and a 
yellow solid that was found to be 266 (0.114 g, 40 %). 
 
Rf = 0.59 (20 % EtOAc/Hexane). m.p. = 171-172 °C, lit 
130-133 °C.
191
 
1
H NMR (300 MHz, CDCl3): δH = 8.31 (1H, 
d, J = 2.6 Hz, H-7), 7.69 (1H, d, J = 3.2 Hz, H-9), 7.65 (1H, 
dd, J = 8.9 and 2.6 Hz, H-5), 7.45 (2H, dd, J 9.0, 6.2, H-4 
and H-12), 7.35 (1H, dd, J = 9.1 and 3.1 Hz, H-11), 3.92 
(3H, s, H-14). 
13
C NMR (75 MHz, CDCl3): δC = 176.0 (C-1), 
156.3 (C-10
#
), 154.4 (C-3), 150.9 (C-13
#
), 134.7 (C-5), 129.5 (C-6), 126.0 (C-7), 125.3 (C-11), 122.1 
(C-2’), 121.8 (C-8’), 119.7 (C-4*), 119.5 (C-12*), 105.8 (C-9), 56.0 (C-14). IR (νm.cm
-1
) = 3071, 2980, 
2953, 2853, 1655, 1612, 1485, 1462, 1445, 1364, 1292, 1242, 1209, 1144, 1123, 1107, 1024, 993, 
904, 872, 814, 785, 719, 687, 629. ESI-MS (m/z) calculated [M+H]
+
 for C14H10O3Cl 261.0318, found 
261.0318. 
 
Rf = 0.29 (20 % EtOAc/Hexane).  m.p. = 143-144 °C, 122-
124 °C.
191
 
1
H NMR (300 MHz, CDCl3): δH = 7.97 (1H, d, J = 
2.7 Hz, H-7), 7.54 (1H, dd, J = 8.7 and 2.7 Hz, H-5), 7.08 
(2H, dd, J = 9.5 and 8.7 Hz, H-4 and H-12), 6.89 (1 H, d, J 
= 2.0 Hz, H-9), 6.45 (1H, dd, J = 10.4 and 2.0 Hz, H-11), 
3.35 (3H, s, H-14). 
13
C NMR (75 MHz, CDCl3): δC = 184.7 
(C-10
#
), 180.0 (C-1
#
), 155.4 (C-3), 143.8 (C-8), 139.7 (C-
12*), 136.7 (C-5), 130.9 (C-11), 129.0 (C-6), 129.0 (C-9), 126.9 (C-7), 122.6 (C-2), 120.2 (C-4*), 95.3 
(C-13), 51.4 (C-14). IR (νm.cm
-1
) = 3071, 3005, 2945, 2831, 1668, 1643, 1603, 1468, 1422, 1288, 
1267, 1203, 1142, 1099, 1003, 945, 837, 821, 779, 714, 677. ESI-MS (m/z) calculated [M+H]
+
 for 
C14H10O4Cl 277.0268, found 227.0268. 
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Following the general procedure, when 270 (0.265 g, 0.821 mmol, 1 eq) was exposed to CAS 
(2.078 g, 3.284 mmol, 4 eq) three new spots were observed on the TLC plate. The three spots 
were successfully separated using flash column chromatography and found to be 269 as white 
crystals (0.097 g, 41 %), 268 as bright yellow crystals (0.045 g, 18 %) and 271 (0.014 g, 4 %) as a 
dark yellow solid. 
 
Rf = 0.26 (20 % EtOAc/Hexane). m.p. = 204-206 °C, lit 
202-204 °C.
191
 
1
H NMR (300 MHz, CDCl3): δH = 8.24 (1H, 
d, J = 2.6 Hz, H-7), 7.62 – 7.55 (2H, m, H-5 and H-9), 7.36 
(1H, d, J = 8.9 Hz, H-4), 6.85 (1H, s, H-12), 4.01 (3H, s, H-
14*), 3.98 (3H, s, H-15*). 
13
C NMR (75 MHz, CDCl3): δC = 
174.8 (C-1), 155.7 (C-13
#
), 154.3 (C-3), 152.3 (C-11
#
), 
147.0 (C-10
#
), 134.0 (C-5*), 129.5 (C-6), 125.8 (C-7), 122.3 (C-2), 119.4 (C-4), 114.5 (C-8), 105.3 (C-
9*), 99.6 (C-12), 56.5 (C-14’), 56.3 (C-15’). IR (νm.cm
-1
) = 3076, 2990, 2972, 2920, 2833, 1636, 
1618, 1566, 1514, 1479, 1462, 1427, 1288, 1271, 1236, 1184, 1167, 1132, 1063, 1028, 1011, 959, 
906, 871, 820, 785, 698, 611. ESI-MS (m/z) calculated [M+H]
+
 for C15H12O4Cl 291.0424, found 
291.0426. 
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Rf = 0.17 (20 % EtOAc/Hexane). m.p. = 142-144 °C, lit 
118-120 °C.
191
 
1
H NMR (300 MHz, CDCl3): δH = 7.94 (1H, 
d, J = 2.7 Hz, H-7), 7.58 – 7.48 (1H, m, H-5), 7.04 (1H, d, J 
= 8.7 Hz, H-4), 6.86 (1H, d, J = 1.1 Hz, H-12), 5.95 (1H, s, 
H-9), 3.82 (3H, s, H-15), 3.33 (3H, d, J = 1.3 Hz, H-14). 
13
C 
NMR (75 MHz, CDCl3): δC = 180.2 (C-1*), 179.9 (C-10*), 
156.0 (C-3
#
), 152.5 (C-11
#
), 144.3 (C-8), 136.6 (C-5), 
128.8 (C-6), 128.1 (C-12), 126.9 (C-7), 122.6 (C-2), 120.1 (C-4), 106.8 (C-9), 98.2 (C-13), 55.7 (C-
15), 51.2 (C-14). IR (νm.cm
-1
) = 3013, 2974, 2936, 2839, 1682, 1643, 1604, 1470, 1412, 1373, 1296, 
1258, 1238, 1200, 1180, 1123, 1045, 988, 968, 910, 833, 775, 737, 718, 698, 640. ESI-MS (m/z) 
calculated [M+H]
+
 for C15H12O5Cl 307.0373, found 307.0370. 
 
Rf = 0.09 (20 % EtOAc/Hexane). m.p. = 200-202 °C, lit 
223-225 °C.
191
 
1
H NMR (300 MHz, CDCl3): δH = 7.67 (2H, 
m, H-7 and H-4), 7.19 (1H, dd, J = 8.4 and 1.0 Hz, H-5), 
5.76 (1H, s, H-9), 5.18 (1H, s, H-12), 3.69 (3H, s, H-15), 
3.68 (3H, s, H-14). 
13
C NMR (75 MHz, CDCl3): δC = 194.3 
(C-1), 181.1 (C-11), 170.8 (C-3), 167.5 (C-13
#
), 153.4 (C-
10
#
), 138.8 (C-5), 128.3 (C-6), 124.8 (C-7), 121.1 (C-2), 
115.1 (C-4), 104.0 (C-9), 102.4 (C-12), 87.0 (C-8), 56.7 (C-14*), 55.6 (C-15*). IR (νm.cm
-1
) = 3076, 
3042, 2938, 2851, 1740, 1670, 1618, 1462, 1358, 1288, 1236, 1184, 1080, 1011, 993, 872, 820, 
768, 698, 663, 629. ESI-MS (m/z) calculated [M+H]
+
 for C15H12O5Cl 307.0373, found 307.0373. 
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The mixture of 324 (0.521 g, 2.017 mmol, 1 
eq) and CAS (2.552 g, 4.035 mmol, 2 eq) 
resulted multiple spots visualized on the TLC 
plate. After purification by flash column 
chromatography, the only product that could 
be successfully isolated and characterised was 
a white solid determined to be 329 (0.082 g, 
24 %) from NMR spectroscopy and SCXRD. Rf 
= 0.32 (30 % EtOAc/Hexane). m.p. = 171-175 
°C. 
1
H NMR (300 MHz, CDCl3): δH = 12.15 (1H, 
s, H-16), 7.51 (1H, dd, J = 8.6 and 2.4 Hz, H-5), 7.42 (1H, d, J = 2.4 Hz, H-3), 7.28 (1H, d, J = 8.4 Hz, 
H-13), 7.04 (1H, d, J = 8.6 Hz, H-6), 6.55 (1H, dd, J = 8.4 and 2.3 Hz, H-12), 6.51 (1H, d, J = 2.2 Hz, 
H-10), 3.91 (3H, s, H-14*), 3.61 (3H, s, H-15*). 
13
C NMR (75 MHz, CDCl3): δC = 201.1 (C-1), 163.3 
(C-11
#
), 162.0 (C-9
#
), 158.5 (C-7
#
), 134.4 (C-5), 131.3 (C-4), 131.1 (C-3), 130.8 (C-13), 120.7 (C-5’), 
120.5 (C-2’), 118.5 (C-6), 104.7 (C-12), 99.1 (C-10), 55.6 (C-14*), 55.5 (C-15*). IR (νm.cm
-1
) = 2972, 
2938, 2851, 1601, 1584, 1514, 1462, 1410, 1323, 1288, 1236, 1202, 1167, 1132, 1115, 1028, 976, 
941, 820, 785, 768, 611. ESI-MS (m/z) calculated [M+H]
+
 for C30H27O8 515.1706, found 515.1702. 
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Following the general procedure, benzophenone 327 
(0.291 g, 1.127 mmol, 1 eq) and CAS (2.138 g, 3.380 
mmol, 3 eq) were combined. Multiple spots were 
visualized on the TLC plate, however after purification 
by flash column chromatography only a single spot 
could be successfully isolated. The yellow oil collected 
and this was determined to be 330 by NMR 
spectroscopy (0.052 g, 18 %). Rf = 0.44 (30 % 
EtOAc/Hexane). 
1
H NMR (300 MHz, CDCl3): δH = 12.13 
(1H, s, H-16), 7.50 (1H, dd, J = 8.7 and 2.4 Hz, H-5), 7.42 
– 7.33 (1H, m, H-11), 7.22 (1H, d, J = 2.4 Hz, H-7), 7.04 (1H, d, J = 8.6 Hz, H-4), 6.59 (2H, d, J = 8.4, 
H-10 and H-12), 3.63 (6H, s, H-14 and H-15). 
13
C NMR (75 MHz, CDCl3): δC = 201.1 (C-1), 161.8 (C-
3), 157.3 (C-9 and C-13), 134.9 (C-5), 131.3 (C-11), 131.2 (C-6), 130.5 (C-3), 120.9 (C-2), 118.4 (C-
4), 116.3 (C-8), 104.1 (C-10 and C-12), 55.9 (C-14 and C-15). IR (νm.cm
-1
) = 3009, 2978, 2947, 
2839, 1636, 1589, 1466, 1435, 1327, 1281, 1250, 1219, 1157, 1111, 1049, 1034, 941, 833, 787, 
756, 725, 632. ESI-MS (m/z) calculated [M+H]
+
 for C30H27O8 515.1706, found 515.1707. 
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Benzophenone 325 (0.409 g, 1.584 
mmol, 1 eq) and CAS (2.00 g, 3.167 
mmol) were combined following the 
general procedure. Multiple spots were 
visualized on the TLC plate as the 
reaction was monitored, however only 
one of the compounds isolated could be 
successfully characterised. This spot 
was collected as a yellow solid and 
determined to be product 331 (0.062 g, 
15 %). Rf = 0.21 (30 % EtOAc/Hexane). m.p. = 148-150 °C. 
1
H NMR (300 MHz, CDCl3): δH = 11.78 
(1H, s, H-16), 7.78 (1H, d, J = 2.4 Hz, H-7), 7.64 (1H, dd, J = 8.6 and 2.4 Hz, H-5), 7.35 (1H, d, J = 2.0 
Hz, H-9), 7.32 (1H, dd, J = 8.2 and 2.0 Hz, H-13), 7.13 (1H, d, J = 8.6 Hz, H-4), 6.86 (1H, d, J = 8.2 Hz, 
H-12), 3.96 (3H, s, H-15), 3.90 (3H, s, H-14). 
13
C NMR (75 MHz, CDCl3): δC = 199.5 (C-1), 162.1 (C-
3), 153.0 (C-11), 149.2 (C-10), 133.9 (C-5), 130.9 (C-7), 130.6 (C-6), 130.2 (C-8), 124.5 (C-13), 119.6 
(C-2), 119.0 (C-4), 112.1 (C-9), 109.9 (C-12), 56.1 (C-15), 56.0 (C-14). IR (νm.cm
-1
) = 3013, 2974, 
2974, 2936, 2858, 2839, 1624, 1566, 1508, 1470, 1412, 1335, 1258, 1238, 1200, 1180, 1142, 
1065, 1026, 872, 814, 795, 756, 698, 660, 621. ESI-MS (m/z) calculated [M+H]
+
 for 
C30H27O8 515.1706, found 515.1704. 
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After dissolving 328 (0.117 g, 0.453 mmol, 1 eq) as 
outlined in the general procedure, CAS (1.433 g, 2.265 
mmol, 5 eq) was added and the reaction mixture stirred 
overnight. Only a single spot was visualized on the TLC 
plate. This product was characterised by NMR 
spectroscopy and determined to be 332 (0.061 g, 60 %). 
Rf = 0.37 (20 % EtOAc/Hexane). m.p. = 178 °C, 175-176 
°C.
210
 
1
H NMR (300 MHz, CDCl3): δH = 8.35 (1H, ddd, J = 7.9, 1.7 and 0.5 Hz, H-7), 7.92 (1H, dd, J = 
7.8 and 1.8 Hz, H-13), 7.74 (1H, ddd, J = 8.7, 7.0 and 1.8 Hz, H-6), 7.62 (1H, ddd, J = 8.5, 1.1 and 
0.5 Hz, H-4), 7.40 (1H, ddd, J = 8.1, 7.1 and 1.2 Hz, H-5), 7.32 (2H, m, H-11 and H-12), 4.04 (3H, s, 
H-14). 
13
C NMR (75 MHz, CDCl3): δC = 177.2 (C-1), 156.0 (C-3), 148.7 (C-9
#
), 146.6 (C-10
#
), 134.8 
(C-6), 126.7 (C-7), 124.1 (C-5), 123.4 (C-11*), 122.8 (C-2’), 121.7 (C-8’), 118.3 (C-4), 117.7 (C-13), 
115.4 (C-12*), 56.5 (C-14). IR (νm.cm
-1
) = 2993, 2955, 2916, 2858, 2839, 1663, 1605, 1566, 1489, 
1470, 1450, 1354, 1335, 1277, 1258, 1238, 1200, 1142, 1065, 1026, 968, 891, 853, 814, 756, 718, 
679, 621. ESI-MS (m/z) calculated [M+H]
+
 for C14H11O3 227.0708, found 227.0704. 
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To a solution of 326 (0.300 g, 1.041 mmol, 1 eq), CAS 
(2.634 g, 4.164 mmol, 4 eq) was added and stirred 
overnight. After purification by flash column 
chromatography, white crystals were collected and 
found to be 333 (0.166 g, 59 %). Rf = 0.50 (30 % 
EtOAc/Hexane). m.p. = 194-196 °C. 
1
H NMR (300 MHz, 
CDCl3): δH = 7.75 – 7.63 (2H, m, H-7 and H-5), 7.26 – 
7.20 (1H, m, H-4), 7.17 (1H, ddd, J = 7.9, 7.2 and 0.8 Hz, 
H-6), 5.64 (2H, d, J = 1.0 Hz, H-10 and H-12), 3.64 (6H, s, H-14 and H-15). 
13
C NMR (75 MHz, 
CDCl3): δC = 194.4 (C-1*), 186.8 (C-11*), 173.8 (C-3), 164.8 (C-9 and C-13), 138.6 (C-5), 125.3 (C-7), 
122.7 (C-6), 120.1 (C-2), 113.5 (C-4), 103.5 (C-10 and C-12), 84.3 (C-8), 56.5 (C-14 and C-15). IR 
(νm.cm
-1
) = 2972, 2938, 2920, 2868, 2816, 1722, 1670, 1636, 1601, 1462, 1358, 1323, 1306, 1236, 
1219, 1184, 1150, 1097, 1063, 993, 924, 889, 854, 768, 716, 629. ESI-MS (m/z) calculated [M+H]
+
 
for C15H13O5 273.0763, found 273.0764. 
 
  
 
333 
 
 Plot Twist  
Experimental 
 
280 
 
7.3.9. CAN-mediated formation of spirofuran 300 
 
 
 
 
 
 
To a rapidly stirring solution of benzophenone 261 
(0.260 g, 0.902 mmol) in MeCN (15 ml), CAN (1.711 g, 
2.706 mmol, 3 eq) dissolved in H2O (6 ml) was added 
dropwise. The yellow solution immediately turned black 
and after 10 minutes no more starting material was 
observed on the TLC plate and a new spot was evident. 
The reaction mixture was transferred to a separation 
funnel, water (20 ml) and EtOAc (50 ml) added to the mixture and the water layer removed. 
Following this, the organic layer was further washed with saturated NaHCO3 and brine. After 
drying over anhydrous Na2SO4 and concentration in vacuo the product was purified by flash 
column chromatography with 10-20 % EtOAc/Hexane as the eluent. A white solid was collected 
(0.036 g, 13 %) and determined to be 300 following characterisation by NMR spectroscopy. Rf = 
0.20 (20 % EtOAc/Hexane). m.p. = 103-105 °C. 
1
H NMR (300 MHz, CDCl3): δH = 7.77 – 7.67 (2H, m, 
H-5 and H-7), 7.26 – 7.21 (1H, m, H-4), 7.18 (1H, ddd, J = 7.9, 7.2 and 0.8 Hz, H-6), 5.77 (1H, s, H-
12), 5.20 (1H, s, H-9), 3.69 (3H, s, H-14*), 3.68 (3H, s, H-15*). 
13
C NMR (75 MHz, CDCl3): δC = 195.4 
(C-1
#
), 181.3 (C-11
#
), 172.5 (C-13
~
), 168.0 (C-3
~
), 153.3 (C-10
~
), 139.0 (C-5*), 125.7 (C-7*), 122.7 
(C-6), 119.9 (C-2), 113.9 (C-4), 104.0 (C-12), 103.0 (C-9), 86.1 (C-8), 56.6 (C-14’), 55.6 (C-15’). IR 
(νm.cm
-1
) = 3063, 2938, 2852, 1719, 1666, 1643, 1601, 1506, 1456, 1402, 1337, 1261, 1205, 1171, 
1099, 1084, 1032, 991, 924, 887, 850, 750, 706, 629. ESI-MS (m/z) calculated [M+CH3+2H
+
]
+
 for 
C16H17O5 289.1076, found 289.1072. 
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7.3.10. General procedure for the conversion of diones to xanthones 
 
 
 
 
 
 
In a 25 ml round bottomed flask, dione (1 eq) was dissolved in freshly distilled THF (5 ml). To this 
5 ml of water was added and 3 equivalents of sodium dithionite was added to the solution while 
being stirred at a high speed. Just after the addition of the sodium dithionite a colour change of 
the mixture was noted and the solution was stirred for a further 15 minutes. A TLC of the 
reaction mixture confirmed that no more starting material was present and the mixture was 
transferred to a separation funnel and diluted by the addition of 15 ml water and 15 ml diethyl 
ether. The water layer was removed and washed with a further 15 ml of water and this layer 
extracted. Concentrated sodium hydroxide (15 ml) was added, the separation funnel stoppered 
and shaken vigorously. A notable change in colour was observed during shaking. The aqueous 
layer (now highly coloured) was collected. Further additions of conc. NaOH along with vigorous 
shaking was repeated until no further colour change was observed in the aqueous layer. The 
basic aqueous layers that were collected and combined were neutralized by the slow addition of 
solid ammonium chloride. Ammonium chloride was added until a solid precipitated out of 
solution, the solid collected by filtration and dried in a desiccator overnight. The solids were 
characterised by NMR, Infrared and Mass spectroscopy. 
 
Dione 259 (0.100 g, 0.413 mmol, 1 eq) was reduced to 
305 with sodium dithionite (0.216 g, 1.239 mmol, 3 eq). 
305 was collected as a cream coloured powder (0.079 g, 
90 %). M.p. = >310 °C. 
1
H NMR (300 MHz, MeOD): δH = 
8.25 (1H, dd, J = 8.1 and 1.7 Hz, H-7), 7.81 (1H, ddd, J = 
8.7, 7.1 and 1.7 Hz, H-5), 7.60 – 7.54 (2 H, m, H-4 and H-
9), 7.49 (1H, d, J = 9.1 Hz, H-12), 7.43 (1H, ddd, J = 8.1, 7.0 and 1.1 Hz, H-6), 7.33 (1H, dd, J = 9.1 
and 3.0 Hz, H-11). 
13
C NMR (75 MHz, MeOD): δC = 179.0 (C-1), 157.7 (C-3
#
), 155.4 (C-13
#
), 151.6 
(C-10
#
), 136.3 (C-5), 127.2 (C-7), 125.9 (C-11), 125.0 (C-6), 123.2 (C-8’), 122.0 (C-2’), 120.5 (C-12), 
119.2 (C-4*), 109.8 (C-9*). IR (νm.cm
-1
) = 3302, 3069, 2947, 2872, 1651, 1614, 1597, 1460, 1342, 
1302, 1223, 1146, 1190, 1130, 871, 816, 787, 748, 711, 619. ESI-MS (m/z) calculated [M-H]
-
 for 
C13H9O3 211.0395, found 211.0395. 
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The reduction of dione 266 (0.257 g, 0.929 mmol, 1 eq) 
was performed using sodium dithionite (0.485 g, 2.786 
mmol) resulting in the formation of a beige powder 306 
(0.171 g, 75 %) after the work up given in the general 
procedure. m.p. = 250 °C, lit 221-222 °C.
211
 
1
H NMR (500 
MHz, d-DMSO): δH = 7.85 (1H, d, J = 2.6 Hz, H-3), 7.45 
(1H, dd, J = 9.0 and 2.7 Hz, H-5), 7.26 (1H, d, J = 8.9 Hz, H-12), 7.21 (1H, d, J = 3.0 Hz, H-9), 7.17 
(1H, d, J = 9.1 Hz, H-6), 7.01 (1H, dd, J = 9.0 and 3.0 Hz, H-11). 
13
C NMR (126 MHz, d-DMSO): δC = 
180.3 (C-1), 158.6 (C-7*), 158.4 (C-10*), 154.0 (C-13*), 138.7 (C-5), 133.0 (C-4), 128.83 (C-3 and C-
11), 128.76 (C-2
#
) 125.5 (C-8
#
), 124.0 (C-12), 123.1 (C-6), 112.4 (C-9). IR (νm.cm
-1
) = 3312, 2984, 
2959, 2878, 1651, 1616, 1476, 1375, 1285, 12238, 1150, 1059, 1034, 1030, 891, 889, 820, 795, 
733, 689, 629. ESI-MS (m/z) calculated [M+H]
+
 for C13H8O3Cl 247.0162, found 247.0157. 
 
In the presence of sodium dithionite (0.179 g, 1.026 
mmol, 3 eq), dione 257 (0.100 g, 0.342 mmol, 1 eq) was 
reduced to 307 following the general procedure 
resulting in the formation of a yellow solid (0.057 g, 64 
%). m.p. = decomposed at 260 °C. 
1
H NMR (300 MHz, 
CDCl3): δH = 8.64 (1H, dt, J = 6.8 and 3.4 Hz, H-12), 8.34 
(1H, dt, J = 7.0 and 3.5 Hz, H-15), 8.27 – 8.19 (1H, m, H-
7), 7.94 – 7.84 (2H, m, H-4 and H-5), 7.80 (2H, dt, J = 6.4 and 3.5 Hz, H-13 and H-14), 7.50 (1H, 
ddd, J = 8.1, 5.8 and 2.3 Hz, H-6), 7.42 (1H, s, H-9). 
13
C NMR (75 MHz, CDCl3): δC = 175.5 (C-1), 
155.1 (C-3
#
), 151.4 (C-10
#
), 146.1 (C-17
#
), 134.4 (C-4*), 129.4 (C-11), 128.7 (C-13’), 127.4 (C-14’), 
125.6 (C-12), 124.5 (C-16), 124.2 (C-6), 123.0 (C-15), 122.4 (C-12), 121.1 (C-2), 118.3 (C-5*), 117.9 
(C-8), 99.1 (C-9). IR (νm.cm
-1
) = 3329, 3074, 1624, 1607, 1581, 1470, 1420, 1286, 1265, 1234, 
1130, 1076, 1022, 889, 858, 842, 771, 745, 698, 661, 635. ESI-MS (m/z) calculated [M+H]
+
 for 
C17H11O3 263.0708, found 263.0708. 
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Following the general procedure, dione 264 (0.146 g, 
0.447 mmol, 1 eq) was reduced by sodium dithionite 
(0.233 g, 1.341 mmol, 3 eq). The product was collected 
as a yellow solid and determined to be 308 (0.090 g, 68 
%). m.p. = decomposed >270 °C. 
1
H NMR (500 MHz, d-
DMSO): δH = 8.63 – 8.56 (1H, m, H-12), 8.29 – 8.24 (1H, 
m, H-15), 8.08 (1H, d, J = 1.5 Hz, H-7), 7.88 (2H, d, J = 1.6 
Hz, H-4 and H-5), 7.83 – 7.77 (2H, m, H-13 and H-14), 7.38 (1H, s, H-9). 
13
C NMR (126 MHz, d-
DMSO): δC = 175.0 (C-1), 154.2 (C-17
#
), 150.6 (C-3
#
), 147.4 (C-10), 134.9 (C-5*), 129.9 (C-6), 129.2 
(C-13’), 128.3 (C-14’), 124.9 (C-7), 123.2 (C-15), 123.15 (C-11 and C-16), 123.09 (C-12), 122.6 (C-
2), 121.4 (C-4*), 117.8 (C-8), 99.7 (C-9). IR (νm.cm
-1
) = 3323, 2981, 2924, 2868, 1626, 1601, 1685, 
1452, 1402, 1267, 1117, 1057, 1034, 1016, 893, 585, 812, 766, 710, 665, 615. ESI-MS (m/z) 
calculated [M+H]
+
 for C17H10O3Cl 297.0318, found 297.0312. 
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7.4. Experimental Procedures for the preparation of 
acridones. 
7.4.1. Benzyl Protection of Anthranilic acid 
 
 
 
 
 
 
Anthranilic acid (10.0 g, 72.9 mmol) and K2CO3 (38.3 g, 
0.277 mol, 3.8 eq) were dissolved in a 5:1 MeOH:H2O 
solution (250 ml MeOH and 50 ml H2O). Benzyl bromide 
(47.4 g, 0.277 mol, 3.8 eq) was added slowly to the 
rapidly stirring solution. The reaction mixture was 
heated under reflux for 2 hours. The methanol was 
removed in vacuo, EtOAc added to dissolve the organic 
content and extracted with water. The organic layer 
was dried over  anhydrous Na2SO4 and concentrated in 
vacuo. The product 290 was purified by column 
chromatography with an eluent containing 0-10 % 
EtOAc/Hexane and collected as a colourless oil that 
formed white crystals on standing (21.29 g, 72 %). Rf = 0.51 (10 % EtOAc/Hexane). m.p. = 60-62 
°C; 53-55 °C.
199
 
1
H NMR (500 MHz, CDCl3): δH = 7.71 (1H, dd, J = 8.0 and 1.7 Hz, H-4), 7.46 – 7.41 
(2H, m, H-10 and H-14), 7.37 – 7.30 (3H, m, H-11, H-12 and H-13), 7.27 – 7.15 (11H, m, H-7, H-16, 
H-17, H-18, H-19, H-20 and H-21), 6.93 – 6.88 (2H, m, H-5 and H-6), 5.34 (2H, s, H-8), 4.18 (4H, s, 
H-15). 
13
C NMR (126 MHz, CDCl3): δC = 168.2 (C-1), 150.8 (C-3), 137.9 (C-16), 136.0 (C-2), 131.8 (C-
7), 131.3 (C-4), 128.5 (C-10, C-11, C-12, C-13 and C-14), 128.3 (C-18 and C-20), 128.22 (C-9), 
128.17 (C-17 and C-21), 126.9 (C-19), 121.3 (C-5*), 120.8 (C-6*), 66.8 (C-8), 56.9 (C-15). IR (νm.cm
-
1
) = 3069, 3028, 2955, 2926, 2853, 1703, 1595, 1489, 1450, 1377, 1290, 1256, 1217, 1117, 1078, 
1049, 1026, 959, 907, 887, 745, 694. ESI-MS (m/z) calculated [M+H]
+
 for C28H26NO2 408.1964, 
found 408.1964.  
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7.4.2. Synthesis of Weinreb amide 
 
 
 
 
 
 
Using the methodology established in our laboratory,
113
 
anthranilic acid (1.00 g, 7.292 mmol) was dissolved in 
CHCl3 (50 ml). DMF was added to the reaction dropwise 
to ensure everything had completely dissolved. CDI 
(1.419 g, 8.750 mmol, 1.2 eq) was added portion-wise 
to the reaction – if necessary more DMF was added to 
ensure the CDI complex remained in solution. Bubbles of CO2 were generated as the CDI was 
added and when the bubbles stopped forming (after about 20 minutes) N,O-
dimethylhydroxylamine.HCl (0.854 g, 8.750 mmol, 1.2 eq) was added and the solution left to stir 
overnight at room temperature. The product - 339 – was collected as a brown oil (1.257 g, 96 %). 
Rf = 0.31 (30 % EtOAc/Hexane). 
1
H NMR (500 MHz, CDCl3): δH = 7.33 (1H, dd, J = 7.8 and 1.6 Hz, H-
4), 7.15 (1H, ddd, J = 8.4, 7.2 and 1.6 Hz, H-6), 6.71 – 6.62 (2H, m, H-5 and H-7), 4.80 – 4.51 (2H, 
m, H-8), 3.62 – 3.53 (3H, s, H-10), 3.31 (3H, s, H-9). 
13
C NMR (126 MHz, CDCl3): δC = 170.0 (C-1), 
146.8 (C-3), 131.3 (C-6), 129.1 (C-4), 117.2 (C-2), 116.7 (C-5*), 116.6 (C-7*), 61.0 (C-10), 34.3 (C-
9). IR (νm.cm
-1
) = 3466, 3358, 2978, 2938, 1670, 1618, 1605, 1493, 1452, 1381, 1313, 1263, 1215, 
1159, 1096, 1061, 995, 976, 885, 750, 690, 632. ESI-MS (m/z) calculated [M+H]
+
 for 
C9H13N2O2 181.0977, found 181.0972. 
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7.4.3. Lithium mediated coupling reactions 
7.4.3.1. The lithiation reaction with benzyl protected anthranilic acid 
 
 
 
 
 
 
 
 
Brominated aromatic 250 (0.500 g, 2.304 mmol, 1.2 eq) 
was weighed out into a two-necked round bottomed 
flask. A stirrer bar was added, a rubber septum placed 
on one neck and the other neck connected to the gas 
line. The chamber was evacuated and filled with N2 in 
triplicate before the addition of THF and the contents of 
the flask cooled to -78 °C in an acetone/liquid N2 bath. 
n-BuLi (1.66 ml, 2.496 mmol, 1.5 M, 1.3 eq) was added 
dropwise to the stirring cold solution and the reaction 
stirred for 30 min at -78 °C. In a single necked round bottomed flask ester 290 (0.782 g, 1.919 
mmol, 1 eq) was weighed out, a dropping funnel fitted and the system evacuated and filled with 
N2. THF was added to dissolve 290 and once dissolved, the solution was cooled to -78 °C. The 
lithiated mixture was transferred from the two necked flask into the dropping funnel above the 
ester solution and introduced to the solution dropwise. This was left to react at -78 °C for a 
further 2 hours and allowed to warm to room temperature. The rapidly stirring reaction was 
quenched by the addition of sat NH4Cl once the mixture had warmed to room temperature and 
the quenched mixture transferred to a separation funnel. Additional water and EtOAc was added 
to the separation funnel and the aqueous layer removed. The organic layer was washed 
sequentially with sat NaHCO3 and brine before being dried over anhydrous Na2SO4 and 
concentrated in vacuo. Following purification by flash column chromatography resulted in the 
collection of product 291 as a thick yellow oil (0.308 g, 31 %) which was characterised primarily 
by NMR spectroscopy. Rf = 0.71 (30 % EtOAc/Hexane). 
1
H NMR (300 MHz, CDCl3): δH = 7.41 (1H, 
dd, J = 7.6 and 1.7 Hz, H-10), 7.27 (1H, ddd, J = 8.2, 7.3 and 1.7 Hz, H-11), 7.20 – 7.14 (6H, m, H-
17, H-18 and H-19), 7.11 (1H, d, J = 3.2 Hz, H-7), 7.06 (1H, dd, J = 8.9 and 3.2 Hz, H-5), 6.97 (1H, 
dd, J = 7.5 and 1.0, H-13), 6.94 – 6.82 (6H, m, H-4, H-12, H-16 and H-20), 4.10 (4H, s, H-14), 3.73 
(3H, s, H-21*), 3.49 (3H, s, H-22*). 
13
C NMR (75 MHz, CDCl3): δC = 197.4 (C-1), 153.5, 153.0, 150.2, 
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137.4, 134.4, 131.1 (C-11), 130.5 (C-10), 130.1, 128.5 (C-16 and C-20), 128.0 (C-17 and C-19), 
126.9 (C-18), 120.8 (C-13), 120.4 (C-4’), 118.7 (C-5), 115.3 (C-7), 113.6 (C-12’), 56.3 (C-15), 56.3 
(C-21*), 55.8 (C-22*). IR (νm.cm
-1
) = 3063, 300, 2939, 2833, 1649, 1591, 1493, 1445, 1412, 1275, 
1217, 1151, 1042, 959, 847, 813, 732, 696, 638. ESI-MS (m/z) calculated [M+H]
+
 for 
C29H28NO3 438.2069, found 438.2069. 
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7.4.3.2. Lithiation reactions with Weinreb amide 
 
 
 
 
 
 
 
 
Using a procedure described by Frye et al.
200
 
brominated 289 (2.409 g, 11.10 mmol, 1 eq) and 
Weinreb amide 339 (2.00 g, 11.10 mmol, 1 eq) were 
combined in a round bottomed flask with a magnetic 
stirrer bar and fitted with a dropping funnel. The entire 
system was evacuated and charged with nitrogen in 
triplicate before the addition of THF to dissolve the 
compounds. The solution was then cooled to -78 °C in an acetone/liquid N2 bath. While stirring 
vigorously, n-BuLi (18.5 ml, 22.20 mmol, 1.2 M, 2 eq) was added to the solution dropwise at a 
rate of 0.5 ml/min and the reaction stirred at -78 °C for a further 20 minutes. The reaction was 
quenched by the addition of 1M HCl and the solution warmed slowly to room temperature. After 
transferring the reaction mixture to a separation funnel and EtOAc added, the organic layer was 
washed further with 1M HCl followed by brine before being dried over anhydrous Na2SO4 and 
concentrated in vacuo. The reaction mixture was purified by flash column chromatography with a 
20 % EtOAc/Hexane eluent and the product 292, collected as a viscous yellow oil (1.57 g, 55 %). Rf 
= 0.44 (30 % EtOAc/Hexane). 
1
H NMR (300 MHz, CDCl3): δH = 7.32 – 7.22 (2H, m, H-11 and H-13), 
6.97 – 6.88 (2H, m, H-4 and H-5), 6.81 (1H, d, J = 2.7 Hz, H-7), 6.68 (1H, d, J = 8.3 Hz, H-10), 6.56 – 
6.50 (1H, m, H-12), 6.39 (2H, s, H-14), 3.77 (3H, s, H-15*), 3.71 (3H, s, H-16*). 
13
C NMR (75 MHz, 
CDCl3): δC = 198.4 (C-1), 153.4 (C-3
~
), 151.0 (C-6
~
), 150.4 (C-9
~
), 135.0 (C-11*), 134.7 (C-13*), 
131.0 (C-8), 118.3 (C-2), 116.8 (C-10), 116.0 (C-4’), 115.5 (C-12), 113.7 (C-7), 112.8 (C-5’), 56.4 (C-
15
#
), 55.8 (C-16
#
). IR (νm.cm
-1
) = 3470, 3344, 3005, 2959, 2833, 1616, 1580, 1545, 1493, 1449, 
1408, 1300, 1275, 1215, 1159, 1042, 959, 860, 816, 750, 727, 700, 648. ESI-MS (m/z) calculated 
[M+H]
+
 for C15H16NO3 258.1130, found 258.1134. 
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7.4.4. Benzyl protection of 2-aminobenzophenone derivative 
 
 
 
 
 
 
In a microwave tube, 2-aminobenzophenone 292 (0.313 
g, 0.901 mmol) and benzaldehyde (0.91 ml, 0.901 mmol, 
1 eq) were combined with 3 ml EtOH and a small 
amount of anhydrous Na2SO4 (0.050 g). After the 
addition of a microwave stirrer bar and sealing the 
reaction was microwaved for 10 min at 100 °C for 150 
W. NaCNBH4 (0.113 g, 1.802 mmol, 2 eq) was added and 
the reaction returned to the microwave under the same 
conditions for a further 50 min (until no more 
benzaldehyde was present on the TLC plate). Following 
this, the reaction was concentrated in vacuo, extracted with EtOAc and washed with sat NaHCO3. 
The organic layer was washed further with water, 1M HCl and brine before being dried over 
anhydrous Na2SO4 and concentration in vacuo. Following purification by flash column 
chromatography using a 10-30 % EtOAc/Hexane eluent solution product 297 (0.424 g, 99 %) was 
collected as a viscous yellow oil. Rf = 0.46 (20 % EtOAc/Hexane). 
1
H NMR (500 MHz, CDCl3): δH = 
9.40 (1H, d, J = 5.9 Hz, H-14), 7.41 (2H, d, J = 7.7 Hz, H-17 and H-21), 7.38 – 7.33 (3H, m, H-18, H-
19 and H-20), 7.32 – 7.26 (2H, m, H-11 and H-13), 6.93 (2H, td, J = 9.1 and 6.6 Hz, H-4 and H-5), 
6.82 (1H, d, J = 2.7 Hz, H-7), 6.70 (1H, d, J = 8.4 Hz, H-10), 6.49 (1H, t, J = 7.6 Hz, H-12), 4.53 (2H, d, 
J = 5.3 Hz, H-15), 3.77 (3H, s, H-22*), 3.72 (3H, s, H-23*). 
13
C NMR (126 MHz, CDCl3): δC = 198.5 (C-
1), 153.3 (C-3*), 151.7 (C-9*), 150.4 (C-6*), 138.5, 135.9 (C-19), 135.4 (C-11
#
), 131.1, 128.7 (C-18 
and C-20), 127.2 (C-13
#
), 127.1 (C-17 and C-21), 117.9, 115.9 (C-4’), 114.3 (C-12), 113.7 (C-7), 
112.8 (C-5’), 111.8 (C-10), 56.4 (C-22
~
), 55.8 (C-23
~
), 46.9 (C-15). IR (νm.cm
-1
) = 3319, 3030, 2943, 
2831, 1620, 1570, 1514, 1493, 1452, 1420, 1277, 1217, 1163, 1040, 959, 853, 812, 733, 696, 648. 
ESI-MS (m/z) calculated [M+H]
+
 for C22H22NO3 348.1600, found 348.1601.  
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7.4.4. CAS mediated ring closure 
 
 
 
 
 
 
A solution containing 20 ml of MeCN and 5 ml CHCl3 was used to dissolve benzophenone 297 
(0.176 g, 0.507 mmol). Water (10 ml) was added to this solution followed by CAS (1.282 g, 2.027 
mmol, 4 eq) in small portions. The reaction was stoppered and stirred at room temperature 
overnight. The mixture was extracted into EtOAc and washed sequentially with sat NaHCO3 and 
brine, the solution was dried over anhydrous Na2SO4. After concentration in vacuo, the reaction 
mixture was purified by flash column chromatography, resulting in the collection of both starting 
material 297 and yellow crystals that were determined to be 298 (0.13 g, 8 %). 
Rf = 0.26 (20 % EtOAc/Hexane). m.p. = 215-216 °C, lit 
210-212 °C.
212
 
1
H NMR (300 MHz, CDCl3): δH = 8.62 (1H, 
dd, J = 8.1 and 1.7 Hz, H-13), 8.01 (1H, d, J = 2.9 Hz, H-3), 
7.63 (1H, ddd, J = 8.7, 6.9 and 1.7 H-11), 7.41 – 7.28 (6H, 
m, H-5, H-6, H,-10, H-12, H-16, H-18 and H-20), 7.22 – 
7.17 (2H, m, H-17 and H-19), 5.61 (2H, s, H-14), 3.95 
(3H, s, H-21). 
13
C NMR (75 MHz, CDCl3): δC = 177.7 (C-1), 
154.7 (C-4), 142.2 (C-9
#
), 137.4 (C-7
#
), 135.6 (C-8), 133.8 
(C-11), 129.3 (C-16* and C-20*), 127.8 (C-13 and C-18*), 125.6 (C-17* and C-19*), 124.7 (C-5*), 
123.3 (C-2), 121.3 (C-6*), 117.0 (C-10*), 115.0 (C-12*), 106.8 (C-3), 55.8 (C-21), 50.8 (C-14). IR 
(νm.cm
-1
) = 3072, 2949, 2843, 1634, 1597, 1557, 1489, 1462, 1450, 1340, 1286, 1271, 1244, 1207, 
1180, 1130, 1051, 1028, 1001, 970, 908, 841, 804, 752, 719, 687. ESI-MS (m/z) calculated [M+H]
+
 
for C21H18NO2 316.1338, found 316.1347. 
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A1 - 1H and 13C NMR Spectra for selected imidazo[1,2-
a]pyridines 
All the NMR spectroscopic data is available in the Digital Appendix. Below are the spectra for 
selected compounds that may be of interest to the reader. 
 
1
H NMR for 85 in CDCl3 at 300 MHz 
 
13
C NMR for 85 in CDCl3 at 75 MHz 
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1
H NMR for 88 in CDCl3 at 500 MHz 
13
C NMR for 88 in CDCl3 at 126 MHz 
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1
H NMR for 102 in CDCl3 at 300 MHz 
13
C NMR for 102 in CDCl3 at 75 MHz 
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1
H NMR for 106 in CDCl3 at 300 MHz 
13
C NMR for 106 in CDCl3 at 75 MHz 
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1
H NMR for 108 in CDCl3 at 500 MHz 
13
C NMR for 108 in CDCl3 at 126 MHz 
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1
H NMR for 109 in CDCl3 at 300 MHz 
13
C NMR for 109 in CDCl3 at 75 MHz 
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1
H NMR for 111 in CDCl3 at 300 MHz 
13
C NMR for 111 in CDCl3 at 75 MHz 
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1
H NMR for 113 in CDCl3 at 300 MHz 
13
C NMR for 113 in CDCl3 at 75 MHz 
 
 
 
General 
 
 
Appendices 
 
 
300 
 
1
H NMR for 115 in CDCl3 at 300 MHz 
13
C NMR for 115 in CDCl3 at 75 MHz 
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1
H NMR for 121 in CDCl3 at 500 MHz 
13
C NMR for 121 in CDCl3 at 126 MHz 
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1
H NMR for 122 in d6-DMSO at 500 MHz 
13
C NMR for 122 in d6-DMSO at 126 MHz 
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A2 - Crystallographic Information for selected imidazo[1,2-
a]pyridines 
 
The crystallographic information for selected compounds can be found below. All the relevant 
crystallographic information for all the crystal structures included in this thesis can be found in 
the digital appendix. 
Crystallographic Information for selected imidazo[1,2-a]pyridines 134, 88 and 137 
 
 
 
 
Compound 134 88 137 
Identification code 15j_cdkjd12_40r_0p 12j_cdkjd4_ba601_0a 15j_cdkjd15_34r 
Empirical formula C18 H20 N4 C18 H19 Br N4 C18 H19 Cl N4 
Formula weight 292.38 371.28 326.82 
Temperature 173(2) K 173(2) K 173(2) K 
Wavelength 0.71073 Å 0.71073 Å 0.71073 Å 
Crystal system Monoclinic Triclinic Monoclinic 
Space group P2(1)/c P-1 P 21/c 
Unit cell dimensions a = 11.6462(4) Å a = 6.13550(10) Å a = 5.7798(2) Å 
 
b = 11.2952(4) Å b = 16.1046(3) Å b = 25.3590(8) Å 
 
c = 11.9410(5) Å c = 17.9030(4) Å c = 22.5801(7) Å 
 
α = 90° α = 67.9870(10)° α = 90° 
 
β = 92.805(2)° β = 89.8320(10)° β = 94.090(2)° 
 
γ = 90° γ = 84.8620(10)° γ = 90° 
Volume 1568.91(10) Å3 1632.54(5) Å3 3301.14(19) Å3 
Z 4 4 8 
Density (calculated) 1.238 Mg/m3 1.511 Mg/m3 1.315 Mg/m3 
Absorption coefficient 0.076 mm-1 2.523 mm-1 0.236 mm-1 
F(000) 624 760 1376 
Crystal size 0.31 x 0.19 x 0.04 mm3 0.44 x 0.11 x 0.08 mm3 0.35 x 0.15 x 0.13 mm3 
Theta range for data 
collection 
1.75 to 25.56° 1.23 to 28.00° 1.61 to 28.00° 
Index ranges 
-14<=h<=14, -13<=k<=13, -
14<=l<=13 
-8<=h<=8, -21<=k<=21, -
23<=l<=23 
-7<=h<=7, -33<=k<=33, -
29<=l<=29 
Reflections collected 13628 23748 46161 
Independent reflections 2936 [R(int) = 0.0713] 7850 [R(int) = 0.0977] 7976 [R(int) = 0.0828] 
Completeness to theta = 
28.00° 
100.00% 99.90% 99.80% 
Absorption correction None Integration Integration 
Max. and min. 
transmission  
0.8237 and 0.4032 0.9699 and 0.9218 
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Refinement method 
Full-matrix least-squares on 
F2 
Full-matrix least-squares on 
F2 
Full-matrix least-squares on 
F2 
Data / restraints / 
parameters 
2936 / 0 / 203 7850 / 50 / 409 7976 / 0 / 423 
Goodness-of-fit on F2 1.062 1.017 0.974 
Final R indices 
[I>2sigma(I)] 
R1 = 0.0695, wR2 = 0.1730 R1 = 0.0583, wR2 = 0.1769 R1 = 0.0461, wR2 = 0.0916 
R indices (all data) R1 = 0.0942, wR2 = 0.1900 R1 = 0.0864, wR2 = 0.1896 R1 = 0.0912, wR2 = 0.1049 
Largest diff. peak and 
hole 
0.555 and -0.425 e.Å-3 2.577 and -0.807 e.Å-3 0.271 and -0.251 e.Å-3 
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Crystallographic Information for selected Zinc Complexes 121, 127 and 130 
 
  
 
Compound 121 127 130 
Identification code 14j_cdkjd8_96_0a 13j_cdkjd10_0a 14j_cdkjd9_257_0a 
Empirical formula C23 H26 Br Cl3 N4 O4 Zn C23 H21 Br N4 O4 Zn C23 H24 Br Cl9 N4 O6 Zn 
Formula weight 674.12 562.72 916.79 
Temperature 173(2) K 173(2) K 173(2) K 
Wavelength 0.71073 Å 0.71073 Å 0.71073 Å 
Crystal system Monoclinic Triclinic Triclinic 
Space group P 21/c P-1 P-1 
Unit cell dimensions a = 16.2492(4) Å a = 8.7640(2) Å a = 8.6355(3) Å 
 
b = 14.9187(4) Å b = 10.9349(3) Å b = 13.0380(4) Å 
 
c = 24.1221(6) Å c = 13.0299(3) Å c = 17.7337(6) Å 
 
α =90° α = 96.7010(10)° α = 106.916(2)° 
 
β = 102.5450(10) ° β = 108.0900(10)° β = 93.724(2)° 
 
γ = 90° γ = 106.1080(10)° γ = 108.358(2)° 
Volume 5708.0(3) Å3 1111.89(5) Å3 1785.86(10) Å3 
Z 8 2 2 
Density (calculated) 1.569 Mg/m3 1.681 Mg/m3 1.705 Mg/m3 
Absorption coefficient 2.576 mm-1 2.940 mm-1 2.521 mm-1 
F(000) 2720 568 912 
Crystal size 0.424 x 0.293 x 0.13 mm3 0.59 x 0.09 x 0.08 mm3 0.34 x 0.29 x 0.07 mm3 
Theta range for data 
collection 
1.28 to 25.24 1.69 to 27.93° 1.22 to 26.34° 
Index ranges 
-21<=h<=21, -19<=k<=19, -
31<=l<=31 
-11<=h<=11, -14<=k<=14, -
17<=l<=17 
-10<=h<=10, -15<=k<=16, -
22<=l<=21 
Reflections collected 106686 26092 19317 
Independent reflections 13793 [R(int) = 0.0948] 5334 [R(int) = 0.1140] 7246 [R(int) = 0.0979] 
Completeness to theta = 
28.00° 
100% 99.90% 99.50% 
Absorption correction Integration Integration Integration 
Max. and min. 
transmission 
0.7903 and 0.4128 0.7988 and 0.2759 0.8433 and 0.4810 
Refinement method 
Full-matrix least-squares on 
F2 
Full-matrix least-squares on 
F2 
Full-matrix least-squares on 
F2 
Data / restraints / 
parameters 
13793 / 0 / 653 5334 / 0 / 304 7246 / 1 / 404 
Goodness-of-fit on F2 0.993 0.921 0.926 
Final R indices 
[I>2sigma(I)] 
R1 = 0.0499, wR2 = 0.1349 R1 = 0.0352, wR2 = 0.0726 R1 = 0.0580, wR2 = 0.1449 
R indices (all data) R1 = 0.0938, wR2 = 0.1464 R1 = 0.0612, wR2 = 0.0783 R1 = 0.1203, wR2 = 0.1648 
Largest diff. peak and 
hole 
2.335 and -2.034 e.Å-3 0.439 and -0.476 e.Å-3 1.729 and -0.976 e.Å-3 
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Crystallographic Information for selected Copper Complexes 123, 128 and 133 
 
  
 
 123 128 133 
Identification code 12j_cdkjd8_bacuac_0a 14j_cdkjd10_253_0a mo_14a_cdkjd9_cu_0a 
Empirical formula C24 H29 Br Cl4 Cu N4 O4 C23 H21 Br Cu N4 O4 C28 H34 Br Cu N4 O6 
Formula weight 722.76 560.89 666.04 
Temperature 173(2) K 173(2) K 173(2) K 
Wavelength 0.71073 Å 0.71073 Å 0.71073 Å 
Crystal system Triclinic Orthorhombic Triclinic 
Space group P -1 P 2/c P-1 
Unit cell dimensions a = 10.0655(7) Å a = 10.3293(5) Å a = 9.8245(8) Å 
 
b = 12.1779(8) Å b = 9.6968(5) Å b = 11.1441(9) Å 
 
c = 12.8618(8) Å c = 25.3960(12) Å c = 13.7793(11) Å 
 
a= 94.595(4)° a= 90° a= 76.226(3)° 
 
b= 104.690(4)° b= 91.8710(10)° b= 82.809(3)° 
 
g = 101.168(4)° g = 90° g = 85.641(3)° 
Volume 1482.21(17) Å3 2542.3(2) Å3 1452.0(2) Å3 
Z 2 4 2 
Density (calculated) 1.620 Mg/m3 1.465 Mg/m3 1.523 Mg/m3 
Absorption coefficient 2.482 mm-1 2.465 mm-1 2.176 mm-1 
F(000) 730 1132 684 
Crystal size 0.719 x 0.272 x 0.212 mm3 0.31 x 0.193 x 0.156 mm3 0.30 x 0.24 x 0.14 mm3 
Theta range for data 
collection 
1.65 to 24.91° 1.60 to 26.45° 2.75 to 28.00° 
Index ranges 
-11<=h<=11, -14<=k<=14, -
15<=l<=15 
-12<=h<=12, -12<=k<=12, -
31<=l<=31 
-12<=h<=12, -14<=k<=14, -
18<=l<=18 
Reflections collected 14786 27558 55868 
Independent reflections 5004 [R(int) = 0.0892] 5226 [R(int) = 0.0543] 6986 [R(int) = 0.0366] 
Completeness to theta = 
28.00° 
96.70% 99.80% 99.80% 
Absorption correction Integration Integration Integration 
Max. and min. 
transmission 
0.7382 and 0.3243 0.7637 and 0.6402 0.7504 and 0.5614 
Refinement method 
Full-matrix least-squares on 
F2 
Full-matrix least-squares on 
F2 
Full-matrix least-squares on 
F2 
Data / restraints / 
parameters 
5004 / 1 / 348 5226 / 0 / 300 6986 / 0 / 370 
Goodness-of-fit on F2 0.967 1.023 1.029 
Final R indices 
[I>2sigma(I)] 
R1 = 0.0447, wR2 = 0.1025 R1 = 0.0442, wR2 = 0.1106 R1 = 0.0331, wR2 = 0.0896 
R indices (all data) R1 = 0.0935, wR2 = 0.1207 R1 = 0.0614, wR2 = 0.1148 R1 = 0.0373, wR2 = 0.0935 
Largest diff. peak and 
hole 
1.025 and -0.623 e.Å-3 1.123 and -0.422 e.Å-3 1.274 and -0.800 e.Å-3 
 
General 
 
 
Appendices 
 
 
307 
 
A3 - An example of the UV-vis spectra and Data Analysis 
obtained in this project  
 
All the data for compounds studied using UV-vis spectroscopy can be found in the Digital 
Appendix. The derivation for the equations used to model the pK data can also be found in the 
Digital Appendix. Below is an example of the data obtained from one of the out-of-cell pK 
titration performed on imidazo[1,2-a]pyridine 124. Table 11 outlines the changes in absorbance 
for the imidazo[1,2-a]pyridine at the specific wavelengths monitored (270, 317, 327, 340 and 380 
nm) as well as the pK value for each data set as determined by a single pK model using SigmaPlot. 
An example of the spectral changes seen is outlined in Figure 111A and a graphical example of 
the single pK model fitted to the data (Figure 111B). 
 
Table 11 – An example of the changes in absorbance of 124 monitored at various wavelengths 
at a 2.030 - 8.044 pH range and the pK value determined by the fit of the absorption data in 
SigmaPlot with a single pK model 
pH 
Absorbance at selected wavelengths (nm) 
A270 A317 A327 A340 A380 
2.030 0.428 0.3292 0.3398 0.2914 0.1345 
2.547 0.4366 0.3271 0.3379 0.2913 0.1366 
2.676 0.438 0.3259 0.3371 0.2913 0.1371 
2.913 0.446 0.3205 0.3319 0.2891 0.1373 
3.233 0.4679 0.3104 0.3228 0.2867 0.14 
3.543 0.5017 0.2958 0.3092 0.2824 0.1441 
3.737 0.5273 0.2801 0.295 0.2799 0.1466 
4.063 0.5894 0.2523 0.2691 0.2681 0.1533 
4.232 0.6221 0.2372 0.2555 0.2638 0.157 
4.524 0.6739 0.212 0.2319 0.2548 0.1624 
4.842 0.7149 0.1954 0.2162 0.2502 0.1676 
5.111 0.7366 0.1828 0.2042 0.245 0.1681 
5.525 0.7611 0.1811 0.2027 0.2476 0.1731 
6.036 0.7723 0.1733 0.1951 0.243 0.1749 
7.074 0.7837 0.1686 0.1903 0.2398 0.1765 
8.044 0.784 0.1661 0.1882 0.238 0.178 
pK  4.1420 4.0826 4.0943 4.1420 4.1896 
Std. Error 0.0138 0.0163 0.0172 0.0435 0.0412 
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A B 
Figure 111 – Changes in the absorbance spectra for 124 over a 2-8 pH range (A) and a graphical 
fit of the changes in absorbance at a wavelength of 270 nm (B) 
 
Along with each graphical fit, a report is generated for each run. Below is an example of the 
report generated from the single pK model applied to the changes in absorbance at a wavelength 
of 270 nm. Similar reports were generated for each wavelength that was monitored for each 
compound observed. 
Nonlinear Regression    
 
Data Source: Data 1 in Notebook1 
Equation: User-Defined, One pKa 
H=10^(-x); 
K1=10^(-pK1); 
Den=H+K1 
f=(H*A0 + K1*A1)/Den; 
 
 
R  Rsqr  Adj Rsqr  Standard Error of Estimate 
 
0.9997 0.9993 0.9992  0.0039  
 
  Coefficient Std. Error t P  
 
A0 0.4278 0.0020 215.3814 <0.0001  
A1 0.7778 0.0018 420.5552 <0.0001  
pK1 4.1420 0.0138 300.2776 <0.0001  
 
Analysis of Variance:  
 
  DF SS MS  
Regression 3 6.1598 2.0533  
Residual 13 0.0002 1.5139E-005  
Total 16 6.1600 0.3850  
 
Corrected for the mean of the observations: 
  DF SS MS F P  
Regression 2 0.2992 0.1496 9880.7578 <0.0001  
Residual 13 0.0002 1.5139E-005  
Total 15 0.2994 0.0200  
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Statistical Tests: 
 
Normality Test (Shapiro-Wilk)   Passed (P = 0.8776) 
 
W Statistic= 0.9725 Significance Level = 0.0500 
 
Constant Variance Test  Passed (P = 0.0517) 
 
Fit Equation Description: 
[Variables] 
x = col(5) ' {{prevmin: 0.000000}} {{prevmax: 10.000000}} 
y = col(6) 
[Parameters] 
A0 = col(6,2) ' {{previous: 0.427761}} 
A1 = col(6,17) ' {{previous: 0.777842}} 
pK1 = 7 ' {{previous: 4.14203}} 
[Equation] 
H=10^(-x); 
K1=10^(-pK1); 
Den=H+K1 
f=(H*A0 + K1*A1)/Den; 
fit f to y 
[Constraints] 
[Options] 
tolerance=1e-010 
stepsize=1 
iterations=200 
 
Number of Iterations Performed = 9 
 
The pK value(s) with a standard error below 1 were taken from each report and analysed in 
Microsoft Excel as shown in Table 12 to determine the average K value and hence the average pK 
value for each compound. 
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Table 12 – pK values determined by a single pK model from SigmaPlot for all the fits made and 
the average pK for compound 124 
pK Std Dev K 
4.1413 0.0536 7.223E-05 
4.1011 0.0135 7.923E-05 
4.1420 0.0138 7.211E-05 
4.0234 0.0311 9.475E-05 
4.0766 0.0136 8.383E-05 
4.0826 0.0163 8.268E-05 
4.0314 0.0329 9.303E-05 
4.0869 0.0176 8.187E-05 
4.0943 0.0172 8.048E-05 
4.0938 0.0912 8.057E-05 
4.1819 0.0384 6.578E-05 
4.1420 0.0435 7.211E-05 
4.2328 0.0883 5.851E-05 
4.1474 0.0528 7.122E-05 
4.1896 0.0412 6.462E-05 
 
Ave K 7.687E-05 
 
Std Dev 1.010E-05 
 
pK 4.11 
 
Error 0.05 
 
This process was repeated for each of the compounds analysed using either the single pK model 
or the two pK model as appropriate. The reports for the two pK model generate two pK values 
and the average pK was determined independently for each pK. 
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A4 - 1H and 13C NMR Spectra for selected compounds 
Below are the 
1
H and 
13
C NMR spectra for a selection of the final compounds obtained from the 
CAS reactions and other novel xanthones and acridones generated in the course of this project. 
Spectroscopic data for the synthetic precursors are available in the Digital Appendix. 
 
1
H NMR for 257 in CDCl3 at 300 MHz 
 
13
C NMR for 257 in CDCl3 at 75 MHz 
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1
H NMR for 329 in CDCl3 at 300 MHz 
13
C NMR for 329 in CDCl3 at 75 MHz 
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1
H NMR for 330 in CDCl3 at 300 MHz 
13
C NMR for 330 in CDCl3 at 75 MHz 
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1
H NMR for 331 in CDCl3 at 300 MHz 
13
C NMR for 331 in CDCl3 at 75 MHz 
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1
H NMR for 332 in CDCl3 at 300 MHz 
13
C NMR for 332 in CDCl3 at 75 MHz 
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1
H NMR for 333 in CDCl3 at 300 MHz 
13
C NMR for 333 in CDCl3 at 75 MHz 
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1
H NMR for 300 in CDCl3 at 300 MHz 
13
C NMR for 300 in CDCl3 at 75 MHz 
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1
H NMR for 305 in d4-MeOD at 500 MHz 
13
C NMR for 305 in d4-MeOD at 126 MHz 
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1
H NMR for 306 in d6-DMSO at 500 MHz 
13
C NMR for 306 in d6-DMSO at 126 MHz 
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1
H NMR for 307 in d6-DMSO at 300 MHz 
13
C NMR for 307 in d6-DMSO at 75 MHz 
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1
H NMR for R = Cl, 308 in d6-DMSO at 500 MHz 
 
13
C NMR for R = Cl, 308 in d6-DMSO at 126 MHz   
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1
H NMR for 298 in CDCl3 at 300 MHz 
 
13
C NMR for 298 in CDCl3 at 75 MHz 
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A5 - Crystallographic Data obtained for Plot Twist crystal 
structures 
 
The crystallographic information for the crystal structures obtained during this thesis can is 
outlined below. All the relevant crystallographic information for these crystal structures is 
included in the digital appendix. 
 
 
 
 
 
Compound 329 333 332 
Identification code 15j_cdkjd16_406-0s 16j_cdkjd5_438_0s 16j_cdkjd6_0s 
Empirical formula C30 H26 O8 C15 H12 O5 C14 H10 O3 
Formula weight 514.51 272.25 226.22 
Temperature 173(2) K 173(2) K 173(2) K 
Wavelength 0.71073 Å 0.71073 Å 0.71073 Å 
Crystal system Triclinic Monoclinic Orthorhombic 
Space group P -1 P 21/c P 21 21 21 
Unit cell dimensions a = 11.0122(2) Å a = 10.2735(5) Å a = 3.90060(10) Å 
 
b = 12.6075(2) Å b = 9.9848(4) Å b = 16.2669(5) Å 
 
c = 20.4557(3) Å c = 12.4392(5) Å c = 16.3196(6) Å 
 
α = 75.1000(10)° α = 90° α = 90° 
 
β = 81.5690(10)° β = 95.832(2)° β = 90° 
 
γ = 64.9630(10)° γ = 90° γ = 90° 
Volume 2484.30(7) Å3 1269.39(10) Å3 1035.49(6) Å3 
Z 4 4 4 
Density (calculated) 1.376 Mg/m3 1.424 Mg/m3 1.451 Mg/m3 
Absorption coefficient 0.100 mm-1 0.108 mm-1 0.102 mm-1 
F(000) 1080 568 472 
Crystal size 0.21 x 0.20 x 0.15 mm3 0.16 x 0.14 x 0.12 mm3 0.38 x 0.07 x 0.05 mm3 
Theta range for data 
collection 
1.031 to 26.328°. 1.993 to 27.997°. 1.768 to 25.999°. 
Index ranges 
-13<=h<=13, -15<=k<=15, -
24<=l<=25 
-13<=h<=13, -13<=k<=13, -
16<=l<=16 
-4<=h<=4, -20<=k<=20, -
19<=l<=20 
Reflections collected 27570 14390 10718 
Independent reflections 10069 [R(int) = 0.0453] 3067 [R(int) = 0.3669] 2028 [R(int) = 0.0917] 
Completeness to theta 
= 25.242° 
99.80% 100.00% 100.00% 
Absorption correction None None None 
Refinement method 
Full-matrix least-squares on 
F2 
Full-matrix least-squares on 
F2 
Full-matrix least-squares on 
F2 
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Data / restraints / 
parameters 
10069 / 0 / 697 3067 / 0 / 183 2028 / 0 / 155 
Goodness-of-fit on F2 1.061 0.861 0.964 
Final R indices 
[I>2sigma(I)] 
R1 = 0.0390, wR2 = 0.0999 R1 = 0.0586, wR2 = 0.1243 R1 = 0.0456, wR2 = 0.0779 
R indices (all data) R1 = 0.0658, wR2 = 0.1128 R1 = 0.0957, wR2 = 0.1419 R1 = 0.0857, wR2 = 0.0891 
Extinction coefficient n/a n/a n/a 
Largest diff. peak and 
hole 
0.204 and -0.172 e.Å-3 0.308 and -0.377 e.Å-3 0.151 and -0.175 e.Å-3 
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